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Abstract
Clostridium difficile is the most common cause of nosocomial diarrhoea today. 
Through the changing epidemiology of C. difficile infection, the emergence and 
decline of different strains of varying virulence and a broad spectrum of disease from 
asymptomatic carriage and mild infection to severe pseudomembranous colitis have 
been observed. The main aim of this three-part thesis was to identify  bacterial factors 
that might explain these variations by  comparing five C. difficile strains - strain 630, 
an historic strain, strain VPI 10463, a reference strain, the hypervirulent ribotype 027 
and the current locally endemic ribotypes 001 and 106. 
The first study  focussed on the growth-related phenotypic and genotypic expression 
of virulence factors in C. difficile. Growth was studied over twenty-four hours, with 
simultaneous assessment of toxin and spore production. Total toxin production was 
measured by a commercial ELISA, while a quantitative ELISA for toxin A and a 
quantitative cytotoxicity assay for toxin B were developed for individual toxin levels, 
and spores were enumerated by  viable counts. Ribotype 027 produced large amounts 
of toxin A and toxin B and was the second highest spore producer after ribotype 106. 
Growth may not affect  virulence, but the ability to produce more toxins and spores 
could. To study the transcription of the genes involved in these processes, a real-time 
RT-PCR was developed. The transcription of the pathogenicity locus (tcdA-E) that 
regulates toxin production in C. difficile, and of spo0A, the initiator of sporulation, 
was studied. There were three key observations: firstly, the transcription of tcdC, the 
negative regulator of toxin production, did not decrease over time, suggesting it has a 
modulatory rather than repressive effect on the process. Secondly, tcdE expression 
was highest in ribotype 027, which might explain its hypertoxicity by  greater toxin 
release. Thirdly, there was almost steady state expression of spo0A during the 
exponential growth phase in ribotypes 106 and 027, the highest spore producers, 
suggesting prolonged activation of sporulation. Thus, distinct inter-strain differences 
exist between C. difficile strains in vitro, which could mirror their virulence in vivo, 
and several traits contribute synergistically to the hypervirulence of ribotype 027. 
iii
The second study aimed to identify suitable laboratory  disinfectants against C. 
difficile. The efficacy  of four commonly-used disinfectants and one decontaminant 
was tested; one disinfectant was a chlorine-based agent commonly used in hospitals. 
In conventional susceptibility tests, all five agents were effective against vegetative 
cells and spores of C. difficile. However, only the chlorine-based disinfectant was 
effective against spores dried onto surfaces, but this too required more than two 
minutes of treatment. The presence of organic matter significantly impaired the 
efficacy of the non-chlorine agents. The spores of epidemic strains were destroyed 
less effectively and exposure to sub-MIC levels of disinfectant increased sporulation, 
especially in ribotype 001, a common outbreak strain. Environmental sampling of the 
laboratory and surrounding areas showed considerable dissemination of C. difficile, 
highlighting the need for effective decontamination in conjunction with basic 
hygiene methods like hand-washing.
The third study examined the biological activity  of C. difficile. Macrophages were 
challenged in vitro with S-layer proteins, flagella, heat-shock proteins and culture 
supernatants of the five strains and cytokine production was measured by specially 
developed ELISAs. No significant inter-strain differences were observed, although 
the epidemic strains generally elicited a slightly greater cytokine response. Using 
epithelial cell lines it was observed that epidemic strains showed greater adherence; 
from inhibition assays, flagella and S-layer proteins were found to contribute equally 
to this. Through these studies, inter-strain differences between epidemic and historic 
isolates were identified with respect to virulence factors, survival in the environment 
and possible behaviour within the host. A sum of these observations suggests 
increased virulence in contemporary versus historical C. difficile strains.
Finally, a supplementary study characterising a collection of ribotype 027 strains 
isolated in Scotland and the Netherlands by typing schemes, gene sequencing, 
susceptibility testing and phenotypic studies was performed. In agreement with other 
studies, the clonality of these hypervirulent strains was observed!
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1. Introduction
Clostridium difficile is a Gram-positive, obligately anaerobic, spore-forming bacillus. 
First isolated in 1935 from the stools of healthy neonates, it was named Bacillus 
difficilis due to the difficulty encountered while attempting to isolate this slow 
growing bacterium (Hall & O'Toole, 1935). C. difficile was first associated with 
infection in 1962, but  there was little evidence to suggest that it  was the primary 
pathogen in any of the infections (Smith & King, 1962). It was only in the late 1970s 
that the role of C. difficile in human infection was established. 
Antibiotic-associated colitis (AAC) and its rare, severe form, pseudomembranous 
colitis (PMC), were identified in the 1950s and Staphylococcus aureus was the 
suspected pathogen (Pearce & Dineen, 1960). However, in 1974, Tedesco and 
colleagues identified PMC patients who had received prior clindamycin treatment 
(Tedesco et al., 1974). Although no pathogen was isolated from any of the patients, 
this ruled out S. aureus as the cause because it was susceptible to clindamycin. In 
1977, Bartlett and colleagues identified a clindamycin-resistant, toxin-producing 
Clostridium species as the cause of AAC in hamsters and even suggested C. difficile 
in particular (Bartlett et al., 1977). The same year, a clostridial toxin that was 
neutralised by the Clostridium sordellii antitoxin was identified in the faeces of 
patients with PMC and even those with antibiotic-associated diarrhoea without colitis 
(Larson & Price, 1977; Rifkin et al., 1977). In 1978, George and colleagues extended 
their search for the PMC pathogen by  isolating all possible Clostridium species from 
the stools of affected patients (George et al., 1978a; George et al., 1978b). They 
observed that, of all the clostridia isolated, only pure cultures of C. difficile elicited 
the same cytotoxicity as that obtained with patient faeces and this was neutralised by 
the monovalent C. sordellii antitoxin. Thus, finally, the causative agent  of PMC had 
been identified as Clostridium difficile. These results were confirmed by other 
investigators in humans and in animal models (Bartlett et al., 1978b; Chang et al., 
1978a). Today, C. difficile is the most common cause of hospital-acquired and post-
antibiotic diarrhoea (Rupnik et al., 2009).
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1.1. The bacterium and its identification 
1.1.1. Morphology 
Under the microscope, C. difficile cells appear as short heavy-bodied to long bacilli, 
2 to 8 µm long and 0.5 µm wide, with elongated subterminal or nearly  terminal 
spores that do not swell the bacilli (George et al., 1979; Hafiz & Oakley, 1976; Hall 
& O'Toole, 1935; Smith & King, 1962). They are Gram-positive, but the stain tends 
to be lost in older cultures. They are also motile with few peritrichous flagella.
1.1.2. Media and colony characteristics
C. difficile produces white, flat, opaque, non-haemolytic colonies with irregular 
margins on reinforced clostridial agar and yellowish, lecithinase negative colonies 
with ground-glass appearance and filamentous edges on the preferred selective media 
used for its isolation like cycloserine cefoxitin fructose egg yolk agar (CCFA) and 
cylcoserine cefoxitin egg yolk agar (CCEY) (Brazier, 1993; George et al., 1979; 
Hafiz & Oakley, 1976). The colonies produce a characteristic yellow-green or 
chartreuse fluorescence under UV light and have an unmistakable dung-like odour 
(George et al., 1979; Wren, 2010). The addition of bile salts such as taurocholate or 
lysozyme to the medium facilitates the outgrowth of spores and is useful in 
environmental sampling (Wilcox et al., 2000; Wilson et al., 1982; Wren, 2010). 
Treatment of faecal samples with alcohol at  a final concentration of 50% followed by 
the use of selective media enhances the recovery  of C. difficile (Borriello & Honour, 
1981; Fedorko & Williams, 1997). Further, rapid identification can be achieved by 
using a proline-aminopeptidase disc along with culture (Fedorko & Williams, 1997).
1.1.3. Antigen detection
Detection of toxin was the first diagnostic method employed for C. difficile; assays 
of toxicity  in hamsters, vascular permeabilisation in rabbit skin and tissue culture 
neutralisation tests with C. sordellii antitoxin were used originally  (Larson & Price, 
1977; Rifkin et al., 1977). Cytotoxicity neutralisation is the most accurate method to 
detect C. difficile toxin (Whittier et al., 1993), but it is time-consuming and requires 
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facilities and expertise. Several commercial enzyme immunoassay (EIA) kits are 
available to detect  C. difficile toxins directly  from faecal samples. Kits like the 
VIDAS C. difficile toxin A assay (BioMerieux) and the C. difficile Tox-A-Test 
(Techlab) detect  toxin A (Whittier et al., 1993), but combined kits that detect both 
toxin A and toxin B such as the TOX A/B test (Techlab) (Aldeen et al., 2000) and 
ImmunoCard Toxins A&B test (Meridian) (van den Berg et al., 2005) are preferable 
due to the existence of A-B+ C. difficile strains (Borriello et al., 1992). These assays 
are quick and easy  to perform; the ImmunoCard assay detects toxin within 20 
minutes. However, owing to variations in sensitivities and specificities and poor 
predictive values, it is preferable to use them in conjunction with culture.
The detection of the glutamate dehydrogenase (GDH) antigen is also possible using 
the C.DIFF CHECK-60 kit (Techlab); however, it detects both toxigenic and non-
toxigenic C. difficile strains and needs to be followed by toxin detection (Snell et al., 
2004). A two-step GDH-toxin detection method is superior to EIA (Gilligan, 2008). 
1.1.4. Gene detection
For a more accurate detection of C. difficile, PCR methods have been developed. Van 
der Berg and colleagues developed a real-time PCR method to amplify tcdB which 
correlated well with culture and cytotoxicity testing (van den Berg et al., 2005). This 
is a suitable first-step identification method for C. difficile. The BD GeneOhm Cdiff 
also employs amplification of tcdB and correlates well with toxigenic culture (Barbut 
et al., 2009a). A rapid real-time PCR method using fluorescence resonance energy 
transfer probes was developed by Sloan and colleagues, which was able to identify 
deletions in the tcdC gene of C. difficile isolates (Sloan et al., 2008). This method is 
also highly sensitive and specific when compared to toxigenic culture. The most 
recent real-time PCR assay involves the detection of tcdA, tcdB and the tcdC deletion 
at position 117, which is characteristic of the hypervirulent ribotype 027 (de Boer et 
al., 2010). These molecular methods are very accurate and can be used directly as 
screening tests prior to toxigenic culture. 
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1.2. The disease
1.2.1. Acquisition of C. difficile 
C. difficile is widely distributed in the environment. It has been isolated from soil, 
water and root vegetables (al-Saif & Brazier, 1996) and also from animals (Songer, 
1996) and a variety of meat products (Weese et al., 2009), suggesting its potential as 
a zoonotic and food-borne disease (Rupnik, 2007). Humans are also an important 
source of C. difficile. Asymptomatic carriage of the bacterium has been identified in 
adults and more commonly in neonates (Collignon et al., 1993; Delmée, 2001). 
However, the main source of C. difficile are infected patients who release large 
numbers of vegetative cells and spores into their environment (Mulligan et al., 1980; 
Wilcox et al., 2003). This is especially significant  in a nosocomial setting in which 
commonly touched surfaces and equipment and even the hands of healthcare workers 
can become contaminated and aid in the dissemination of C. difficile (Fekety  et al., 
1981; Gerding et al., 1995). Being transmitted by the faecal-oral route, the ingestion 
of C. difficile into the gut of the host is the primary  step towards infection (Lyerly  et 
al., 1988; Worsley, 1998); contaminated hands and thus food are normally 
responsible for this. This transmission has been demonstrated in animals (Fekety  et 
al., 1980). Under suitable conditions in the gut, C. difficile is able to colonise the 
host, the spores germinate into vegetative cells that produce toxins and other 
virulence factors, and also spores, which are once again shed during diarrhoea 
(Poxton et al., 2001). In this way, the cycle of transmission of C. difficile from host 
to environment and vice-versa continues (Fig. 1.1). The reservoirs of C. difficile and 
its environmental spread are discussed in greater detail in Chapter 4 (4.1.1-4.1.2).
Clostridium difficile infection (CDI), previously  known as Clostridium difficile-
associated disease (CDAD) is primarily a nosocomial occurrence, sometimes 
referred to as healthcare-associated CDI (HA-CDI), but community-associated CDI 
(CA-CDI) is not unheard of (Limbago et al., 2009). Although it  can be difficult to 
distinguish between the two, the incidence of community-associated cases has been 
increasing in recent years (Norén et al., 2004; Riley et al., 1995).
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Fig. 1.1. Transmission of C. difficile in a nosocomial setting 
C. difficile can be acquired from the environment, primarily in the form of spores, by direct 
ingestion with food or from contaminated equipment. Once established in the gut of the host, 
the bacterium multiplies and produces spores, which are shed into the environment. In 
infected patients, frequent diarrhoea can result in the release of large numbers of spores. If 
the environment is not effectively decontaminated, the spores can persist for long periods of 
time and transmission can occur through the contamination of objects and also the hands of 
health care workers. From these sources, C. difficile can be transmitted to other susceptible 
individuals, who could in turn become a source of infection. In this way, the faecal-oral 
transmission of C. difficile  in the environment and the host continues. Adapted from http://
www.infectionprotection.org.uk/stages/c-diff.html.
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1.2.2. Risk factors
1.2.2.1. Exposure to antibiotics
ʻColonisation resistance’ by the normal indigenous gut microbiota is key in 
preventing colonisation by C. difficile (Wilson, 1993). Thus, its disruption by 
antibiotics and the subsequent lack of competition is the most important risk factor 
for CDI (Bartlett et al., 1980; Kelly & LaMont, 1998). The role of exposure to 
antibiotics in C. difficile infection was first  demonstrated in the hamster model; even 
pre-exposure to vancomycin, which was considered to be protective (Fekety  et al., 
1979), followed by the oral administration of C. difficile resulted in disease (Larson 
et al., 1978). A range of antibiotics has been shown to impact the susceptibility of the 
host to C. difficile (Bartlett  et al., 1978a; Bartlett  et al., 1980). When first identified, 
CDI was synonymous with the use of clindamycin and its effect was demonstrated in 
animal models (Chang et al., 1978a; Tedesco et al., 1974). However, the replacement 
of clindamycin by third-generation cephalosporins and broad-spectrum penicillins 
led to them being implicated most frequently  in CDI (Bartlett, 2008; Brown et al., 
1990). Fluoroquinolones were initially considered to be unlikely  suspects in CDI due 
to their minimal disruptive effects on the anaerobic microbiota of the gut (Golledge 
et al., 1992; Riley  et al., 1991). However, the emergence of resistant epidemic strains 
in the last decade has caused a shift in perspective (Kuijper et al., 2006; McDonald et 
al., 2005). The duration of antibiotic exposure has also been identified as a risk factor 
for CDI; increased duration and use of multiple antibiotics like quinolones, 
cephalosporins, clindamycin and macrolides can increase incidence (Brown et al., 
1990; Pépin et al., 2005a). The role of fluoroquinolones in recent epidemics caused 
by a hypervirulent C. difficile strain is discussed in greater detail in Chapter 6 (6.1.3). 
1.2.2.2. Age
C. difficile colonisation of neonates and the lack of disease in this group is well-
known (Behrman & Donta, 1982; Collignon et al., 1993; Stark et al., 1982) and 
asymptomatic carriage by healthy  adults is common (Delmée, 2001; Kato et al., 
2001; Ozaki et al., 2004). Historically, C. difficile infection, was a disease of the 
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elderly. A significant risk factor was age above 65 years (McFarland & Stamm, 1986; 
Pépin et al., 2004; Sunenshine & McDonald, 2006), possibly due to a combination of 
confounding factors such as the presence of underlying conditions, increased 
antibiotic treatment, the inability  to mount an effective immune response and 
alterations in the normal gut  microbiota (Hopkins & Macfarlane, 2002; McFarland & 
Stamm, 1986). 
More recently, however, disease in previously low-risk groups has been identified. 
These include children, peripartum women and young healthy adults with no prior 
exposure to antibiotics or recent hospitalisation (Benson et al., 2007; Centers for 
Disease Control and Prevention, 2005). Most of these infections are likely to be 
community-acquired and linked with less morbidity, possibly  due to the age and 
health status of the individuals (Karlström et al., 1998; Naggie et al., 2010), but 
severe disease does occur (Centers for Disease Control and Prevention, 2005).
1.2.2.3. Underlying disease 
The presence of underlying conditions and immunosuppression increase with age 
and so does the risk of CDI (Pépin et al., 2004). Underlying conditions can include 
gastrointestinal, pulmonary and urinary tract infections, renal disease, cellulitis, 
cancer, anaemia, diabetes mellitus and even the need for emergency surgery 
(Changela et al., 2004; Harbarth et al., 2001; Kyne et al., 2002). Notably, similar 
conditions add to the risk of infection in children: underlying gastrointestinal 
pathology and surgery, renal disease, cancer and hypogammaglobulinaemia (Benson 
et al., 2007; McFarland et al., 2000). High prevalence of C. difficile infection has 
also been identified in patients with irritable bowel disease (IBD) and increased 
mortality is associated with patients with IBD and CDI (Ananthakrishnan et al., 
2008; Pituch, 2009). CDI has also been associated with HIV infection, norovirus 
outbreaks and seasonal influenza (Polgreen et al., 2010; Sanchez et al., 2005) 
(Svraka et al., 2010), although this link is most  likely due to the compromised 
immune status of the host and antimicrobial use. The severity of underlying 
conditions was thought to play an indirect role in CDI by aggravating other risk 
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factors such as the duration of hospitalisation and bacterial exposure (McFarland et 
al., 1990) but it has now been observed to play a more direct role in disease, possibly 
by impairing the immune response of the host (Kyne et al., 2002).
1.2.2.4. Duration of hospitalisation
Hospitalisation is an important risk factor in CDI as hospitals themselves are a 
source of infection (Kaatz et al., 1988). The rate of colonisation among hospitalised 
adults was observed to be more than 20% and the risk of acquiring C. difficile was 
directly  proportional to the length of stay (Johnson & Gerding, 1998; McFarland et 
al., 1989). Patients moved between wards were also found to be at increased risk, 
possibly due to increased duration of hospitalisation and increased exposure to 
antibiotics and environmental contamination (Starr et al., 2003). However, not all 
studies agree with these observations; reports in which the duration of hospitalisation 
has no implication on CDI have also been published (Brown et al., 1990).
1.2.2.5. Gastric acid suppression
Proton pump inhibitors (PPIs) that lower gastric acidity  are often suggested as a risk 
factor (Cunningham & Dial, 2008; Dial et al., 2006). Their effect  in infection and 
subsequent inflammation was demonstrated in the animal model and the risk 
associated with them was comparable to that associated with antibiotics (Kaur et al., 
2007). Vegetative cells of C. difficile were able to survive in the gastric contents of 
patients receiving PPIs at a pH above 5 and this could perhaps aid survival of the 
bacteria and increase the risk of infection (Jump et al., 2007). However, PPIs did not 
affect spore germination and the mechanism by  which they could promote CDI is 
still unknown (Nerandzic et al., 2009). In most investigations so far the association 
of PPIs with CDI has either not been demonstrated (Loo et al., 2005; Wilcox et al., 
2008) or has been weak at best (Muto et al., 2005).
1.2.2.6. Other interventions
Treatments such as anti-neoplastic drugs, diuretics, stool softeners, antacids, 
laxatives and immunosuppressive agents like corticosteroids have also been 
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associated with C. difficile infection and carriage (Anand & Glatt, 1993; Faris et al., 
2010; McFarland et al., 1990; Raveh et al., 2006). In-hospital procedures like the 
administration of enemas, nasogastric tubes, endoscopy and surgery have also been 
linked with CDI, but these are most likely  to reflect environmental contamination 
(McFarland et al., 1990; Spencer, 1998). In one report, underlying conditions and 
treatments individually were not  found to affect CDI, but a combination of two or 
more of these significantly increased the frequency of CDI (Wiström et al., 2001)
1.2.2.7. Strain type
C. difficile strains can exhibit a range of pathogenic potential; a correlation between 
the type of strain colonising a patient, its ability to produce toxins and the symptoms 
of disease has been observed (Wren et al., 1987), but a lack of association has also 
been documented (Wilson et al., 2010). Certain hypervirulent strains have recently 
been identified like ribotype 027 (Pépin et al., 2005b), ribotype 078 (Jhung et al., 
2008) and ribotype 017 (Arvand et al., 2009). Others like ribotypes 001 and 106 
have also been associated with severe disease (Arvand et al., 2009; Sundram et al., 
2009). However, the changing epidemiology suggests that other strains have similar 
abilities to cause disease (Bauer et al., 2010; Rupnik et al., 2003b; Taori et al., 2009). 
Moreover, the pathogenicity of the infecting strain alone does not determine the 
severity of disease; host factors are also deemed important (McFarland et al., 1991).
1.2.2.8. Host immune response
The ability of the host to mount an immune response against C. difficile is believed 
to play a significant role in the severity  and recurrence of disease. Antibody 
production against C. difficile is possibly stimulated early in life (Kelly & Kyne, 
2011); neonates are exposed to the bacterium in the environment (Bolton et al., 
1984) or even in the birth canal (Hafiz et al., 1975). It has also been suggested that 
antibodies to C. difficile can be acquired from colostrum (Wada et al., 1980). This 
response is possibly enhanced by environmental exposure later on in life. Thus, not 
surprisingly, most adults have serum IgG and IgA against the toxins and other 
antigens of C. difficile (Pantosti et al., 1989; Sánchez-Hurtado et al., 2008). 
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The correlation between antibody  levels and the clinical course of infection has been 
demonstrated in several studies; short acute infection, asymptomatic carriage and a 
decreased risk of relapse were observed in patients with higher levels of serum IgG, 
IgM and IgA against  the toxins and cell-somatic antigens and more faecal IgA 
(Aronsson et al., 1985; Mulligan et al., 1993; Warny et al., 1994). In one study, 
serum IgA was found to be responsible for the neutralisation of toxin A in the 
convalescent phase of infection (Johnson et al., 1995). In a course-related study, 
although the levels of IgA, IgM  and IgG between patients were found to be similar at 
the time of admission to hospital, by the time of colonisation with C. difficile, the 
IgG response to the toxins and other antigens were much higher in asymptomatic 
carriers and dropped significantly in those who developed infection (Kyne et al., 
2000). Also, among patients who showed no differences in antibody  levels at the 
onset of diarrhoea, increased levels of IgM on day  3 and of serum IgA and IgG on 
day 12 were observed in those who did not relapse (Kyne et al., 2001). The strength 
and time of the immune response to C. difficile appear to be critical; a greater 
anamnestic response can avert symptoms and an early  response in infection can 
prevent recurrence (Kelly & Kyne, 2011). 
Antibodies to non-toxin antigens of C. difficile have also been thought to play  a role 
in infection. In an early study, higher levels of IgG to surface-layer proteins (SLPs) 
were seen in the convalescent phase of infection and the highest levels were seen in 
patients who later relapsed (Pantosti et al., 1989). In another study, it was found that 
asymptomatic carriers had higher levels of IgM  to SLPs and patients who could not 
mount an IgM response suffered recurrent infection (Drudy et al., 2004). Antibodies 
against flagella proteins FliC and FliD and surface-associated proteins Cwp66 and 
Fbp68 were found to be lower in symptomatic patients as compared to controls when 
there was no difference in antibodies to the toxins, suggesting that they might have a 
role in colonisation (Péchiné et al., 2005a). 
A study  of the immune cell populations in the colonic biopsies of patients with 
diarrhoea not caused by C. difficile and those with mild or severe CDI revealed that 
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there was a significant reduction in the B/plasma cells and macrophages in the latter, 
while the numbers of T cells did not vary between the groups (Johal et al., 2004b). A 
specific reduction in IgA producing cells and an increase in IgG producing cells was 
observed in patients with CDI and especially in those with pseudomembranous 
colitis. Further, both in this study and others, biopsies of patients who relapsed 
contained fewer IgA producing cells than those of patients who did not (Wroe, 2009). 
Thus, recurrence of CDI may be associated with a reduction in IgA producing cells.
1.2.3. Clinical presentations
CDI is characterised by the presence of diarrhoea which is normally  observed during 
or shortly  after antibiotic therapy, but diarrhoea can occur post cessation of antibiotic 
therapy (Kelly & LaMont, 1998). The clinical presentation of disease, however, can 
range from asymptomatic carriage to mild disease to fulminant colitis. In mild cases 
of CDI, diarrhoea is watery, does not contain blood or mucus and normally  ceases 
with stopping antibiotic therapy, and for asymptomatic carriers, treatment is not 
recommended. When CDI is more serious, colitis coupled with abdominal pain, 
malaise, fever, dehydration and delirium can occur (Kelly & LaMont, 1998; Starr, 
2005). In this form of the disease, pseudomembranes are usually  absent. When 
pseudomembranous colitis occurs, the symptoms are the same, but are much more 
severe. Classic pseudomembranes contain raised yellow necrotic plaques scattered 
over the colonic mucosa (Castagliuolo & LaMont, 1999; Hafiz & Oakley, 1976; 
Kelly  & LaMont, 1998). Fulminant colitis is rare (Dallal et al., 2002) but  exhibits the 
most intense complications such as perforation and toxic megacolon. Thus, not 
surprisingly, mortality rates of about 40% are associated with fulminant colitis 
(Sailhamer et al., 2009). High fever, chills, leukocytosis and hypoalbuminemia are 
also commonly observed (Bartlett, 2008; Bartlett, 2010a; Kelly & LaMont, 1998). 
1.2.4. Diagnosis
The laboratory diagnosis of CDI in a patient presenting with diarrhoea and other 
symptoms can be confirmed by the detection of toxins. The cytotoxicity assay 
involving the exposure of fibroblasts to C. difficile toxin followed by their 
11
neutralisation with C. sordellii antitoxin (Chang et al., 1978b) was the ‘gold 
standard’ for testing until the introduction of an enzyme linked immunoassays for 
toxin A or both toxin A and toxin B (Bartlett, 2008; Bartlett, 2010b; Lyerly  et al., 
1983). Today, a variety  of commercial immunoassays and gene detection kits exist 
for the rapid detection of C. difficile (1.1.3-1.1.4), but toxigenic culture remains the 
most accurate method for the laboratory diagnosis of C. difficile (Delmée et al., 
2005; Reller et al., 2007).
The clinical diagnosis of CDI does not involve sigmoidoscopy or colonoscopy, 
unless the diagnosis is doubtful (Kelly & LaMont, 1998). In fact, it has been shown 
that nurses are able to diagnose CDI accurately from information like recent use of 
antibiotics, presence of fever and characteristic ‘clostridial’ odour (Johansen et al., 
2002; Wilcox, 2007). For pseudomembranous colitis, direct visualisation by 
sigmoidoscopy or colonoscopy is required, but due to the lack of specificity, they 
must be used in conjunction with laboratory techniques to confirm the diagnosis 
(Gerding et al., 1995). Flexible sigmoidoscopy is recommended for hospitalised 
patients presenting symptoms of CDI in whom toxins cannot be detected by 
laboratory tests (Johal et al., 2004a).
1.2.5. Treatment and outcomes
1.2.5.1. Conventional antimicrobial therapy
The treatment of C. difficile infection involves the discontinuation of the inciting 
antibiotic, followed by the administration of antimicrobials, despite their drawbacks. 
In 20% of CDI patients symptoms are resolved without treatment, but for those 
requiring antibiotic therapy, metronidazole and vancomycin are the drugs of choice 
(Starr, 2005). Successful treatment with both metronidazole and vancomycin has 
been observed (Burdon et al., 1979; Keighley  et al., 1978; Pashby  et al., 1979). 
Metronidazole was selected as the first-line treatment for CDI due to the higher cost 
of vancomycin and its potential to select  for vancomycin-resistant enterococci 
(Gerding, 2009). However, the acquisition of C. difficile during metronidazole 
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treatment was also observed and it was suggested that vancomycin be the first-line 
treatment (Mogg et al., 1979). The debate between these two antibiotics was resolved 
by a comparative study, which showed that both were suitable for the treatment of 
mild CDI, but vancomycin is superior for the treatment of severe disease (Zar et al., 
2007). In patients with fulminant colitis, vancomycin treatment can increase the odds 
of survival by 4-fold (Sailhamer et al., 2009), whereas metronidazole has been 
related to increased failure of therapy and recurrence (Musher et al., 2005; Pepin et 
al., 2005; Wilson et al., 2010). However, this advantage of vancomycin in severe 
disease was not demonstrated in CDI caused by  the hypervirulent  ribotype 027 
(Pepin, 2008). Oral vancomycin is preferred for the treatment of pregnant and breast-
feeding women and those who fail to respond to metronidazole treatment (Razavi et 
al., 2007). Both antibiotics are equally effective in the treatment of first  recurrences, 
irrespective of the agent used for the resolution of the initial episode (Pépin et al., 
2006). A combination of metronidazole and vancomycin may be used in critically ill 
patients (Kelly & LaMont, 1998).
1.2.5.2. New alternatives
Antibiotics other than vancomycin and metronidazole have been tested against C. 
difficile. These include bacitracin, teicoplanin, fusidic acid, nitaxozanide, rifaximin, 
linezolid and ramoplanin (Baines et al., 2011; Monaghan et al., 2008). Teicoplanin 
was found to be slightly better than vancomycin and metronidazole (Nelson, 2007), 
while nitazoxanide, which is normally used to treat parasite-infections (Monaghan et 
al., 2008), bacitracin and fusidic acid were not found to be of added advantage 
(Gerding & Johnson, 2010). Rifaximin and rifampin have been found to be useful in 
preventing recurrence of disease when administered immediately after vancomycin 
therapy, but resistance to this antibiotic has also been observed (Johnson et al., 2007; 
Lagrotteria et al., 2006; O'Connor et al., 2008). REP3123, a narrow-spectrum 
antibacterial agent, demonstrated high selectivity  for C. difficile and was more 
efficient at inhibiting the production of toxins and spores in C. difficile strains when 
compared to vancomycin and metronidazole (Citron et al., 2009; Ochsner et al., 
2009). The most recent antibiotic tested against C. difficile is fidaxomicin (OPT-80), 
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which appears to have a higher clinical cure than vancomycin (Poxton, 2010). Fewer 
relapses have also been noted with fidaxomicin, probably due to its minimal effects 
on the normal gut microbiota (Tannock et al., 2010). 
1.2.5.3. Surgery
Prompt surgical intervention for patients with fulminant colitis who do not respond 
to aggressive antimicrobial therapy  can increase the chances of survival (Kelly  & 
LaMont, 1998; Sailhamer et al., 2009). The main aim of surgery is to prevent 
complications like bowel perforation and faecal peritonitis and thus, avoid the high 
morbidity and mortality associated with these conditions (Klingler et al., 2000). 
Despite this, the mortality associated with surgery  is high due to the ill health of 
patients requiring it (Kelly & LaMont, 1998).
1.2.5.4. Toxin neutralisation
The alternate therapies for CDI are aimed at removal of the toxins from the gut to 
prevent tissue damage, restoration of the normal microbiota and improvement of 
immunity. 
C. difficile toxin A and toxin B can bind to anion-exchange resins cholestyramine and 
cholesterol, but these toxin-binding compounds were found to be clinically 
ineffective (Thompson, 2008) especially since cholestyramine binds to vancomycin 
(McFarland et al., 2000). Tolevamer, an anionic polymer that binds both toxins, was 
found to be as effective as vancomycin in the treatment of mild to moderate CDI in 
initial trials (Louie et al., 2006). However, it was later found to be inferior to 
conventional antimicrobial therapy (Gerding & Johnson, 2010) possibly because it 
was unable to neutralise the highly cytotoxic toxin B (Baines et al., 2009). 
The neutralisation of toxicity using bovine immunoglobulin has been demonstrated 
in hamsters (Lyerly et al., 1991). This effect was also observed in humans (Warny  et 
al., 1999) but no large-scale trials have been conducted so far. The whey protein in 
immunised cow’s milk has also shown potential for use in treatment, but the results 
remain inconclusive so far (Gerding & Johnson, 2010; Young et al., 2007).
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1.2.5.5. Probiotic therapy
Since the perturbation of normal intestinal microbiota leads to C. difficile infection, 
its restoration is important, especially  following antibiotic therapy. Investigations 
into the use of probiotics containing yeasts like Saccharomyces boulardii, or bacteria 
such as Lactobacillus species in C. difficile treatment have been inconclusive; 
although there may be some benefit in secondary prevention, there is also a risk of 
fungaemia and bacteraemia, especially in immunocompromised and chronically ill 
individuals (Miller, 2009; Tung et al., 2009; Verna & Lucak, 2010). The less 
appealing form of probiotic therapy involves faecal transplants. This method has 
been mainly used for patients with recurrent CDI and has been found to be highly 
effective and safe (MacConnachie et al., 2009; van Nood et al., 2009). Another 
approach for biotherapy  is to induce colonisation by  a non-toxigenic C. difficile 
strain. Administration of a non-toxigenic strain after antimicrobial treatment has been 
successful in hamsters (Borriello & Barclay, 1985; Merrigan et al., 2009), but 
treatment in humans could be complicated by ongoing antibiotic treatment and the 
susceptibility of the non-toxigenic strains to it. In phase I clinical trials using a non-
toxigenic strain, the organism was found to be well-tolerated after vancomycin 
therapy and was isolated from faecal samples of all the subjects, confirming 
colonisation (Tatarowicz et al., 2010). Further trials will determine the use of this 
approach in CDI treatment. 
1.2.5.6. Antibody therapy and vaccines
Active and passive immunisation against C. difficile toxins would be most suitable to 
protect against CDI. Preliminary studies with a parenteral vaccine containing toxoid 
A and toxoid B have been shown to resolve recurrent diarrhoea with a simultaneous 
increase in serum IgG levels against  both the toxins (Sougioultzis et al., 2005). 
Transcutaneous injection of toxoid A in conjunction with cholera toxin in mice 
induced systemic and mucosal responses, suggesting an alternate strategy for 
immunisation (Ghose et al., 2007). More recently, oral immunisation of hamsters 
with spores of Bacillus subtilis expressing the cell-binding domains of toxin A and 
toxin B was found to confer protection from infection (Permpoonpattana et al., 
15
2011). Also, an immune response to toxin A alone was found to be effective against 
CDI. Passive immunity with individual monoclonal antibodies against  toxin A and 
toxin B when added to antibiotic treatment was able to significantly reduce the risk 
of recurrence (Lowy et al., 2010). Administration of monoclonal antibody  to toxin A 
alone did not reduce the rate of recurrence (Leav et al., 2010). Whether monoclonal 
antibodies will support  therapy or be prophylactic is yet to be determined (Kyne, 
2010). Results from one study  suggested that the oral administration of a monoclonal 
antibody to toxin A conjugated to an inert support would be more effective at the 
neutralisation of toxin A than free antibody (Sutton et al., 2008). The only current in-
use antibody therapy for CDI is intravenous immunoglobulin, which appears to be 
beneficial in severe disease and recurrences, but current data is insufficient to support 
its widespread use (O'Horo & Safdar, 2009).
1.2.5.7. Carriage and recurrence
The outcome of colonisation by C. difficile is dependent on a combination of the 
above-mentioned risk factors, that is, it can result in symptomatic disease or 
asymptomatic carriage. Patients who have acquired C. difficile during hospitalisation 
can become asymptomatic carriers (McFarland et al., 1989). Alternately, following 
symptomatic disease and treatment, recurrence of infection can be observed. 
Recurrence can occur in 20 to 30% of patients and could either be a relapse caused 
by the same strain or a re-infection with a new strain (Starr, 2005; Wilcox & Spencer, 
1992). The treatment of recurrences involves either supportive management without 
antibiotics or treatment with the antibiotic used for the initial episode (Maroo & 
Lamont, 2006). Recurrence itself is a risk factor; a single recurrence increases the 
risk for subsequent recurrences (Maroo & Lamont, 2006).
1.2.6. Prevention and control
Two main aspects of the prevention and control of C. difficile infection are the 
elimination of the source of infection by effective decontamination of the 
environment and the restriction on the use of antibiotics that are not only an 
important risk factor for disease, but also aid the selection of resistance in 
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microorganisms (Blondeau, 2009; O'Connor et al., 2009). The role of appropriate 
and thorough environmental disinfection in restricting the spread of C. difficile and 
even curbing outbreaks is discussed in detail in Chapter 4 (4.1.6-4.1.8) including the 
agents and strategies most suitable for this purpose. Good antibiotic stewardship  can 
also decrease the incidence of symptomatic disease and contribute to control of CDI 
(Brown et al., 1990; Dellit  et al., 2007; Vonberg et al., 2008). The complete 
restriction of high-risk antibiotics like fluoroquinolones has been shown to be 
effective in controlling an outbreak by  an epidemic strain (Kallen et al., 2009). 
However, not just targeting high-risk antibiotics, but optimisation of the use of 
antibiotics is essential to the prevention and control of CDI (Valiquette et al., 2007).
1.3. Typing schemes
1.3.1. Early methods
The early typing schemes for C. difficile were based on the phenotype of the 
organisms. Crossed immunoelectrophoresis, analysis of protein patterns by SDS-
PAGE and plasmid profiles proved to be useful in identifying dominant strains in 
outbreaks and differentiating them from sporadic isolates (McKay et al., 1989; 
Poxton et al., 1984; Tabaqchali et al., 1984; Wüst  et al., 1982). Bacteriophage and 
bacteriocin typing was also able to differentiate C. difficile strains from one another 
and from other clostridia (Sell et al., 1983). In 1985, Delmée and colleagues 
developed serogrouping (Delmée et al., 1985). They initially identified six 
serogroups, two of which consisted of non-toxigenic strains and two of which were 
found to be outbreak-specific. A comparison of serogrouping with SDS-PAGE 
protein profiles showed that both methods could be used for typing C. difficile strains 
(Delmée et al., 1986). Further, dominant serogroups and sub-types in serogroups 
with varying protein profiles were identified; serogroup A consisted of isolates 
having 12 different profiles. Serogrouping is often used as a standard for comparison 
with other schemes (Brazier, 2001). Surface-layer typing was another phenotypic 
method used to type C. difficile, which exploited inter-strain variability in the sizes of 
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the low and high molecular weight SLPs (McCoubrey & Poxton, 2001; McCoubrey 
et al., 2003). 
1.3.2. REA
The use of restriction endonuclease analysis (REA) in C. difficile typing was first 
demonstrated by Kuijper and colleagues (Kuijper et al., 1987). They used HindIII to 
restrict whole cell-DNA and observed distinguishing restriction patterns for different 
strains on agarose gels. The method correlated well with the protein profiles of the 
strains. Analysis of a large number of isolates by  this method identified a total of 206 
REA types that  grouped into 75 groups (Clabots et al., 1993). This is a rapid and 
highly  discriminatory method for typing C. difficile but inter-laboratory  comparisons 
are difficult and is not amenable to image analysis. REA analysis using CfoI has also 
been used for typing C. difficile strains (Devlin et al., 1987). 
1.3.3. Ribotyping
Ribotyping is a method based on the variability in length of the 16S-23S intergenic 
spacer regions in different alleles and was first suggested as a typing method for C. 
difficile by Gürtler (Gürtler, 1993). By  amplifying these regions of DNA and running 
them on long denaturing polyacrylamide gels, he identified different banding patterns 
for different strains and was able to group  24 strains into 14 ribotypes. Ribotyping 
was found to be a simple reproducible method to study a large number of isolates 
(Cartwright  et al., 1995). In 1996, O’Neill and colleagues modified Gürtler’s method 
making it faster and easier (O'Neill et al., 1996). They extracted DNA by boiling 
with a resin, re-designed the primers to give bands between 260 and 585 bp and used 
high resolution agarose for greater discrimination. By 1996, 116 ribotypes were 
defined (Stubbs et al., 1999). A modification of the primers used for ribotyping by 
Bidet and colleagues was observed to further improve the readability  and stability of 
the bands obtained (Bidet  et al., 1999; Bidet et al., 2000). Ribotyping is the method 
of choice for C. difficile typing in the UK and Europe (Brazier, 2001). More recently, 
capillary gel electrophoresis-based PCR ribotyping has been developed, which 
overcomes the problem of inter-laboratory variations (Indra et al., 2008).
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1.3.4. Toxinotyping
Toxinotyping is a method based on the inter-strain variability in the toxin genes, tcdA 
and tcdB (Rupnik et al., 1997). These variations are concentrated in the 3’ third of 
tcdA (A3 fragment) and the 5’ third of tcdB (B1 fragment). The restriction of these 
DNA regions with enzymes like EcoRI, AccI and HincII formed the basis for 
toxinotyping (Rupnik et al., 1998). The method correlated well with PFGE, 
serogrouping and ribotyping, although several ribotypes may group within a single 
toxinotype (Rupnik et al., 2001). Twenty-five toxinotypes have been identified so far. 
1.3.5. PFGE
Pulsed-field gel electrophoresis (PFGE) involves the analysis of the whole genome 
of an organism after restriction using infrequent cutting enzymes like SmaI and SacII 
(Brazier, 2001). PFGE typing of C. difficile correlates well with serogrouping (Kato 
et al., 1994) and can be even more discriminatory  than ribotyping (Bidet et al., 
1999). It is often considered to be the gold standard for typing pathogenic bacteria. 
Using a modification to the method seven sub-types in PCR ribotype 001 isolates 
were identified (Gal et al., 2005). PFGE is commonly  used in North America and the 
strains are assigned North American pulsed-field (NAP) types (Tenover et al., 2011).
1.3.6. AP-PCR
Arbitrarily-primed polymerase chain reaction (AP-PCR) involves the amplification 
of non-specific fragments of DNA using short primers under low-stringency 
conditions (Killgore & Kato, 1994; Wilks & Tabaqchali, 1994; Wullt  et al., 2003a). It 
is more discriminatory than immunoblotting, but not as reproducible as ribotyping.
1.3.7. MLST and MLVA
Multilocus sequence typing (MLST) was used to determine epidemiological links 
between C. difficile isolates (Lemée et al., 2004). By sequencing the toxin genes and 
their positive regulator, the binary toxin genes and other genes involved in virulence, 
several C. difficile clones were identified (Lemée et al., 2005). Multilocus variable-
number tandem-repeat analysis (MLVA) has also been shown to be useful for C. 
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difficile typing (Marsh et al., 2006). By comparing seven variable regions on the C. 
difficile genome, groups of strains were found, which corresponded well to REA 
groups. MLST and MLVA used in conjunction were very useful to identify genetic 
lineages and the genetic relationships between them (Marsh et al., 2010).
1.3.8. slpAST
The inter-strain differences in the variable region of the slpA gene of C. difficile were 
found to be sufficiently discriminatory  to be used as a typing scheme (Karjalainen et 
al., 2002). Surface-layer protein A gene sequence typing (slpAST) involves PCR 
amplification of the variable region of slpA, followed by sequencing or RFLP. It 
correlated well with serogrouping: the slpA variable region was 100% identical in 
strains within a serogroup, while inter-serogroup identity  was low. It is a useful 
genotyping tool (Joost et al., 2009; Kato et al., 2010; Ní Eidhin et al., 2006).
1.4. Virulence factors
1.4.1. Toxin A and toxin B
Toxin A (TcdA) and toxin B (TcdB) of C. difficile are its most important  virulence 
factors. They belong to the family of ‘large clostridial cytotoxins’ (Schirmer & 
Aktories, 2004) which also includes the haemorrhagic and lethal toxins of C. 
sordellii and the !-toxin of C. novyi. The C. difficile exotoxins TcdA and TcdB have 
molecular weights of 308 kDa and 269 kDa, respectively (Barroso et al., 1990; Dove 
et al., 1990; Sauerborn & von Eichel-Streiber, 1990). Traditionally, TcdA is termed 
an enterotoxin, while TcdB is termed a cytotoxin (Taylor et al., 1981). TcdA does, 
however, possess cytotoxic activity, but it is a 100 to 1000-fold less than that of 
TcdB; TcdB was believed to have no enterotoxic activity (Donta et al., 1982; 
Sullivan et al., 1982), but more recently it has been observed that TcdB can be as 
enterotoxic as TcdA (Savidge et al., 2003). Both toxins exhibit high structural and 
functional similarity  (Just et al., 1995b; Lyerly et al., 1986; Taylor et al., 1981). They 
are encoded and regulated by genes of the pathogenicity  locus (PaLoc) of C. difficile, 
which are described in Chapter 3 (3.13). 
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1.4.1.1. Structure
Investigations into the structures of C. difficile TcdA and TcdB revealed functional 
dualism with a C-terminal binding domain and an N-terminal catalytic domain (von 
Eichel-Streiber et al., 1992). A middle hydrophobic region was then identified 
(Barroso et al., 1994). This tripartite toxin structure has now been replaced with a 
four-domain ABCD structural model: the glucosyltransferase domain, the cysteine 
protease domain, the translocation domain and the receptor-binding domain (Fig. 
1.2) (Albesa-Jové et al., 2010). 
The N-terminal of the toxins is responsible for their catalytic activity. In this region 
the amino acid residues from 516 to 546 are structurally and functionally important 
for toxicity (Hofmann et al., 1997; Soehn et al., 1998). The four conserved cysteine 
residues in the hydrophobic region play a role in endocytosis (Barroso et al., 1994). 
The C-terminal of the toxins contains short  combined repetitive oligopeptides 
(CROPs) (von Eichel-Streiber et al., 1992) and mediates cell-binding (Sauerborn et 
al., 1997). The translocation domain has a minimal pore forming region from 
residues 830 to 990 and the residues from 1501 until the CROPs are essential for 
translocation (Genisyuerek et al., 2011). TcdA and TcdB both lack signal peptides for 
extracellular secretion (von Eichel-Streiber & Sauerborn, 1990).
1.4.1.2. Cell-binding 
TcdA and TcdB must be internalised via receptor-mediated endocytosis (Barth et al., 
2001) and then processed to reach the cytosol where they  can elicit cytotoxic effects 
(Voth & Ballard, 2005).
Toxin-receptor interaction is the first step in the process of entry  of toxins into cells. 
Carbohydrate receptors for TcdA, with a Gal"1-4GlcNAc core, were identified in the 
brush border membranes of hamsters (Krivan et al., 1986) and on human intestinal 
epithelial cells (Tucker & Wilkins, 1991). A receptor for TcdB has not yet been 
identified (Voth & Ballard, 2005). It has been shown that TcdB exhibits biological 
activity on intestinal epithelial cells only when applied basolaterally, suggesting that 
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unlike TcdA receptors, its receptors are present only on the basolateral surface of 
epithelial cells (Sutton et al., 2008). This supports the hypothesis that epithelial 
damage by toxin A or physical damage to the epithelium is required prior to TcdB-
mediated cytotoxicity (Lyerly et al., 1985).
Fig. 1.2. ABCD domain structure of clostridial glucosylating toxins 
The ABCD model of clostridial glucosylating toxins is shown with C. difficile TcdB  as an 
example. The glucosyltransferase domain (A, residues 1-543) is located at the N-terminus. 
The binding domain (B) at the C-terminus is comprised of repetitive sequences (CROPs). 
The cysteine protease domain (C, residues 544-767), characterised by the DHC domain, is 
involved in the processing and cleavage of the toxin. The DXG domain in the translocation 
domain (D) is part of the aspartate protease domain originally suggested to be involved in 
cleavage of the toxin. The hydrophobic region in the translocation domain (residues 
956-1128) is involved in pore formation. This overlaps with the newly identified minimal-pore 
forming region (residues 830-990) in which the glutamate residues at positions 970 and 976 
are crucial for pH-dependent toxin uptake. The residues 830-1500 are essential for 
translocation of the catalytic domain into the cytosol, while the residues 1501-1851 have 
been suggested to form an additional domain, possibly involved in binding. Adapted from 
Schirmer & Aktories, 2004 and Jank & Aktories, 2008.
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1.4.1.3. Membrane translocation
Membrane translocation of the toxins requires an acidified endosome. At acidic pH, 
the toxins undergo structural changes that  lead to the exposure of hydrophobic 
domains and the subsequent insertion of the toxin into the endosomal membrane 
(Qa'Dan et al., 2000); even a brief acidic pulse was found to be sufficient for 
insertion and increased permeability of cells to toxin (Barth et al., 2001). The C-
terminal of the toxin remains in the endosome, while the N-terminal reaches the 
cytosol (Pfeifer et al., 2003). This receptor-mediated endocytosis is a dynamin-
dependent process governed by clathrin (Fig. 1.3) (Papatheodorou et al., 2010). 
The N-terminal of TcdB was found to be capable of modifying Rho proteins, but was 
unable to intoxicate cells, suggesting pH-dependent proteolytic cleavage of the 
holotoxin during translocation into the cytosol (Pfeifer et al., 2003). TcdB undergoes 
proteolytic cleavage between the Leu543 and Gly544 residues in VPI 10463 
resulting in two fragments; one of 207 kDa fragment and the other of 63 kDa 
(Rupnik et al., 2005). The 63 kDa fragment is the cytotoxic N-terminal of the 
holotoxin and is linked to the 207 kDa fragment by  a peptide bond until 
translocation. The cleavage is dependent  on the presence of the cytosolic factor, 
inositol hexakiphosphate (InsP6), which causes a conformational change in the toxin 
(Reineke et al., 2007). This InsP6-dependent processing requires cysteine residues 
and therefore, occurs via a cysteine protease and not via an aspartate protease as 
suggested by Reineke and co-workers (Egerer et al., 2007). The cysteine protease is 
composed of residues 544 to 955. The Lys600 residue is essential for InsP6 to bind to 
the cysteine protease domain (Egerer et al., 2009).
1.4.1.4. Effect on cells
Both TcdA and TcdB are capable of inducing rounding of epithelial cells and their 
detachment and removal from the basal lamina (Just  et al., 1994; Ketley  et al., 1987; 
Mahida et al., 1996). This leads to acute mucosal inflammation, oedema, infiltration 
of polymorphonucleocytes and increased mucosal permeability (Ketley  et al., 1987; 
Savidge et al., 2003). The toxins also induce apoptosis in cells such as epithelial 
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cells, T-cells and eosinophils (Fiorentini et al., 1998; Mahida et al., 1996; Mahida et 
al., 1998). TcdB has been found to induce apoptosis in proliferating cells and 
necrosis in non-proliferating cells (Lica et al., 2011). The characteristic cell rounding 
observed in TcdB-treated epithelial cells was found to be a result of the increased G- 
to F-actin ratio, suggesting an indirect catalytic effect on actin filaments owing to 
inactivation of Rho proteins (Huelsenbeck et al., 2007; Just  et al., 1994; Pothoulakis 
et al., 1986). 
Fig. 1.3. Entry of C. difficile toxins into cells via clathrin-and dynamin-mediated endocytosis 
The schematic model of the uptake and delivery of toxin B  is represented. Receptor-
mediated endocytosis is dependent on the presence of dynamin and controlled by clathrin. 
The acidic pH of the endosome triggers a conformational change in the toxin and results in 
pore formation in the endosomal membrane. Cytosolic InsP6 then interacts with the toxin, 
which causes autocatalytic cleavage and the release of the catalytic glucosyltransferase 
domain into the cytosol, where it is able to act on the target cytosolic GTPases. This 
subsequently leads to the disruption of the actin cytoskeleton and cell death. Adapted from 
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1.4.1.5. Effect of glucosylation on GTPases
GTPases belong to a superfamily of low molecular weight proteins which act as 
molecular switches in key signalling pathways; they  are involved in processes such 
as immune cell migration, epithelial barrier function, adhesion, progression of the 
cell-cycle, cytokine secretion, super-oxide production, phagocytosis and endocytosis 
(Aktories et al., 2000). Rho GTPases occur in the cytosol in their inactive GDP-
bound form and are associated with guanine nucleotide dissociation inhibitors (GDI); 
in their active form, they  are membrane associated (Fig. 1.4) (Jank & Aktories, 2008; 
Schirmer & Aktories, 2004). Guanine nucleotide exchange factors (GEFs) activate 
GTPases and enables GTPases to interact  with effectors to control cell signalling, 
while GTPase-activating proteins (GAP) inactivate GTPases by hydrolysis of bound 
GTP. C. difficile toxin A and toxin B act by the functional inactivation of GTPases.
Preliminary  studies showed that  the toxins did not act on Rho via cGMP, cAMP or 
protein kinase C and therefore, acted directly  on Rho and not on Rho-activating 
proteins (Just  et al., 1994; Just et al., 1995a). Further investigations into the enzyme 
activity of the toxins revealed that the observed covalent modification of Rho was 
not a result of ADP-ribosylation or phosphorylation (Dillon et al., 1995), but an 
uptake of one glucose molecule per molecule of Rho proteins (Just et al., 1995b; Just 
et al., 1995c). The toxins were thus confirmed to be monoglucosyltransferases that 
used UDP-glucose as the co-substrate. They were found to glucosylate RhoA/B/C at 
Thr37 and Rac and Cdc42 at Thr35 and recent evidence suggests that the 
glucosylation of Rac1 and not Rho that causes the observed cytopathic effects in 
intoxicated cells (Halabi-Cabezon et al., 2008). 
1.4.1.6. Immune response generated
The glucosylation of Rho proteins and subsequent actin depolymerisation in 
epithelial cells in vivo leads to cell-rounding and detachment from the basal 
membrane (Mahida et al., 1996). The resulting lack of tight junctions causes 
increased colonic permeability, fluid accumulation and possible perforation, which 
may lead to watery diarrhoea (Lyerly  et al., 1982; Nusrat  et al., 2001). The following 
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acute inflammatory response involves the extravasation of large numbers of 
neutrophils, mast cells and macrophages and the release of pro-inflammatory 
cytokines like IL-1", TNF-! and IL-8 (Kelly & Kyne, 2011; Savidge et al., 2003). 
TcdA also induces enteric neurons to secrete substance P (Castagliuolo et al., 1997) 
which activates mast cells, increasing mucosal secretion and inflammation (Wershil 
& Castagliuolo, 1998). Sloughed epithelial and immune cells and fibrin together 
constitute the resulting pseudomembrane (Knoop et al., 1993; Linevsky et al., 1997).
Fig. 1.4. Effect of C. difficile toxins on the GTPase cycle of Rho proteins 
Rho, in its inactive form, is bound to GDP and associated with a guanine dissociation 
inhibitor (GDI). Activation of Rho proteins is catalysed by a guanine nucleotide exchange 
factor (GEF). Rho is active in its GTP-bound form and interacts with various effectors. 
Hydrolysis by a GTPase-activating protein (GAP) renders it inactive. Glucosylation by C. 
difficile toxin A and toxin B  blocks the coupling of the Rho GTPases with effectors (1), which 
renders them functionally inactive. It also inhibits nucleotide exchange induced by GEFs (2), 
blocks the Rho/GDI interaction (3) and inhibits GTP hydrolysis stimulated by GAPs (4). 













































Some C. difficile strains also produce a binary  toxin (CDT). Clostridial binary toxins 
are comprised of two molecules that are not linked through covalent or non-covalent 
bonds but both molecules are required for activity (Rupnik et al., 2003a). This family 
of toxins includes C. perfringens type E iota toxin, C. spiroforme toxin and the C2 
toxin from C. botulinum C and D. 
CDT is coded on the CDTLoc, which consists of three genes: cdtA, which codes 
forthe enzymatic component, cdtB, which codes for the binding component, and the 
regulator, cdtR (Carter et al., 2007; Perelle et al., 1997). cdtA and cdtB show 81% 
and 84% identity  with iap and ibp genes of the C. perfringens type E iota toxin, 
suggesting a common ancestor for these genes (Perelle et al., 1997). cdtA is 1383 bp 
long and cdtB is 2631 bp long and are transcribed as a single mRNA (Rupnik et al., 
2003a). cdtR belongs to the lytTR response regulator family (Carter et al., 2007). In 
strains that do not produce the binary  toxin, the CDTLoc is replaced by a 68 bp 
sequence and it is shortened in strains that contain pseudogenes for cdtA and cdtB 
(Fig. 1.5) (Carter et al., 2007). The toxin consists of two subunits which are both 
produced and secreted and the toxin is activated by  trypsinisation; CDTa is the 
enzymatic subunit  and CDTb is the binding subunit which is responsible for the 
translocation of CDTa into the cytoplasm (Barth et al., 2004; Perelle et al., 1997). 
CDT is an actin-specific ADP-ribosyltranferase that was first identified in 1988 
(Popoff et al., 1988). Originally, it was not  found to be cytotoxic to tissue epithelial 
cells or lethal to animals on intraperitonial injection (Popoff et al., 1988); however, 
cytotoxicity induced by it appears to be similar to that of toxin A and toxin B 
(Rupnik et al., 2003a). The toxin acts by covalently modifying actin at  the Arg177 
residue (Popoff et al., 1988; Schwan et al., 2009). It inhibits F-actin formation and 
causes microfilament depolymerisation and tubule-formation (Schwan et al., 2009). 
The induced cellular microtubule-based protrusions were found to increase the 
adherence of C. difficile cells to epithelial cells. 
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The role of CDT in the pathogenesis of CDI is still unknown, but  its ability to 
contribute to disease has been demonstrated. The toxin was shown to induce fluid 
accumulation in the ligated loop model (Geric et al., 2006). However, in the same 
study, infection of hamsters with a C. difficile strain which was A-B-CDT+ resulted 
in colonisation but no infection, suggesting that the binary toxin alone is not able to 
cause disease but can serve as an additional virulence factor for C. difficile. The 
presence of the binary toxin in C. difficile ribotype 027 has been suggested as a 
factor for its hypervirulence. This has been further discussed in Chapter 6 (6.1.4.2.2).
Fig. 1.5. CDTLoc of C. difficile 
Schematic representation of the CDTLoc comprising cdtA, cdtB and cdtR, shows the 
complete 6.2 kb  locus, the 4.2 kb  locus in strains like C. difficile 630 that contain 
pseudogenes instead of cdtA and cdtB and the 68 bp  sequence that replaces the CDTLoc in 
binary toxin-negative strains. The boundaries of the CDTLoc are conserved in all C. difficile 
strains. Adapted from Carter et al., 2007.
1.4.3. Spores
C. difficile produces metabolically-dormant spores which represent the infectious 
stage of the bacterium (Wilson et al., 1982). Spores play a role in the transmission, 
persistence and pathogenesis of C. difficile. It has been demonstrated that C. difficile 
spores can resist disinfection and persist in the environment for long periods of time. 
Mice can acquire these spores from the contaminated environment, asymptomatic 
carriage or infection can subsequently  be induced and the antibiotic treatment could 
cause (super)shedding of spores through faeces of the infected animals excreted over 
extended periods of time, causing increased dissemination of spores and transmission 
6.2 kb 
      cdtR                cdtA           cdtB 
68 bp 
4.2 kb 
      cdtR      cdtAB pseudogenes 
CD2601      CD2602                    trpS 
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to susceptible individuals (Lawley  et al., 2009a; Lawley  et al., 2010). The sources of 
C. difficile spores and their survival, persistence and transmission are discussed in 
detail in Chapter 4 (4.1.1-4.1.5, 4.1.7).
Once ingested, C. difficile spores attach to the gastrointestinal tract via proteinaceous 
exosporial filaments (Panessa-Warren et al., 1997). Although spores are highly 
infective, only  vegetative cells of C. difficile produce the toxins that  lead to infection 
(Sorg & Sonenshein, 2010). Thus, germination and outgrowth of spores is essential. 
Germination only occurs in nutrient-rich environments and is mediated via receptors 
on the spore surface (Foster & Johnstone, 1990; Setlow, 2003). These receptors are 
specific and use environmental conditions such as bile salt concentrations, pH and 
the presence of amino acids as cues for effective germination (Giel et al., 2010; 
Howerton et al., 2011). C. difficile spores have been shown to germinate in response 
to bile salts and taurocholate-mediated germination in the small intestine is most 
likely to occur in human infection (Howerton et al., 2011; Lawley et al., 2009b). 
Sodium taurocholate was found to act as a germinant only in the presence of glycine 
(Sorg & Sonenshein, 2008), while chenodeoxycholate and deoxycholate could 
facilitate germination, but were incapable of sustaining the growth of vegetative cells 
(Sorg & Sonenshein, 2008; Wheeldon et al., 2008a). Contrary to these observations, 
it was found that glycine and taurocholate had no effect  on germination but the 
presence of K+, Pi and a pH of 6 enhanced the process (Paredes-Sabja et al., 2008). 
Thus, C. difficile spores could also germinate in the duodenum at pH 6 or in the 
colon where the concentration of K+ is high. Spore germination was reduced by 
acidic conditions and lower temperature, but not affected by aerobic conditions 
(Wheeldon et al., 2008a). 
The role of spores in pathogenesis is directly linked to the disruption of normal gut 
microbiota by antibiotics. Intestinal microbiota is able to modify primary  bile salts 
like cholate and chenodeoxycholate to secondary bile salts like deoxycholate and 
lithocholate (Sorg & Sonenshein, 2008; Wilson, 1983). In the presence of 
chenodeoxycholate, spores show a reduced affinity for taurocholate and thus, there is 
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inhibition of sporulation (Sorg & Sonenshein, 2010). Further, the outgrowth of 
spores that  do germinate is inhibited by  deoxycholate (Giel et al., 2010; Sorg & 
Sonenshein, 2010). Thus, in the presence of normal gut microbiota C. difficile spores 
are unable to successfully undergo germination and outgrowth. However, when the 
microbiota is perturbed there is a change in the ratio of primary to secondary bile 
salts due to the reduced numbers of bile salt-modifying bacteria, which makes 
conditions favourable for the germination and outgrowth of spores into toxin-
producing vegetative cells (Giel et al., 2010). This has been demonstrated in mice; 
mice treated with antibiotics have less diverse microbiota with fewer Bacteroides and 
Firmicutes (Giel et al., 2010; Lawley et al., 2009a) and their caecal contents 
stimulate significantly greater spore germination and outgrowth. Further, normal 
microbiota in mice was able to modify taurocholate and reduce its ability to induce 
germination. Although a precise germination factor has not yet been identified it is 
most likely a small, heat-stable, water-soluble bile salt present at high levels in vivo 
in response to antibiotics (Giel et al., 2010).
Sporulation initiation in C. difficile is controlled by  a two-component signal 
transduction system (TCS) in which environmental and cellular signals are sensed by 
sporulation-associated histidine kinases that phosphorylate Spo0A (Underwood et 
al., 2009). The Spo0A response regulator is the master-regulator of sporulation in 
Clostridium and Bacillus species (Molle et al., 2003). Spo0A and the gene encoding 
it, spo0A, are discussed later in Chapter 3 (3.1.5).
1.4.4. Surface-associated proteins 
In order to establish an infection, pathogenic bacteria must normally be able to bind 
to host cells, colonise tissues, invade them and then persist or disseminate to other 
tissues while continually interacting with and modulating the immune system 
(Pizarro-Cerdá & Cossart, 2006). In C. difficile, a number of cell-surface associated 
virulence factors have been identified that act as adhesins and are also 
immunodominant (Péchiné et al., 2005b). These virulence factors include the S-layer 
proteins, cell wall proteins (CWPs), flagella and heat-shock proteins (HSPs). 
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The S-layer of C. difficile is composed of two protein subunits that form a regularly 
arranged lattice and are essential for the structure of the cell wall (Cerquetti et al., 
2000; Sára & Sleytr, 2000). They are derived from a common precursor protein 
encoded by the slpA gene (Karjalainen et al., 2001). The SLPs are involved in 
adherence to mucus and epithelial cells (Calabi et al., 2002). They  were also found to 
be the most commonly recognised antigens in CDI patients (Wright  et al., 2008). The 
flagella of C. difficile may also be involved in adherence; the flagellar filament, FliC, 
and the flagellar cap, FliD, are both able to mediate binding to mucus (Tasteyre et al., 
2001a). Antibody responses to both these antigens have been observed in patients 
(Péchiné et al., 2005a). FliD appears to have a more important role in the initial 
attachment to mucus and this exposure to the immune system probably results in the 
detected higher antibody response to it as compared to FliC. The cell wall proteins 
Cwp66 and GroEL are both heat-shock proteins that  are involved in adherence 
(Hennequin et al., 2001b; Waligora et al., 2001), and Cwp66 was found to be highly 
immunogenic in patients (Péchiné et al., 2005a). These proteins are described in 
detail in Chapter 5 (5.1.1). 
The surface-associated proteins Fbp68, Cwp84 and CwpV are also important 
virulence factors. Fbp68 is a fibronectin-binding protein present mainly in the 
cytoplasmic membrane of C. difficile cells (Hennequin et al., 2003). It is able to bind 
to immobilised and soluble fibronectin and also fibrin, which can directly help  in 
attachment to the surfaces of a variety of host cells and also indirectly aid binding 
through interactions of fibronectin with other structural proteins like collagen and 
fibrin. Fbp68 has also been found to elicit a high antibody response in patients 
(Péchiné et al., 2005a). 
Cwp84 is a cysteine protease containing the conserved Pept_C1 domain of the 
papain family (Savariau-Lacomme et al., 2003). It can specifically degrade 
extracellular matrix (ECM) proteins such as fibronectin, laminin and vitronectin 
(Janoir et al., 2007). This proteolytic degradation could allow C. difficile toxins to 
penetrate further into the basement membrane and also enhance the dissemination of 
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bacteria. Further, Cwp84 is involved in the maturation of the SLPs; it cleaves the 
SlpA precursor protein into its two subunits, but  is not  essential for this process 
(Kirby  et al., 2009). Due to its surface-association, Cwp84 is able to induce a very 
intense antibody response in patients (Péchiné et al., 2005b). 
CwpV is another surface-expressed putative adhesin in C. difficile (Emerson et al., 
2009). Just like the SLPs, it is also post-translationally modified into two subunits of 
40 and 120 kDa, but Cwp84 is not involved in this maturation (Kirby  et al., 2009). 
The expression of cwpV is phase-variable and controlled by a site-specific 
recombinase (Emerson et al., 2009). This variation may aid in evasion of the host 
immune system. Phase-variable expression of C. difficile flagella has also been 
suggested (Twine et al., 2009). Thus, even though individually these surface-
associated proteins are not responsible for specific functions, taken altogether, they 
participate in the attachment of the bacteria to the host, colonisation of the host and 
modulation of the immune response of the host. 
The SLPs, Cwp66, Cwp84 and other similar proteins are encoded on the same cluster 
of the genome suggesting linked functions in maintenance of the cell wall in C. 
difficile (Calabi et al., 2001; Calabi & Fairweather, 2002; Waligora et al., 2001). 
1.4.5. Others 
The production of other virulence factors such as hyaluronidase, collagenase, 
protease and other hydrolytic enzymes that might contribute to adhesion and 
dissemination in vivo have also been identified in some C. difficile strains (Borriello 
et al., 1990; Hafiz, 1974; Seddon et al., 1990). In some strains, the presence of a 
capsule-like material has also been detected which could be involved in adhesion as 
well as evasion of the immune system of the host  through its anti-phagocytic 
properties (Davies & Borriello, 1990). Rarely, the presence of fimbriae on the surface 
of C. difficile cells has also been identified, although their role in infection has been 
debated (Borriello et al., 1990). Their absence does not appear to affect colonisation 
or infection (Borriello et al., 1988; Taha et al., 2007). 
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1.5. Aims 
The main intention of this thesis was to identify inter-strain differences between 
historic and epidemic strains of C. difficile. Five strains of C. difficile were selected 
and used throughout this work. These were C. difficile strain 630, an historic isolate 
and the first strain to be sequenced, strain VPI 10463, a reference strain, ribotype 
027, a hypervirulent epidemic isolate, and ribotypes 001 and 106, which are locally 
endemic in Scotland. A total of four studies were performed and their aims were as 
follows: 
1. The first study was aimed at  understanding the expression of the toxins and spores 
of the five C. difficile strains in a growth-dependent manner. This involved 
studying the phenotypes of the strains by measuring toxin production using 
immunoassays and spore production by viable counts. The expression of toxins 
and spores at the genetic level was analysed by studying the transcription of the 
five genes of the pathogenicity  locus and spo0A using a real-time RT-PCR assay. 
The hypothesis for this study was that the hypervirulent epidemic strains exhibited 
greater transcription and release of both toxins and spores, which could result in 
the increased severity of disease often associated with them.
2. The second study was aimed at identifying the most  suitable disinfectant against 
C. difficile for use in the laboratory  from amongst five commonly-used agents, 
including one decontaminant. The susceptibility  of the C. difficile strains to the 
agents was studied by conventional laboratory  tests, followed by surface 
disinfection tests. The effects of organic matter on disinfection and on the 
exposure of spores to sub-inhibitory  concentrations of the agents on toxin 
production were also studied. Further, contamination of the laboratory 
environment was also investigated. The hypothesis for this study was that the 
hypervirulent epidemic strains were more resistant to disinfection procedures and 
thus were able to survive longer in the environment. Further, the incorrect  use of 
cleaning agents and the subsequent exposure of these strains to sub-inhibitory 
concentrations of the agents could affect their virulence.
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3. The third study was aimed at examining the biological activities of the five C. 
difficile strains. This involved studying virulence factors of the strains such as S-
layer proteins, heat-shock proteins and toxins for their ability to induce cytokine 
production by  macrophages, and investigating the importance of flagella and S-
layer proteins in adherence to epithelial cells. The hypothesis for this study  was 
that the antigens of the epidemic strains would elicit a greater immune response 
within the host and thus, mediate greater damage. Further, their antigens would 
exhibit high adhesion to epithelial cells and thus, aid colonisation. 
4. The fourth and final study was aimed at characterising a collection of ribotype 027 
strains isolated in Scotland and another from the Netherlands. This involved 
typing the strains by several molecular methods, studying their phenotype, 
investigating their susceptibility to antibiotics and identifying genetic mutations 
that characterise them. Comparisons with the five strains used in the previous 
studies were also made. The hypothesis of this study was that there was a clonal 
spread of ribotype 027 strains. 
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2. Materials and Methods
2.1. Bacterial strains
2.1.1. Reference strains
Throughout this work, two reference strains were used. These were C. difficile strain 
630, which belongs to ribotype 012 and also represents an historic isolate found in 
Scotland, and strain VPI 10463, a known high toxin producer commonly used as a 
reference strain in toxin production studies. 
2.1.2. Epidemic strains
The three C. difficile strains selected for comparison in growth-related, immune 
response and disinfectant studies were representative of the most commonly isolated 
PCR ribotypes in Scotland - ribotype 106, ribotype 001 and the hypervirulent 
ribotype 027. 
2.1.3. Hypervirulent strains
Seven isolates of PCR ribotype 027 from Scotland and five isolates from the 
Netherlands were compared using different phenotypic and genotypic methods to 
identify clonal expansion of this ribotype in a small study. The isolates and their 
sources are listed in Table 2.1.
2.1.4. Clinical isolates
Twenty-five clinical isolates of different ribotypes and antibiotic sensitivity patterns 
(Mutlu et al., 2007) were selected for disinfectant sensitivity assays. They  are listed 
in Table 2.2. 
2.2. Phenotypic characteristics 
2.2.1. Growth
C. difficile strains were cultured from freeze-dried stocks by re-suspending the cells 
in 200 µl anaerobe identification medium (AIM; 20 g/L proteose peptone, 5 g/L yeast 
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extract, 5 g/L trypticase, 5 g/L NaCl, 0.75 g/L cysteine-HCl, 0.4 g/L Na2CO3; pH 7.1) 
(Brown et al., 1996), followed by plating on blood agar (39 g/L Columbia blood agar 
base, 5% defibrinated horse blood) which were incubated anaerobically (80% N2, 
10% H2, 10% CO2) at 37°C in a Mark III workstation (Don Whitley  Scientific) for 
48 h. The strains were subcultured again on blood agar. The purity  of the strains was 
checked by Gram-staining and the purified strains were stored as spores in 
Robertson’s cooked medium (Watt, 1973) at room temperature.
Table 2.1. Isolates of PCR ribotype 027 and their sources
Isolates from Scotland Isolates from the Netherlands
MPRL Number Source MPRL Number Source
4863 Glasgow Western 4828 Haarlem Verpl
4864 Glasgow Western 4829 Amersfoort
4865 Glasgow Victoria 4830 Haarlem
4866 Glasgow Western 4831 Amsterdam
4867 Dundee Ninewells 4832 Harderwijk
4868 Glasgow Victoria
4883 Edinburgh Royal Infirmary
2.2.2. Starter cultures
To grow C. difficile, starter cultures were always prepared by inoculating 0.5 ml of 
the purified spore suspensions into 3 ml of pre-reduced AIM and incubating them 
anaerobically  for 16 h at 37°C till an OD600 of 1.0 (±0.05) was achieved. The 
appropriate volume of the starter culture was then inoculated into pre-reduced AIM 
to give a 1% culture, which was grown anaerobically at 37°C for 24 h. The purity of 
the cultures was checked by Gram-staining and also by aerobic and anaerobic 
subculture on blood agar.
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Table 2.2. Clinical isolates used in this study and their antibiotic sensitivity profiles
Strain no. Ribotype Antibiotic sensitivity profile a
erythromycin clindamycin ceftriaxone tetracycline moxifloxacin
1 a106 R R R S R
2 a106 R R R S R
4 a023 S S R S S
5 a014 R R S S S
6 a042 R S S S S
8 106 R R R S R
9 a002 S R R S S
10 a070 S S S S S
11 a005 S S S S S
12 a049 S S S R S
13 a014 R R R S R
14 a002 R R S S S
15 a005 R R S S S
16 a106 R R R S S
17 a171 ** ** ** ** ** 
18 a126 ** ** ** ** ** 
19 a013 ** ** ** ** ** 
20 a001 R R R S R
21 a020 R R R S S
22 a001 R R R S R
23 a001 R R R R R
24 a013 R R R R S
25 ** R R R S R




To study the growth curves of the strains, 3 ml of the starter culture was inoculated 
into 300 ml pre-reduced AIM. The growth of the strains was studied over 24 h by 
measuring OD600. At 0, 4, 8, 12, 16, 20 and 24 h, the culture was gently mixed and 1 
ml of the culture was transferred to a cuvette inside the anaerobic workstation, sealed 
and then removed to the CE 2021 spectrophotometer (Cecil Instruments) to measure 
OD600 compared to a medium blank. The growth curves were performed in triplicate. 
In some studies, viable counts were also performed. At every 4 h, 100 µl culture was 
removed and serially  diluted 10-fold in pre-reduced AIM. At every time-point, 100 µl 
of three selected dilutions were spread onto blood agar plates and incubated at 37°C 
for 24 h. The plates were counted and the number of cells/ml culture was determined. 
To study the growth more closely, a 0.1% culture was used and OD600 of the culture 
was measured every hour up to 8 h and then every 24 h from 24 h up to 10 d. 
2.2.4. Toxin production
Total toxin (A+B) production was studied using the C. difficile TOX A/B II™ kit 
(Techlab). Supernatants were collected by centrifuging 1 ml of culture at 16000 g for 
1 min. They were diluted 5-fold in buffered diluent. The wells provided with the kit 
were coated with affinity purified goat antibodies specific for toxin A and toxin B. 
Two wells were prepared for each sample by adding one drop (50 µl) of the 
conjugate containing two horseradish peroxidase coupled antibodies - a mouse 
monoclonal antibody specific for toxin A and a goat polyclonal antibody  specific for 
toxin B. Sample (100 µl) was added to each well. For the positive controls, one drop 
of the provided positive control was added per well and for the negative controls, one 
drop of diluent was added. The wells were sealed, incubated at 37°C for 50 min and 
washed 5 times with the provided wash solution composed of PBS and a detergent. 
Two drops (100 µl) of substrate (tetramethylbenzidine and peroxide) was then added 
to the wells and they were incubated at room temperature for 10 min with constant 
shaking. The reaction was stopped by adding one drop (50 µl) of the stop solution 
(0.3 M sulphuric acid) to each well. After incubating the plates for 2 min at room 
38
temperature, the intensity of the colour developed was determined by measuring 
absorbance at 450 nm with the subtraction of absorbance at 620 nm (A450/620). To 
measure the individual production of toxin A and toxin B, ELISAs were performed 
as described later (2.5.4). Culture supernatants were collected at the different time-
points, aliquoted and stored at -70°C until use; samples were only thawed once. 
2.2.5. Spore production
Spore production was assessed by viable counts. At selected time-points, 10 ml of 
the culture was collected by centrifugation at 4000 g for 10 min. The cell pellets 
were washed twice in distilled water and re-suspended in 50% ethanol. They were 
incubated at room temperature for 1 h with constant shaking. The cells were 
collected by centrifugation and washed twice with distilled water. The final cell 
pellet containing the alcohol-resistant spores was re-suspended in 1 ml distilled 
water. Ten-fold dilutions of this suspension were prepared in distilled water, spread 
plated on blood agar and incubated anaerobically for 48 h. The number of spores/ml 
culture was determined from the colony counts obtained.  
2.2.6. Motility assay
C. difficile was cultured anaerobically at 37°C on blood agar for 24 h. Three colonies 
were picked up from the plate and inoculated into the top 5 mm of a tube containing 
25 ml pre-reduced 0.05% brain heart infusion (BHI; Fluka) agar. The cultures were 
incubated anaerobically  overnight (approximately  16 h). Growth was observed and 
the distance travelled from the zone of inoculation was recorded in centimetres (cm). 
2.2.7. Autoagglutination assay
C. difficile was cultured anaerobically  at 37°C on blood agar for 24 h. Five colonies 
were suspended in pre-reduced PBS, pH 7.2, to OD600 of 1.00 (±0.05). The 
suspension was incubated anaerobically for 24 h at 37°C, after which the OD600 was 
measured again. The autoagglutination was calculated as follows:
% autoagglutination = [(starting OD600 - final OD600) / starting OD600] # 100
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2.2.8. S-layer typing
C. difficile was cultured anaerobically (50 ml) at  37°C in AIM overnight 
(approximately 16 h). Surface-layer proteins (SLPs) were extracted from the culture 
as described later (2.4.4). The high molecular weight  and low molecular weight SLP 
subunits were separated on an SDS-PAGE gel (2.4.7). The molecular weights of the 
subunits were determined using the protein marker on the gel and the Phoretix-1D 
software (TotalLab). S-layer types were assigned using these values. 
2.3. Genotypic studies
2.3.1.1. DNA extraction
Genomic DNA (gDNA) was extracted from 1 ml of an overnight culture of C. 
difficile collected by centrifugation at 16000 g for 2 min. When using the 
NucleoSpin® kit (Macherey-Nagel GmbH), cells were lysed in a proteinase K/SDS 
solution at 56°C for 3 h. DNA in the lysate was bound to a silica filter by  the addition 
of ethanol. After washing with two buffers to remove contaminants, DNA was eluted 
under low ionic strength using 100 µl of alkaline elution buffer. Alternately, cells 
were boiled in 100 µl of a 5% suspension of Chelex®100 (BioRad) prepared in 
DEPC water (Ambion) for 10 min to destroy the cell membranes and proteins and 
denature the gDNA. The suspension was centrifuged at 16000 g for 2 min to separate 
the resin and cell debris from the supernatant containing DNA. The concentration of 
DNA was determined using the ND-1000 spectrophotometer (Nano Drop 
Technologies), using the elution solution as the blank. The DNA was aliquoted and 
stored at -20°C. 
2.3.2. Ribotyping 
Amplification of the 16S-23S rRNA intergenic spacer region was performed as 




Reactions (50 $l) were set up  containing 1.5 mM MgCl2, 10 mM  Tris-HCl, 50 mM 
KCl, 2 U of Taq polymerase (Promega), 0.2 mM of each dNTP, 50 pmol of each 
primer and 10 $l gDNA. The thermal profile used for the PCR was as follows:
Initial denaturation 94°C 3 min
35 amplification cycles:
Denaturation  96°C 1 min
Annealing  56°C 1 min
Final extension 72°C 5 min
The PCR products were concentrated by heating at 75°C for 45 min. Electrophoresis 
was performed in a 3% Metaphor agarose gel (Cambrex Bio Science) containing 30 
$l of SafeView Nucleic Acid Stain (NBS Biologicals) at 80 V for 3 h along with a 
100 bp ladder (Promega). The gels were photographed under UV light  and the data 
were analysed using the Gel Compar software (Bionumerics). 
2.3.3. Toxinotyping 
Toxinotyping was performed as previously described (Rupnik et al., 1997). The first 
3 kb of tcdB (PCR fragment B1) and 3 kb of the repetitive region of tcdA (PCR 
fragment A3) were amplified by PCR. This was followed by  restriction fragment 
length polymorphism (RFLP) analysis of both the amplified products. The primers 
used to amplify the B1 fragment were:
5’-AGAAAATTTTATGAGTTTAGTTAATAGAAA-3’ 
5’-CAGATAATGTAGGAAGTAAGTCTATAG-3’
The primers used to amplify the A3 fragment were:
5’-TATTGATAGCACCTGATTTATATACAAG-3’ 
5’-TTATCAAACATATATTTTAGCCATATATC-3’
PCR reactions (50 $l) were set up  containing 1.5 mM  MgCl2, 10 mM Tris-HCl, 50 
mM KCl, 0.5 U of Taq polymerase, 0.2 mM of each dNTP, 50 pmol of each primer 
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and 5 $l gDNA. For amplification of A3, 5 mg of bovine serum albumin (BSA, 
Sigma-Aldrich), 0.05% W1 and TMA (tetramethylammonium chloride, Sigma-
Aldrich) at  a final concentration of 1 mM were also added to the reaction. The 
thermal profile used was:
Initial denaturation 93°C 3 min
35 amplification cycles:
Annealing/Extension 47°C 8 min
Denaturation  93°C  4 s
Final extension 47°C  10 min
PCR products were concentrated by heating at 75°C for 45 min and RFLP was 
performed at 37°C for 2 h. For the A3 fragment, 10 $l of the product was digested 
with 2 $l of EcoRI. For the B1 fragment, two digestions were performed with AccI 
and HindI in which 2 $l of the product was digested with 2 $l of enzyme. 
2.3.4. Binary toxin detection
The binary toxin genes, cdtA and cdtB, were detected as previously described 
(Stubbs et al., 2000). The primers used to amplify cdtA were:
5’-TGAACCTGGAAAAGGTGATG-3’ 
5’-AGGATTATTTACTGGACCATTTG-3’
The primers used to amplify cdtB were:
5’-TTAATGCAAGTAAATACTGAG-3’ 
5’-AACGGATCTCTTGCTTCAGTC-3’
PCR reactions (50 $l) were set up  containing 1.5 mM  MgCl2, 10 mM Tris-HCl, 50 
mM KCl, 1 U of Taq polymerase, 0.2 mM of each dNTP, 50 pmol of each primer and 
5 $l gDNA. The thermal profile used was:
Initial denaturation 94°C 5 min
35 amplification cycles:
42
Denaturation  94°C 30 s
Annealing  52°C 30 s
Extension   72°C 1 min
Final extension 72°C 5 min
2.3.5. Flagellum analysis
fliC and fliD were amplified as previously described. The primers used for fliC 
(Tasteyre et al., 2000b) were:
5’-ATGAGAGTTAATACAAATGTAAGTGC-3’ 
5’-CTATCCTAATAATTGTAAAACTCC-3’
The primers used to amplify fliD (Tasteyre et al., 2001b) were:
5’-ATGTCAAGTATAAGTCCAGTAAG-3’ 
5’-TTAATTACCTTGTGCTTGTG-3’
PCR reactions (50 $l) were set up with 1.5 mM MgCl2, 10 mM Tris-HCl, 50 mM 
KCl, 1 U of Taq polymerase, 0.2 mM  of each dNTP, 50 pmol of each primer and 5 $l 
gDNA. The thermal profile used was:
Initial denaturation 94°C 5 min
35 amplification cycles:
Denaturation  94°C 30 s
Annealing  55°C 30 s
Extension   72°C 1 min
Final extension 72°C 10 min
RFLP was performed at 37°C for 30 min. The reactions (20 µl) were set up with 2 $l 
of the product and 2 $l of the restriction enzyme. fliC products were digested with 
RsaI, HindIII and HpaI and fliD products were digested with AccI, DraI, EcoRI, 
HpaI, HincII, HindIII, RsaI and XbaI.
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2.3.6. PCR amplification of tcdC 
tcdC was amplified as described (Spigaglia & Mastrantonio, 2002) using the primers:
5’-TTAATTAATTTTCTCTACAGCTATCC-3’ 
5’-TCTAATAAAAGGGAGATTGTATTATG-3’
Reactions (50 $l) were set up with 1.5 mM MgCl2, 10 mM Tris-HCl, 50 mM KCl, 1 
U of Taq polymerase, 0.2 mM of each dNTP, 50 pmol of each primer and 5 $l 
gDNA. The thermal profile used was:
Initial denaturation 94°C 5 min
30 amplification cycles:
Denaturation  95°C 1 min
Annealing  52°C 30 s
Extension   72°C 1 min
Final extension 72°C 10 min
2.3.7. PCR amplification of tcdR
tcdR was amplified as described (Spigaglia & Mastrantonio, 2004) using the primers:
5’-CTCAGTAGATGATTTGCAAGAA-3’ 
5’-TTTTAAATGCTCTATTTTTAGCC-3’ 
Reactions (50 $l) were set up with 1.5 mM MgCl2, 10 mM Tris-HCl, 50 mM KCl, 1 
U of Taq polymerase, 0.2 mM of each dNTP, 50 pmol of each primer and 5 $l 
gDNA. The thermal profile used was:
Initial denaturation 94°C 5 min
30 amplification cycles:
Denaturation  94°C 1 min
Annealing  50°C 1 min
Extension   72°C 1 min
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Final extension 72°C 10 min
2.3.8. PCR amplification of tcdE
A region of the C. difficile genome containing tcdE was amplified as previously 
described (Tan et al., 2001) using the following primers:
5’-CGCGGATCCATGCACAGTAGTTCACCTT-3’ 
5’-CCCCCAAGCTTCCAACTGACCATGCACC-3’
Reactions (50 $l) were set up with 1.5 mM MgCl2, 10 mM Tris-HCl, 50 mM KCl, 1 
U of Taq polymerase, 0.2 mM of each dNTP, 50 pmol of each primer and 5 $l 
gDNA. The thermal profile used was:
Initial denaturation 94°C 2 min
Annealing  49°C 45 s
Extension   72°C 2 min
35 amplification cycles:
Denaturation  94°C 30 s
Annealing  52°C 30 s
Extension   72°C 50 s
Final extension 72°C 2 min
2.3.9. PCR amplification of gyrA and gyrB








PCR reactions (50 µl) were set up  containing 1.5 mM MgCl2, 10 mM  Tris-HCl, 50 
mM KCl, 1 U of Taq polymerase, 0.2 mM of each dNTP, 50 pmol of each primer and 
5 $l gDNA. The thermal profile used was:
Initial denaturation 95°C 3 min
30 amplification cycles:
Denaturation  95°C 1 min
Annealing  46°C 1 min
Extension   72°C 1 min
Final extension 72°C 10 min
2.3.10. PCR amplification of slpA
slpA was amplified as described (Karjalainen et al., 2002). For amplification of the 
whole gene, the primers used were:
5’-ATGAATAAGAAAAACTATTAGCAATAGGC-3’ 
5’-AGCTGATACCTTTACCATACTTG-3’
To amplify the variable region, the primers used were:
5’-ATGAATAAGAAAAACTATTAGCAATAGGC-3’ 
5’-TCTATTCTATCTTCTCCATGCTAC-3’
PCRs were performed in 50 µl reactions containing 1.5 mM MgCl2, 10 mM Tris-
HCl, 50 mM KCl, 1 U of Taq polymerase, 0.2 mM of each dNTP, 50 pmol of each 
primer and 5 $l gDNA. The thermal profile used was:
Initial denaturation 95°C 5 min
35 amplification cycles:
Denaturation  95°C 30 s
Annealing  45°C 1 min
Extension   72°C 2 min
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Final extension 72°C 10 min
2.3.11. Electrophoresis
PCR products were loaded onto a 1.5% agarose gel (Sigma-Aldrich) prepared in 
Tris-borate-EDTA buffer (TBE) containing 10 $l of SafeView nucleic acid stain 
(NBS Biologicals) along with a 100 bp or 1 kb ladder (Promega) depending on the 
PCR, to determine the product size. Electrophoresis was carried out at 100 V for 100 
min. The products were visualised under UV light. 
2.3.12. Gene sequencing
C. difficile genes were sequenced to identify  genomic differences between them. The 
genes were amplified by  PCR and the products were visualised on a 1.5% agarose 
gel. Once the size and purity of the products was confirmed, they were cleaned of 
dNTPs and phosphoric groups by treatment with Antartic phosphatase (New England 
BioLabs) at 37°C for 15 min followed by inactivation of the enzyme at  80°C for 15 
min. Two reactions were set up  for sequencing in a BigDye reaction - one with the 
forward primer and one with the reverse primer, both at 3.2 pmol. The generated 
sequences were analysed using the Chromas Lite software (http://www. 
technelysium.com.au/chromas_lite.html) and aligned using the MultAlin software 
(Corpet, 1988). Further, the protein sequences were obtained using the ExPASy 
Translate tool (Gasteiger et al., 2003) (the Swiss Institute of Bioinformatics (SIB); 
http://www.expasy.ch/tools/dna.html) and compared using MultAlin. 
2.4. Extraction of Antigens
2.4.1. Dialysis culture of C. difficile
C. difficile strain VPI 10463 was used to obtain toxin A and toxin B as it is a known 
high toxin producer based on a dialysis culture method (Kamiya et al., 1988). Starter 
cultures were prepared as described in 2.2.2. Dialysis tubing with a molecular weight 
cut-off (MWCO) of 10,000 Da was prepared by boiling twice in distilled water for 
10 min. Once cooled, the tubing was sealed at one end and attached to the ventilated 
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lid of a culture bottle containing 400 ml AIM. The tubing was filled with 100 ml 
sterile saline (0.85% NaCl). The apparatus was autoclaved and placed under 
anaerobic conditions overnight. Starter culture was added to the dialysis bag and the 
culture was allowed to grow anaerobically  at  37°C for 5 d. While medium 
components could diffuse into the dialysis tubing to support bacterial growth and 
small proteins could diffuse out of the tubing, toxin A and toxin B which are larger 
than the MWCO of the tubing, were contained within it. After 5 d, the culture was 
harvested by  centrifugation at 5000 g for 20 min. The supernatant was dialysed 
against TBS (0.02 M Tris-HCl, 0.5 M  NaCl; pH 7.5) at 4°C overnight, filtered 
through a 0.22 $m filter and stored at 4°C. 
2.4.2. Purification of toxins by affinity chromatography
Toxin A was purified by affinity  chromatography (Kamiya et al., 1989; Krivan & 
Wilkins, 1987). Bovine thyroglobulin (500 mg, Sigma-Aldrich) was dissolved in 100 
ml 0.1 M  MOPS (morpholinepropanesulfonic acid; pH 7.0) that had been clarified by 
centrifugation at 8000 g and filtered through a 0.22 µm filter. CNBr-activated 
Sepharose gel (4.4 g; Amersham Biosciences) was washed thoroughly in 1 mM  HCl 
to remove any additives and was allowed to react overnight at 4°C with 60 ml of the 
bovine thyroglobulin prepared. The mixture was blocked with 40 ml 0.1 M 
ethanolamine at 4°C for 30 min and washed in 0.1 M MOPS buffer. The coupled 
beads were packed into a column (C10; Amersham Biosciences) and washed at 37°C 
with 120 ml pre-warmed basic buffer (0.1 M glycine-NaOH with 0.5 M NaCl; pH 
10.0) and 120 ml pre-warmed acidic buffer (0.1 M glycine-HCl with 0.5 M  NaCl; pH 
2.0). The column was equilibrated at 4°C with 120 ml TBS. Dialysed filtrate from 
above was applied to the column. The flow through containing toxin B was collected 
and toxin A bound to the column was eluted with 50 ml TBS at 37°C. Absorbance of 
the fractions was measured at 280 nm. The fractions were pooled, sterilised through a 
0.22 $m filter and stored at 4°C. To reuse the column, it was washed with 60 ml 
acidic buffer at room temperature and equilibrated with 60 ml TBS at 4°C. The 
presence of toxins was determined using the C. difficile Tox A/B II™ kit.
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2.4.3. Purification of toxins by ammonium sulphate precipitation 
C. difficile toxins were prepared by ammonium sulphate precipitation (Pothoulakis et 
al., 1986). The pH of the dialysed filtrate containing toxins was adjusted to 7.2 by the 
addition of solid Tris base. Ammonium sulphate was slowly added to the filtrate with 
constant stirring at 4°C until it was 70% saturated. After stirring for 1 h at 4°C, 
precipitated toxin B was collected by centrifugation at 3000 g for 15 min and re-
suspended in PBS. The supernatant was then saturated to 20% with ammonium 
sulphate. After stirring for 1 h, the supernatant was collected by  centrifugation, 
saturated to 50% and incubated for a further 1 h with constant stirring. Precipitated 
toxin A was collected by centrifugation at 3000 g for 15 min and re-suspended in 
PBS. The crude toxins were dialysed against PBS overnight with three changes of 
PBS. The presence of toxins was confirmed using the C. difficile Tox A/B II™ kit.
2.4.4. Preparation of S-layer proteins
Overnight cultures (50 ml) of C. difficile were harvested by centrifugation at 4000 g 
for 20 min. The cell pellets obtained were washed twice in 10 ml PBS, re-suspended 
in 3.75 ml of 5 M guanidine hydrochloride (GHCl) and incubated at room 
temperature for 2 h with constant shaking for extraction of S-layer proteins. The cell 
debris was separated from the supernatant containing the SLPs by  centrifugation at 
4000 g for 20 min. The supernatant was dialysed against  PBS for 24 h with three 
changes of PBS. The dialysed protein was collected, aliquoted and stored at -20°C.
2.4.5. Preparation of flagella 
Overnight cultures (1 L) of C. difficile were harvested by centrifugation at 13000 g 
for 10 min at 4°C. The cell pellets obtained were washed once in 500 ml PBS, re-
suspended in 20 ml PBS and left overnight at 4°C. The cells were homogenised at 
full speed in a Waring blender for 2 min and centrifuged at 12000 g for 10 min at 
4°C. The supernatant  was centrifuged at 12000 g for 10 min at 4°C to remove cell 
debris. The supernatant was then centrifuged at  25000 g for 1 h at 4°C to collect the 
flagella. The pellets were re-suspended in 1 ml PBS, aliquoted and stored at -20°C!"
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2.4.6. Preparation of heat-shock proteins
C. difficile was grown till the culture reached an OD600 of 0.5-0.7 and divided into 3 
aliquots of 25 ml. The aliquots were incubated at  different temperatures for 30 min 
excluding the time taken to reach the optimum temperatures of 42°C for expression 
of GroEL, 60°C for expression of Cwp66 and 37°C for the non-shock control. 
Immediately  after the heat treatment, the cultures were collected by centrifugation at 
4000 g for 20 min. The cells were lysed at 37°C in a sonicating water bath for 5 min 
to release the heat-shock proteins. The cells were pelleted by centrifugation at 16000 
g for 2 min and the supernatants were collected, aliquoted and stored at -20°C.
2.4.7. SDS-PAGE
Denaturing SDS-PAGE was performed in a vertical minigel apparatus (Bio-Rad). 
The gels were prepared by combining pre-determined volumes of 40% acrylamide 
solution, Tris-HCl buffers, SDS solution, ammonium persulphate solution (APS) and 
TEMED in distilled water to obtain a 4% stacking gel (prepared in 0.75 M  Tris-HCl; 
pH 6.8, 0.2% SDS) and a 12% resolving gel (prepared in 0.25 M Tris-HCl; pH 8.8, 
0.2% SDS). The samples were prepared by boiling 10 µl of protein with 10 µl of a 
double-strength sample buffer (0.125 M Tris-HCl; pH 6.8, 4% SDS, 20% glycerol, 
2% 2-mercaptopethanol, 0.002% bromophenol blue) at 100°C for 3 min. The 
samples were loaded on the gel in 10 µl volumes with 6 µl of Mark 12™ Unstained 
Protein Standard (Invitrogen). Electrophoresis was performed in a 0.5 M Tris-glycine 
buffer with 0.1% SDS at 150 V for 1.5 h. The gels were washed once in distilled 
water for 5 min and stained with colloidal Coomassie blue stain G250 (Severn 
Biotech) for 1 h. This was followed by washing in distilled water for 1 h and then 
overnight for complete destaining. The gels were visualised under epi-white light.
2.4.8. Bradford assay
The concentration of toxins was determined by the Bradford assay  (Bradford, 1976). 
Bradford reagent (Sigma-Aldrich) was used and the assay was performed according 
to the manufacturer’s instructions for a 96-well plate assay protocol. Two-fold 
dilutions of BSA (Sigma-Aldrich) were prepared in DEPC water (Ambion) ranging 
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from 2 mg/ml to 0.125 mg/ml as protein standards. The standards and samples (5 µl) 
were added to the wells of a 96-well plate in duplicate, followed by the addition of 
250 µl of Bradford reagent at  room temperature. Negative controls were maintained 
with PBS. The plates were placed on a shaker for 30 s, followed by incubation at 
room temperature for 30 min, following which absorbance at 595 nm (A595) was 
measured. The A595 values of standard BSA dilutions were plotted against 
concentration to generate a standard curve, from which protein concentrations of the 
samples were extrapolated using the GraphPad Software Prism 4.0.
2.4.9. Limulus amoebocyte lysate (LAL) assay 
An end-point LAL assay was performed to detect LPS contamination in the antigens 
using the Pyrochrome® reagent (Associates of Cape Cod) as per the manufacturer’s 
instructions. The reagent was re-suspended in 3.2 ml of buffer and kept on ice until 
use. To prepare the standard, 0.2 ng E. coli endotoxin was re-suspended in 4 ml LAL 
reagent water (LRW) to obtain a concentration of 0.5 endotoxic units per millilitre 
(EU/ml). Two-fold dilutions of standard were used to generate standard curves. 
Antigens were diluted in PBS and 50 µl was added to two wells in a 96-well plate. 
Negative controls with PBS were maintained. The Pyrochrome® reagent (50 µl) was 
added to each well and the plate was incubated at 37ºC for 30 min. The reaction was 
stopped by adding 25 µl of 50% acetic acid and A405 was measured.
2.4.10. Silver staining
The antigens were run on an SDS-PAGE gel with an LPS control. For silver staining, 
the gel was covered with fixative (25% propan-2-ol, 7% acetic acid) and incubated 
overnight to fix any LPS to the gel. The fixative was discarded and the gel was 
oxidised in 154 ml oxidiser (0.7% periodic acid in fixative) for 15 min. The gel was 
washed in distilled water four times for 1 h. Freshly-prepared ammoniacal silver 
nitrate solution (0.076% NaOH, 0.014% ammonia solution, 0.078% silver nitrate 
solution) was added to the gel for 15 min. The gel was washed four times in distilled 
water and incubated with freshly-prepared developer (0.005% citric acid in 0.019% 
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formaldehyde) until optimal staining intensity was achieved. After washing in 
distilled water twice for 10 min, the gel was visualised under epi-white light.
2.5. Immunoassays
2.5.1. Dot blots
Dot blots were performed for antigen detection. Squares of approximately  1 cm2 
were marked on a nitrocellulose membrane (BioTrace NT; Gelman Sciences) in 
pencil. The membrane was washed in PBS for 10 min and dried at room temperature. 
Samples were inoculated onto the nitrocellulose membrane by allowing 2 µl of the 
sample to diffuse onto the centre of each square. The membrane was dried 
completely by  incubating at room temperature first for 10 min and then at 37°C for 5 
min. The membrane was subsequently washed twice in PBS-Tween for 10 min and 
blocked with 3% PBS-gelatin for 45 min at 37°C. The blocking solution was 
replaced with 5 ml of a suitable dilution of primary  antibody  prepared in 1% PBS-
gelatin and the membrane was incubated at 37°C for 3 h. After washing twice in 
0.05% PBS-Tween, 5 ml of a suitable dilution of the detection antibody prepared in 
1% PBS-gelatin was added and the membrane was incubated at  37°C for 1 h. The 
membrane was washed thoroughly in 0.05% PBS-Tween and then in three washes of 
distilled water to remove any residual Tween 20. The horseradish peroxidase (HRP) 
colour development solution (BioRad) was prepared by mixing freshly-prepared 
solution A (60 mg 4-chloro-1-naphthol dissolved in 20 ml methanol) with solution B 
(60 µl hydrogen peroxide added to 100 ml PBS). This development solution was 
added to the membrane and it was incubated at room temperature in the dark with 
constant shaking for up to 45 min until the purple colour of the reaction became 
visible. The reaction was stopped by washing the membrane in several washes of 
distilled water. The membrane was dried and stored at room temperature.
2.5.2. Western blots
For western blotting, antigens were run on an SDS-PAGE gel along with a ColorPlus 
prestained protein marker (New England Biolabs). The nitrocellulose membrane was 
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immersed in transfer buffer (0.025 M Tris, 0.192 M  glycine; pH 8.3, 20% methanol) 
for 10 min. The gel was washed in distilled water and also placed in the transfer 
buffer for 10 min. The western blot cassette was set  up with the gel and the 
nitrocellulose membrane in contact. Antigens were transferred from the gel onto the 
membrane at 5 V overnight at 4°C. The membrane was washed in PBS-Tween for 10 
min, blocked, treated with antibodies and developed as described in 2.5.1. 
2.5.3. Protein quantification from dot blots
For the quantification of proteins, images of the nitrocellulose membranes were 
analysed using Adobe Photoshop CS. The method was first standardised with dot 
blots performed with lipopolysaccharide (LPS). LPS extracted from E. coli R1 was 
dissolved in the 0.2% triethylamine (TEA). Two-fold dilutions of the LPS, ranging 
from 500 ng/ml to 15.125 ng/ml, were prepared in distilled water. The dot blots were 
performed as described in 2.5.1 with WN1 222-5 monoclonal antibody. After the dot 
blot was completed, the nitrocellulose was photographed and the image was stored as 
a TIFF file. Using Adobe Photoshop CS, areas were selected over the centre of each 
dot with the same numbers of pixels and the intensity of the pixels was obtained 
from the histogram generated. The intensity of the background was subtracted from 
these values and the values were plotted against  the protein concentration to generate 
a standard curve from which the concentration of protein in the unknown sample 
could be determined. 
2.5.4. ELISA procedure
ELISAs were developed for the separate quantification of C. difficile toxin A and 
toxin B as well as for seven cytokines. In general, the primary  antibody was diluted 
in 0.1 M carbonate-bicarbonate buffer, pH 9.6 and coated onto a Nunc MaxiSorp® 
flat-bottom 96-well plate and incubated overnight at 4°C. The plate was washed 
thoroughly  with 0.05% PBS-Tween and blocked with 100 µl 3% PBS-gelatin for 5 h 
at room temperature. After washing in 0.05% PBS-Tween again, 50 µl of 2-fold 
dilutions of the standard prepared in 1% PBS-gelatin and 50 µl of samples was added 
to the plate. The plate was incubated at 4°C overnight for cytokine ELISAs and at 
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37°C for 1 h for the toxin ELISAs. It was then washed and 50 µl of the secondary 
antibody diluted in 1% PBS-gelatin was added to the plate. For the toxin ELISAs, 
after incubation at 37°C for 1 h, the plate was washed and 50 µl of the HRP-
conjugated detection antibody diluted 1:1000 in 1% PBS-gelatin was added to all the 
wells. The plate was incubated at 37°C for 1 h. For the cytokine ELISAs, after 
incubation at room temperature for 5 h and washing, 50 µl of 1:1000 Streptavidin-
peroxidase (KPL) prepared in 1% PBS-gelatin was added to each well to react with 
the Biotin-conjugated secondary antibody. The plate was incubated at 37°C for 30 
min. After washing thoroughly, 100 µl of TMB (3,3’,5,5’-tetramethylbenzidine) 
substrate was added to the wells and the plate was allowed to develop. The reaction 
was stopped by the addition of 100 µl 0.2 M  sulphuric acid to each well. The A450 
was measured using a plate reader. All the reactions were performed in duplicate. 
Negative controls with only 1% PBS-gelatin were also maintained in duplicate. The 
results obtained were analysed using the GraphPad Software Prism 4.0. Nonlinear 
regression analysis was used to determine the concentrations of toxins in the samples 
from the standard curves generated. 
2.5.5. Preparation of standards
Toxin A was purchased from Calbiochem®, Merck and toxin B was purchased first 
from Sigma-Aldrich and then from Calbiochem®, Merck. As per the manufacturer’s 
instructions, vials containing the toxins were centrifuged prior to opening to prevent 
any loss of material. Lyophilised toxin (2 µg) was dissolved in 200 µl DEPC treated 
water to obtain a concentration of 10 µg/ml. This stock was stored at 4°C. For the 
cytokine ELISAs, human-recombinant proteins for TNF-!, IL-1", IL-6, IL-10 and 
IL-12 (eBioscience), and IL-8 (PeproTech EC) were reconstituted and diluted as per 
the manufacturer’s instructions. These standards were aliquoted and stored at -20°C. 
2.5.6. Development of ELISAs 
Checkerboard assays were performed to determine suitable antibody  concentrations 
to be used in ELISAs. Recommended dilutions of primary antibody  were prepared in 
1% PBS-gelatin and 50 µl was coated onto ELISA plates. After blocking in 100 µl 
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blocking solution, 50 µl of 2-fold dilutions of standards were added to the plates and 
incubated. Then, 50 µl of recommended dilutions of secondary antibody was added, 
followed by incubation with 50 µl 1:1000 of detection antibody or Streptavidin-
peroxidase, depending on the ELISA. The plates were developed with 100 µl TMB. 
The reaction was stopped with 100 µl sulphuric acid and A450 was measured. 
Standard curves were generated for the different combinations of antibody 
concentrations tested. From these, the concentrations of primary and secondary 
antibodies that generated the best-fit curves over the range of standard concentrations 
tested were determined. These were used for future experiments. 
2.6. Cell culture and related assays
2.6.1. Cell lines
The THP-1 cell line, a human monocytic cell line derived from the peripheral blood 
of a 1-year old male with acute monocytic leukaemia, was used to measure cytokine 
production in response to various C. difficile antigens. Vero cells, derived from the 
kidney  epithelial cells of the African green monkey, were used for cytotoxicity 
assays and adherence assays. For adherence assays, additional cell lines were used - 
Caco-2, human epithelial colorectal adenocarcinoma cells, HT29-16E (HT29-MS), 
human colonic adenocarcinoma cells and a non-mucus secreting derivative of 
HT29-16E (HT29-NMS). The cells were recovered from stocks frozen in liquid 
nitrogen by  rapidly thawing at 37°C, adding 15 ml of pre-warmed medium to dilute 
the cryoprotectant and centrifuging at  1000 g for 5 min. Cells were re-suspended in 
fresh medium, counted and diluted to a suitable concentration. All cell lines were 
maintained in a humid incubator at 37°C with 5% CO2.
2.6.2. Cell counts
Cell suspensions were mixed with equal volumes of Trypan blue solution (Fluka) and 
allowed to stand for 5 min. Trypan blue was excluded from viable cells which were 
counted using an improved Neubauer counter:
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viable count = no. of cells counted x dilution factor x 104
where, no. of cells counted = average of no. of cells in 5 squares
 dilution factor = 2
Cells were maintained at a concentration of 0.5-1x106 cells/ml. 
2.6.3. Culture and passaging of cells
THP-1 cells were initially cultured in RPMI-1640 medium (Sigma-Aldrich) 
supplemented with 20% foetal bovine serum (FBS), 6 mM  L-glutamine, 10 mM 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) with added Pen-Strep 
(100 U/ml penicillin, 10 µg/ml streptomycin) to prevent bacterial contamination. 
FBS was heat inactivated (HI) at 56°C for 35 min with constant shaking and then 
filter sterilised. This was the initial growth medium (IGM). Cells were passaged up 
to three times in IGM  until they started proliferating rapidly. They  were then 
transferred to the normal growth medium (NGM) comprising of RPMI-1640 medium 
supplemented with 6 mM  L-glutamine and 10% HI-FBS, with Pen-Strep. Cells were 
maintained in NGM. Frozen stocks were regularly  prepared by  freezing 
approximately 106 cells/ml in FBS containing 3% glycerol as the cryoprotectant. 
Vero cells, Caco-2 cells and both types of HT29-16E cells were cultured in the same 
way in Dulbecco’s minimal eagle medium (DMEM, Sigma-Aldrich) supplemented 
with 10% HI-FBS, 1% non-essential amino acids and Pen-Strep. The cells were 
checked regularly  by microscopic examination. When the monolayers reached 90% 
confluence, they were passaged by washing with pre-warmed PBS, followed by 
treatment with 0.05% trypsin-EDTA (Sigma-Aldrich) at 37°C for 5 min. Warm 
medium was then added to the cells; FBS in the medium inactivated the trypsin. The 
typsinized cells were scraped off and collected by centrifugation at  1000 g for 5 min. 
They  were re-suspended at a concentration of 5x105 cells/ml in fresh medium. 
Frozen stocks were regularly prepared by freezing approximately  5x105 cells/ml in 




The MycoSensor PCR Assay Kit (Stratagene) was used to detect Mycoplasma 
infections in the THP-1 cell line when culturing was proving difficult. Cells were 
cultured in NGM without  Pen-Strep for 7 d to maximise the strength of the signal. 
THP-1 cells were allowed to grow for 48 h after passaging. Then, 100 µl of the 
culture supernatant  was collected by centrifugation at  16000 g for 30 s and diluted 
1:10 in DEPC water. It was subsequently boiled at 100°C for 5 min and centrifuged 
at 16000 g for 5 s. The StrataClean resin was re-suspended by vortexing for 30 s and 
10 µl of the resin was added to the supernatant and mixed gently. The sample was 
centrifuged for approximately 10 s to pellet the resin. The resulting supernatant was 
removed to a fresh tube and used as the template in the PCR. 
A PCR reaction (50 µl) was set up with 10 mM  Tris-HCl, 50 mM  KCl, 3 mM MgCl2, 
200 µM of each dNTP, 2 U Taq and 5 µl of the prepared supernatant. A negative 
control was maintained with 5 µl DEPC water and a positive reaction was included 
with 5 µl of the positive control template. An additional reaction was set up which 
also included 4 µl of the provided internal control. The thermal profile used was: 
35 amplification cycles:
Denaturation  94°C 30 s
Annealing  55°C 1 min
Extension   72°C 1 min
The products were visualised on a 1.5% agarose gel as described in 2.3.11.
2.6.5. Differentiation of THP-1 cells and confirmation by flow 
cytometry 
Flow cytometry was used to confirm the differentiation of the monocytic THP-1 cells 
into macrophage-like cells. THP-1 cells were diluted to 5x105 cells/ml and 
challenged with different concentrations of PMA (phorbol,12-myristate,13-acetate, 
Sigma -Aldrich). At 24 h, four 1 ml aliquots of cells challenged with 100, 50, 10 and 
5 ng/ml PMA respectively were collected along with four 1 ml aliquots of untreated 
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cells by  centrifugation at 1000 g for 5 min. Cells were washed with 200 µl of buffer 
(1% PBS-BSA) before staining with fluorescent antibodies for CD4 and CD11b 
surface markers. From each group, one sample was used as an unstained control for 
flow cytometry, one sample was stained with fluorescein isothiocyante (FITC) anti-
human CD4 antibody (eBioscience), one with allophycocyanin (APC) anti-human 
CD11b antibody (eBioscience) and one was double-stained with both antibodies. The 
unstained samples were washed once and re-suspended in 100 µl of buffer. Staining 
reactions were set up in 100 µl volumes. For CD4 single staining, 5 µl of antibody 
was added to cells, for CD11b single staining, 20 of µl antibody was used and for 
double staining, 5 µl of anti-CD4 and 20 µl of anti-CD11b were added to the 
reactions. Cells were incubated at 4°C for 40 min in the dark. After staining, they 
were washed twice in 200 µl of buffer and fixed in 10% paraformaldehyde (PFA) at 
room temperature for 10 min. They were washed again, re-suspended in 100 µl of 
buffer and stored at 4°C in the dark until they  were run on the BD FACSCalibur™ 
(BD Biosciences) machine. The data were analysed using the FlowJo 9.0 software. 
2.6.6. Stimulation of differentiated THP-1 cells with antigens
For the antigen-challenge assays, THP-1 cells were counted and adjusted to a density 
of 5x105 cells/ml in NGM containing either 10 ng/ml or 50 ng/ml PMA (phorbol,12-
myristate,13-acetate, Sigma-Aldrich). To each well of a 96-well tissue culture plate 
(Greiner), 100 µl cells was added and incubated at 37°C for 24 h for differentiation 
into macrophage-like adherent cells. After incubation, cells were washed with 100 µl 
of pre-warmed PBS and serial dilutions of the C. difficile antigens prepared in NGM 
were added to the wells. LPS from E. coli R1 (100 ng/ml) was used as a control. 
Supernatants were collected at 4 h for TNF-! detection and at 24 h for the detection 
of IL-1", IL-6, IL-8, IL-10 and IL-12p70. They were stored at -20°C until use.
2.6.7. Cytotoxicity assay
Vero cells (50 µl) at a concentration of 5x105 cells/ml were added to each well of a 
96-well tissue culture plate and incubated overnight at 37°C with 5% CO2 to allow 
formation of monolayers. Cells were washed in pre-warmed PBS and the medium 
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was replaced with dilutions of C. difficile culture supernatants prepared in DMEM. 
Samples (50 µl) were added to wells in duplicate. Negative controls were maintained 
which contained only  medium. For the generation of standard curves, C. difficile 
toxin B (Calbiochem®, Merck) was diluted in DMEM  to a concentration of 250 ng/
ml and 2-fold dilutions were added to the plate in duplicate to a minimum 
concentration of 0.25 ng/ml. C. difficile toxin A (Calbiochem®, Merck) diluted to 125 
ng/ml was added to two wells to check for its effect  on the assay. Further, to confirm 
that the observed cytotoxicity was due to C. difficile toxins alone, a neutralisation 
assay was performed with C. sordellii antitoxin (Pro-Lab Diagnostics). Samples were 
prepared with 5 µl supernatant, 5 µl of antitoxin and 40 µl of medium and added to 
the wells of a different plate in the manner described above. The plates were 
incubated at 37°C with 5% CO2 for 48 h. 
The plates were checked microscopically and an MTT ((3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay  was performed to quantify  the 
cytotoxicity caused by toxin B. The plates were washed twice with pre-warmed PBS 
and 20 µl of 5 µg/ml thiazolyl blue tetrazolium bromide (Sigma-Aldrich) was added 
to the wells, followed by incubation at 37°C with 5% CO2 for 4 h. Formazan 
produced by cells was dissolved in 100 µl of DMSO and A570 was measured. 
Standard curves generated from the dilutions of toxin B were used to quantify  the 
amounts of toxin B in the culture supernatants. 
2.6.8. Adherence assay
A sterile coverslip was added to each well of 6-well tissue culture plates (Greiner) for 
the adherence assays. Vero cells, Caco-2 cells and both types of HT29-16E cells (1 
ml) were added separately  to the coverslips in the 6-well plates at a concentration of 
2x105 cells/ml and incubated at  37°C with 5% CO2 to allow formation of monolayers 
over the coverslips. Except  for the Vero cells that were incubated for 48 h, the other 
cell lines were incubated for 7 d before the assay was performed. C. difficile starter 
cultures were inoculated the day before the assay  was to be performed and incubated 
anaerobically at 37°C overnight. 
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The starter culture (1 ml) was inoculated into 9 ml of pre-reduced AIM and the 
medium from the cell lines was replaced with antibiotic-free medium. The bacterial 
culture was allowed to grow for approximately  4 h until an OD600 of 0.5-0.7 was 
achieved. The medium from the cell lines was replaced with 1 ml of the bacterial 
suspension and the plates were incubated at 37°C anaerobically  for 3 h to allow for 
attachment of the bacteria to the cell lines. The non-adherent bacteria were washed 
off the coverslips with sterile PBS and the attached bacterial cells and monolayers 
were fixed to the coverslips with 100% methanol at 4°C for 10 min. After washing 
thrice with sterile PBS, the cells were stained with crystal violet for 5 min at room 
temperature. The coverslips were washed again and dried at  room temperature. The 
coverslips were mounted onto glass slides, cell-side down and visualised under 
1000X magnification. The number of C. difficile cells per field were enumerated; at 
least 10 fields were per coverslip  were investigated. The adherence of strains was 
compared to each other.
To identify the effect of flagella and S-layer proteins on bacterial adherence, cell 
lines were pre-incubated with the proteins diluted in the antibiotic-free medium 
instead of the medium alone before the bacterial cultures were added to them. The 
bacteria were enumerated in the same way  as above. The effect of the proteins of a 
strain were tested on the attachment of that strain only.
2.7. Real-time RT-PCR
2.7.1. Development of a real-time RT-PCR assay
2.7.1.1. Bacterial strain and genes
C. difficile strain 630 was used as the reference strain to develop a real-time RT-PCR 
assay to study  gene expression in C. difficile genes as it was the only fully  sequenced 
genome available at the time this study was started (Sebaihia et al., 2006). The genes 
of the PaLoc - tcdA, tcdB, tcdC, tcdR and tcdE - and spo0A were studied. Two 




The growth of C. difficile strain 630 was studied in two independent growth curves 
as described in 2.2.3. At every 4 h from the time of inoculation (0 h) to 24 h, OD600 
readings were taken. Simultaneously viable counts were also performed. The values 
obtained from the two methods were plotted against time and the correlation between 
the two determined, so that in future studies cell numbers/ml could be estimated 
during growth without performing viable counts. This information was required to 
collect optimal numbers of vegetative cells for RNA extraction at  the different time-
points and to standardise the number of cells collected at each time-point.
2.7.1.3. RNA extraction and DNase I treatment
The workspace and equipment to be used for RNA extraction were treated with 
RNaseZap® (Ambion) to obtain an RNase-free environment. RNA was extracted 
using the RiboPure™-Bacteria kit  (Ambion) according to the manufacturer’s 
instructions. From 4 h onwards, a standardised volume of culture was collected in 
duplicate (50 ml at 4 h to 5 ml at  24 h) by centrifuging at 4000 g for 10 min. At 0 h, 
50 ml of the culture was collected. The pellets obtained were centrifuged again at 
16000 g for 2 min to remove as much medium from them as possible. The dried cell 
pellets were snap-frozen in 70% ethanol-ice mixture and stored at -20°C. After 24 h, 
the samples were stored at -80°C for a maximum of 5 d before use. 
Before RNA extraction, the pellets were thawed and mixed thoroughly with 350 µl 
RNAWIZ™. The mixture was added to 250 µl Zirconia beads, vortexed vigorously in 
a Mini Beadbeater™ (Biospec Products) for 3 min and centrifuged at 16000 g for 5 
min at 4°C. Approximately 250 µl of bacterial lysate was transferred to a fresh tube 
and treated with 50 µl chloroform, mixed vigorously  for 30 s and incubated at room 
temperature for 10 min. After centrifuging the sample at 16000 g for 5 min at 4°C, 
the 200 µl upper aqueous phase containing RNA was mixed thoroughly with 100 µl 
of 100% ethanol and RNA was bound to a silica filter. After three washes with 
buffers provided in the kit, RNA was eluted in a low ionic strength elution buffer that 
was pre-warmed to 95°C. A total of 100 µl of RNA was collected. The RNA was 
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treated with 4 µl DNaseI (Ambion) in 11 µl DNase buffer at 37°C for 1 h, followed 
by deactivation of the DNase with 20 µl DNase Inactivation Reagent (Ambion) for 2 
min at room temperature. The samples were centrifuged at 16000 g for 1 min to 
pellet the DNase Inactivation Reagent. The RNA was aliquoted into fresh RNase-free 
tubes and stored at -80°C. Before storage, the samples were run on a 1.5% agarose 
gel with a 1 kb DNA ladder and visualised under UV light. The quantity and quality 
of RNA were assessed using an ND-1000 spectrophotometer. The concentration of 
RNA was determined using the elution solution as the blank and the purity  was 
determined from the ratio of absorbance at 260 nm to that at 280 nm (A260/280). 
2.7.1.4. Reverse transcription (RT)
Complementary DNA (cDNA) was prepared from the RNA extracted from cells 
collected at 4, 8, 12, 16, 20 and 24 h using the SuperScript® VILO™ cDNA 
Synthesis Kit (Invitrogen) according to the manufacturer’s instructions. In each 
reaction, 2 µg RNA was added to 4 µl VILO™ Reaction Mix containing buffered 
random primers, MgCl2 and dNTPs and 2 µl SuperScript® Enzyme Mix containing 
SuperScript® III RT, RNaseOUT™ Recombinant Ribonuclease Inhibitor and a 
propriety helper protein and the volume was made up to 20 µl with DEPC water. The 
mixture was gently vortexed and incubated at 25°C for 10 min followed by 
incubation at  42°C for 60 min. The reaction was terminated by incubation for 5 min 
at 85°C. The quantity  and quality of the cDNA samples were assessed using an 
ND-1000 spectrophotometer. A cDNA pool was prepared with 15 µl cDNA from 
each of the six samples. Further, the individual samples were diluted 40-fold in order 
to achieve a concentration equivalent to 50 ng RNA. All the cDNA samples were 
aliquoted and stored at -20°C.
2.7.1.5. Primer designing 
Primers for the eight genes were designed using the Primer 3 software (Rozen & 
Skaletsky, 2000) based on the genome of C. difficile strain 630 (Sebaihia et al., 
2006). The primers for all the genes in the study  were designed such that they 
yielded products of 100 bp for all the genes to facilitate inter-gene comparison of 
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transcription as the Ct value obtained during the amplification of the products would 
not be affected by the product size. The primers were also designed to have similar 
temperatures of melting (Tm) to enable running reactions of multiple genes 
simultaneously. The primers and their characteristics are listed in Table 2.3. 
Table 2.3. Primers used in this study and their characteristics
Gene Name bp Tm GC% Primer sequence
tcdA A1 20 60.38 50.00 5' GCTATTGCTGCAGTCGGATT 3'
A2 22 59.02 45.45 3' TACCATTAACAGTCTGCCAACC 5'
tcdB B1 20 60.54 50.00 5' TGGTGAAGATGGTGTCATGC 3'
B2 22 59.53 40.91 3' TTCTCCCTCAAAATTCTCATCC 5'
tcdC C1 23 59.69 39.13 5' TTTAAGAGCACAAAGGGTATTGC 3'
C2 21 60.24 52.38 3' TGACCTCCTCATGGTCTTCAG 5'
tcdR R1 24 57.30 33.33 5' AACTCAGTAGATGATTTGCAAGAA 3'
R2 23 57.20 34.78 3' TTAAATCTGTTTCTCCCTCTTCA 5'
tcdE E1 26 59.64 34.62 5' AAATATGTGCTTATGTGGATTACCAG 3'
E2 24 59.49 33.33 3' TTCATCCTTAGCATTCATTTCATC 5'
spo0A S1 20 56.75 45.00 5' TGTTGAGCTTTTAGGTGCAG 3'
S2 23 59.90 34.78 3' TGCATGTCTTATTGCTCTTTCAA 5'
tpi T1 22 59.54 45.45 5' ACTGCTGAAGATGCTAATGACG 3'
T2 26 60.17 34.62 3' TTCCACCGTATTGTATTCTAACTTCA 5'
rrn 16S1 20 60.02 50.00 5' AGTGAAAGGCTACGGCTCAA 3'
16S2 20 59.90 50.00 3' CTACGCATTTCACCGCTACA 5'
2.7.1.6. Primer testing
The primers were tested in a conventional PCR with gDNA extracted from strain 630 
in 50 µl reactions. Each reaction contained 2 µM of each primer, 1.5 mM MgCl2, 10 
mM Tris-HCl, 50 mM  KCl, 1 U of Taq polymerase, 0.2 mM of each dNTP and 5 $l 
of gDNA. The thermal profile used for the PCR was as follows:
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Initial denaturation 95°C 2 min
40 amplification cycles:
Denaturation  95°C 1 min
Annealing  56°C 1 min
Extension   72°C 1 min
Final extension 72°C 10 min
The products obtained were checked by  electrophoresis as described in 2.3.12. The 
primers were then tested at different concentrations in a real-time PCR experiment 
using the Mx3000P QPCR system (Stratagene). Three reactions were set up for each 
gene containing 2 µM, 1 µM and 500 nM  of each primer. Each reaction contained 25 
µl SYBR® Green JumpStart™ Taq ReadyMix™ (Sigma), 5 µl gDNA of strain 630, 
the primers and DEPC water up to 50 µl. The thermal profile used was as follows:
Initial denaturation 95°C 3 min
40 amplification cycles:
Denaturation  95°C 20 s
Annealing  56°C 20 s
Extension   72°C 20 s 
Final dissociation 95°C 1 min
   50°C 1 min
   95°C 30 s
Amplification of the products was checked from the Ct value and the specificity  of 
the primers was determined from the Tm of the products obtained in the dissociation 
curves generated by the Mx3000P QPCR software (Stratagene).
2.7.1.7. Primer optimisation
Four primer concentrations were selected for preliminary testing for each gene - 50 
nM, 100 nM, 200 nM and 400 nM. Real-time PCR reactions were performed as 
above and negative controls with DEPC water were maintained. From these, two 
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suitable concentrations were selected for further testing. For tcdE alone, two higher 
concentrations were selected. The selected primer concentrations from these 
experiments were tested again in duplicate before the final primer concentrations for 
each gene were selected. 
2.7.1.8. Standard curves
Standard curves were performed in duplicate for each gene with the selected primer 
concentrations in order to determine the efficiency of the individual PCR reactions. 
Four-fold dilutions of gDNA were prepared such that  the amount  of gDNA in the 
samples ranged from 800.0 ng to 12.5 ng. 
For each gene, PCR reactions were set up for each gDNA concentration with the 
selected primer concentrations in 20 µl reactions containing 10 µl SYBR® Green 
JumpStart™ Taq ReadyMix™ using the thermal profile above. The standard curves 
were obtained from the Mx3000P software. From these, the efficiency of the PCR 
reactions for each gene was determined. The range of DNA quantity over which the 
PCR reactions were most efficient was also determined. The standard curves were 
repeated with 4-fold dilutions of the cDNA pool prepared, such that the reactions 
contained cDNA from 775.0 ng to 12.0 ng. 
2.7.1.9. Real-time PCR
Real-time PCR was performed for the 4, 8, 12, 16, 20 and 24 h samples. The cDNA 
samples were suitably diluted. Each 20 µl reaction contained 2 µl cDNA, 10 µl 
SYBR® Green JumpStart™ Taq ReadyMix™, the selected primer concentrations and 
DEPC water. On each plate, duplicate reactions were performed for three genes of 
interest and the housekeeping gene at the six time-points. Also, duplicate reactions 
were set up with the dilutions of the cDNA pool to obtain the efficiency of the PCR 
for each gene in the run. RNA (no RT) controls were included to check for 
contamination of the RNA preparations with gDNA. DEPC water controls were also 
included to identify contamination of the PCR reagents and primers, if any. Positive 
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controls with gDNA were maintained. The PCR was performed using the thermal 
profile described in 2.7.1.6. 
2.7.1.10. Analysis
The data for each run was generated by  the Mx3000P software and the Ct values and 
amplification curves of each sample was checked. Further, the dissociation curves 
were checked to check the product specificity. The efficiency of the PCR reaction for 
each gene was determined from the standard curves generated. The expression of the 
genes of interest at each time-point was normalised to that of rrn at that time-point 
using the Ct value at 4 h as the calibrator or base-line for the expression and was 
calculated by the Pfaffl method (Pfaffl, 2001) as follows:
Ratio =
where, target = gene of interest
 ref = housekeeping gene
 E target = Real-time PCR efficiency of the gene of interest
 E ref = Real-time PCR efficiency of the reference gene
 !Ct target = Ct value target at 4 h - Ct value target at 8 / 12 /16 / 20 / 24 h
 !Ct ref = Ct value ref at 4 h - Ct value ref at 8 / 12 /16 / 20 / 24 h
2.7.2. Real-time PCR
2.7.2.1. Bacterial strains and growth
Growth curves were performed over 24 h for C. difficile strains 630 and VPI 10463 
and ribotypes 027, 001 and 106 in 300 ml volumes as described in 2.2.3. Growth was 
assessed by OD600 measurement only.
2.7.2.2. RNA extraction
RNA was extracted by three methods: using the RiboPure™-Bacteria kit (Ambion) 
as described in 2.7.1.3, RNAWIZ™ (Ambion) or TRIZOL® (Invitrogen) according to 
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(E target) !Ct target (control-sample)
_____________________________________
(E ref) !Ct ref (control-sample)
the manufacturer’s instructions. At every 4 h from 4 h to 24 h, standardised volumes 
of culture were collected as described in 2.7.1.2 and 2.7.1.3 in duplicate. 
When using RNAWIZ™ or using TRIZOL®, cell pellets were treated immediately with 
500 µl of either reagent, vortexed vigorously in a Mini Beadbeater™(Biospec 
Products) for 3 min and stored at -80°C for a maximum of 7 d before use. Before 
RNA extraction, pellets were thawed and incubated at room temperature for 5 min to 
allow for the dissociation of nucleoprotein complexes. Chloroform (100 µl) was 
added to the samples and they  were mixed thoroughly for approximately 30 s and 
incubated at room temperature for 10 min. The mixture was subsequently centrifuged 
at 12000 g for 15 min at 4°C. The upper aqueous phase containing the RNA was 
transferred to a new tube and RNA was precipitated with 250 µl isopropanol after 
incubation at  room temperature for 10 min and centrifugation at 12000 g for 10 min 
at 4°C. The supernatant was discarded and the RNA pellet was washed with 500 µl 
of 75% ethanol followed by centrifugation at 7500 g for 5 min at 4°C. The pellet was 
air-dried for approximately 10 min and re-suspended in 100 µl DEPC water. DNaseI 
treatment was performed and the quantity and quality  of the RNA were assessed 
using an ND-1000 spectrophotometer.
2.7.2.3. Reverse transcription 
cDNA was prepared using the SuperScript® VILO™ cDNA Synthesis Kit according 
to the manufacturer’s instructions as described in 2.7.1.4. The quantity and quality  of 
the cDNA samples were assessed using an ND-1000 spectrophotometer. 
2.7.2.4. cDNA pool and dilutions
cDNA (2 µg) was diluted 4-fold to get a starting concentration equivalent to 500 ng 
RNA. A cDNA pool was prepared using 15 µl cDNA from each of the six samples. 
Four-fold dilutions of the 500 ng pool were prepared corresponding to 125, 31.25 
and 7.8125 ng RNA. These dilutions were used to generate standard curves. For the 
genes of interest, individual cDNA samples were diluted 40-fold to achieve a 
concentration equivalent  to 50 ng RNA. For the housekeeping gene, rrn, cDNA 
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samples were diluted to obtain a concentration equivalent to 1 ng RNA. The samples 
were aliquoted and stored at -20°C.
2.7.2.5. Real-time PCR
PCR reactions were set up in 20 µl volumes with 5 µl of cDNA. On each 96-well 
plate, reactions were set up  in duplicate for three genes of interest and rrn. Standard 
curves for the four genes, negative controls, no-RT controls and positive controls 
were also run in duplicate. The thermal profile used was as described in 2.7.1.6. The 
data was analysed as before.
2.8. Sensitivity assays
2.8.1. Antibiotics and agents
Eight antibiotics were selected for antimicrobial susceptibility testing (AST) of the 
C. difficile strains. These were vancomycin, metronidazole, ceftriaxone, tetracycline, 
erythromycin, clindamycin, ciprofloxacin and moxifloxacin. The concentrations 
tested and the guidelines for interpretation of the results are listed in Table 2.4.





MIC interpretive criteria (μg/ml)a
Susceptible Intermediate Resistant
Vancomycin (V) 0.5 – 8.0 ≤ 2 4 – 16 ≥ 32
Metronidazole (M) 0.5 – 8.0 ≤ 8 16 ≥ 32
Ceftriaxone (C) 16.0 – 256.0 ≤ 16 32 ≥ 64
Clindamycin (CL) 0.25 – 64.0 ≤ 2 4 ≥ 8
Tetracycline (T) 0.5 – 64.0 ≤ 4 8 ≥ 16
Erythromycin (E) 0.25 – 64.0 ≤ 2 4 ≥ 8
Moxifloxacin (MX) 0.25 – 128.0 ≤ 2 4 ≥ 8
Ciprofloxacin (CP) 4.0 – 128.0 ≥ 16
a Adapted from the CLSI criteria for anaerobes and published data (Mutlu et al., 2007). 
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Five agents were tested for similar studies. These were Actichlor, a disinfectant 
routinely used in hospitals, Decon 90, a laboratory decontaminant and Microsol 3+, 
TriGene Advance and Virkon, three commonly-used laboratory disinfectants. The 
active ingredients of these agents, manufacturers and recommended working 
concentrations are listed in Table 2.5. 
Table 2.5. Agents used in this study




Actichlor Sodium dichloroisocyanurate Ecolab 1000 ppm chlorine
Decon 90 Anionic and non-anionic surfactants Decon Laboratories Ltd. 1:10 dilution
Microsol 
3+
Tertiary alkylamine and quaternary 
ammonium compounds Anachem Ltd. 1:10 dilution
TriGene 
Advance
Polymeric biguanide hydrochloride and 
organic quaternary compounds 
Medichem 
International Ltd. 1:100 dilution
Virkon Potassium peroxymonosulfate Antec International Ltd. 1:100 dilution
2.8.2. Determination of minimum inhibitory concentration (MIC)
Minimum inhibitory  concentrations were determined by three methods: Wadsworth 
agar-dilution method, E-test and broth-microdilution. The agar-dilution method was 
used to determine the MICs of antibiotics and disinfectants, the E-test was used only 
for antibiotics and broth-microdilution was used only for disinfectants. For all three 
methods, the C. difficile strains were grown on blood agar at 37°C for 24 h 
anaerobically. Growth was lifted from five or more colony edges and inoculated into 
3 ml of pre-reduced thioglycollate broth (Oxoid) supplemented with 5 $g/ml haemin 
and 1 $g/ml vitamin K1 (NCCLS, 2004) and incubated at 37°C anaerobically 
overnight. The optical density of the cultures was adjusted to a 0.5 McFarland 
standard by addition of pre-reduced broth and these were used for MIC testing. 
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For the agar-dilution method, antibiotic stocks were prepared at 10000 µg/ml, which 
were diluted to a concentration equivalent to ten times (10X) the initial concentration 
to be tested and disinfectant stocks were prepared at 10X of the manufacturer’s 
recommended working concentration in distilled water. Two-fold dilutions of the 
stocks were prepared in distilled water till 10X of the lowest concentration to be 
tested was achieved. The medium used for the test was Brucella agar (Oxoid) 
supplemented with 5% defibrinated horse blood, 5 $g/ml haemin and 1 $g/ml 
vitamin K1. The test plates were prepared by adding 1 ml defribrinated horse blood, 2 
ml of the test agent and 17 ml cooled molten agar. The plates were pre-reduced for 2 
h and inoculated with a sterile multi-point inoculator and incubated anaerobically. All 
inoculations were carried out starting from the plate with the lowest concentration of 
agent. In addition to the test plates, control plates prepared with distilled water were 
inoculated to check for contamination: two plates were inoculated before the test 
plates, two were inoculated after them and two were inoculated in between different 
test agents. Of each of these sets, one plate was incubated aerobically and one 
anaerobically. Growth on the plates was checked after 24 h and 48 h of incubation at 
37°C and the MIC of each agent for each strain was determined as the lowest 
concentration of the agent to inhibit visible bacterial growth. The E-test was only 
employed for moxifloxacin which was unavailable in powdered form. Standardised 
cultures were swabbed onto pre-reduced enriched Brucella agar plates prepared as 
the control plates in the agar-dilution method, such that a lawn of growth would be 
obtained. Test strips, containing an exponential gradient of antibiotic, were placed 
smoothly  on the surface of each plate. The plates were incubated anaerobically at 
37°C and checked at  24 and 48 h for growth. The MIC was determined as the 
concentration of antibiotic indicated on the strip where the zone of inhibition began. 
The tests were performed in triplicate. 
MICs by  broth-microdilution were performed in 96-well plates (Greiner). Two-fold 
dilutions of test agents were prepared in pre-reduced AIM and 100 µl of each dilution 
was added to the plate in duplicate. Standardised culture (10 µl) was added to each 
well. Positive controls (medium and culture) and negative controls (medium and 
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agent) were maintained. Negative controls were required for each agent to quantify 
turbidity resulting from it  being dissolved in AIM rather than water. The plates were 
incubated anaerobically at 37°C for 48 h. OD600 was measured after shaking for 5 
min. The lowest concentration of agent to inhibit visible bacterial growth was 
recorded as the MIC. The experiments were performed in triplicate.
2.8.3. Preparation of spores
C. difficile cultures (500 ml) were incubated anaerobically at 37°C for 7 d. The 
cultures were collected by  centrifugation at 4000 g for 10 min. Alcohol-resistant 
spores were prepared as described in 2.2.5. The number of spores in each sample was 
determined from serial dilutions. The spore preparations were standardised to a 
concentration of 106 spores/ml by dilution in distilled water. 
2.8.4. Spore viability assays
The agents were tested for their activity against spores in a suspension test at the 
recommended working concentration and 1/2 and 1/5 of the same. For each test, 100 
µl of spore suspension was added to 900 µl of each dilution and mixed thoroughly. At 
2, 10 and 30 min, 100 µl of the test was inoculated into 900 µl pre-reduced AIM, 
mixed and incubated at 37°C for 5 d in duplicate. Positive controls without agent and 
negative controls without spores were maintained. The tubes were examined for 
growth. Samples from tubes with no visible growth were plated to identify cidal or 
static activity. These were examined for growth after 5 d of anaerobic incubation. 
2.8.5. Determination of log10 reduction 
To determine log10 reduction in spores in suspension tests, spores were treated with 
agents at the recommended working concentration in the presence or absence of 
organic matter. For tests without organic matter, 100 µl of spores (approximately 104 
spores) in distilled water was added to 900 µl of disinfectant. After 10 min, the 
spores were collected by  centrifugation at 16000 g for 2 min. The pellets were 
washed twice with distilled water. The spores were re-suspended in 1 ml distilled 
water and 100 µl of this suspension was plated in duplicate and incubated at 37°C 
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anaerobically  for 48 h. Positive controls were maintained. For tests in the presence of 
organic matter, 0.27% BSA was introduced. The reduction was calculated as:
log10 reduction = log10 (N0/N10), 
where, N0 = the number of spores in the positive control, and
 N10 = the number of viable spores recovered from the test at 10 min. 
2.8.6. Surface decontamination testing
Five hard, non-porous surfaces were used in this study - aluminium, glass, plastic, 
vinyl self-adhesive tile and white ceramic tiles. Surfaces were autoclaved and dried 
in a hot-air oven before use; the vinyl tiles could not  be autoclaved and were cleaned 
with 70% ethanol for 10 min before use. Once prepared, squares of approximately 1 
cm2 were marked out on each surface with a wax crayon. The squares were 
artificially contaminated with 10 µl of spore suspension (approximately 103 spores) 
of one C. difficile strain and left to air-dry  for 2 h. Subsequently, 50 µl of cleaning 
agent at the recommended working concentration was added to the dried spore 
suspension. At 2 min and 10 min, the area was scratched with a pipette tip 10 times 
to mimic scrubbing. The agent was aspirated from the surface and the area was 
washed with 100 µl distilled water. The aspirated agent and wash were added to 850 
µl distilled water to obtain a final volume of 1 ml. An aliquot (100 µl) of this was 
plated on blood agar and incubated anaerobically  for 48 h. Positive controls were 
maintained, in which only  water was used for cleaning. Negative controls were also 
included using uncontaminated squares on each surface. The log10 reduction was 
calculated (2.8.5) from two independent experiments. 
2.8.7. Effect of sub-MIC concentrations on sporulation 
C. difficile strains were cultured in media containing 1/4 MIC of each agent as 
determined from 2.8.2 to study the effect of sub-MIC concentrations on growth and 
sporulation. The agents were diluted in AIM with and without 0.5% sodium 
taurocholate. The dilutions (200 µl) were added to the wells of a 24-well plate 
(Greiner) and allowed to pre-reduce for 4 h. Starter cultures were prepared (2.2.2) 
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and 1 ml of this culture was added to 11 ml of pre-reduced AIM  and incubated 
anaerobically  at 37°C for approximately  4 h until an OD600 of 0.3 (±0.05) was 
achieved. Positive controls without agents and negative controls without culture were 
maintained. The experiments were performed in duplicate. Following incubation, 
OD600 of the cultures was measured to check the growth of the cultures. They  were 
left under aerobic conditions for 24 h to ensure death of the vegetative cells. Spore 
production was determined by plating 10-fold serial dilutions of the cultures on 
blood agar and incubating anaerobically for 5 d. 
2.9. Detection of environmental contamination
2.9.1. Sampling
To examine the prevalence of environmental contamination with C. difficile, 93 sites 
in and around our laboratory were sampled with contact  plates. Sampling was 
performed in duplicate; for 40 sites, one CCEY agar and one blood agar plate were 
used and for the remaining 53 sites, two blood agar plates were used. The plates were 
incubated at 37°C for 5 d. The total load of anaerobic bacteria and the percentage of 
C. difficile were calculated from the colonies obtained on the plates.
2.9.2. DNA extraction and typing
The suspected C. difficile isolates were sub-cultured on blood agar for 48 h and their 
identity  was confirmed by  colony morphology, odour and the characteristic golden-
yellow fluorescence under UV light. DNA extraction was performed using 
Chelex®100 (BioRad) (2.3.1) followed by ribotyping (2.3.2). 
2.10. Statistical analysis
All statistical tests were performed using the GraphPad Software Prism 4.0. Non-
linear regression analysis was performed for assays involving standard curves. Inter-
strain comparisons were performed by area under curve (AUC) analyses and 1-way 
analysis of variance (ANOVA) testing.
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3. Growth-related virulence of C. difficile
3.1. Introduction 
Virulence is a measure of the degree to which a pathogen can cause disease in a host. 
For bacteria, the conditions and rate of growth are closely related to the production 
of virulence factors. The virulence of C. difficile is primarily dependent on the 
production of its spores and its two toxins - toxin A and toxin B - which together 
maintain the cycle of C. difficile infection and transmission. This study investigates 
whether the level of expression of toxins and spores varies between C. difficile 
strains was investigated. 
3.1.1. Role of growth rate in virulence
The growth rate of a microorganism is an important factor in its pathogenesis and 
can contribute to the outcome of an infection (Brown & Williams, 1985; Smith, 
1990). In some organisms, it has been observed that virulence increases with the 
growth rate (Marsh et al., 1994). A fast growing organism can overcome the initial 
non-specific immune response generated by the host, allowing the disease to be 
established before the specific response can be generated (Smith, 1990). Rapid 
growth of organisms can be beneficial if receptors for adhesins are expressed earlier 
and adherence to cells can be induced sooner. It can also compensate for the loss of 
bacterial numbers at the primary site of infection. In acute disease, rapid growth is 
required to evade the initial non-specific immune response. In chronic infection, 
however, the slower the growth rate, the less the immune response generated and the 
longer the pathogen can persist within the host and cause disease. For a carrier status, 
an extended resistant  stationary phase may be beneficial to the organism. Thus, the 
growth rate is significant in the type of infection established and the outcome of 
disease. Growth rates is governed by the internal environment of the host and the site 
of infection. The size of the pathogen population depends not  only on the growth 
rate, but also on the tissue’s ability to sustain it (Smith, 2000).
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The growth of organisms in vivo can vary significantly from growth in vitro as it  is 
dependent on the host  environment (Smith, 1990). This observation calls into 
questions the use of in-vitro studies altogether. Furthermore, certain virulence factors 
may only  be expressed within the host, but others such as production of 
siderophores, responses to nutrient limitation and sensitivity to antibiotics can be 
observed in vitro (Brown & Williams, 1985; Gilbert et al., 1990). Thus, in-vitro 
studies can be used as a starting point for investigation of bacterial virulence factors.
In C. difficile infection, the clinical spectrum ranges from mild diarrhoea to 
fulminant colitis, suggesting that several strains of varying virulence exist (Knoop  et 
al., 1993). However, comparisons between growth of different C. difficile strains 
with varied virulence, including potentially ‘hypervirulent’ strains, have not revealed 
any significant variations in growth rates and patterns (Merrigan et al., 2010; Warny 
et al., 2005) suggesting that growth rate does not influence virulence, at least in vitro.
3.1.2. Toxins and spores as virulence factors
The toxins and spores of C. difficile are its main virulence factors. During CDI, 
vegetative cells produce both toxins and spores. The toxins elicit their enterotoxic 
and cytotoxic effects within the gastrointestinal tract of the host (1.4.1.2) and the 
damage leads to diarrhoea and disease (1.2.3). During this process, vegetative cells 
produce spores, which are released into the environment. The spores survive and 
persist in the environment and are transmitted to susceptible individuals within 
whom they can germinate into vegetative cells and resume the infection cycle 
(1.4.3). Sporulation and toxin production were suggested to be alternative 
mechanisms for survival (Akerlund et al., 2006) but more recently it has been shown 
that both processes are co-regulated (Underwood et al., 2009).
3.1.2.1. Toxin A or toxin B?
The lethality  of C. difficile toxins has been a subject of debate since their discovery. 
Which is more important in disease: toxin A or toxin B? Toxin A was originally 
observed to cause more severe disease and increase mortality in mice and hamsters 
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(Taylor et al., 1981) but in another study, toxin B was found to be more lethal to 
mice per milligram of protein as compared to toxin A (Sullivan et al., 1982). It was 
then demonstrated that  a crude filtrate of C. difficile VPI 10463 administered 
intragastrically to hamsters could cause hemorrhagic fluid to accumulate in the 
stomach, small intestine and caecum, but when toxin A was removed by 
immunoadsorption, no diarrhoea or pathology was observed (Lyerly  et al., 1985). 
When only toxin B was administered to the hamsters, no damage was caused even at 
high amounts, but when a small amount of toxin A was added to toxin B, CDI 
pathology was observed. Also, toxin B administered to animals with bruised ceca 
resulted in illness and death. Interestingly, multiple small doses of toxin A which 
were individually  harmless seemed to have a cumulative effect over time. These 
observations indicated that toxin A was more potent than toxin B and that initial 
damage by  toxin A or physical damage to the intestinal epithelium was required to 
mediate toxin B cytotoxicity. In another study, it was shown that the intensity  of 
inflammation induced in CDI was not dependent on the concentration of toxin B 
(Vernet et al., 1989). However, a study showing that toxin B was ten times more 
potent at inducing morphological damage in human colonic cells than toxin A 
suggested that  it could play  an equally important role in the pathogenesis of C. 
difficile (Riegler et al., 1995). 
This debate was further complicated by the discovery of A-B+ C. difficile strains 
(Depitre et al., 1993; Kato et al., 1999). The cytopathic effects, substrate specificity 
and receptor-binding domain of toxin B of these strains were similar to the lethal 
toxin of C. sordellii, possibly  owing to recombinational exchange (von Eichel-
Streiber et al., 1995). Axenic mice treated with these strains did not develop 
diarrhoea or die but the animals were successfully colonised and even protected from 
subsequent infection (Depitre et al., 1993). However, human infection was observed 
with these strains reaffirming the importance of toxin B in CDI (Drudy et al., 2007a).
A recent study  using toxin A and B mutants also showed that toxin B was essential in 
CDI (Lyras et al., 2009). Toxin A mutants produced wild-type levels of toxin B and 
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were as lethal to hamsters as wild-type strains, while toxin B mutants were able to 
colonise hamsters but were lethal to only 21% of the infected animals. The most 
recent investigation into the importance of the two toxins demonstrated that both 
toxins were equally essential for virulence (Kuehne et al., 2010). Individual toxin A 
and toxin B knockout strains were able to cause disease in hamsters, whereas a 
double-mutant was only able to colonise the animals and not induce any symptoms.
3.1.2.2. Kinetics of toxin and spore release during growth
Growth-related toxin and spore production has been studied in several C. difficile 
strains over the years. In most studies, an exponential phase of 12 hours followed by 
a stationary phase of 12 hours has been observed (Ketley  et al., 1984; Rolfe & 
Finegold, 1979). Growth was not found to be variable between C. difficile strains 
despite their toxigenic potential (Vernet  et al., 1989). Amounts of toxin in culture 
filtrates were observed to increase in the stationary phase of growth as numbers of 
vegetative cells decreased (Ketley et al., 1984; Onderdonk et al., 1979; Rolfe & 
Finegold, 1979). Strains producing greater amounts of toxin A also produced greater 
amounts of toxin B (Tucker et al., 1990; Vernet et al., 1989). A correlation between 
the strain of C. difficile and the amount of toxin produced was observed. Strains 
belonging to serogroups A, C, G and H produced lower levels of toxin as compared 
to VPI 10463 (Karlsson et al., 2003; Wren et al., 1987). Spores were detected only 
after the exponential phase (Kamiya et al., 1992; Ketley  et al., 1986; Onderdonk et 
al., 1979). These studies together gave a general idea of the behaviour of C. difficile 
in vitro and demonstrated that toxin and spore production in C. difficile could vary 
with the phase of growth and the strain in question. Any variations observed were 
probably  due to differences in the media used or the size of the initial inoculum 
(Dupuy & Sonenshein, 1998; Hundsberger et al., 1997; Mathis et al., 1999). 
3.1.3. Pathogenicity locus
The pathogenicity locus (PaLoc) or toxigenic element of C. difficile is a 19.6 kb 
chromosomal region that codes for toxin A and toxin B (Fig. 3.1) (Hammond & 
Johnson, 1995). This highly stable and conserved region consists of five open 
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reading frames (ORFs) - tcdR is the first (5’) gene in the PaLoc, followed by tcdB, 
tcdE, tcdA and tcdC, respectively (Cohen et al., 2000; Hammond & Johnson, 1995). 
The PaLoc has features of a distinct genetic element. It has a single integration site, 
unidirectional orientation, gene with sequences dissimilar to any others on the 
chromosome and conserved bordering sequences (Braun et al., 1996). It is not an 
independent mobile genetic element as no transposon-, phage- or plasmid-like 
elements or inverted repeats characteristic of mobile genetic elements are found 
adjacent to it (Braun et al., 1996). In non-toxigenic strains, the PaLoc is replaced by 
a unique conserved 115 bp  fragment (Braun et al., 1996; Hammond & Johnson, 
1995). This fragment does not contain an ORF but does have several internal repeat 
regions which are characteristic of an insertion sequence (Hammond & Johnson, 
1995). Also, a hairpin loop upstream of the 115 bp fragment which forms a 
transcription terminator might play a role in the integration and possible 
recombination of the PaLoc (Braun et al., 1996).
It was originally believed that the PaLoc was necessary for virulence and that only 
strains producing both toxins could produce clinically  significant disease, but disease 
caused by A-B+ strains has been widely reported (Drudy et al., 2007a; Limaye et al., 
2000). Thus, the complete PaLoc is not essential for disease (Cohen et al., 2000). 
Cases of diarrhoea caused by non-toxigenic C. difficile strains have been also 
reported suggesting that there are other virulence determinants present  in C. difficile 
(Martirosian et al., 2005).
3.1.3.1. tcdA and tcdB
The toxin genes, tcdA and tcdB, lie within 1.4 kb of each other on the PaLoc and are 
transcribed in the same direction (Hammond & Johnson, 1995; Hammond et al., 
1997). tcdA and tcdB are genes of 8133 bp and 7089 bp, respectively  (Barroso et al., 
1990; Dove et al., 1990). Both toxin genes have a G+C content of less than 28% and 
exhibit a high level of similarity  of approximately  66% (von Eichel-Streiber et al., 
1990; Voth & Ballard, 2005). Characteristic of clostridial toxin genes tcdA and tcdB 
have a very long spacing between the start codon ATG and the transcription start in 
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the promoter and have stem-loop transcriptional terminators at their 3’ ends (von 
Eichel-Streiber et al., 1992). The genes are 49% identical and 14% of the regions 
show conserved substitutions (von Eichel-Streiber et al., 1992). The most 
homologous regions of the toxins are the N- and C-termini. The N-termini show 64% 
homology, which explains the similarity in their biological activity on the same 
cellular substrates. This structural and functional similarity suggests that the genes 
arose by duplication. The C-terminal CROP clusters in the two genes are also highly 
homologous but those in tcdB are more varied. There is only  one region in the gene 
products that has an amino acid homology of only  30% - residues 1441 to 1689 in 
TcdA and residues 1440 to 1692 in TcdB. The variations in this region and in the C-
terminal CROPS might explain the difference in the effects of the toxins in vivo and 
could be the reason why they induce distinctive and specific polyclonal antibodies. 
Fig. 3.1. PaLoc of C. difficile and ORFs outside it
The pathogenicity locus of C. difficile is shown using that of strain VPI 10463 as an example. 
The 19.6 kb PaLoc contains five open reading frames: the toxin genes tcdA and tcdB, the 
positive regulator of toxin production tcdR, the negative regulator tcdC and tcdE, which 
codes for a holin-like protein involved in the release of toxins. There are four conserved 
genes upstream of the PaLoc - cdu3, cdu2, cdu2ʼ and cdu1  - and four conserved genes 
downstream of it - cdd1, cdd2, cdd3 and cdd4 - which could play a role in regulation or 
integration of the PaLoc genes. The direction of the arrows indicates the direction of 
transcription of the genes. The positions of the primers designed for real-time RT-PCR in this 
study are indicated below the PaLoc map. In non-toxigenic C. difficile strains the PaLoc is 
replaced by a 115 bp DNA fragment which bears similarity to an insertion sequence. Adapted 
from Braun et al., 1996.
0           5                  10                15          20 kb 
cdu2    cdu1                   cdd1       cdd2 cdd3 cdd4 
tcdR      tcdB       tcdE               tcdA                 tcdC 
R1 R2                 B1 B2 E1 E2    A1 A2             C1 C2   
115 bp 
cdu3    cdu2’ 
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3.1.3.2. tcdR
tcdR is the first gene of the PaLoc and is the positive regulator of toxin production. It 
is a 552 bp gene that lies upstream of tcdB and is transcribed in the same direction as 
the toxin genes (Hammond & Johnson, 1995). The role of tcdR in toxin production 
was first demonstrated in an expression vector system (Moncrief et al., 1997). It was 
observed that with tcdR in trans, toxin A and toxin B production was 500-fold and 
800-fold higher, respectively, than expression in the absence of tcdR. This proved 
that the toxin genes had their own promoters which could be stimulated by TcdR. 
TcdR is an alternate sigma factor (Mani & Dupuy, 2001). It  is a basic protein of 184 
amino acids and molecular weight of 22 kDa with a C-terminal helix-turn-helix motif 
characteristic of DNA-binding proteins (Braun et al., 1996; Hammond & Johnson, 
1995; Hundsberger et al., 1997). Sequence comparison showed that TcdR was 28% 
identical to UviA, the positive regulator of bacteriocin production in C. perfringens 
and 21% identical to Orf-22 of C. botulinum 468, the positive regulator of neurotoxin 
C1 production (Hundsberger et al., 1997; Moncrief et al., 1997). These three genes 
have similar promoters and regulate transcriptional control over their respective toxin 
genes (Hundsberger et al., 1997; Marvaud et al., 2000). 
TcdR regulates the transcription of the PaLoc by mediating binding of the RNA 
polymerase holoenzyme to promoters of the toxin genes (Mani & Dupuy, 2001). It 
cannot bind to the promoters itself, but can bind to RNA polymerase in the absence 
of the promoters and possibly alters the structure of RNA polymerase to stabilise 
promoter-binding. The promoter of tcdR is highly homologous to those of tcdA and 
tcdB (Braun et al., 1996). Thus, it is not surprising that along with activating the 
transcription of the toxin genes, it also activates its own expression and is auto-
regulated (Mani & Dupuy, 2001; Mani et al., 2002). tcdR regulation is controlled by 
environmental stimuli through its two promoters: one is involved in basal expression 
of the gene during the exponential phase of growth and does not require TcdR, while 
the other is TcdR-dependent and is affected by growth phase and also by the presence 
of carbon sources such as glucose (Mani et al., 2002).
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3.1.3.3. tcdC
tcdC is the last gene of the PaLoc and is the negative regulator of toxin production. It 
is a 695 bp  gene located downstream of tcdA and is transcribed in the opposite 
direction to the toxin genes (Dove et al., 1990; Hammond & Johnson, 1995; Phelps 
et al., 1991; von Eichel-Streiber et al., 1992). It was originally thought that tcdC was 
not required for toxin production (Phelps et al., 1991). However, transcriptional and 
translational studies showing that its expression was inversely  correlated to that of 
the other PaLoc genes suggested that tcdC negatively regulated toxin production 
(Govind et al., 2006; Hundsberger et al., 1997).
TcdC is a highly acidic 26 kDa protein containing stretches of repetitive amino acids 
and shows no homology  to any  known protein (Braun et al., 1996; Hundsberger et 
al., 1997). It is a membrane-associated protein that can form dimers (Govind et al., 
2006; Matamouros et al., 2007). It has a transmembrane domain at the N-terminal 
and an active domain at the C-terminal (Matamouros et al., 2007). The N-terminal is 
antigenic but not required for activity. The C-terminal is highly similar to that of 
Bacillus cereus BD-0954 and Lactobacillus casei A2 bacteriophage A2-p22 protein 
and appears to be a conserved domain. The latter proteins are coded near or in 
temperate bacteriophage genomes suggesting that the PaLoc could have similar 
origins. Although the regulation of gene expression by transcription factors localised 
within cell membranes seems unlikely, membrane-associated transcriptional factors 
have been identified in other organisms such as the RpoE sigma factor of E. coli 
(Dartigalongue et al., 2001). 
TcdC specifically represses transcription of the PaLoc by destabilising the TcdR-
containing holoenzyme which initiates transcription of the toxin genes (Dupuy et al., 
2008; Matamouros et al., 2007). Like TcdR, TcdC cannot directly bind to the 
promoters of the toxin genes but it can bind to the TcdR-RNA polymerase complex. 
The TcdR-holoenzyme is more sensitive to TcdC than the TcdR-holoenzyme-
promoter complex. TcdC sequesters TcdR in the manner of a classical anti-sigma 
factor. However, it  can also interact directly with RNA polymerase and perhaps 
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represses toxin production by more than one mechanism. TcdC expression appears to 
be growth phase-dependent with greater amounts of protein being detected in the 
membrane fraction of cells in the exponential phase than in the stationary phase of 
growth (Govind et al., 2006). This is in agreement with expression of tcdC seen 
previously  (Hundsberger et al., 1997). However, recent studies have not consistently 
observed such expression patterns and have suggested that TcdC might have a 
regulatory rather than a repressive role in toxin production (Merrigan et al., 2010).
The tcdC gene has been shown to carry  a number of deletions and extensive 
molecular analyses have been performed to define these mutations. Initially, three 
tcdC genotypes were identified: A, B and C (Spigaglia & Mastrantonio, 2002). tcdC-
A shows a 39 bp deletion, while tcdC-B and tcdC-C show an 18 bp deletion. The 
truncation of TcdC to 61 amino acids from 232 amino acids is observed in tcdC-A, 
while tcdC-B and C code for the same protein of 226 amino acids. Apart from tcdC-A 
and tcdC-B, 15 other unique tcdC genotypes have been identified, with 18 bp or 36 
bp deletions (Curry  et al., 2007). Of these, the tcdC-sc1 genotype carries an 18 bp 
deletion along with a single nucleotide deletion at position 117 (%117) which 
introduces a stop  codon and truncates the TcdC protein to 65 amino acid residues 
(Curry  et al., 2007; MacCannell et al., 2006). This genotype was found to be 
conserved in strains belonging to ribotype 027 which produced high levels of toxin 
(Curry  et al., 2007). The 18 bp deletions were initially  believed to correlate with 
greater virulence but this was later found to be untrue (Matamouros et al., 2007). The 
%117 deletion might be of greater significance in virulence (Curry et al., 2007). 
3.1.3.4.  tcdE
tcdE is a 501 bp  gene located between tcdA and tcdB and is believed to have a role in 
the secretion of toxins from within C. difficile cells as the toxins do not have signal 
peptides for release (von Eichel-Streiber & Sauerborn, 1990).
TcdE is a highly  hydrophobic protein of 166 amino acids and molecular weight of 19 
kDa (Dove et al., 1990; Hundsberger et al., 1997). It has structural features similar to 
those of bacteriophage holin proteins such as homologue yqxH of B. subtilis, holins 
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of Streptococcus thermophilus bacteriophage Sfi19 and of S. pneumoniae phage 
Cp-1 (Tan et al., 2001). The greatest similarity between these proteins was found in 
the 46 amino acids present at the C-terminal. 
The role of tcdE was investigated using an expression vector system (Tan et al., 
2001). Cells expressing TcdE stopped growing on the induction of tcdE; the loss of 
cell membrane integrity, which was characterised by the fusion of the periplasm and 
the cytosol and the lack of membrane secretory vesicles, resulted in cell lysis. Thus, 
TcdE could function as a lytic protein and aid toxin release. However, recent  studies 
have found that TcdE does not induce lysis or affect membrane integrity (Govind & 
Dupuy, 2010). Instead, it facilitates toxin release by a phage-like system. TcdE, 
which is predicted to contain three transmembrane domains, could perhaps form 
gated channels in the membrane specific for the toxins, which would explain the lack 
of cytoplasmic leakage observed in these studies. 
3.1.3.5.  Upstream and downstream of the PaLoc
Upstream of tcdR lie cdu3, cdu2, cdu2’ and cdu1 which are genes of 238, 939, 192 
and 378 bp, respectively (Braun et al., 1996). They are all transcribed in the same 
direction as the toxin genes. Cdu1 has features similar to those of repressor proteins 
and DNA-binding proteins and could be an effector molecule in regulation, while 
Cdu2 and Cdu2’ together could function as a Na+-transporter. 
Downstream of tcdC are cdd1, cdd2, cdd3, cdd4 which are genes of 243, 735, 759 
and 903 bp, respectively. cdd1 shares the same orientation as tcdC, while the other 
genes are transcribed in the opposite direction. Cdd2-4 might be functionally-linked 
proteins that could form an ABC transporter system commonly associated with 
macrolide resistance in Gram-positive bacteria. 
3.1.4. Expression of the PaLoc 
3.1.4.1. Transcriptional analysis
Studies by Moncrief and colleagues were the first to suggest transcriptional 
regulation of toxin genes when they showed that tcdR in trans was required for toxin 
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production and that the mRNAs for the toxin genes were detected in a growth phase-
dependent manner (Moncrief et al., 1997). tcdB levels began to rise at 8 hours and 
continued to rise during the stationary  phase, while tcdA expression did not occur till 
the late exponential to early stationary phase.
Transcription of the entire PaLoc was first investigated by  Hammond and co-workers 
using hybridisation probes (Hammond et al., 1997). They found that probes designed 
for tcdA, tcdB, tcdR and tcdE all hybridised to a transcript  of 17.5 kb but the tcdC 
probe did not. The tcdA probe also hybridised to a band of 8.4 kb, while the tcdB 
probe hybridised to two additional bands - one of 8.1 kb and 7.4 kb. Probes for tcdR 
and tcdE also hybridised to the 8.1 kb band. From these observations, it was evident 
that the toxins were being transcribed monocistronically  and polycistronically. It was 
concluded that  the toxin A transcript was processed immediately  form the 17.5 kb 
band, while the toxin B transcript was processed from the three different bands. The 
tcdR and tcdE probes hybridised with bands of 700 bp and 1 kb, respectively along 
with the 8.1 kb band and were thus co-transcribed with tcdB. Transcription from the 
full-length transcript and the individual transcripts occurred concurrently  suggesting 
that expression of the toxin genes was co-regulated. Also, the transcription initiator 
site for the 17.5 kb transcript was identified approximately  236 bp upstream of tcdR 
and for tcdA and tcdB, the initiator sites were 233 bp and 164 bp  upstream of the 
respective genes indicating regulation at the transcriptional level. Further, very  few 
variations were observed in the intergenic regions of the PaLoc between strains with 
varying toxigenic potential suggesting that the observed regulation was not a result 
of differences in the DNA sequences of the regulatory regions.
Hundsberger and colleagues demonstrated growth-related transcription of the PaLoc 
(Hundsberger et al., 1997). They showed that all five genes were transcribed 
throughout growth. However, the amount of tcdC mRNA produced was high in the 
exponential phase and decreased in the stationary phase, whereas the opposite 
transcription pattern was observed for the four remaining genes; transcription of 
tcdR, tcdB, tcdE and tcdA was detected only  at basal levels during the exponential 
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phase and increased during the stationary phase. No read-through transcripts from 
outside the PaLoc were detected and therefore, transcription was driven from the 
promoters for tcdR and tcdC. Two transcription units were observed due to the 
presence of a bidirectional terminator between tcdA and tcdC and five transcription 
initiator sites ptcdR, ptcdB1, ptcdB2, ptcdE and ptcdA were suggested.
Dupuy and co-workers found that the tcdB transcript was initiated within or upstream 
of tcdR and the tcdA transcript was initiated upstream of tcdE; no second promoter 
site for tcdB was found (Dupuy & Sonenshein, 1998). When C. difficile was grown 
in a medium devoid of glucose, low levels of tcdA and tcdB mRNA were detected 
during the early exponential phase but there was a rapid accumulation of mRNAs 
towards the end of the exponential phase and maximum detection in the early 
stationary phase. The level of tcdA mRNA detected was almost 2-fold higher than 
that of tcdB but the increase in their mRNA and protein levels occurred 
simultaneously. The correlation between the time of transcription and translation of 
the toxins suggested that they were co-regulated.
Even in C. difficile strain 8864, which has an insertion between tcdE and tcdA and 
deletion of the 3’ regions of tcdA and tcdC, all the PaLoc genes were transcribed 
during growth and the transcription was phase-dependent (Soehn et al., 1998). 
Expression of tcdR, tcdB and tcdE was low in the early exponential phase but 
increased later and reached the maximum level in the stationary phase but that of 
tcdC and tcdA was independent of growth and remained at a constant low level. 
In general, greater levels of toxin mRNA were detected in more toxic strains and 
more transcripts of tcdA than tcdB were detected, normally  at a ratio of 3:1 
(Hammond et al., 1997; Mathis et al., 1999). Although the pattern of transcription of 
the PaLoc was the same in all the above-mentioned studies, the precise timing of the 
exponential and stationary phases varied. These differences in times of growth and 
expression possibly arose owing to factors such as inoculum size and type of 
medium used (Dupuy & Sonenshein, 1998; Hundsberger et al., 1997; Mathis et al., 
1999).
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Expression of the PaLoc has been observed to be repressed by the codY gene (Dineen 
et al., 2007). CodY is able to bind strongly to the promoter of tcdR and weakly to the 
promoters of tcdA and tcdB. It also binds to three sites upstream of tcdR. 
Interestingly, CodY also inhibits the transcription of tcdC but to a lesser degree than 
the other genes. Thus, toxin repression by CodY appears to occur directly through 
the control of tcdR expression. 
3.1.4.2. Response to environmental stimuli
Toxin production in C. difficile varies in response to the environmental conditions 
such as available nutrients and changes in temperature. Dupuy and Sonenshein found 
that toxin mRNAs began to accumulate in the late exponential phase only  in glucose-
deficient complex media (Dupuy & Sonenshein, 1998). The level of transcription 
declined significantly in the presence of glucose in a dose-dependent manner; at  a 
concentration of 1% glucose in the medium, toxin production was almost completely 
repressed. The same effect was observed with fusion vectors expressing tcdR and 
tcdA suggesting that repression occurred through the promoters of these genes. 
Fructose and mannitol also repressed toxin gene expression but this was not seen 
with non-fermentable sucrose or starch. Buffering the medium to pH 7 had no effect 
on repression. For C. difficile cells grown in brain-heart infusion broth containing 
glucose, the level of tcdA mRNA was 15% lower than that seen in the glucose-
deficient tryptone yeast extract medium. The differences in toxin levels correlated 
with the differences in gene expression. Minimal differences in promoters of the 
toxin genes suggested the involvement of regulatory mechanisms such as catabolite 
repression (Dupuy & Sonenshein, 1998). 
To further investigate this nutritional link with toxin production, Karlsson and co-
workers studied growth and toxin production of C. difficile in defined and complex 
media with and without glucose (Karlsson et al., 1999). In both media, growth rate 
and growth phase did not affect toxin production. In the defined medium, lower 
glucose concentrations resulted in lower toxin production but in the complex 
medium, the opposite effect was observed. Thus, glucose was not exerting catabolite 
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repression on the toxin genes. When select amino acids were added to the complex 
glucose-deficient medium, toxin production was notably reduced. This suggested that 
high toxin production observed in C. difficile strains after the exponential phase of 
growth could be a result of amino acid limitation. The addition of the amino acid 
mixture to the glucose-containing complex medium had no effect on toxin 
production. Thus, high toxin production was a result of stress; addition of glucose 
and removal of biotin led to the concomitant down-regulation of the toxins and other 
proteins. 
The addition of biotin and amino acids such as lysine, glutamine, glutamic acid, 
asparagine and cysteine have also been shown to inhibit toxin production (Karlsson 
et al., 2008; Yamakawa et al., 1996; Yamakawa et al., 1998). Addition of cysteine to 
the growth medium blocked synthesis of the toxins and approximately  40 other 
proteins which were involved in metabolic pathways utilising alternate energy 
sources such as succinate, butyrate, carbon monoxide and folate. Further, 
simultaneous transcription of tcdA, tcdR, folD and sigH suggested a common 
regulatory mechanism and an association between toxin production, alternate energy 
metabolism and initial sporulation events. 
The repression of toxin production by  CodY also changed with environmental 
conditions; greater repression was observed in the presence of branched-chain amino 
acids and GTP (Dineen et al., 2007). This suggested that toxins were expressed and 
released only when cells were deprived of nutrients (Dineen et al., 2010). 
Toxin production was also found to be temperature-dependent (Karlsson et al., 
2003). This dependence was unaffected by  the nutritional constituents of the medium 
in which C. difficile was grown. Maximum toxin production was observed at 37°C, 
with much lower levels of toxin detected at 22°C and 42°C. Corresponding increases 
in mRNA levels of tcdA and tcdB were also detected at 37°C. This was a clear 
indication of adaptation to host conditions. tcdR expression was also temperature-




spo0A is the gene that encodes the master-regulator for sporulation Spo0A in 
Clostridium and Bacillus species, although there are genetic differences between the 
two species (Burns et al., 2010b; Molle et al., 2003). Spo0A directly and indirectly 
regulates expression of several genes controlling stationary-phase events such as 
sporulation, DNA replication, flagellum synthesis and others (Molle et al., 2003; 
Underwood et al., 2009). 
Spo0A is essential for sporulation in C. difficile (Underwood et al., 2009). 
Inactivation of spo0A led to a completely asporogenous phenotype but did not affect 
growth of the bacterium. However, it did lead to reduced toxin production in the 
stationary phase of growth. This decrease was not because of diminished ability  of 
cells to release toxins, indicating that  spo0A exerted transcriptional or translational 
control on toxin production. The link between toxin production and spo0A has also 
been identified in other Clostridia. In C. perfringens, inactivation of spo0A or lower 
levels of transcription of spo0A resulted in a lack of spore and enterotoxin production 
(Huang et al., 2004; Huang & Sarker, 2006). 
As observed in Bacillus subtilis, spo0A transcription in C. difficile was switched on 
at the mid-exponential phase of growth and increased gradually during transition into 
the stationary phase (Fujita & Losick, 2005; Saujet et al., 2011). Interestingly, this 
increased spo0A expression at the end of the exponential phase corresponded with 
increased expression of tcdR, tcdA and tcdB, indicating a transcriptional link between 
spore and toxin production (Saujet et al., 2011).
3.1.6. Changing epidemiology of C. difficile in Scotland
The incidence of C. difficile infection in Scotland has been closely monitored since 
mandatory reporting was introduced in September 2006. The first surveillance report 
focussed on disease in patients above 65 years and identified two predominant 
ribotypes: 106 (64%) and 001 (18.5%) (Health Protection Scotland, 2008a). Only 
three cases of ribotype 027 were identified. However, by  2008, incidence of ribotype 
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027 disease was on the rise and even outbreaks caused by it had been reported 
(Health Protection Scotland, 2008b). In 2009, ribotypes 106 and 001 remained the 
most common strains but there was an emergence of ribotypes 027 and 078 (Health 
Protection Scotland, 2009a). Also in 2009, surveillance of infection in the age group 
from 15 to 65 years was carried out for the first time and 311 cases of CDI were 
reported in this group  (Health Protection Scotland, 2009b). Until early 2010, 
incidence of infection owing to ribotypes 106, 001 and 027 remained more or less 
constant but towards the end of the year, prevalence of these ribotypes had decreased 
and an emergence of ribotypes 015, 002, 014,020 and 005 was observed (Health 
Protection Scotland, 2010; Health Protection Scotland, 2011). Over this short period 
of time, there has been a change in the predominant C. difficile strains in Scotland. 
A look at the history  of C. difficile in Scotland reveals that several different ribotypes 
were responsible for infection over the years and there has been an ongoing change 
in predominant strains (Taori et al., 2009). Ribotype 012, to which the reference and 
the first-sequenced strain 630 belongs, represented 5% of C. difficile isolates 
collected between 1979 and 2004 but is no longer reported in the infected population. 
The incidence of ribotype 001 has increased over the years from 1.5% to 75.8% by 
October 2005, whereas ribotype 106 was not identified in Scottish isolates till 2004 
and was responsible for 8.1% of cases by 2005 (Mutlu et al., 2007). The same year 
witnessed the first case of ribotype 027 infection and its prevalence has increased 
steadily until recently (Health Protection Scotland, 2011). 
The aim of this study was to identify characteristics that differentiated historic strains 
such as strain 630 from recently endemic ribotypes such as 027, 001 and 106. All 
these C. difficile strains are multidrug-resistant and have been associated with severe 
disease (Arvand et al., 2009; Sundram et al., 2009; Wüst  et al., 1982). The study 
aimed at  measuring growth and simultaneous toxin and spore production in these 
strains over a 24 hour period by OD600 measurement, immunoassays and viable 
counts, respectively at  the phenotypic level and by quantitative real-time PCR of the 
genes involved in toxin and spore production at the genetic level.
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3.2. Methods
Growth of five C. difficile strains - strain 630, VPI 10463, ribotype 027, ribotype 001 
and ribotype 106 - was studied over 10 d and 24 h (2.2.3). 24 h growth curves with 
sampling every 4 h was chosen as the standard methodology for all virulence factor 
investigations. Total toxin production was measured using a commercial combined 
ELISA kit (2.2.4) and spore production was measured by viable counts (2.2.5). To 
study transcription of the PaLoc genes and spo0A, a real-time RT-PCR method was 
developed (2.7.1) and performed (2.7.2). In order to correlate transcription of the 
genes to production of the individual toxins, several methods for quantification of the 
individual toxins were investigated. Firstly, purification of toxin A and toxin B from 
dialysis cultures was attempted (2.4.1-2.4.3) to obtain standards for development of 
immunoassays. Following the failure of these methods, commercial toxins were 
purchased (2.5.5). For the quantification of toxins, dot blots (2.5.1) were used and a 
system for protein quantification from dot blots was developed (2.5.3). However, due 
to the lack of sensitivity of this technique and the availability  of commercial 
antibodies to the toxins sandwich ELISAs for the individual toxins were developed 
instead (2.5.6). The ELISA for toxin A was performed successfully  (2.5.4) but that 
for toxin B was unsuccessful in detecting the toxin from culture supernatants. Thus, 
for toxin B, the standard cytotoxicity  (and neutralisation) assay was modified to 
make it a quantitative method (2.6.7). Results from these experiments were collated 
and statistically analysed by AUC and ANOVA (2.10). Further, the tcdC, tcdR and 
tcdE genes of the strains were sequenced to identify genetic differences between 
them (2.3.6-2.3.8, 2.3.13). Growth-related release of virulence factors and inter-strain 
differences were demonstrated. 
3.3. Results 
In this study, growth of five strains of C. difficile was studied and the simultaneous 
production of toxin A and toxin B, as well as spores, were analysed by phenotypic 
assays and gene transcription analysis. 
91
3.3.1. Growth, total toxin production and spore production
Growth of the five C. difficile strains over 24 h and over 10 d both showed similar 
patterns (Fig. 3.2). Comparing growth of the strains individually  at each time-point 
over the 24 h period, the only difference observed was for ribotypes 001 and 106 
which showed a slight but significant increase in cell density at 4 h when compared 
to strains 630 and VPI 10463 (p<0.001) but not when compared to ribotype 027. 
Total toxin (A+B) production as measured by the combined ELISA kit varied 
significantly between the strains (Fig. 3.3). In ribotype 027, total toxin production 
increased significantly  between 8 and 12 h. By 12 h, ribotype 027 and VPI 10463 
produced significantly more toxin than the other strains (p<0.001). Ribotype 106 
produced more toxin than 001, which in turn was greater than strain 630. All the 
strains produced alcohol-resistant spores and their numbers in culture increased 
gradually over time, except in ribotype 106 which showed a dramatic increase in 
spore production beyond 8 h (Fig. 3.4). 
Growth, toxin production and spore production were statistically  analysed (Fig. 3.5). 
Over the 24 h, there was only a significant difference (p<0.05) between growth of 
strain 630 and ribotype 027. In the exponential phase, this difference was observed 
between strain 630 and ribotypes 027 and 106, but in the stationary phase there was 
no difference between the strains. Total toxin production over 24 h and in the log 
phase of growth were significantly different between all the strains (p<0.001); 
ribotype 027 and VPI 10463 produced significantly  higher amounts of total toxin. In 
the stationary  phase, there was a significant difference between ribotype 027 or VPI 
10463 and the other strains (p<0.001) but there was no difference between them; 
both strains caused a saturation of the ELISA in this phase of growth. Spore 
production in ribotypes 106 and 027 was significantly  more than that in the other 
strains (p<0.001). The difference was less significant between strain 630 and 
ribotype 001 (p<0.01). Thus, growth rate clearly did not contribute significantly to 
the virulence of C. difficile. However, it was evident that ribotype 027 produced large 
amounts of toxin that could contribute to its increased virulence. Also, increased 
spore production in ribotypes 106 and 027 could enhance their virulence.
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Fig. 3.2. Growth of five strains of C. difficile 
Growth of C. difficile (a) strain 630 (!), (b) VPI 10463 (!), (c) ribotype 027 ("), (d) ribotype 
001 (") and (e) ribotype 106 (#) was studied over a period of 24 h (black) and 10 d (grey) by 
measuring OD600. Over 24 h, the patterns of growth were similar for all the strains; however, 
at 4 h, ribotypes 001 and 106 showed significantly increased growth as compared to strains 
630 and VPI 10463 (p<0.001) and ribotype 027 (p<0.05). This could be indicative of the 
behaviour of these strains in vivo; faster initial growth may aid colonisation. Bars indicate +/- 
SEM of 4 growth curves performed in triplicate each time. During the 10 d growth curve, 
there was no significant difference between the strains. Growth was measured once in 
triplicate.
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Fig. 3.3. Toxin production in five C. difficile strains
Along with growth (black), total toxin A+B  production (grey) was also measured in strain 630 
(a, !), VPI 10463 (b, !), ribotype 027 (c, "), ribotype 001 (d, ") and ribotype 106 (e, #) over 
24 h using the C. difficile TOX A/B II™ kit (Techlab). In all the strains, toxin production 
increased over the duration of growth. By 12 h, VPI 10463 and ribotype 027 produced levels 
of toxin that were high enough to saturate the ELISA. VPI 10463 and ribotype 027 produced 
markedly greater amounts of toxin as compared to ribotypes 001 and 106, which produced 
more toxin than strain 630. The difference in virulence of the strains in terms of total toxin 
production was clearly demonstrated during the growth curves. Bars indicate +/- SEM of 3 
growth curves in which each sample was tested in duplicate.
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Fig. 3.4. Spore production in five C. difficile strains
Spore production (grey) in strain 630 (a, !), VPI 10463 (b, !), ribotype 027 (c, "), ribotype 
001 (d, ") and ribotype 106 (e, #) during growth over 24 h (black) was determined by viable 
counts. At each time-point, 10 ml of culture was collected and treated with alcohol at a final 
concentration of 50%. Serial dilutions of these alcohol-resistant spores were plated in 
triplicate for the counts. Ribotype 106 produced the most spores and a sharp  increase in 
these numbers was observed at 8 h. Ribotype 106 was followed by 027, ribotype 001 and 
strain 630 in that order. Strain VPI 10463 was the lowest spore producer as predicted. Bars 
indicate +/- SEM of 3 experiments performed in duplicate.
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Fig. 3.5. Summary of growth, total toxin production and spore production of five strains of C. 
difficile
C. difficile strains 630 (!) and VPI 
10463 (!) and ribotypes 027 ("), 
001 (") and 106 (#) were studied. 
(a) Over 24 h, there was a difference 
in growth between strain 630 and 
ribotype 027 (p<0.05). This was 
observed in the exponential phase 
between strain 630 and ribotypes 
027 and 106 (p<0.05) but there was 
no difference in the stationary phase 
between any of the strains. (b) Toxin 
production differed significantly 
between all the strains over 24 h
(p<0.001). This was true for the log 
phase as well (p<0.001). In the 
stationary phase, there was a 
significant difference between the 
strains when compared to ribotype 
027 or strain VPI 10463 (p<0.001) 
but there was no difference between 
them. (c) Spore production was 
measured by viable counts. Spore 
production was significantly different 
between the strains over 24 h
(p<0.001) but this was less between 
ribotype 001 and 630 (p<0.01). 
Ribotypes 106 and 027 were the 
major spore producers. Bars indicate 
+/- SEM of 4 experiments for growth 
and 3 each for toxin and spore 
production performed in triplicate. 
Analysis was performed by AUC and 
1-way ANOVA.
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3.3.2. Development of a real-time RT-PCR to study gene 
transcription
A real-time RT-PCR assay  to study transcription of the PaLoc and spo0A in C. 
difficile was designed and standardised using strain 630. Firstly, growth was 
measured simultaneously by OD600 and viable counts (Fig. 3.6). These correlated 
well and volumes required to obtain 5x108 cells at every time-point were estimated 
(50 ml at 4 h to 5 ml at 24 h). RNA was extracted from these samples and their purity 
was checked by A260/280 and on an agarose gel (Fig. 3.7.a). The samples were pure 
but the yield of RNA decreased considerably beyond 4 h (Fig. 3.7.b). 
Fig. 3.6. Growth of C. difficile strain 630
Growth of C. difficile strain 630 was 
measured every 4 h by viable counts 
(!) and OD600 (!). From these, the 
volume of culture required to collect 
5x108 cells at every time-point was 
calculated. Bars indicate +/- SEM of 2 
experiments.
Fig. 3.7. RNA extracted from samples during growth of C. difficile strain 630
(a) RNA extracted from approximately 5x108 cells of C. difficile strain 630 every 4 h was run 
on a 1.5% agarose gel as a preliminary purity check. The bands for 16S and 23S rRNA were 
visualised. Lanes 1-6 and 7-12 show RNA from samples collected at 4, 8, 12, 16, 20 and 24 
h in growth curves 1 and 2, respectively. (b) Although pure RNA was efficiently extracted at 
all time-points, the amount of RNA extracted decreased from 4 h onwards. 
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Primers designed for the assay were tested in a conventional PCR and were found to 
be suitable as 100 bp products were obtained for all the genes (Fig. 3.8). They also 
gave suitable amplification in a real-time PCR experiment (Fig. 3.9).
Fig. 3.8. Amplification of the genes of interest by conventional PCR
Primers designed for the 8 genes to be studied by real-time PCR were tested with gDNA of 
strain 630 in a conventional PCR. 100 bp products were obtained for all the genes. 
Fig. 3.9. Real-time PCR amplification of the genes of interest
All the genes in this study were suitably amplified using the primers designed when the 
primers were used at high concentrations in real-time PCR reactions. Products with different 
temperatures of melting (Tm) were obtained, which was useful to differentiate between them 
and detect any contamination of the primers.
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After testing different primer concentrations (Fig. 3.10.a) two were selected for each 
gene (Fig. 3.10.b). From these, final concentrations of 200 nM of each primer were 
selected for tcdA,B,C and R, 500 nM for tcdE and 100 nM from spo0A, tpi and rrn.
Fig. 3.10. Primer optimisation 
(a) Different primer concentrations were initially selected for optimisation of the RT-PCR 
reactions for the different genes in this study. From the amplification obtained using these 
preliminary concentrations, two suitable concentrations were selected. (b) The experiments 
were repeated with the two selected primer concentrations to determine which was most 
suitable.
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From the standard curves obtained for each gene with the selected primer 
concentrations, the reactions were found to be efficient and reproducible for DNA 
concentrations ranging from 12.5 to 800 ng (Fig. 3.11). cDNA for the genes of 
interest were thus diluted to an equivalent of 50 ng, but for amplification of rrn (Fig. 
3.12.a) samples were required to be diluted to 1 ng (Fig. 3.12.b) to bring them within 
the range of amplification of the genes of interest. For the final assays, only  rrn was 
used as a normaliser because tpi amplification varied over time (Fig. 3.12.c).
Fig. 3.11. Standard curves of the genes of interest with gDNA
The standard curves generated demonstrated efficient and reproducible reactions. Although 
the efficiency of some of the reactions was very low, they were consistent. 
Fig. 3.12. Amplification of the housekeeping genes/normalisers rrn and tpi
(a) rrn amplification 
using cDNA diluted 
to an equivalent of 
50 ng gave low Ct 
values due to early 
saturation of the reaction. (b) To obtain Ct values in the range of the genes of interest, cDNA 
was diluted to an equivalent of 1 ng of RNA. (c) tpi was tested but not selected as the 
normaliser because varied amplification was observed at different time-points. 
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After standardisation, a real-time RT-PCR assay was performed using cDNA 
prepared from the RNA extracted from C. difficile strain 630 cells every 4 h and the 
selected primer concentrations. Standard curves with dilutions of the cDNA pool 
were run for each gene simultaneously and gave similar results to those obtained 
with gDNA. The data were analysed to obtain the transcriptional trends of the PaLoc 
genes and spo0A over 24 h (Fig. 3.13). This method was then used to study gene 
expression in strain VPI 10463 and ribotypes 027, 001 and 106. 
Fig. 3.13. Preliminary real-time RT-PCR results for C. difficile strain 630
Using the optimised real-time RT-PCR assay, the trends of transcription of the six genes of 
interest over 24 h were identified.
3.3.3. Transcription of the PaLoc and spo0A 
Transcriptional analysis of the PaLoc genes and spo0A was successfully  performed 
by real-time RT-PCR for the five C. difficile strains in this study. After 
standardisation, the assay  was first performed for strain VPI 10463. It was observed 
that the transcription of tcdA, tcdB and tcdR increased over 24 h, while that of tcdC 
decreased. tcdE levels were found to increase till 12 h, after which they decreased, 
followed by a transient increase at 24 h. As these results were similar to previous 
observations, this method was applied to the epidemic ribotypes 027, 001 and 106 
and the experiments were repeated for strain 630. Varying patterns of gene 
expression were observed in all the strains (Fig. 3.14). 
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tcdA expression increased until 12 h in ribotype 027, ribotype 106 and strain 630 and 
then decreased, whilst remaining almost constant in ribotype 001 over time. A similar 
trend was observed for tcdB in ribotype 106 and strain 630, although in the latter, 
levels were below the 4 h value. In ribotype 001, an increase in tcdB transcription 
was observed at 20 h. Interestingly, ribotype 027 was the only strain to show 
constantly increasing tcdB expression over the 24 h period studied, although it  was 
less than that of tcdA. tcdR transcription increased steadily over time in strain 630 
but in ribotypes 027, 001 and 106, peak expression was observed at 12 h followed by 
a decline. A transient increase in tcdR expression was observed at 24 h in ribotypes 
027 and 106. Notably, tcdC transcription was similar to tcdR and at similar levels, 
contrary to the observations in VPI 10463. tcdE transcription increased markedly 
until 12 h in ribotype 027 and VPI 10463 but in the other strains expression of tcdE 
was almost steady. spo0A transcription decreased over time in all the strains, as 
expected, but in ribotypes 027 and 106 there was increasing or almost stable gene 
expression till 12 h, which could be the reason for their higher spore production.
Inter-strain differences were statistically analysed (Fig. 3.15 and 3.16). In the 
exponential phase (0-12 h) there was a significant difference in tcdA expression 
between ribotype 027 and ribotypes 001 and 106 (p<0.01). tcdB expression was 
significantly different  between VPI 10463 and the other strains in the exponential 
phase (p<0.01) and the stationary phase (12-24 h) (p<0.001). tcdC expression was 
the highest in ribotype 027 in the exponential phase of growth but there was no 
significant difference between the strains throughout the 24 h. Interestingly, tcdR 
expression was significantly higher in ribotype 027 and VPI 10463 in the exponential 
phase of growth. In the stationary phase, the difference between ribotype 027 and the 
other strains was significantly  different (p<0.001) while strain 630 and ribotype 001 
showed similar levels of transcription (p<0.01). tcdE expression only  varied 
significantly in the stationary  phase between the strains (p<0.01). The expression of 
spo0A in ribotype 027 was significantly higher in the exponential (p<0.001) and 
stationary phases (p<0.01). Thus, the inter-strain differences in gene expression were 
identified. 
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Fig. 3.14. Transcription of the PaLoc and spo0A in five C. difficile strains
Transcription of the PaLoc and spo0A was studied by real-time RT-PCR in strain 630, VPI 
10463, ribotype 027, ribotype 001 and ribotype 106. (a) In 630, tcdA and tcdB expression 
increased until 12 h and then decreased. tcdR and tcdC expression increased over time; that 
of tcdE remained constant. (b) In VPI 10463, the expression of tcdR, tcdA, tcdB and tcdE 
increased over 24 h, while that of tcdC decreased. (c) In ribotype 027, tcdR, tcdE, tcdA and 
tcdC transcription peaked at 12 h and then decreased. tcdB transcription increased over 24 
h. (d) In ribotype 001, tcdR and tcdC transcription was similar, while that of tcdB, tcdE and 
tcdA did not vary. (e) In ribotype 106, tcdR, tcdB, tcdA and tcdC transcription peaked at 12 h, 
while that of tcdE increased until 16 h. Bars indicate +/- SEM of 6 experiments for tcdA and 
tcdB expression and 4 experiments for tcdR, tcdE and tcdC expression.
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Fig. 3.15. Summary of tcdA, tcdB and tcdC transcription in five strains of C. difficile
Gene expression in strain 630 (!), 
VPI 10463 (!), ribotype 027 ("), 
ribotype 001 (") and ribotype 106 (#) 
was measured by real-time RT-PCR. 
(a) tcdA expression was significantly 
different between ribotype 027 and 
the other strains, except VPI 10463, 
but only in the exponential phase 
(p<0.05). VPI 10463 and ribotype 
027 demonstrated the highest tcdA 
expression. (b) tcdB transcription in 
VPI 10463 was significantly different 
compared to the other strains over 
the entire growth curve (p<0.001). In 
the exponential phase, this difference 
was significant (p<0.01) and it was 
greater in the lag phase of growth 
(p<0.001). (c) Transcription of tcdC 
was highest in ribotype 027, followed 
by ribotype 106 and VPI 10463, but 
there was no significant difference 
between the strains in either the 
exponential or stationary phases of 
growth. Bars indicate +/- SEM of 6 
experiments for tcdA and tcdB 
expression and 4 for tcdC.
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Fig. 3.16. Summary of tcdR, tcdE and spo0A transcription in five strains of C. difficile
Gene expression in strain 630 (!), 
VPI 10463 (!), ribotype 027 ("), 
ribotype 001 (") and ribotype 106 (#)
was measured by real-time RT-PCR. 
(a) tcdR expression was significantly 
different between ribotype 027 and 
the other strains. This difference was 
more significant between ribotype 
027 and strain 630 and ribotype 001 
(p<0.001) and less significant when 
compared to ribotype 106 and VPI 
10463 (p<0.01). (b) tcdE expression 
in VPI 10463 and ribotype 027 was 
the highest, but not significantly 
different over the entire growth curve. 
There was a significant difference 
between ribotype 027 and the other 
strains in the stationary phase
(p<0.01) (c) spo0A transcription was 
significantly higher in ribotype 027 in 
the exponential phase (p<0.01) and 
the stationary phase (p<0.001) when 
compared to the other strains. Bars 
indicate +/- SEM of 4 experiments for 
tcdR and tcdE expression and 6 for 
spo0A.
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3.3.4. Toxin purification and detection
In order to correlate toxin production with individual gene expression, quantitative 
methods were required for each toxin. Thus, attempts were made to purify C. difficile 
toxin A (TcdA) and toxin B (TcdB) from dialysis cultures of VPI 10463. Toxins 
prepared by affinity chromatography (Fig. 3.17.b) and by ammonium sulphate 
precipitation (Fig. 3.17.c) were checked for purity on SDS-PAGE gels and several 
bands were observed that suggested either protein degradation or contamination, 
making them unsuitable as pure standards for immunoassays. When commercial 
toxins became available, dot blots (Fig. 3.17.d) were attempted with toxin detection 
using monoclonal antibodies (Table 3.1). A method to quantify proteins from dot 
blots using imaging software was developed with LPS (Fig. 3.17.e). However, the 
dot blots were insensitive to small quantities of toxin and not reproducible. Hence, 
there was a need for a sensitive and reproducible method for toxin quantification. 
Table 3.1. Antibodies used to detect C. difficile toxins and their working concentrations
Method Order Toxin A Toxin B





























NB600-1066, Clone PCG4) 
0.5 μg/ml
Polyclonal antibody














Fig. 3.17. Initial methods employed to purify and quantify C. difficile toxins
Dialysis cultures of C. difficile  VPI 
10463 were used to prepare the 
toxins. (a) Affinity chromatography 
was used to obtain toxin A. Toxins 
were detected using a commercial 
ELISA kit in 17 fractions during the 
elution of toxin A and in 20 samples 
post-elution. (b) These proteins 
were run on an SDS-PAGE gel and 
multiple bands were detected. A 
few faint bands above the 200 kDa 
mark were obtained but these could 
not be seen on Western blots. (c) 
Toxin purification was attempted by 
ammonium sulphate precipitation; 
salt concentrations of 70% and 
50% were used to for toxins B  and 
A, respectively. Dialysed proteins were then run on an SDS-PAGE gel. Multiple bands were 
obtained by this method too. (d) Dot blots were then attempted with commercial toxin A and 
toxin B and monoclonal antibodies, but the method was not found to be sensitive enough to 
detect the small amounts of toxin present in the early hours of C. difficile growth. (e) A 
method to quantify proteins from dot blots was developed using E. coli R1 LPS; the amount 
of protein could be quantified using pixel intensity of the spots detected in Adobe Photoshop 
CS. 
When polyclonal antibodies for the C. difficile toxins became available, sandwich 
ELISAs were developed for both toxins using commercial standards and antibodies 
in Table 3.1. The ELISA for toxin A was standardised by performing a checkerboard 
assay using the polyclonal antibody for capture (Fig. 3.18.a). The ELISA for toxin B 
was similarly standardised (Fig. 3.18.b), but it was found to be more sensitive using 
the monoclonal antibody  for capture (Fig. 3.18.c). Although the ELISA for toxin B 
was functional with a commercial standard, detection of the toxin from culture 
supernatants was unsuccessful, even in the late stationary phase of growth of VPI 
10463, the strain showing the highest levels of toxin production. Attempts to alter 
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conditions like changing incubation times, temperatures and pH and even 
neutralisation of toxin A did not  alter the outcome. Thus, the cytotoxicity  assay was 
used for detection of toxin B instead; for quantification of toxin B, dilutions of the 
commercial standard were run in each experiment to generate standard curves, just as 
in an ELISA. The methods finally  selected for toxin quantification were the ELISA 
for toxin A (Fig. 3.17.d) and the modified cytotoxicity assay for toxin B (Fig. 3.17.e). 
Both methods were both found to be highly  reproducible and sensitive over a range 
of 0.5 to 500 ng/ml toxin.
Fig. 3.18. Development of an ELISA for toxin A and a cytotoxicity assay for toxin B
Sandwich ELISAs were developed for quantification of C. difficile toxin A and toxin B  from 
culture supernatants. They were standardised by performing checkerboard assays with 2-
fold dilutions of monoclonal antibodies, polyclonal antibodies and commercial standards. The 
polyclonal antibody was used for capture and the most suitable concentrations of both 
antibodies were identified from the standard curves generated (a) for toxin A and (b) for toxin 
B. (c) The ELISA for toxin B was found to be more sensitive when the monoclonal antibody 
was used for capture. When tested with culture supernatants, (d) the toxin A ELISA proved to 
be sensitive and reproducible; however, the toxin B ELISA was unsuccessful in detecting any 
toxin from supernatants. (e) Therefore, a modified quantitative cytotoxicity assay was used 
instead, which was also found to be highly reproducible. 
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3.3.5. Individual toxin A and toxin B production 
Toxin A and toxin B were detected in the cultures of all strains (Fig. 3.19). Ribotype 
027 produced the most  toxin A up to 12 h (p<0.001) and the amounts increased until 
24 h. All the other strains produced low levels of toxin A until 12 h. Beyond 12 h, 
large amounts of toxin A were detected in cultures of VPI 10463, as expected, and 
these were similar to those of ribotype 027. Ribotypes 106 and 001 produced toxin A 
at similar levels, which were significantly  lower than VPI 10463 and ribotype 027 
(p<0.001) and slightly higher than strain 630. The levels of toxin B detected in the 
cultures were higher than those of toxin A in all strains over time. VPI 10463 showed 
a steady  increase in toxin B production which reached high levels at 24 h. Ribotype 
027 produced significantly more toxin B than the other strains at 8 h (p<0.01) and 
this level remained almost constant until 24 h. In ribotypes 106 and 001, toxin B 
production increased gradually up to 20 h and then increased sharply  at 24 h. 
Interestingly, in strain 630, toxin B production decreased over time. Differences in 
toxin production between the five strains were statistically compared over the 
different phases of growth (Fig. 3.21). Ribotype 027 produced the greatest amount of 
toxin A and toxin B in both the exponential and the stationary phases of growth. In 
the stationary  phase, ribotype 027 produced significantly  more toxin A (p<0.05) and 
toxin B (p<0.001) when compared to the other strains. 
The extracellular levels of both toxins increased over time in all the strains, even 
when gene expression decreased and the release of toxins was thus assessed from a 
ratio of the amount of extracellular toxin to gene expression (Fig. 3.20); a line 
parallel to the x-axis indicated matched gene expression and protein amounts. For all 
the strains, the increased release of toxin A was evident after 12 h on entry  into the 
stationary phase of growth. This release was most prominent in ribotype 106. For 
toxin B release in ribotype 106, the same pattern as toxin A was observed. In strain 
VPI 10463, the release of toxin B appeared to be steady over the 24 h, while in strain 
630, there was a gradual release of toxin B. In ribotypes 027 and 001, there was a 
steady release of toxin B after the late exponential phase (8-12 h).
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Fig. 3.19. Production of toxin A and toxin B in five C. difficile strains
Production of toxin A (light grey) and toxin B  (dark grey) in the strains was studied over 24 h 
of growth (black) using an in-house quantitative ELISA for toxin A and the modified 
quantitative cytotoxicity assay for toxin B, respectively. Toxin A production increased in the 
strains over time. Ribotype 027 was the highest producer of toxin A up  to 12 h. The levels of 
toxin B  in the strains also increased over time, except in strain 630. Ribotype 027 and VPI 
10463 produced the greatest amounts of toxin A and toxin B. Toxin B  levels were higher than 
those of toxin A in the strains. Bars indicate +/- SEM of 6 experiments performed in 
duplicate.
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Fig. 3.20. Release of toxin A and toxin B in five C. difficile strains
The correlation of toxin production to toxin gene transcription was assessed by analysing 
ratios of toxin A value:tcdA expression (light grey) and toxin B  value:tcdB expression (dark 
grey) at different time-points. In all the strains, the release of toxin A at 12 h is evident. For 
toxin B, earlier release is indicated. Bars indicate +/- SEM of 6 experiments.
The non-toxin genes of the PaLoc were amplified by PCR (Fig. 3.22) and sequenced 
in order to identify any genetic differences between the strains, but no mutations 
were identified in any of the genes in any strain other than the tcdC gene of ribotype 
027, which had the characteristic frameshift mutation at position 117 and the 18 bp 
deletion from nucleotides 330 to 347 (6.4.11).
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Fig. 3.21. Summary of toxin A and toxin B production in five C. difficile strains
Toxin production by strain 630 (!), 
VPI 10463 (!), ribotype 027 ("), 
ribotype 001 (") and ribotype 106 (#) 
was measured. (a) Toxin A production 
was measured by ELISA. There was 
a significant difference between the 
strains and ribotype 027 over the 24 
h (p<0.05). During the log phase, 
ribotype 027 produced the most toxin 
A and in the stationary phase this 
difference was significant (p<0.01). 
(b) Toxin B  production was measured 
using a cytotoxicity assay. Over 24 h, 
the difference between ribotype 027 
and the other strains was significant 
(p<0.05). Ribotype 027 produced the 
most toxin B during the log phase 
and this was significant in the 
stationary phase (p<0.05). Bars 
indicate +/- SEM of 6 experiments 
performed in duplicate. Analysis was 
performed by AUC and 1-way ANOVA.
Fig. 3.22. Amplification of the non-toxin genes of the PaLoc for sequencing 
Accessory genes of the PaLoc - (a) tcdC, (b) tcdR and (c) tcdE - were amplified by PCR and 
the products were sequenced. No mutations or deletions were identified in tcdR and tcdE. In 
tcdC, the only genetic changes detected were the ∆117 and 18 bp mutations which are 
characteristic of ribotype 027.
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3.4. Discussion
The cumulative data from this study suggest that there has been a change in the 
phenotype of C. difficile strains responsible for infection in Scotland towards 
increased virulence and potentially, more severe disease. 
The phenotypic experiments demonstrated that although there was no significant 
difference in growth of the five C. difficile strains studied, there were differences in 
their respective abilities to produce toxins and spores. Growth of the five strains was 
similar to each other and to several previous studies (Dupuy & Sonenshein, 1998; 
Ketley  et al., 1984; Vernet et al., 1989). The exponential phase of growth lasted for 
12 hours, followed by  the stationary phase. Total toxin production was highly diverse 
among the strains and ribotype 027 produced the highest levels of toxin, followed by 
ribotype 106. Spore production was highest in these strains, but ribotype 106 
produced more spores than ribotype 027. Ribotype 001 produced less toxin and 
spores than ribotypes 027 and 106 but these were always more than strain 630. This 
is indicative of the changing epidemiology; ribotype 001 over-took strain 630 owing 
to enhanced toxin production and sporulation and it was then replaced by ribotype 
106 and ribotype 027 which were even more toxigenic and sporogenic. The reference 
strain VPI 10463 produced the highest levels of toxin and least number of spores as 
previously  observed, thus confirming that the growth conditions were suitable 
(Mukherjee et al., 2002). 
The majority  of these observations are in agreement with previous work. The lack of 
inter-strain variability in growth confirmed the hypothesis that growth rate did not 
impact on virulence in C. difficile (Merrigan et al., 2010; Warny  et al., 2005). They 
also showed a correlation between strain type and the amount of toxin produced 
(Wren et al., 1987). However, unlike in some studies, an inverse correlation between 
toxin levels and spore counts was not observed; high toxin producers also sporulated 
more (Akerlund et al., 2006), suggesting a link between the two processes (Kamiya 
et al., 1992). Also, contrary to a study by Burns and colleagues, strain 630 neither 
sporulated earlier nor did it do so to a greater extent as compared to ribotype 027 
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(Burns et al., 2010a). However, this could suggest that isolates belonging to the same 
ribotype could show varied sporulation (Burns et al., 2010b). One of the main 
limitations of this study was the use of a single isolate from each ribotype. 
When individual toxin production was assessed, the results showed that strains which 
produced more toxin A also produced more toxin B and that the ratio of extracellular 
toxin A:toxin B was almost 1:1. Both these observations matched with previously 
reported data (Mukherjee et al., 2002; Tucker et al., 1990; Vernet  et al., 1989). Only 
in strain 630 did toxin A levels increase over time, while those of toxin B decreased. 
Strain 630 has been observed to produce considerably lower levels toxin A and tcdR 
transcript than VPI 10463 and has been shown to have reduced induction of gene 
expression in the stationary  phase of growth (Dineen et al., 2007). This phenomenon 
could possibly explain these data. Greater toxin B production was detected earlier in 
the hypervirulent ribotype 027 as seen by Murray and co-workers (Murray  et al., 
2009). Toxin release was primarily  observed in the transition between the 
exponential and stationary phases of growth. As previously observed by others, the 
data presented here also suggested that ribotype 027 is capable of producing up to 20 
times more toxin (A or B) than other strains (Warny  et al., 2005), except  VPI 10463. 
This is a clear phenotypic advantage in this strain. Toxin production was detected in 
the early exponential phase and throughout the period of growth. This observation 
differs from studies in which glucose-containing media such as BHI were used to 
assess toxin production (Merrigan et al., 2010). Glucose represses toxin production 
(Dupuy & Sonenshein, 1998). The medium used in this study was anaerobe 
identification medium (AIM) that  does not contain any glucose. It does, however, 
contain cysteine but at sub-inhibitory levels. This may explain the earlier detection of 
toxins in this study and the greater levels detected in the stationary phase of growth. 
Another interesting observation was the detection of more toxin A and than toxin B 
at 24 hours in all the strains, except strain 630. Toxin A is an enterotoxin with the 
ability  to bind to epithelial cells in the gut via receptors (Krivan et al., 1986; Tucker 
& Wilkins, 1991) and cause the initial damage by glucosylation of Rho proteins 
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(Aktories et al., 2000). In several animal studies, it has been observed that in the 
absence of toxin A, toxin B is unable to induce the pathology characteristic of CDI 
(Lyerly et al., 1985). Even in cell cultures with Caco-2 cells, it  has been 
demonstrated that  when the toxin A challenge is removed, there is no damage caused 
to the epithelial barrier (Sutton et al., 2008). Thus, large amounts of toxin A may 
contribute to increased disease severity and perhaps, increased potential of ribotypes 
027, 106 and 001 to induce CDI in healthy  humans; greater the initial damage to the 
gut by  toxin A, greater the chance of toxin B causing extensive cytotoxicity. Toxin B 
is significantly more cytotoxic than toxin A, but its role in the development of the 
pathology of CDI is debated. However, strains lacking the potential to produce toxin 
B have not yet been isolated. It has been shown that  C. difficile strains in which toxin 
B was knocked-out were ineffective in colonising hamsters, contrary to studies in 
other systems (Lyras et al., 2009). However, more recently it  has been suggested that 
both toxins are important in CDI (Kuehne et al., 2010). Whatever the importance of 
toxin B in disease, it is clear that the current epidemic strains produce large quantities 
of it. This, coupled with production of large amounts of toxin A, could explain the 
severity of disease associated with ribotypes 027, 106 and 001.
As observed by others, the inter-strain differences in production of toxin A and toxin 
B did not result  from mutations or deletions in the accessory  genes of the PaLoc 
tcdC, tcdR and tcdE, except perhaps the %117 deletion in the tcdC gene of ribotype 
027 (Murray  et al., 2009). The differences were due to levels of transcription of the 
PaLoc genes. Greater expression of the toxin genes tcdA and tcdB in high toxin 
producing strains like ribotype 027 and VPI 10463 was clearly observed. Though this 
was not surprising, it was interesting to note the varied patterns of transcription of 
these genes in the other strains. Whether increasing until 12 hours and then 
decreasing or staying constant over the 24 hours period studied, the relationship 
between gene expression and toxin production was evident. However, this too 
differed between the toxins. For toxin A, it  would appear that gene transcription 
peaked at 12 hours and toxin levels detected in culture thereafter were a result of 
accumulation. This was observed less markedly and from 8 hours onwards in toxin 
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B. Although transcription of tcdB was lower than tcdA in all the strains, levels of 
toxin B were always higher than toxin A, suggesting more efficient production of 
toxin B or perhaps, greater proteolysis of toxin A in culture. The latter has been 
suggested by other researchers (Murray et al., 2009).
tcdR transcription increased steadily over time in strain 630, but  in ribotypes 027, 
001 and 106, peak expression was observed at 12 hours followed by a decline. A 
transient increase in expression was observed at  24 hours in ribotypes 027 and 106. 
Interestingly, tcdC transcription showed a similar pattern and at similar levels, 
contrary to the observations for VPI 10463 (Hundsberger et al., 1997). tcdC is the 
negative regulator of toxin production (Dupuy  et al., 2008; Matamouros et al., 2007) 
and its transcription and translation have been shown to decrease as C. difficile 
cultures enter the stationary phase of growth (Govind et al., 2006; Hundsberger et 
al., 1997). Further, the deletions found in tcdC in ribotype 027 have been used to 
explain the excessive toxin production in this strain as the truncated TcdC protein 
would be ineffective in preventing the complexing of TcdR with RNA polymerase 
(Curry  et al., 2007). Contrary to these studies, the data from this study showed that 
tcdC transcription increased over time, at least until 12 hours and then decreased. 
Although there was an evident decrease in tcdC expression, it did not fit into the 
previously  described pattern, as the tcdR expression observed was similar and at 
similar levels. This suggests that tcdC might have a modulatory effect on toxin 
production, rather than a strictly inhibitory  one. Another recent study has also made 
this suggestion (Merrigan et al., 2010). Also, both toxins were detected in the 
exponential and stationary phases of growth, despite increasing tcdC expression. 
Others have also shown this expression of tcdC in both the phases of growth, 
although it was slightly  diminished in the stationary phase (Dineen et al., 2007; 
Karlsson et al., 2008). It is possible that TcdC, being a membrane associated protein, 
has an effect on the release of the toxins. These hypotheses can be tested by  gene 
knockout and protein interaction studies and would greatly add to the understanding 
of toxin production and release in C. difficile. Of note was the tcdE transcription in 
ribotype 027 and VPI 10463, the highest toxin-producing strains; it increased until 12 
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hours and then diminished. This increase corresponded with an increase in 
extracellular toxin levels observed in both these strains. The almost steady 
expression of tcdE in the other strains corresponded to a slower release of toxins. The 
increased tcdE transcription in ribotype 027 may  also contribute to its hypervirulence 
owing to its role in toxin release (Govind & Dupuy, 2010; Tan et al., 2001).
spo0A, the master-regulator of sporulation, was selected as an indicator of the 
magnitude of the spore producing capacity of C. difficile strains. Despite the 
expected decrease in gene expression, the trends over the first few hours were 
considered important in identifying inter-strain differences. Remarkably, increasing 
or almost stable spo0A expression in ribotypes 027 and 106 correlated well with their 
increased spore production observed at  24 hours. Thus, it is likely that increased 
duration of spo0A transcription in the early stages of growth keeps the sporulation 
cycle active for a longer period of time, resulting in a greater number of spores being 
produced and released into the environment, irrespective of environmental stresses. 
The link between toxin and spore production has now been described (Karlsson et 
al., 2008; Underwood et al., 2009). The increased spo0A transcription in ribotype 
027 might also affect its increased toxin production and add to its hypervirulence. 
From the data presented here, it can be concluded that  C. difficile-ribotype 027 has 
several phenotypic advantages that  could be responsible for its emergence as a 
deadly pathogen. Further, toxin B of this ribotype has been shown to be more 
effectively endocytosed into cells and has demonstrated toxicity to a variety of cell 
types in zebrafish larvae as compared to toxin B produced by strain 630, clearly 
indicating its increased virulence potential in vivo (Stabler et al., 2009). However, 
ribotype 106 also possesses traits that explain its presence as the most common strain 
associated with CDI in Scotland during this study. Increased toxin and spore 
production in the local endemic strains has given further insight into the evolving 
bacterial factors affecting the epidemiology of CDI. It is likely that C. difficile strains 
are adapting to produce larger amounts of more potent virulence factors, leading to 
increased frequency of more severe disease. 
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4. Disinfectants and C. difficile
4.1. Introduction
C. difficile is a spore-producing bacterium and it  is these spores that allow for the 
dissemination of C. difficile in the environment and facilitate the spread of disease. 
Thus, it is of extreme importance to successfully destroy C. difficile spores in order 
to prevent infection. To this end, a wide range several sporicidal agents have been 
developed but several limiting factors can diminish their efficacy  and frequency of 
use. The effects of some commonly-used laboratory agents on different C. difficile 
strains were studied. 
4.1.1. Reservoirs of C. difficile 
C. difficile in the environment is a harmless organism (Brazier & Borriello, 2000) 
and the first screening of the environment led to the isolation of C. difficile from soil, 
mud, hay and animal dung (Hafiz, 1974). An extensive survey of the environment 
carried out in Wales showed the presence of C. difficile in soil and fresh waters like 
lakes and rivers (al-Saif & Brazier, 1996). Interestingly, it was also found in sea 
water, swimming pools and tap  water, suggesting that the spores were resistant to 
salinity and common water treatment processes. More recently, C. difficile has been 
found in soil along with other clostridia, though at much lower levels (del Mar 
Gamboa et al., 2005). Not surprisingly, vegetables, especially root vegetables, have 
been found to be contaminated with C. difficile (al-Saif & Brazier, 1996). Metcalf 
and co-workers isolated the bacterium from 4.5% of vegetables purchased at grocers 
(Metcalf et al., 2010b) and Bakri and co-workers isolated it from 7.5% of packaged 
salads (Bakri et al., 2009). Interestingly, the strains detected in these studies had been 
previously associated with human disease. 
Animals are also a potential reservoir of C. difficile. Direct  or indirect contact with 
animals and environmental contamination by animals can be responsible for a range 
of enteric diseases (Steinmuller et al., 2006). C. difficile has been isolated from a 
variety of animals, whether diarrhoeic or not (Songer, 1996); carriage and infection 
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have been reported in horses, calves, pigs, chickens and even household pets (Arroyo 
et al., 2007; Keel et al., 2007; Rodriguez-Palacios et al., 2006; Rodriguez-Palacios et 
al., 2007b; Simango & Mwakurudza, 2008; Songer & Anderson, 2006). Not 
surprisingly, contamination of the environment of these animals has also been noted 
and often an overlap between human isolates, animal isolates and those from the 
environment has been observed (Arroyo et al., 2005; Keel et al., 2007; O'Neill et al., 
1993; Weese et al., 2010a). 
C. difficile has also been isolated from a variety  of meat products; however, the 
degree of contamination is also quite varied. Reports of heavy contamination of meat 
products in North America include those by Songer and co-workers who isolated it 
from approximately 40% of all uncooked beef, pork and turkey products and even 
47% of ready-to-eat products (Songer et al., 2009b). Similarly, Weese and co-
workers found 12% of ground beef and 71% of ground pork products to be 
contaminated with C. difficile (Weese et al., 2009). They also isolated the bacterium 
from 12.8% of all retail chicken samples (Weese et al., 2010b). Lower prevalence of 
C. difficile in meats has been reported in Europe. In a study in Austria, only  3% of 
mixed beef and pork products were found to be contaminated, while individual beef 
and pork products were free of C. difficile (Jöbstl et al., 2010). In a similar study 
from France, C. difficile was identified at a low prevalence of 1.9% and exclusively 
from vacuum-packed meats (Bouttier et al., 2010). Contrary to these findings, a 
study performed in our laboratory  in which over a hundred packaged meat samples 
from around the UK were tested, no C. difficile was isolated from any of the samples. 
As observed in animals, the strains of C. difficile identified from several of these 
foods have been isolated from human disease. Of the five ribotypes isolated from just 
1.8% of pork samples in a study in Canada, three overlapped with those involved in 
human disease in the region (Metcalf et al., 2010a). A similar study found 20.8% of 
beef and 14.3% of veal samples to contain C. difficile strains, 25% of which 
overlapped with human strains (Rodriguez-Palacios et al., 2007a). The presence of 
C. difficile in meat products can possibly be explained by contamination during the 
processing of the meats (Songer et al., 2009b; Weese, 2010). It is also possible that 
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anaerobic conditions in vacuum packages may  aid sporulation (Bouttier et al., 2010). 
Spores have been found to survive recommended cooking temperatures (Rodriguez-
Palacios et al., 2010). However, the significance of their presence in food and role in 
dissemination is debated as the human infectious dose for C. difficile is yet unknown 
(Gould & Limbago, 2010; Weese, 2010). Further, whether animals are a source of 
human infection or vice versa is still unidentified; nevertheless, both are reservoirs of 
C. difficile (Gould & Limbago, 2010).
Humans are undoubtedly a reservoir of C. difficile; the organism was first identified 
as a commensal in the faecal microbiota of healthy infants (Hall & O'Toole, 1935). 
Since then, the asymptomatic carriage of C. difficile has often been demonstrated in 
healthy children (Donta & Myers, 1982; Holst  et al., 1981). Bolton and co-workers 
found a 30.7% carriage rate among babies within the first month, with almost half 
the colonised infants being faecal toxin-positive, but  showing no signs of diarrhoea 
or colitis (Bolton et al., 1984). Similarly, Collignon and co-workers observed C. 
difficile carriage in 26% of hospitalised infants and even though some of them had 
diarrhoea, they did not  require specific treatment for CDI (Collignon et al., 1993). 
Some investigators have also found the carriage rate in children under the age of two 
years to be significantly  higher than in older children (Matsuki et al., 2005). In one 
special baby unit, carriage in infants ranging from 10% to 57% was observed over a 
year of sampling (Taffinder et al., 1997). 
Asymptomatic carriage of C. difficile in healthy  adults has been reported to range 
from approximately  2% to 15% (Delmée, 2001; Kato et al., 2001; Nakamura et al., 
1981; Ozaki et al., 2004; Ryan et al., 2010). Both toxigenic and non-toxigenic strains 
have been identified from these adults. The same strain can be carried by an 
individual for several months or it  can be replaced by a new strain or the two strains 
can co-exist within the host (Kato et al., 2001). Carriage in hospital patients with no 
antibiotic history or antibiotic-associated diarrhoea has also been documented (Varki 
& Aquino, 1982). Asymptomatic patients can harbour epidemic strains and 
contribute to the nosocomial spread of C. difficile (Riggs et al., 2007). But, perhaps 
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the most important reservoir is symptomatic patients in a nosocomial environment. 
C. difficile is the primary  agent for pseudomembranous colitis (Bartlett et al., 1978b; 
George et al., 1978b; Larson et al., 1978) but it has also rarely  been identified from 
extra-intestinal sites. Hafiz and co-workers isolated C. difficile from the vaginal 
specimens of almost 72% of women attending a special clinic and the urethra of 
100% of men with non-specific urethritis and suggested that C. difficile might have a 
role in sexually transmitted disease (Hafiz  et al., 1975). However, 18% of women 
attending a family clinic were also C. difficile-positive, suggesting carriage in the 
urogenital tract. Of the children tested, 7% had positive samples, all of whom were 
under the age of one. C. difficile has been identified as the cause of chronic 
osteomyelitis (Riley & Karthigasu, 1982), a splenic abscess (Saginur et al., 1983), an 
infected lateral leg wound (Urbán et al., 2010) and other diseases ranging from 
peritonitis to bacteraemia (Byl et al., 1996; Deptu&a et al., 2009; García-Lechuz et 
al., 2001). Within the GI tract, C. difficile has also been identified as the cause of 
intra-abdominal hypertension and abdominal compartment syndrome (Shaikh et al., 
2008). 
4.1.2. Transmission of C. difficile
C. difficile is spread via the faecal-oral route (Lyerly et al., 1988). For CDI to occur, 
spores or vegetative cells must be delivered to the patient’s gastrointestinal tract, 
either by ingestion or direct inoculation via contaminated equipment (Worsley, 
1998). 
Symptomatic patients shed large amounts of both vegetative cells and spores into the 
environment (Mulligan et al., 1980; Wilcox et al., 2003). The environments of 
patients with more severe disease and frequent bowel movements were found to be 
more contaminated than those of patients who were asymptomatic or had mild 
diarrhoea (Kim et al., 1981; Mulligan et al., 1980; Samore, 1999). Direct contact 
with such an environment, in the case of patients sharing a room, was found to be a 
significant risk factor for the acquisition of nosocomial CDI (Chang & Nelson, 
2000). The same authors also found that being a ‘neighbour’ in a room adjacent to a 
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patient with diarrhoea was a greater risk for CDI and might reflect hand-to-hand 
transmission of the organism by healthcare workers. In one study, 16% of samples 
from the rooms of patients not in isolation for CDI were found to be culture positive 
(Dumford et al., 2009).
The transmission of CDI in the hospital can also be affected by antibiotic usage. 
Fenton and co-workers documented the spread of C. difficile to 5% of hip fracture 
patients in a ward within six months (Fenton et al., 2008). Similarly, in another study 
9.5% of previously C. difficile-negative patients acquired the bacterium during 
hospitalisation, influenced by the use of antibiotics (Rotimi et al., 2002). However, 
duration of hospitalisation can cause carriage among patients to increase even in non-
epidemic conditions (Rudensky et al., 1993) and aid the dissemination of disease. 
C. difficile transfer from symptomatic patients to family  contacts has also been 
reported (Kim et al., 1981; Sutphen et al., 1983). Similarly, the transmission of C. 
difficile between healthy  family members has also been observed (Kato et al., 2001), 
although it was not very common. However, in the same study  it was observed that 
cross-transmission can occur between healthy  carriers in the community in clusters. 
The spread of C. difficile between asymptomatic children on the same ward has also 
been recorded (Larson et al., 1982). Transmission outside the hospital environment is 
best represented by community-acquired C. difficile infection (Kyne et al., 1998; 
Riley et al., 1995; Wilcox et al., 2008).
4.1.3. Role of surfaces in transmission of C. difficile 
The role of the contaminated inanimate object in the spread of nosocomial disease is 
much debated (Hota, 2004) even though there have been reports of intensive 
disinfection of the environment leading to the end of an outbreak (Kaatz et al., 
1988). In hospitals, C. difficile has been isolated from a variety of items, mainly 
those in direct contact with a patient, including portable commodes, bathing tubes 
and electronic thermometers (Gerding et al., 1995). Apart from objects most likely to 
be contaminated by faeces such as toilet seats, bedpans and scales, it was also found 
on floors, dust, mops and bed-linen (Fekety et al., 1981; Kim et al., 1981). Verity and 
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co-workers found the bed-frame to be the most common site from which C. difficile 
was recovered (Verity  et al., 2001). In one study, approximately 35% of all sampled 
surfaces were C. difficile culture-positive; commodes and toilet/sluice room floors 
were the sites from which C. difficile was most frequently cultured (Fawley & 
Wilcox, 2001). In another study, 4.9% of the samples yielded C. difficile and they 
were all recovered from the sluice room (Malamou-Ladas et al., 1983). This 
difference might be representative of the different methods used for sampling; in the 
first study, lysozyme was added to the test  medium which greatly  enhanced recovery 
of the bacterium from the samples, whereas a germinant was not used in the latter. It 
is also of note that carpeted floors contaminated with C. difficile remained so for a 
longer period of time than non-carpeted hard-surface floors (Skoutelis et al., 1994). 
C. difficile has also been isolated from areas outside patient rooms. One study 
revealed the contamination of 31% of surfaces in physician work areas including 
telephone keypads, desktop computers, tabletops and doorknobs (Dumford et al., 
2009). In the same study, 10% of surfaces in nursing work areas and 21% of portable 
medical equipment such as medication carts, medication bar code scanners and 
portable computers were contaminated. Acquisition of spores from such objects has 
not been demonstrated and suggests that the concentration of spores outside patient 
rooms is lower (Donskey, 2010); nevertheless, they are contaminated. Even nursing 
uniforms can be contaminated with C. difficile (Perry  et al., 2001). Although the 
transfer of bacteria from contaminated uniforms to patients was not assessed, they 
are a potential source of cross-infection. An investigation into the contamination of 
stethoscopes showed that they were not a source of C. difficile, although they did 
harbour bacteria responsible for other nosocomial infections like coagulase-negative 
Staphylococcus aureus (Marinella et al., 1997). However, in a later study C. difficile 
was isolated from 4.9% of stethoscopes (Alleyne et al., 2009). As stethoscopes come 
into contact with the skin of multiple patients, they are likely to be sources of CDI. 
Air samples have been found to be C. difficile-negative (Kim et al., 1981; Malamou-
Ladas et al., 1983) but contamination of air vents has been reported (Fawley & 
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Wilcox, 2001). Recently, C. difficile was isolated from the air in an elderly care bay 
in the absence of an outbreak or even a confirmed case of CDI (Roberts et al., 2008). 
The detection of C. difficile in the air was variable at different times of the day  and 
interestingly, all the environmental samples tested were negative strongly suggesting 
that aerial dissemination was most likely, possibly due to activities such as bed-
making, unloading a laundry chute or even cutting a cast, which can release large 
numbers of fomites in the air (Greene et al., 1962a). Best and co-workers also found 
that C. difficile was isolated most frequently from the air during periods of peak 
activity such as ward rounds, visiting hours and patient trolley services (Best  et al., 
2010).
Interestingly, most of the C. difficile strains isolated from the environment commonly 
matched those isolated from patients (Dumford et al., 2009; Fawley & Wilcox, 2001) 
further strengthening the link of a contaminated environment to disease; however, 
which comes first is yet to be fully understood (McFarland, 2002).
4.1.4. Acquisition of C. difficile by healthcare workers 
The exposure of healthcare workers to excretions and secretions contaminated with 
C. difficile is high and hence, they are at high risk of occupationally acquired 
infection, especially if they receive antibiotics (Donskey, 2004). However, some 
investigators found no carriage of C. difficile by  healthcare workers (Carmeli et al., 
1998) despite direct contact  with patients with CDI. Currently, the incidence of CDI 
among this group seem low; fewer than fifteen cases have been reported so far 
(Dorn, 2009).
Strimling and co-workers reported a case in which three nurses developed CDI from 
direct contact with a patient (Strimling, 1989). The nurses were all young, healthy 
individuals with no history of antibiotic consumption for six months before 
development of CDI and as environmental samples were negative for C. difficile, the 
patient was the most probable source of infection. Arfons and co-workers reported 
four cases of CDI in healthy individuals: a physician, a medical student, a nurse and 
an x-ray technician, who received short doses of antibiotics for varying conditions 
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(Arfons et al., 2005). Hell and co-workers described the acquisition of C. difficile by 
a healthy  nurse who had received oral clindamycin after a root canal, which 
developed into diarrhoea (Hell et al., 2009). Interestingly, ribotyping revealed that 
the isolate belonged to ribotype 053, which was the same as that infecting three 
patients the nurse had been in direct contact with; two of the patient isolates were 
indistinguishable by  multilocus variant analysis (MLVA) from that isolated from the 
nurse, clearly  demonstrating the risk of spread of CDI from patient to healthcare 
worker. A similar case was also reported previously (Ray & Donskey, 2003). The 
most recent report of CDI in a healthcare worker involved a nurse receiving 
antibiotics for a sinus condition who had frequently encountered CDI patients for 10 
years, but none for a month before the onset of disease (Dorn, 2009). Further, there 
were no outbreaks or clusters of C. difficile in the hospital, suggesting that C. difficile 
was acquired prior to the antibiotic treatment, which facilitated progression to 
diarrhoea and disease. 
Contamination on the hands of healthcare workers has often been described on wards 
with patients suffering from CDI (Fekety et al., 1981; Kim et al., 1981; Samore et 
al., 1996). In non-isolation rooms, healthcare workers generally  do not use gloves 
and use alcohol-based products for hand hygiene (Dumford et al., 2009) and there 
are no specific protocols and guidelines pertaining to the protection of healthcare 
workers from the acquisition of C. difficile; the guidelines are mostly aimed towards 
the protection of other patients (Vonberg et al., 2008). It has been suggested that 
healthcare workers (and patients) acquire C. difficile from contaminated surfaces 
(Weber et al., 2010). A correlation between transmission of C. difficile among 
patients and contamination of the hands of healthcare workers has been clearly 
observed (McFarland et al., 1989). Further, this contamination of the hands of 
healthcare workers can correspond directly to the levels of environmental 
contamination (Samore et al., 1996). In the study by Samore and co-workers, a 
frequently isolated strain showed the characteristics of an epidemic strain; it caused 
symptomatic disease, was carried by personnel and transmitted to them and patient 
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contacts and also contaminated the environment, thus showing the link between these 
factors (Samore et al., 1996).
4.1.5. Laboratory-acquired CDI
Although CDI is a dreaded nosocomial infection, the risk of acquiring C. difficile 
from the laboratory has not been recognised. However, two cases of CDI caused by 
the hypervirulent ribotype 027 have been reported in laboratory personnel (Bouza et 
al., 2008). The first  case involved a healthy 27-year old female who suffered from 
severe diarrhoea which cleared without the need for antibiotics. The causative 027 
strain was found to have the same antibiotype as the strains recovered from faecal 
samples she was previously working with. The second case involved a healthy 35-
year old pregnant female who received a single dose of an antibiotic to cure a urinary 
tract infection. She subsequently developed severe diarrhoea and was treated with 
vancomycin. The 027 strain causing her CDI had the identical antibiotype to a 
patient 027 received by the laboratory (Bouza et al., 2008). 
The exposure of laboratory workers to relatively high inocula of C. difficile and 
potential highly virulent patient strains increases the risk of both acquisition and 
potential severity of CDI. For these reasons, the authors of the above study (Bouza et 
al., 2008) suggested that the use of class II biosafety cabinets, the effective 
decontamination of surfaces, preferably with chlorine-containing disinfectants, the 
use of disposable gloves and proper hand-washing with soap and water must be 
enforced in laboratories. 
The transmission of C. difficile among healthy individuals is possible and just as for 
healthcare workers, the risk of constant exposure of laboratory workers to the 
organism is high and hence, appropriate safety  precautions and decontamination 
procedures must be followed in laboratories working with C. difficile too.
4.1.6. Need for effective environmental decontamination
Nosocomial acquisition and the environment as the main source of contamination 
has been clearly demonstrated (Delmée et al., 1988; Kim et al., 1981). The need to 
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reduce the bacterial load on surfaces is evident, but whether disinfectants are 
essential for this purpose is debated as surfaces come into contact with intact skin 
which provides a barrier (Rutala & Weber, 2001). However, regular cleaning and 
disinfection must be performed as a precautionary measure in addition to others such 
as the use of disposable equipment and stringent hand-washing must be implemented 
alongside surface disinfection (Testore et al., 1988). 
Several reports regarding the control of outbreaks by effective decontamination exist. 
Kaatz and co-workers demonstrated that the use of an unbuffered hypochlorite 
solution (500 ppm available chlorine) reduced environmental contamination by 79% 
(Kaatz  et al., 1988) and resulted in the end of an outbreak. They  also showed that 
buffered hypochlorite (1600 ppm available chlorine) could bring about a 98% 
reduction in environmental contamination. In another study, the use of a 
glutaraldehdye-based disinfectant on a ward with 10 CDI patients helped to 
gradually control an outbreak without the isolation of patients (Testore et al., 1988). 
Cartmill and co-workers observed that the use of a 1:1000 hypochlorite solution for 
regular surface cleaning resulted in negative environmental samples (Cartmill et al., 
1994). They also found that deep cleaning of wards, which involved clearing it of all 
curtains and linen and washing the floors and walls, decreased the environmental 
burden of C. difficile to below detectable levels. Similarly, in a university-based 
hospital, cleaning of patient rooms and environmental areas with unbuffered 1:10 
hypochlorite led to a 50% reduction in CDI rates after two months (Apisarnthanarak 
et al., 2004). Mayfield and co-workers witnessed a significant reduction in the 
incidence of CDI when quaternary ammonium compounds were replaced with 
hypochlorite for cleaning and disinfection (Mayfield et al., 2000). A similar 
observation by  McMullen and co-workers demonstrated the benefits of hypochlorite 
solution in endemic and hyper-endemic situations (McMullen et al., 2007). The 
cross-contamination of serial patients in the same room and between patients in 
adjacent rooms has also been controlled by  extending hypochlorite treatment to all 
lateral surfaces and areas within and outside of patient rooms (Whitaker et al., 2007). 
Even just terminal cleaning of rooms with hypochlorite (5000 ppm available 
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chlorine) has been shown to reduce CDI incidence by 48% (Hacek et al., 2010). 
Besides chlorine-based agents, hydrogen peroxide vapour treatment has also been 
proved to be effective in completely  eliminating environmental contamination by C. 
difficile and decreasing the incidence of CDI (Boyce et al., 2008). Thus, the 
importance of surface decontamination in reducing the dissemination and acquisition 
of C. difficile is unquestionable. 
Although the need to disinfect high-contact surfaces is obvious, the disinfection of 
floors is highly debated as it is thought that they play a negligible role in disease 
transmission (Favero & Bond, 2001). In one study, it was found that when certain 
types of disinfectants (oxygen- and aldeyhde/alcohol-based but not quaternary 
ammonium compounds) were used to clean floors, there was a reduction in the total 
bacterial count, but when only  detergent was used, there was introduction of a greater 
bacterial load into the environment (Dharan et al., 1999). Despite the clear efficacy 
of disinfectants in reducing environmental contamination, there was no difference in 
the incidence of infection in either treatment. The results from a separate but  similar 
study also showed that the disinfection of floors was unnecessary  and had no impact 
on the infection rate; although insignificant, the use of detergent alone was linked 
with lowered incidence of disease (Danforth et al., 1987). 
An argument in favour of floor disinfection was made by Exner and co-workers 
(Exner et al., 2004). In an experimental model mimicking the cleaning of floors 
using a mop they demonstrated that the use of detergents was as ineffective as using 
water alone. Further, there was a spread of bacteria from the area of contamination to 
clean areas. The authors thus suggested that  disinfection must be part of a holistic 
approach for hospital hygiene. 
The use of disinfectants on floors is considered to be an added expense with no 
scientific backing (Rüden & Daschner, 2002). Also, the side-effects associated with 
such use makes them less appealing to housekeeping staff. Moreover, detergent 
cleaning produces shiny floors which are more visually  pleasing (Danforth et al., 
1987). However, the use of a single cleaning strategy  could ensure uniformity in 
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cleaning and training procedures (Rutala & Weber, 2001). Voss and co-workers 
suggested that  disinfection of floors as routine practice is not necessary, but must  be 
performed if the situation demands it (Voss et al., 2003); contamination of floors 
with body fluids and faecal matter would be such conditions (Rutala & Weber, 2001). 
Thus, floor disinfection is still debatable but that of high-contact areas in preventing 
the spread of nosocomial disease is not.
4.1.7. Survival of spores and vegetative cells
Vegetative cells and spores of C. difficile have different susceptibilities to a variety  of 
conditions, including nutrients (Buggy et al., 1983); the presence of taurocholate in 
agar improves the recovery  of spores but has no effect on the recovery of vegetative 
cells. Using pre-reduced media had the same effect. However, it has been observed 
that when C. difficile strains were grown in faecal emulsions for 72 hours and 
aliquoted and stored, the recovery of vegetative cells and spores was not affected by 
storage at 4°C or -20°C (Freeman & Wilcox, 2003) which could be a result of the 
strains being in a buffered environment. These distinguishing characteristics are 
important in the recovery of C. difficile when estimating the levels of environmental 
contamination. However, the key differences in the survival of vegetative cells and 
spores within the host and in the environment are of greater significance.
Environmental shedding of C. difficile commonly  persists at the time of resolution of 
diarrhoea of a patient and can continue after therapy (McFarland et al., 1989; 
Mulligan et al., 1980; Sethi et al., 2010). Even healthy individuals treated with 
antibiotics shed large amounts of C. difficile, which is reversed at the end of 
treatment (Chachaty  et al., 1993). The number of vegetative cells in the stool of 
patients before antibiotic treatment for CDI is significantly  higher than after 
treatment has begun (Jump  et al., 2007). Following treatment, mainly  spores are 
recovered from the stool of patients, demonstrating the resistance of spores to 
antibiotics that clearly eliminate vegetative cells. Further, within the host, spores are 
able to survive the low pH of the gastric contents of patients who are not on acid-
suppressive therapy, while vegetative cells cannot. The survival of vegetative cells 
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increases in gastric contents as the pH increases, with significant survival above pH 5 
(Jump  et al., 2007). Thus, the internal environment of the host may influence the 
number of vegetative cells and spores released into the environment. 
Vegetative cells of C. difficile in suspension dried onto surfaces such as glass in five 
to 10 minutes and could only  be recovered for up to 15 minutes (Buggy et al., 1983). 
On the other hand, the recovery of spores of C. difficile was unaffected even after 
overnight drying of the suspension on the surface. However, it was later shown that 
the reason for the lack of recovery  of vegetative cells from surfaces was that they 
died of desiccation (Jump et al., 2007). Vegetative cells have been found to survive 
on moist surfaces at room temperature under aerobic conditions for 3 hours, 6 hours 
and sporadically up to 12 hours (Jump et al., 2007; Weber et al., 2010). In their 
studies, Jump and co-workers showed that under anaerobic conditions, vegetative 
cells survived for 12 to 24 hours; spores, being more robust, survived for up to 24 
hours on dry or moist surfaces (Jump et al., 2007). C. difficile spores can persist  on 
hospital floors for several months; artificial contamination of the floor of an unused 
hospital room and subsequent sampling revealed that even though the number of 
organisms recovered declined tremendously during the first few days of sampling, C. 
difficile could still be isolated from the floor for five months (Kim et al., 1981).
4.1.8. Decontamination strategies for C. difficile
The need for agents to control the dissemination of C. difficile led researchers to test 
the efficacy of various chemical agents against it, especially  its spores. Some of the 
earliest disinfectant studies against clostridial spores employed glutaraldehyde 
(Kelsey et al., 1974). At a concentration of 2%, glutaraldehyde was able to kill 
spores of C. difficile in 10 minutes, while at 0.2%, 30 minutes were required (Dyas & 
Das, 1985); dilutions much less than these were unable to inactivate spores (Rutala et 
al., 1993a). However, a study investigating two glutaraldehdye-based disinfectants 
found that up to 4 hours of direct contact could be required for a 4 log10 reduction in 
spore counts (Horejsh & Kampf, 2011). On the other hand, at a concentration of 2%, 
the oxygen-releasing compound they tested was able to bring about a 4 log10 
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reduction in one hour; as the concentration was decreased, the time required for the 
same reduction increased. Active oxygen-based agents have been found to be 
significantly more effective than quaternary  ammonium compounds in disinfecting 
bathrooms, toilets and furniture in a healthcare centre (Dharan et al., 1999). 
Glutaraldehdye can cause dermatitis and asthma in users (Wullt et al., 2003b) and 
thus, is not preferable for long-term usage.
Sodium hypochlorite (bleach, NaOCl) has been one of the most widely tested 
disinfectants against C. difficile, not only in the laboratory but also in hospitals. 
Bleach at 5000 ppm is the most suitable to obtain a 6 log10 reduction in C. difficile 
spores in 10 minutes, with 3000 ppm requiring 15 minutes and 1000 ppm requiring 
15 to 25 minutes for the same effect (Perez et al., 2005). Even when tested on spores 
dried on stainless steel, 5000 ppm bleach had the same effect (Omidbakhsh, 2010). 
The efficacy of 5000 ppm bleach could be further enhanced by spraying the bleach 
onto the surface, allowing contact of 3 minutes, followed by wiping the surface with 
a cloth dipped in the same bleach (Alfa et al., 2010). However, due to the quick 
drying of bleach and the difficulty in spreading an even concentration over a surface, 
less cleaning and disinfection might be achieved (Omidbakhsh, 2010). Also, the use 
of bleach at concentrations of 5000 ppm requires the use of special personal 
protective equipment (PPE) (Alfa et al., 2010). A formulation of super-oxidised 
water that releases hypochlorous acid and free chlorine radicals can eliminate spores 
in five minutes, but its efficacy decreases in the presence of organic matter (Shetty  et 
al., 1999). Thus, pre-cleaning is required but it is non-toxic and non-corrosive. A 
similar anolyte investigated by Robinson and co-workers was able to bring about a 
2.5 log10 reduction in spores within 10 seconds of treatment and was able to 
inactivate spores below the level of detection in 20 seconds (Robinson et al., 2010). 
Being effective, cheap and environmentally compatible, these electrochemically 
activated solutions might be the next step in hospital disinfection. 
Sodium dichloroisocyanurate (NaDCC) agents are considered to be superior 
disinfectants to bleach, especially in the presence of organic matter (Bloomfield & 
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Uso, 1985). The use of one such disinfectant was able to reduce the incidence of CDI 
cases on a hospital ward where environmental contamination corresponded to 
incidence rates (Wilcox et al., 2003). However, in one investigation it was observed 
that though bleach was superior to NaDCC against  vegetative cells, they were both 
equally sporicidal (Fawley  et al., 2007). Under clean conditions, an agent containing 
1000 ppm NaDCC and a detergent required just three minutes for a 3 log10 reduction 
in spores of ribotype 027 seeded onto stainless steel, but  contact of 9 minutes was 
required to eliminate spores to levels below the detection limit of approximately 5 
log10 (Wheeldon et al., 2008b). This efficacy was further reduced in the presence of 
organic matter; 30 minutes were required for a reduction greater than 3 log10. Ungurs 
and co-workers observed that 1000 ppm of NaDCC gave a minimal reduction in 
spore load even after two hours, but increasing the concentration to 6000 ppm 
resulted in complete decontamination in 20 minutes (Ungurs et al., 2011). Wiping the 
surface with the agent  increased cleaning efficiency and pre-cleaning with detergent 
was even more superior as soil tends to quench the effect of NaDCC. 
Peracetic acid is also sporicidal. At a concentration of 10% it was found to be less 
efficient than NaDCC, but it is less harmful to personnel (Wheeldon et al., 2008b). 
Its drawback however, is that 30 to 60 minutes could be required for inactivation of 
spores. In a different investigation, it was observed that a peracetic acid disinfectant 
could inactivate 99.9% of spores within 15 minutes and could cause a 4 log10 
reduction within five minutes despite soiling (Wullt et al., 2003b). Contrary to the 
results of Wheeldon and co-workers, Block observed that peracetic acid was better 
than NaDCC (Block, 2004). It  completely disinfected stainless steel contaminated 
with C. difficile spores in 10 minutes, but was less effective on polyvinyl chloride.
Accelerated hydrogen peroxide (AHP) compounds can also inactivate C. difficile 
spores in 10 minutes (Perez et al., 2005) as effectively as bleach at 5000 ppm and 
even produce a 2 to 3 log10 reduction in surface-dried spores in one minute (Alfa et 
al., 2010). AHP disinfectants performed better than stabilised hydrogen peroxide 
disinfectants (SHP) (Alfa et al., 2010). An AHP gel could kill 6 log10 dried spores 
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within 10 minutes. Further, it formed a uniform layer over the surface due to its 
viscosity  and took 10 minutes to dry, thus ensuring that the required contact time for 
sporicidal activity was achieved before the surface was visibly dry (Omidbakhsh, 
2010). A hydrogen peroxide dry mist system for the contamination of entire rooms 
was recently tested. Shapey and co-workers found that environmental contamination 
by C. difficile could be reduced by 94% with this system and it was effective against 
the three main UK epidemic ribotypes 106, 001 and 027 (Shapey  et al., 2008). 
Similar results were obtained in another study in which the hydrogen peroxide dry 
mist system achieved a 91% reduction in contamination as compared to the 50% 
reduction obtained by hypochlorite cleaning (Barbut  et al., 2009b). Ozone (25 ppm) 
as a gaseous sterilant has also been tested and found to be effective in bringing about 
at least a 4 log10 reduction in C. difficile spores (Sharma & Hudson, 2008).
More recently, alternatives to chlorine- and oxygen-releasing agents have been 
sought. Acidified nitrite was tested for its sporicidal activity  against C. difficile and 
was found to be effective and also unaffected by the presence of organic matter 
(Wullt  et al., 2003b). Being harmless to users or surfaces, it is a practical sporicide 
but must be freshly prepared for optimum activity. Metals as sporicidal agents have 
also been studied. Gant and co-workers studied three copper-based biocides which 
achieved a 2 to 3 log10 reduction in C. difficile spores in 30 minutes (Gant et al., 
2007). Surface cleaning using ultramicrofibre cloths dipped in these agents was also 
effective at decontaminating surfaces seeded with ribotype 027 spores. Metallic 
copper is bactericidal, but not sporicidal (Wheeldon et al., 2008c). However, when 
the spores were exposed to 1% sodium taurocholate, a 3 log10 reduction resulted in 
three hours, which was unaffected by soiling. Triggering germination by treating 
surface-dried spores with a solution containing sodium taurocholate also increased 
their susceptibility  to UV-C radiation (Nerandzic & Donskey, 2010). A UV-C device 
has also been tested for its ability  to decontaminate rooms (Nerandzic et al., 2010). 
A 2 to 3 log10 reduction in spores was achieved in approximately  45 minutes when 
the device was tested with contaminated surfaces and when used in rooms, an 80% 
reduction in positive samples was obtained. 
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Currently in the UK, chlorine-containing agents that release 1000 ppm of chlorine 
are recommended for cleaning areas occupied by CDI patients either with a detergent 
pre-clean or in combination with a detergent (Department of Health, 2009); chlorine-
based agents have a broad spectrum of activity (Fig. 4.1). However, no such 
recommendation has been made for the disinfection of laboratory  surfaces that 
potentially get  contaminated with high concentrations of C. difficile vegetative cells 
and spores.
4.1.9. Differences in susceptibilities
Spores are resistant to several disinfectants as mentioned above, especially  in the 
presence of organic matter (Fawley et al., 2007; Wheeldon et al., 2008b). Vegetative 
cells have a lower ability to survive in air and are more susceptible to the effect of 
sporicides (Jump et al., 2007; Wheeldon et al., 2008c). But the key question is 
whether there is any difference in the susceptibilities of different strains of C. 
difficile to different agents. 
Differences in the sporulation capacities of different ribotypes of C. difficile have 
been reported. Studies have shown that the hypervirulent ribotype 027 is capable of 
robust spore production (Akerlund et al., 2008; Merrigan et al., 2010) and the 
epidemic ribotype 001 produces significantly high numbers of spores compared to 
non-prevalent strains. The sporulation of ribotype 001 was found to be further 
enhanced when exposed to non-chlorine-based disinfectants (Wilcox & Fawley, 
2000) which could explain its extensive dissemination and persistence in the 
environment. In the study  by Wullt and co-workers, no differences in susceptibilities 
of different strains were observed to either glutaraldehdye, peracetic acid or acidified 
nitrite (Wullt et al., 2003b); strains belonging to serogroups A and C were used along 
with a common nosocomial strain. Similarly, during the testing of a peroxy 
compound, it was found that the spores of ribotype 027 were inactivated as 
efficiently as those of the other strains tested (Horejsh & Kampf, 2010). However, 
whether other agents can have similar effects on both vegetative cells and spores 
needs to be explored. 
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Fig. 4.1. Mechanisms of inactivation by some biocides 
Chlorine-releasing agents, hydrogen peroxide and glutaraldehdye have a broad spectrum of 
activity against vegetative cells and spores of bacteria, which makes them some of the most 
frequently used disinfectants. Adapted from Russell et al., 1997.
!"
Spore              Vegetative cell   
Spore core 
-  Hydrogen peroxide? 
-  Glutaraldehyde 
-  Formaldehyde  
Spore cortex 
-  Chlorine-releasing agents 
-  Glutaraldehyde 
-  Nitrous acid 
Cytoplasmic coagulation 
- Glutaraldehyde 
-  Copper (II) salts 






Leakage of intracellular contents 












- Acridine dyes 
-  Hydrogen peroxide 
-  Iodine 
-  Glutaraldehyde 
-  Ethylene oxide 
-  Hydrogen peroxide 
-  Chlorine-releasing agents 
-  Copper (II) salts 
-  Glutaraldehyde 
-  Formaldehyde 
-  Chlorine-releasing agents 
-  Ethylene oxide 
136
4.1.10. Static or cidal?
Several types of agents exist to decontaminate the environment; clear definitions of 
the different types of agents (Block, 2001) help us to identify the agent most suitable 
to achieve the desired outcome. A disinfectant is a chemical or physical agent which 
is able to eliminate undesired microorganisms from the inanimate environment, but 
may not kill bacterial spores. A disinfectant can sometimes be referred to as a 
germicide or a bactericide; however, a germicide generally refers to an agent that  is 
able to kill microorganisms that are not bacteria, like fungi and viruses. A sporicide is 
an agent which destroys bacterial spores. In strict  terms, a disinfectant can bring 
about decontamination of an environment, that is, it  can render an item or surface 
free of pathogens to such an extent  that it is unable to transmit pathogens and is safe 
to handle. On the other hand, a sporicide can be considered to be a sterilant as it is 
able to render an area free of the more resistant forms of microorganisms. Some 
agents can be bacteriostatic, that is, they can prevent the growth of bacteria and other 
living forms, but not destroy them. The difference between cidal and static activity  of 
agents can sometimes depend on factors like temperature, time and pH (Fig. 4.2). For 
many agents, the outcome is dependent on cleaning (or pre-cleaning) with detergent, 
which involves the removal of visible dirt like soil, blood, proteins and debris from 
surfaces, before decontamination. 
With respect  to C. difficile, selected disinfectants are required to be bactericidal as 
well as sporicidal. Many commonly-used bactericidal agents like phenols, quaternary 
ammonium compounds, biguanides and alcohols are sporistatic; they may prevent 
the germination or outgrowth of spores but are sporicidal only  at elevated 
temperatures (Russell, 1990; Russell, 1998). Even sporicidal agents such as 
aldehydes, chlorine compounds, peroxy acids and hydrogen peroxide are sporicidal 
at only  very  high concentrations (Russell, 1990). Although bacteriostatic and 
sporistatic concentrations for an individual chemical disinfectant might be similar, 
sporicidal concentrations are often considerably  higher than those that are 
bactericidal (Russell, 1998). These characteristics of disinfectants can be determined 
by a range of standardised tests. 
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Fig. 4.2. Microbial inactivation by disinfectants: factors affecting it and possible outcomes 
Biocides or disinfectants, unlike antibiotics, have a variety of target sites in bacterial cells; 
they can exert non-selective primary and secondary toxic effects on target cells. The efficacy 
of a biocide can depend on its concentration, the duration of exposure, environmental factors 
such as temperature, pH and organic matter and most importantly, the bacterial load. 
Adapted from Russell et al., 1997.
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Over the years, a variety of methodologies have been developed to test  the efficacy 
of disinfectants internationally (Reybrouck, 2007; Russell, 1998; van Klingeren, 
2007). There are three stages in disinfectant testing as described by the European 
Committee for Standardisation (CEN) guidelines, CEN/TC 216 (Humphreys, 2010; 
Reybrouck, 2007). The first phase involves laboratory tests like suspension tests to 
determine the basic concentration-time dynamics of the disinfectant against the 
selected bacteria. In the second stage, these suspension tests can be modified to 
incorporate factors like organic matter, making the results more relevant to a 
practical situation. Other laboratory tests mimicking real-life conditions are also 
performed to evaluate activity under the actual conditions of use. In the third stage, 
field tests are performed, but these are generally more difficult to perform and 
analyse due to the variation in conditions between one location and another. 
When the decontamination of spore-forming bacteria like C. difficile is required, it is 
essential to determine the sporicidal activity of disinfectants. As part  of preliminary 
testing, bacteriostatic concentrations of disinfectants can be determined by broth- and 
agar-dilution techniques; the minimum inhibitory concentration (MIC) value thus 
obtained can be used to estimate the sporistatic concentration of the agent as they are 
generally closely related concentrations (Russell, 1998). 
The tests to determine the sporicidal activity of disinfectants can be divided broadly 
into three categories: suspension tests, carrier tests and ‘in-use’ surface tests. In a 
suspension test, a standardised inoculum of bacteria is added to a defined volume of 
disinfectant and after different times of testing, an aliquot of this mixture is removed 
and cultured to check for growth. Interfering substances like organic matter and 
blood can be introduced into these tests. Good mixing of test bacteria and agents in 
suspension tests improves their reproducibility (Humphreys, 2010). However, there 
may be a carry-over of small amounts of the disinfectant into the recovery medium 
that might give a false result; a bacteriostatic effect could be interpreted as a 
bactericidal effect (Shippen, 1928). The Association Française de Normalisation 
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(AFNOR) suspension test is one such method to determine sporicidal activity of 
disinfectants (Espigares et al., 2003; Her'andez et al., 2000; Russell, 1998). 
Carrier tests involve the use of inanimate objects like steel, porcelain and even silk 
thread contaminated with a standardised inoculum. Once the contaminant  has dried 
on the carrier, it is submersed in the disinfectant for a defined period of time, 
followed by neutralisation of the agent and transfer of the carrier to growth medium. 
The disadvantage of this type of test is that it is difficult to standardise the number of 
bacteria dried onto a surface and also to analyse the loss of viable cells due to drying 
on the surface (Reybrouck, 2007; van Klingeren, 1995). The Association of Official 
Analytical Chemists (AOAC) sporicidal test  is an example of a widely used carrier 
test as described in several studies (Gröschel, 1991; Rutala et al., 1993b). 
Surface tests are performed to get a more real understanding of the interaction 
between the disinfectant and contaminating bacterium under practical conditions. A 
standardised inoculum is dried onto a surface like stainless steel or polyvinyl 
chloride. Subsequently, a small volume of disinfectant is added to the surface for a 
specified contact period. The viable organisms remaining on the surface are 
recovered and enumerated. These tests are more likely to reflect a real-life situation 
as the ratio of disinfectant to inoculum is decreased (Humphreys, 2010; van 
Klingeren, 2007). Such tests are described in documents such as BS EN 14349 and 
BS EN 13697 of the British Standards Institute (Humphreys, 2010).
While performing such sporicidal assays, the individual steps must be standardised to 
get reliable and reproducible results. The method for preparing the spore suspensions 
must be standardised and the inocula must be the same in every experiment (Russell, 
1998). The medium in which the spores are prepared could affect the action of the 
disinfectants and must be carefully evaluated (Perez et al., 2005). Further, the 
disinfectant must be adequately neutralised after the desired time of exposure to 
prevent sporistasis in the recovery medium (Russell, 1998). This can be achieved by 
diluting the disinfectant to sub-inhibitory levels, chemical neutralisation with a non-
toxic agent or by  washing the filter used to remove the agent, followed by incubation 
140
of the filter on solid media. Also, it is essential to ensure that conditions for the 
revival of damaged spores are suitable in order to avoid false negative results; this 
might require prolonged incubation periods or alteration of the recovery medium. 
The aim of this study was to identify the most suitable laboratory agents for the 
decontamination of surfaces contaminated with C. difficile. The agents used for 
testing were thus selected from those available within our laboratory. They included 
Decon 90, Microsol 3+, TriGene Advance and Virkon, as described in Table 2.4. For 
comparison with decontamination that is routinely performed in hospitals, Actichlor, 
was also included in this study. The strains used for all the studies were the reference 
strains, 630 and VPI 10463 and the epidemic ribotypes 027, 001 and 106.
4.2. Methods
The first  stage in disinfectant testing involved qualitative tests; minimum inhibitory 
concentration (MIC) testing was performed using vegetative cells of the five C. 
difficile strains by the Wadsworth agar-dilution method and by  broth-microdilution
(2.8.2). MIC testing by  agar-dilution was also performed for 23 clinical isolates 
(Table 2.2). For C. difficile spores, survival assays were performed (2.8.4). Further, 
quantitative assays were performed to determine the extent of sporicidal activity  by 
the measuring the log10 reduction (2.8.5) in suspension tests. The scope of these tests 
was extended to clean and dirty  conditions - the absence and presence of organic 
matter, respectively - to understand how environmental conditions affect 
decontamination. Also, a practical test (2.8.6) was performed to determine the 
efficacy of the decontamination of surfaces contaminated with C. difficile spores. 
The surfaces selected were those commonly encountered in laboratories as well as 
hospitals: aluminium, glass, plastic, vinyl tiles and ceramic tiles. Further, the effect 
of sub-MIC concentrations of the agents on the sporulation capacity  of the different 
C. difficile strains was tested (2.8.7). Finally, to understand the extent to which C. 
difficile can disseminate in and around a laboratory performing C. difficile research, 
environmental sampling was performed using contact plates (2.9.1). The colonies 
were enumerated from the plates and ribotyping was performed (2.9.2).
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4.3. Results
Through a series of quantitative and qualitative tests it was possible to determine 
which of the commonly available disinfectants in our laboratory were suitable to 
decontaminate our immediate environment of C. difficile. Also, the level of C. 
difficile contamination within our laboratory was examined.
4.3.1. MIC determination 
Growth of vegetative cells of the five C. difficile strains was effectively suppressed 
by all the agents tested. The MICs of the agents for all strains were lower than the 
manufacturer’s recommended working concentration as determined by agar-dilution 
and are represented as a fraction of the recommended working concentration in Table 
4.1. The same results were obtained by broth-microdilution. However, for Actichlor, 
Decon 90 and Virkon, higher concentrations were required to destroy vegetative cells 
of the epidemic ribotypes 027 and 001. Microsol 3+ appeared to be the most 
effective agent, active at a 128-fold dilution of the recommended concentration, 
followed by  TriGene Advance, which was effective at a 32-fold dilution of the 
recommended concentration. Disinfectant sensitivity profiles of the clinical isolates 
of all ribotypes, except ribotype 001, matched the profile of ribotype 106. 
Table 4.1. Minimum inhibitory concentration (MIC) of the agents for vegetative cells of five C. 
difficile strains determined by agar-dilution and broth-microdilution and represented as a 
fraction of the recommended working concentration
Agent
Minimum Inhibitory Concentration







Actichlor 1/8 1/8 1/2 1/8 1/8
Decon 90 1/4 1/4 1/2 1/2 1/4
Microsol 3+ 1/128 1/128 1/128 1/128 1/128
TriGene Advance 1/32 1/32 1/32 1/32 1/32
Virkon 1/8 1/8 1/4 1/4 1/8
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4.3.2. Effect on spore viability
The agents tested were also found to be sporicidal at the recommended concentration 
in suspension tests at 2 min, 10 min and 30 min of testing (Table 4.2). Once again it 
was observed that ribotype 027 required a greater concentration of Actichlor for 
destruction of its spores; spores survived at a 2-fold dilution of the recommended 
concentration. This was also true for the epidemic ribotype 106. For Virkon, any 
dilution below the recommended concentration was not sporicidal at 2 min, making 
it a less effective disinfectant  than Actichlor. These studies demonstrate the 
importance of accurate preparation of disinfectants before use. Interestingly, 
Microsol 3+ and TriGene Advance were found to be sporicidal at a 5-fold dilution of 
the recommended concentration even at 2 min of exposure. However, this could be a 
result of prolonged exposure to low concentrations of the active ingredients in these 
agents as no neutraliser or washing step was included.
Table 4.2. Minimum sporicidal concentration of five agents represented as a fraction of the 
recommended working concentration after different times of exposure 
Agent a Time of exposure
Minimum Sporicidal Concentration








2 min <1/5 <1/5 1/2 <1/5 1/2
10 min <1/5 <1/5 <1/5 <1/5 <1/5
30 min 1/5 <1/5 <1/5 <1/5 <1/5
Decon 90
2 min 1 1/2 1/2 1 1/2
10 min 1/2 <1/5 <1/5 1/2 <1/5
30 min <1/5 <1/5 <1/5 <1/5 <1/5
Virkon
2 min 1 1 1 1 1
10 min 1 <1/5 1 <1/5 <1/5
30 min 1 <1/5 1 <1/5 <1/5
a The minimum sporicidal concentration for Microsol 3+ and TriGene Advance for all the 
strains was less than 1/5 recommended concentration at 2, 10 and 30 min.
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4.3.3. Determination of log10 reduction 
All the selected agents, except Decon 90, are marketed as sporicidal agents. Thus, it 
was of interest to determine the log10 reduction in spore numbers brought about by 
them at the recommended concentration. To avoid exposure of the spores to small 
traces of any  active ingredients, they  were washed thoroughly after being treated 
with the agents. Under clean conditions in the absence of organic matter, Actichlor 
was found to be the most effective sporicidal agent, bringing about a 3 log10 
reduction of C. difficile spores at 10 min, while Microsol 3+, TriGene Advance and 
Virkon only caused an approximately 1.5, 1.7 and 1.2 log10 reduction, respectively 
(Table 4.3). In the presence of organic matter, the efficacy of all the cleaning agents, 
except Actichlor, dropped considerably. The drop in efficacy of Virkon from 
approximately 1.2 log10 in the absence of organic matter to approximately 0.2 log10 
in its presence was especially notable. Also, interestingly, in the presence of organic 
matter, for all the agents except Actichlor, the log10 reduction for the epidemic strains 
was more markedly perceptible as compared to the non-epidemic strains (Fig. 4.3). 
As these experiments were not performed with more than 103 spores/test, it is 
possible that the activity  of Actichlor has been underestimated and it brings about a 
greater log10 reduction at the time tested.
Table 4.3. Average log10 reduction in spores of five C. difficile strains in the absence and 
presence of organic matter
Agent
log10 reduction (Mean ± Std. Error) b
Organic matter negative Organic matter positive
Actichlor 3.093 ± 0.2239 3.076 ± 0.2429
Decon 90 0.5159 ± 0.06722 0.3384 ± 0.101
Microsol 3+ 1.519 ± 0.1025 0.7288 ± 0.1294
TriGene Advance 1.698 ± 0.0806 0.5399 ± 0.09384
Virkon 1.171 ± 0.1705 0.1657 ± 0.04113
b The log10 reduction is an average of the five C. difficile strains
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Fig. 4.3. Efficacy of five agents (log10 reduction) against five strains of C. difficile in the 
absence and presence of organic matter
The efficacy of Actichlor (A), Decon 90 (D), Microsol 3+ (M), TriGene Advance (T) and Virkon 
(V) was tested against the spores of five strains of C. difficile. Only Actichlor effectively 
destroyed spores of all the strains in the absence or presence of organic matter, causing a 3 
log10 reduction in spores. The efficacy of all the other agents decreased significantly in the 
presence of organic matter, especially in terms of destroying spores of the epidemic 
ribotypes 027 (c), 001 (d) and 106 (e). Bars indicate +/- SEM of 2 experiments.
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4.3.4. Decontamination of surfaces
To test the decontamination of surfaces using the selected agents, 1 cm2 areas were 
artificially contaminated with 103 spores of each strain, allowed to dry and then 
cleaned, in an attempt to mimic a real-life situation. Further, the surface was washed 
by aspiration of disinfectant and subsequent washes. It was observed that only 
chlorine-releasing Actichlor was able to completely decontaminate all the surfaces 
tested; however, more than 2 min (Fig. 4.4.a) and up to 10 min (Fig. 4.4.b) were 
required to see this effect. For all the other agents, although there was a greater log10 
reduction in spore numbers after 10 min of treatment as compared to 2 min, it  was 
still negligible compared to the initial level of contamination. Here too it was found 
that the spores of the epidemic strains were less effectively destroyed by all the non-
chlorine agents. The spores of strain 630, which was previously epidemic in 
Scotland, were also more resistant to cleaning, while spores of VPI 10463, which is 
rarely isolated from patients, were the most effectively destroyed.
4.3.5. Effect of sub-MIC concentrations on sporulation
The five C. difficile strains were cultured for 5 d in the presence of concentrations 
corresponding to 1/4 of the MIC of all the agents, except Actichlor. The growth of all 
the strains as measured by OD600 was considerably lower only in the presence of 
TriGene Advance (Fig. 4.5.a). The presence of sodium taurocholate in the medium 
did not affect the growth of the strains. However, it  did augment sporulation in all the 
strains when grown with Decon 90 and Microsol 3+. 
Exposure to sub-MIC concentrations of the agents led to high numbers of spores 
being produced by all the epidemic strains; this increase was most notable in 
ribotype 001, followed by ribotypes 027 and 106, respectively (Fig. 4.5.b). Overall, 
the epidemic strains appeared to be more affected by exposure to sub-MIC 
concentrations of different agents as compared to the reference strains. Also, the 
spores produced by  ribotype 001 appeared to be more resilient when compared to 
ribotypes 027 and 106 as the presence of taurocholate had a lower impact on their 
germination and outgrowth. 
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Fig. 4.4.a. Level of surface decontamination after 2 minutes of exposure to five agents
After 2 min of exposure, Actichlor (A) was found to be the most effective decontaminant, 
while Decon 90 (D), Microsol 3+ (M), TriGene Advance (T) and Virkon (V), fared poorly. 
However, complete decontamination of the surfaces was not achieved even with Actichlor, 
illustrating the need for longer exposure of contaminated surfaces to cleaning agents in 
order to effectively destroy spores of C. difficile. Bars indicate +/- SEM of 2 experiments.
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Fig. 4.4.b. Level of surface decontamination after 10 minutes of exposure to five agents
After 10 min of exposure to the agents, only Actichlor (A) successfully destroyed all C. 
difficile spores. The other agents brought about a negligible log10 reduction, especially 
against the epidemic ribotypes 027 (c), 001 (d) and 106 (e). Bars indicate +/- SEM of 2 
experiments.
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Fig. 4.5.a. Effect of sub-MIC concentration of non-chlorine agents on growth of five C. 
difficile strains
When grown anaerobically in the presence of sub-MIC concentrations of all the agents 
except Actichlor, the growth of the five C. difficile strains was only markedly affected by 
TriGene Advance (T), suggesting that it might be bacteriostatic at the concentration used. 
There was no notable difference between the growth of the strains in the presence of Decon 
90 (D), Microsol 3+ (M) or Virkon (V). The presence of sodium taurocholate in the medium 
did not affect the growth of the strains. 
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Fig. 4.5.b. Effect of sub-MIC concentration of non-chlorine agents on sporulation of five C. 
difficile strains
Exposure to sub-MIC concentrations of non-chlorine-based agents appeared to enhance the 
sporulation of C. difficile ribotype 001 (d) considerably, followed by ribotype 027 (c) and 106 
(d), respectively. The presence of sodium taurocholate in the medium aided sporulation at 
sub-MIC levels of Decon 90 (D) and Microsol 3+ (M), but spores were not detected (ND) at 




To examine the level of contamination by  C. difficile in and around our laboratory, 
93 sites were selected for sampling (Fig. 4.6. and Table 4.4). Sampling was 
performed in duplicate using contact plates with either CCEY agar or blood agar. 
Samples were collected from different areas in the laboratory carrying out varying 
degrees of work with C. difficile. Also, areas around the laboratory were sampled, 
including clean media preparation areas, corridors and offices. 
Of the 93 sites sampled, 23 (24.73%) were found to be positive for C. difficile. As 
expected, majority of the positive samples were detected in the areas of highest 
intensity of C. difficile work; 11 of the 45 sites in area A and 10 of the 15 sites in area 
B were positive. Interestingly, the other two positive sites were in areas E and F, 
showing the potential for spread even in areas that should be mainly  C. difficile-free. 
Along with C. difficile, a large number of other anaerobes were isolated from all the 
sites (Fig. 4.7).
A total of 60 C. difficile colonies were isolated from all the positive sites. Ribotyping 
was performed on these to identify if the contamination of the environment was due 
to a single strain or several different types. The typing was not successful for samples 
from three of the 23 sites. Of the 60 colonies, PCR reactions for only  38 (63.33%) 
were successful. Although the gel image was not of suitable quality to analyse using 
the ribotyping software, four distinct banding patterns were obtained (Fig. 5.6.). The 
types were assigned as i, ii, iii and iv, which constituted 57.89% (22/38), 21.05% 
(8/38), 2.63% (1/38) and 18.42% (7/38), respectively of the total number of typed 
colonies. Colonies of single types were obtained from 17 sites and three sites yielded 
two colony types (Fig. 4.8). These sites were in areas A, B and E and were a bench, 
the interchange tray of an anaerobic chamber and the keypad of a centrifuge, 
respectively. The most predominant type i strain was one of the two C. difficile- 
types identified from each of these sites. 
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Fig. 4.6. Map of the areas selected for environmental sampling in and around the laboratory 
Ninety-three sites in and around our laboratory were sampled for C. difficile using contact 
plates. The areas have been colour-coded according to the intensity of work with C. difficile 
being carried out in them and they have been labeled A to M. The number of positive 
samples detected/the total number of sites sampled are stated in the parentheses alongside 
each area label. As expected, the areas in which maximum C. difficile work is performed 
were found to be the most contaminated. The specific sites sampled in each area are listed 


























Table 4.4. List of the 93 sites sampled in each area, of which the 23 encased in boxes were 
found to be C. difficile-positive
A: 45 sites Sink 2 (outer edge) Non-C. diff workerʼs gloves (palm)
Bench 1 and on it: Door of adjacent culture lab Non-C. diff workerʼs gloves (top)
Discard jar (lid) 37°C incubator door 
(exterior)
D: 1 site
Disinfectant spray bottle (base) 37°C incubator (interior wall) Waste disposal area
Vortex (upper surface) Fridge (handle) E: 3 sites
Pipetteboy (handle) Fridge (interior door) Centrifuge (keypad)
Pipette rack (upper suface) Storage cupboard (door) Plate drier (door)
Pipette-tip box (lid) Computer keyboard Scales (surrounding area)
Multichannel pipette (base) Ceiling F: 4 sites
Lab book of user (cover) Air vent on ceiling Door (exterior laminate surface)
Top drawer below bench 
(exterior)
B: 15 sites Door (handle)
Back of chair Bench 7 Door metal panel (outwards)
Base of chair Sink 3 (interior) and: Door metal panel (inwards)
Floor under it Tap handle G: 1 site
Lab coat of user of bench 1 Wall above it Bead beater (lid)
Fingers of user of bench 1 Anaerobic chamber 1 (door) H: 1 site
Bench 2 and on it: Of anaerobic chamber 2: Media preparation area
Wire gauze (upper surface) Interior floor I: 4 sites
Bench 3 and: Interior shelf Office desk 1 and:
Metal box on shelf above it 
(exterior)
Interior wall Phone on it (receiver)
Floor below it Interchange tray Office desk 2
Bench 4 Interchange door Carpet (at the entrance)
Shelf above bench 4 Floor below it J: 3 sites
On bench 5: Bijoux bottle 
(exterior)
Music player Counter
Pipette rack Fridge/freezer (door) Microwave (door)
Benchtop centrifuge (lid) -70°C freezer (door) Coffee table
PCR machine (lid) C: 11 sites K: 2 sites
RBC shaker (vertical surface) Bench 8 Exit button
Shaker (upper surface) Bench 9 Floor
Shelf above bench 6 and: Desk L: 2 sites
Freeze drier on it QPCR machine (door) Door of ladiesʼ toilet
Sink 1 (interior) and: Spectrophotometer (top)
face)
Door of mensʼ toilet
Tap handle Power pack (upper surface) M: 1 site
Soap dispenser Heating block (upper 
surface)
Door handle on the cold room door
Wall above it -20°C freezer (door) Miscellaneous:
Floor below it Computer mouse Sole of a lab workerʼs shoe
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Table 4.5. C. difficile-positive sites and numbers and types of C. difficile colonies identified 
from each of them
Site
Total no. of 
C. difficile 
colonies 
No. of typed colonies of each assigned type
i ii iii iv
Bench 1 1 1
Vortex 3 2
Pipetteboy 2 2
Bench 2 1 1
Bench 3 12 3 1
Floor below bench 3 2 2
Shelf above bench 4 2 2
Benchtop centrifuge 2 2
RBC shaker 2 1
Freeze drier 1 1
Sink 2 2 2
Bench 7 3 3
Sink 3 3 2
Tap handle 2 1
Chamber 1 1 ** ** ** **
Interior floor 4 ** ** ** **
Interior shelf 3 ** ** ** **
Interior wall 2 1
Interchange tray 5 4 1
Interchange door 2 1
Floor 1 1
Centrifuge 3 2 1
Door metal panel 1 1
** Undetermined
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Fig. 4.7. Sites contaminated with C. difficile
For each of the 23 C. difficile-positive sites, the total number of colonies obtained on non-
selective blood agar (grey area) and the number of C. difficile colonies among them (white 
area) were enumerated. The specific number of C. difficile colonies isolated from each site 
are noted above the bars. Further, the positive sites are separated according to their location 
(A, B, E and F) as represented in Fig. 5.4.
Fig. 4.8. Types of C. difficile identified from the laboratory environment
PCR ribotyping was successfully performed on 63.33% of the 
colonies isolated from 20 of the 23 sites sampled. (a) Although 
the gel images were not of suitable quality to be analysed by the 
ribotyping software, on observing them by eye, 4 distinct banding 
patterns were identified among the samples. These were 
assigned as i, ii, iii and iv. (b) These assigned strain types i, ii, iii 
and iv constituted 57.89%, 21.05%, 2.63% and 18.42% 
respectively of the total number of typed colonies. From 17 sites, 
colonies of only one banding pattern were obtained; from 3 sites, 
two types of colonies were identified.
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4.4. Discussion
‘It would seem that tests of the sporicidal activity of disinfectants are, for practical 
purposes, best performed by pessimists’ (Kelsey  et al., 1974). Although the results 
from the initial laboratory tests in this study  were encouraging, when challenged with 
conditions normally encountered in the real-world, just one disinfectant stood out as 
a likely candidate for the battle against C. difficile contamination. Unfortunately, it is 
not one routinely used in the laboratory.
The primary challenge with disinfectant testing is that most of the accepted test 
methods do not mimic the real environment in a hospital or laboratory and the results 
thus do not translate to practical conditions; the requirement of a 3 log10 reduction 
under clean conditions in 60 minutes is clearly not realistic. In this study, the MIC 
results against vegetative cells indicated good efficacy of all the agents studied 
against the five C. difficile strains selected. Although exponential phase cultures 
consisting of mainly  vegetative cells were selected for these tests, it is possible that 
there were some spores present. Using this method, it was not possible to identify  if 
the agents had any cidal effects on either the vegetative cells or spores of C. difficile. 
It has previously been shown that minimum bactericidal concentrations (MBCs) can 
be much higher than inhibitory concentrations (Russell et al., 1999). Thus, it is 
possible that  for Decon 90, Virkon and even Actichlor, the manufacturers’ 
recommended concentrations might not actually  be cidal even for the vegetative cells 
of C. difficile; this is less likely for TriGene Advance and Microsol as their MICs are 
much lower than the recommended concentration. 
In the next stage of testing too, with a standardised spore preparation, it appeared as 
though all the agents were sporicidal at the manufacturers’ recommended 
concentrations even at  2 minutes of exposure. The method used ensured that a 10-
fold dilution of the disinfectant concentrations was tested in the recovery medium. 
However, it is possible that yet again a sporistatic result was obtained due to the 
prolonged exposure of the spores to low but effective concentrations of the agents 
tested. Dilution of disinfectants in the recovery stage is generally  considered to be 
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suitable (Russell, 1998) but as the effect of dilutions on spores was not validated 
independently, the killing of spores could not be confirmed. No growth was observed 
on the recovery  agar from the dilutions that showed a static/cidal effect, suggesting 
that there was destruction of spores. However, it is clear that had a neutraliser been 
used or if the agents had been removed by  washing, more conclusive results about 
the true effect of the agents would have been obtained. Of note from these results is 
the observation that for Decon 90, Virkon and Actichlor, the static/cidal effect was a 
result of using them at the recommended concentration or a 2-fold dilution of the 
same, which emphasises the importance of preparing these agents at the correct 
concentration. It was also interesting to find that higher concentrations of Actichlor, 
which is commonly used in hospitals, were required for inactivation of spores of 
ribotypes 027 and 106 in 2 minutes, suggesting the possibility that the epidemic 
ribotypes may have a greater resistance to commonly-used cleaning agents. The fact 
that no growth was observed for Microsol 3+ and TriGene, suggests that  they have a 
strong cidal or static effect on C. difficile. 
To confirm the efficacy  of the agents, log10 reduction studies were performed in 
suspension tests and this time the agents were removed by thorough washing. 
Organic matter was also introduced into the tests to create practical conditions. From 
the results, it  was clear that of the agents tested, Actichlor should be the agent of 
choice for the decontamination of C. difficile. The effect of all the other agents was 
mediocre even at 10 minutes in suspension and decreased further in the presence of 
organic matter. From these results, it  could be confirmed that the results obtained in 
the previous set of experiments were due to sporistasis. Oddly, the generally 
observed decrease in efficacy of NaDCC disinfectants in the presence of organic 
matter (Ungurs et al., 2011; Wheeldon et al., 2008b) was not seen here with 
Actichlor. Also, there was no noteworthy difference in the effect  of the biocides on 
the different C. difficile strains. 
On a variety of clean non-porous surfaces too, only Actichlor was able to destroy all 
the spores seeded onto them but it required more than 2 minutes and up to 10 
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minutes for this result. These results for Actichlor are contrary  to those of Ungurs 
and co-workers, who only observed a minimal reduction in C. difficile spores even 
after 120 minutes using 1000 ppm of free chlorine, as was used in this study (Ungurs 
et al., 2011). In a real-life situation, 10 minutes of exposure to any agent is a very 
optimistic expectation (Block, 2004). Further, although this period of exposure may 
be required even for the most effective chlorine-releasing agents (Wheeldon et al., 
2008b), prolonged contact with NaDCC agents are not realistic due to the odour, 
corrosive effects on surfaces and irritation to users (Ungurs et al., 2011). To further 
understand the cleaning of surfaces, it would be useful to perform similar tests in the 
presence of dried organic matter on the surfaces and perhaps, extend the studies to 
porous surfaces like wood and fabric. Interestingly, at 10 minutes on all the surfaces, 
the lower log10 reduction was observed for the epidemic ribotypes 027, 001 and 106.
The exposure of C. difficile spores to sub-MIC concentrations of disinfectants is a 
realistic possibility, but whether the sporulation capacity of the strains in vivo 
following this exposure changes remains unknown. In this study, the growth of all 
the strains was only  markedly  reduced by sub-MIC levels of TriGene Advance; this 
was perhaps due to a bacteriostatic effect which then resulted in no spores being 
detected in these cultures. In the presence of the other non-chlorine-based agents, 
ribotype 001 produced considerably more spores than ribotypes 027 and 106; 
however, these numbers were much greater than that of strain 630. The addition of 
sodium taurocholate to the test medium did not affect the growth of the strains but 
did positively affect the number of spores detected. The increased sporulation of 
ribotype 001 in the presence of sub-inhibitory concentrations of non-chlorine 
disinfectants has been documented and the data here are in agreement with this 
observation for not only  ribotype 001 but also the other epidemic ribotypes 027 and 
106. This observation could potentially  explain the wider dissemination of these 
strains in the nosocomial environment but further studies have to be performed to 
determine the clinical significance of such exposure, not  just in terms of 
environmental contamination, but also with regards to the possibly altered in-vivo 
virulence of these strains.
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Evidence for the widespread contamination of the laboratory  environment with C. 
difficile has been shown in this study  and it is equally important to control this spread 
in laboratories due to the potential of laboratory-acquired CDI. Although the level of 
contamination was relatively high in the small area tested, it  could possibly be 
higher; perhaps, if the detection medium contained sodium taurocholate or lysozyme 
which enhance germination (Wilson et al., 1982) more contamination may have been 
detected. Also, as this sampling was performed only once, it was not  possible to 
determine if this contamination is constant or transient. Regular sampling of surfaces 
and trials with different cleaning regimens would be useful. The sampling of 
commonly-used equipment would be important since the contamination of these, as 
observed in this study, can expose other workers to C. difficile who might not be 
aware of the risks of CDI, especially the antibiotic aspect. 
The need for effective biocides against C. difficile, especially its spores, is clear. 
However, until an effective method for decontamination is developed, regular 
assessment of contamination in laboratories should be performed to determine the 
areas most prone to contamination. It has been shown in hospitals that frequent 
contact sites can be heavily contaminated (Fawley  et al., 2005). In the same study, 
approximately 14% of high-reach environmental sites which were not cleaned often 
were found to be C. difficile-positive. These sites, like shelves, were found to be 
contaminated in our laboratory as well and may act as reservoirs from where spore 
transfer can potentially take place after disturbance of air due to activity. C. difficile 
has been commonly but sporadically  isolated from air in hospitals, mainly  during 
peak activity times such as ward rounds, visiting hours and trolley  services and 
during activities such as opening doors and bed-making (Best et al., 2010). Also, the 
strains found causing disease were related to those isolated from the environment and 
air. The acquisition of C. difficile from the environment and air by the host has been 
documented using animal faecal-oral transmission models (Larson et al., 1980; 
Lawley  et al., 2010). It is possible that there is similar dissemination of C. difficile 
across a laboratory and sampling the surfaces and air within a laboratory actively 
doing C. difficile research would give a good measure of the degree of spread. Clean 
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surfaces and clean air are very important from an environmental perspective; lowest 
aerial contamination is associated directly  with the best ventilation, the least human 
activity and the most intensive housekeeping (Greene et al., 1962b).
When testing for disinfectant activity, most  European standards require a biocide to 
cause a 5 log10 reduction (Fraise, 2011), a norm that may be too rigorous and could 
lead to over-use of disinfectants (van Klingeren, 1995). In this study, approximately 
103 spores were used to contaminate the test surfaces, but the environment might not 
be as heavily  contaminated and thus, may  be more efficiently cleaned. Also, unlike 
vegetative cells, preparing such concentrated spore suspensions of C. difficile are 
difficult at best (Fraise, 2011). However, in areas of intensive C. difficile work, 
contamination of surfaces by high concentrations of spores is a possibility and thus, 
tests with large concentrations of spores in the presence of organic matter and even 
faecal material should be performed. Also, along with the biocides themselves, the 
method of cleaning must also be evaluated as it  has been observed that wiping of 
surfaces with the wrong agents can cause cross-contamination (Dharan et al., 1999; 
Ungurs et al., 2011).
The contaminated environment is important in the transmission of C. difficile and 
just as in hospitals, laboratories can be a source of transmission of CDI, due to both 
the virulent types of strains and high concentrations of C. difficile routinely present. 
Reports of laboratory-acquired CDI led to this evaluation of the type of disinfectants 
and cleaning agents used in our laboratory. From these studies, it would appear that 
chlorine-releasing agents should be the decontaminants of choice in laboratories, just 
as in hospitals (Fraise, 2011) although care has to be taken while using them owing 
to their possible toxic and corrosive side-effects and their reduced efficacy on soiled 
surfaces (Ungurs et al., 2011). 
The battle against C. difficile must be extended to the laboratory as it can be a source 
of disease transmission. The use of safety cabinets and disposable equipment, 
education and training of staff and the rigorous decontamination of surfaces are all 
required to reduce the threat of laboratory-acquired CDI. As suggested before, 
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cleaning the environment with detergents reduces the load of contamination but 
effective, user-friendly sporicidal agents are needed to tackle the spread of C. difficile 
(Wilcox, 1996). An agent that is sporicidal, effective at high contamination levels on 
vegetative cells on moist surfaces and spores dried onto surfaces in a practicable 
time, despite preparation in hard water and presence of organic material, and which 
is also non-corrosive and non-toxic would be the ideal biocide to rid any area of C. 
difficile (Kelsey  et al., 1974; McDonnell & Pretzer, 2001). Until such time as an 
effective method is developed to destroy C. difficile, basic hygiene must  be 
maintained as described in the following poem (Donskey, 2010):
How many times must a doctor be told
Wash your hands and wear gloves, please?
Yes, and how many times will another stand by
Pretending he just doesn’t see?
And how many times must we remind
Those things that we touch must be cleaned?
The answer, my friend, is blowin’ in the wind
The answer is blowin’ in the wind.
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5. Interactions of C. difficile with human cells
5.1. Introduction
The toxins and spores of C. difficile are its most important virulence factors. 
However, C. difficile expresses several surface-associated proteins that  are also 
involved in the infection process. These proteins are highly immunogenic but, 
perhaps more importantly, they  may participate in the very  first step of infection: 
adherence to host cells. The interactions between virulence factors and host cells can 
potentially affect the outcome of disease. The immune response elicited by 
macrophages in response to surface-associated proteins and toxins of different C. 
difficile strains and the role of flagella and S-layer proteins in adherence to epithelial 
cells were investigated. 
5.1.1. Surface-associated proteins
5.1.1.1. S-layer proteins
Surface-layers are porous crystalline membranes composed of identical proteins or 
glycoproteins which form the outermost envelope of some Gram-positive and Gram-
negative bacteria (Sidhu & Olsen, 1997; Sleytr & Messner, 1993). They have a 
variety of functions such as maintenance of the shape and rigidity of the cell 
envelope, molecular sieving, protection against complement-killing, interaction with 
macrophages and generation of an immune response and adhesion and colonisation. 
They can even be essential for virulence in some bacteria (Sára & Sleytr, 2000). 
In most bacterial species, the S-layer is composed of a single glycosylated protein 
(Sára & Sleytr, 2000) but in C. difficile, it is composed of two S-layer proteins 
(SLPs) - a surface-exposed protein with a lower molecular weight between 32 and 38 
kDa (LMW SLP) and a cell wall-associated protein with a higher molecular weight 
between 42 and 48 kDa (HMW SLP) (Fig. 5.1) (Fagan et al., 2009; Takeoka et al., 
1991). Using techniques such as freeze-etching and negative staining, it was 
determined that the S-layers in C. difficile had a distinct arrangement; the two protein 
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subunits were structurally superimposed on one another with the outer LMW SLP 
layer showing square symmetry and the inner HMW SLP layer showing hexagonal 
symmetry (Cerquetti et al., 2000; Takeoka et al., 1991). Also, it was initially 
suggested that C. difficile SLPs were glycosylated owing to the disparity  between the 
observed and predicted molecular weights of the two proteins (Cerquetti et al., 
2000). Indeed, in one study the glycosylation of HMW SLPs of all the strains 
investigated and of some LMW SLPs of the same strains was observed (Calabi et al., 
2001). However, more recent data have now confirmed that C. difficile SLPs are not 
glycosylated and therefore, assembly of this unique S-layer is not dependent on 
glycosylation but on non-covalent interactions between the SLPs (Qazi et al., 2009).
Fig. 5.1. Model of the cell wall of C. difficile 
In the cell wall of C. difficile, the two SLP subunits are arranged above the peptidoglycan 
layer. The HMW SLP (light grey) is embedded in the wall while the LMW SLP (dark grey) is 
surface-exposed. Other cell-wall proteins are also found above the peptidoglycan layer. 
Adapted from Fagan et al., 2009.
The unique 2160 bp slpA gene codes for the 73.4 kDa SlpA precursor protein (Fig. 
5.2) (Karjalainen et al., 2001; Karjalainen et al., 2002). SlpA has a two-domain 
structure characteristic of surface-expressed proteins. It has a signal sequence at the 
N-terminal and a C-terminal with three imperfect intermolecular repeat sequences 
(Karjalainen et al., 2001). The S-layer homologous (SLH) domain which anchors the 
SLPs to secondary  cell wall polymers in most bacteria is not found in C. difficile 
(Calabi et al., 2001; Mukherjee et al., 2002). The maturation of SlpA is required for 
the generation of the mature LMW SLP and HMW SLP subunits (Karjalainen et al., 
2001; Mukherjee et al., 2002). Post-translational cleavage of the precursor was found 
S-layer proteins/ 





to occur at two sites - at the N-terminal to remove the signal peptide and internally at 
approximately position 355 to separate the two protein subunits (Calabi et al., 2001). 
It is for this reason that only one band was observed when SLPs extracted from C. 
difficile strains were run on a native protein gel, whereas two distinct bands were 
observed under reducing conditions (Calabi et al., 2001). Cleavage of the LMW SLP 
and the HMW SLP after removal of the signal peptide could be mediated by the cell 
wall protein (CWP) and cysteine protease Cwp84 (Kirby et al., 2009). However, 
Cwp84 was not found to be essential for this process and maturation of the proteins 
occurred even through the action of extracellular trypsin and possibly occurs directly 
through host gut proteases in vivo. 
Fig. 5.2. Structural organisation of the SlpA precursor protein of C. difficile 
The SlpA precursor protein undergoes cleavage twice - once to remove the signal peptide 
and again to generate the HMW SLP and the LMW SLP subunits. The cysteine protease 
Cwp84 can mediate this cleavage, although this action is not specific; extracellular trypsin 
and chymotrypsin are also able to cleave the SlpA precursor into its two subunits. Adapted 
from Karjalainen et al., 2002 and Fagan et al., 2009.
Analysis of SlpA showed that the N-terminal of the protein corresponded to the 
LMW SLP while the C-terminal corresponded to the HMW SLP (Karjalainen et al., 
2001). Several variations were observed in the N-terminal domain, while the C-
terminal was more conserved. The role of the N-terminal in adherence to epithelial 
cells was detected and it was thus suggested that  the variability observed in the N-
terminal was due to antigenic selection owing to its exposure on the bacterial surface. 
The C-terminal showed homology with autolysins LytC (CwlB) and LytB of Bacillus 
subtilis as well as the N-terminal of Cwp66, which also exhibits N-acetylmuramoyl-
0                  719 aa 
  Signal            Variable region            Conserved region  
 peptide  (LMW SLP)     (HMW SLP) 
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L-alanine amidase activity (Calabi et al., 2001; Karjalainen et al., 2001; Mukherjee 
et al., 2002). Investigations with several strains showed that there was no homology 
between the two SLPs of the same strain suggesting that each protein had a unique 
function (Calabi et al., 2001; Cerquetti et al., 2000). Further, very little homology 
was observed between the N-termini of the proteins between different strains. This 
high inter-strain variability  in sequences and molecular weights of the SLPs between 
strains has formed the basis of genetic and phenotypic typing schemes (Kato et al., 
2010; McCoubrey  et al., 2003; Mukherjee et al., 2002). The signal sequences of 
SlpA proteins, however, are highly conserved between strains (Calabi et al., 2001). 
They  have been identified as Sec-dependent signal peptides and indicate the role of 
secA in the transport of the SLPs across the cell membrane (Mukherjee et al., 2002). 
The limited variability in the HMW SLPs of different C. difficile strains was found to 
be a result of sequence insertion rather than point mutations (Calabi et al., 2001). 
Only two conserved motifs were identified in the LMW SLP spanning the C-terminal 
residues 245 to 274 and 304 to 321, respectively  (Calabi & Fairweather, 2002; Fagan 
& Fairweather, 2010). These are essential for interaction of the LMW SLP with the 
HMW SLP to form an ‘end-to-end’ complex in the S-layer. 
slpA is encoded in a region of the C. difficile genome which contains at  least 28 
paralogues coding for proteins with homology to the HMW SLP (Fig. 5.3) (Calabi et 
al., 2001; Calabi & Fairweather, 2002). These genes and their intergenic regions 
appear to be fairly  conserved across strains (Mukherjee et al., 2002). Together these 
results suggest that this gene cluster is involved in cell wall synthesis. secA is located 
immediately downstream of slpA. Simultaneous expression of these genes was 
observed during growth (Calabi et al., 2001). slpA was transcribed throughout 
growth from the early exponential into the stationary  phase (Savariau-Lacomme et 
al., 2003). The 3.2 kb transcript observed proved co-transcription with or6f. This 
correlated well with the abundance of SLPs detected extracellularly during the 
growth of C. difficile (Mukherjee et al., 2002).
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Fig. 5.3. Genetic organisation of part of the DNA cluster in C. difficile strain 630 that includes 
slpA, cwp66 and cwp84
The genes encoding surface-associated proteins in C. difficile  are arranged close to one 
another on the genome and are transcribed in the same direction. slpA is transcribed 
bicistronically with orf6 throughout growth. Polycistronic and monocistronic transcription of 
cwp66 and cwp84, respectively, is only observed in the exponential phase of growth. The 
secA gene is immediately downstream of slpA. Adapted from Savariau-Lacomme et al., 
2003 and Calabi et al., 2001.
The SLPs of C. difficile are undoubtedly immunogenic. The HMW SLP is conserved 
and therefore shows strong antigenic cross-reactivity with antisera to a variety  of 
strains (Calabi et al., 2001; Cerquetti et al., 2000) but the LMW SLP is the dominant 
antigen (Cerquetti et al., 1992). It has been observed that patients with recurrent 
disease have lower IgM  to SLPs than those with a single episode (Drudy et al., 
2004). In fact, SLPs have been identified as useful candidates for active and passive 
immunisation in the hamster model (Ní Eidhin et al., 2008; O'Brien et al., 2005).
C. difficile SLPs also play a role in adherence. SLPs from three C. difficile strains 
were all found to bind similarly to HEp-2 cells (Calabi et al., 2002). In the same 
study, using recombinant SLPs it was shown that there was stronger adhesion with 
the HMW SLP than there was with the LMW SLP. The use of anti-HMW SLP 
antiserum reduced adherence of bacterial cells to epithelial cells by approximately  20 
to 30%, while pre-incubation of recombinant HMW SLP with antiserum prevented 
any inhibition, thus confirming the role of the HMW SLP in binding. Further, 
adherence of native and recombinant SLPs to normal mucosal biopsy specimens 
from the human gastrointestinal tract was investigated. Both protein types were able 
to adhere to epithelium and lamina propria from the stomach, duodenum and colon. 
Maximum binding was observed on apical surfaces of epithelial cells suggesting the 
orf6      slpA            secA                   orf8        orf9      cwp66               cwp84 
Transcript 1                                                                 Transcript 2                                Transcript 3 
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presence of receptors for SLPs on the brush border. Adherence was also strongest  to 
the apexes of villi indicating that the state of differentiation of host cells might be 
important for this interaction. The proteins also adhered to the extracellular matrix 
(ECM) in particular, to the proteins collagen I, thrombospondin and vitronectin. The 
HMW SLP showed equivalent binding as compared to the native protein, while the 
LMW SLP attached to only a few surface epithelial cells. 
It was hypothesised that specific adherence of bacteria to the brush border membrane 
through SLPs could allow for targeted delivery of toxins and that the subsequent 
destruction of the epithelium and ECM could enhance further damage and possibly 
aid in evasion from the immune system (Calabi et al., 2002). Recombination of slpA 
genes between strains has also been suggested as a mechanism to evade the immune 
system of the host (Ní Eidhin et al., 2006).
5.1.1.2. Flagella 
Bacterial flagella are sensory and motor surface organelles (Macnab, 2003). They are 
required for motility, adhesion and invasion of mucosal surfaces and interact directly 
with the immune system of the host (Ramos et al., 2004). Flagella are present on the 
surface of most C. difficile strains but  non-flagellated strains do exist (Delmée et al., 
1990). However, flagellum proteins have been purified and the encoding genes have 
been amplified from seemingly non-motile strains suggesting that the expression of 
flagella could be phase-variable (Pituch et al., 2002; Twine et al., 2009). It has also 
been proposed that translation of flagellum proteins may be regulated by 
environmental signals and that strains that  appear non-motile in vitro may very well 
be motile in vivo (Tasteyre et al., 2000b).
When C. difficile flagella were first  identified, the 39 kDa protein was found to be 
similar in all flagellated strains and thus, was found to be responsible for cross-
agglutination observed in serogrouping reactions (Delmée et al., 1990). Also, the 
presence or absence of flagella had no correlation with toxin production and hence, 
was not considered to be a virulence determinant. However, this did not imply  that 
flagella had no role in adherence or colonisation. 
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The fliC gene codes for the flagellin filament, while the fliD gene codes for the 
flagellar cap. fliC is a gene of 870 bp  and the FliC protein is composed of 290 amino 
acid residues (Tasteyre et al., 2000a). Only one copy of fliC is found in the C. 
difficile genome. The flagella have the characteristic three repetitive domains found 
in surface-exposed proteins. They also have structural features commonly found in 
other flagellin proteins. FliC has several conserved alanine residues which are 
responsible for the mainly  !-helical conformation of the filament. It also shows the 
presence of a LIAN sequence used for export of flagellar subunits. The N- and C-
terminals of FliC which are responsible for secretion and polymerisation, 
respectively, are conserved. The central region is divergent between strains as is it 
surface-exposed and thus, undergoes selection by antigenic drift. It  is responsible for 
cross-reactivity between strains, which hinders typing methods like serogrouping 
(Delmée et al., 1990). However, the genetic differences are sufficient to be applied to 
a typing method involving RFLP analysis of fliC (Tasteyre et al., 2000a; Tasteyre et 
al., 2000b). Interestingly, in one study high conservation of FliC was observed 
between clinical strains isolated over a short period of time (Twine et al., 2009).
fliD is a 1524 bp gene that codes for the FliD cap protein (Tasteyre et al., 2001b). 
Just like fliC, there is only copy of fliD in the C. difficile genome. FliD is 56 kDa 
protein composed of 507 amino acids. FliD is also surface-exposed, but unlike FliC, 
it is highly conserved and consists of no variable domains, suggesting it  has a very 
specific function in adherence to cell or mucus receptors. On treatment with a range 
of restriction endonucleases fliD shows two main RFLP patterns further illustrating 
the conservation of its genetic sequence. Translational variation observed for FliC in 
phenotypically non-flagellated strains has been observed for FliD as well. 
In initial studies, the predicted molecular weight of C. difficile flagella was different 
from the observed weight but glucosylation was not detected suggesting alternate 
post-translational modification of the protein (Tasteyre et al., 2000a). In a more 
recent study, a discrepancy of approximately  398 Da was detected, which indicated 
the addition of a glycan molecule (Twine et al., 2009). This was confirmed by mass 
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spectrometry  and O-linked glycan units were detected on the flagella. Further, a 
glycosyltransferase CD0240 was detected immediately  downstream of fliC along 
with other glycosyltransferases and genes involved in glycan biosynthesis (Fig. 5.4). 
The presence of CD0240 was found to be essential for flagellin production; 
interruption of the gene resulted in suboptimal production of flagellin. This 
confirmed that C. difficile flagella are glycoproteins. This made C. difficile the first 
example of a Gram-positive bacterium in which glycosylation was required for the 
assembly of flagella and subsequent motility. 
Fig. 5.4. Genetic organisation of part of the DNA cluster in C. difficile strain 630 that codes 
for the flagella proteins
The genes encoding the different flagellar proteins are arranged in close proximity on the C. 
difficile genome. Of these, fliD codes for the flagellar cap, fliC codes for the flagellin filament 
and flgB codes for the flagellum rod. C. difficile flagella are glycosylated by glycosyl-
transferases such as CD0240 and CD0244 which are responsible for the addition of glycan 
units to flagella by O-linkages. Adapted from Twine et al., 2009.
Just like other surface proteins, flagella interact with the immune system of the host. 
Antibodies to FliC and FliD have been detected in patient sera, although FliD was 
found to be more immunogenic (Péchiné et al., 2005a). Unsurprisingly, C. difficile 
flagella are also involved in adherence. The adherence of FliC, FliD and crude 
flagella to mucous membranes was investigated (Tasteyre et al., 2001a). All three 
protein preparations bound to the axenic caecal mucus from mice but not to porcine 
stomach mucus suggesting the absence of receptors for C. difficile flagella in pigs. 
However, the role of flagella in adherence to mucus was confirmed. When 
attachment of the proteins to Vero cells was studied, no adhesion was observed with 
FliC, intermediate adhesion was observed with crude flagella and maximum 
fliD   CD0238    fliC          CD0240              CD0241/42/43    CD0244          flgB 
Flagellar cap             Flagellin      Glycosyl-        Glycan    Glycosyl-          Rod
         transferase  biosynthesis    transferase 
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adhesion was observed with FliD. No binding was seen under denatured conditions. 
Thus, the native conformation of FliD is important in binding. Overall, FliC and FliD 
were both involved in attachment to mucus. In mice, no difference in colonisation 
was detected between flagellated and non-flagellated strains but flagellated strains 
showed greater adherence to mouse caeca in vivo. The presence of toxin B enhanced 
both adherence and colonisation; the damage caused to host cells by  toxin B possibly 
led to the exposure of additional receptors, which could be bound by flagella. 
5.1.1.3. GroEL
Heat-shock proteins (HSPs) in bacteria are highly conserved stress-inducible 
constitutive proteins which are involved in maintaining homeostasis within the 
bacterial cells (Zügel & Kaufmann, 1999). These molecular chaperones are 
important antigens in humoral and cellular immune responses elicited in the host. 
GroEL is a HSP expressed by C. difficile belonging to the Hsp60 family  (Hennequin 
et al., 2001b). It is encoded on the 1940 bp groESL operon. A single copy of the 
operon exists on the genome and it appears to be positively and negatively regulated. 
The operon includes the 1632 bp groEL gene and the 285 bp groES gene which code 
for 58 kDa and 10 kDa proteins, respectively. Neither protein has a signal peptide 
and both have a predominantly  !-helical structure with one potential transmembrane 
domain. GroEL is highly conserved between different C. difficile strains. 
The expression of GroEL is strongly induced following heat-shock above 40°C 
(Hennequin et al., 2001a; Hennequin et al., 2001b). Transcription of groEL was 
found to increase rapidly after heat-shock at  43°C for five minutes and reached a 
plateau within an hour. After this treatment, a 3-fold increase in protein production 
was detected (Hennequin et al., 2001a). A large amount of GroEL was found in the 
cell membrane fraction and extracellularly. The increase in groEL transcription was 
less prominent at 48°C; however, GroEL was detected in the cytoplasmic and 
membrane fractions and also in the cell wall fraction (Hennequin et al., 2001b). It 
was uniformly distributed over the cell surface and also found in the extracellular 
space. Further, conditions of stress such as acidic environment, iron-deprivation or 
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high osmolarity  induced significant transcription and translation of this HSP 
(Hennequin et al., 2001a). The presence of ampicillin caused a significant  increase in 
groEL transcription, but slower translation of the protein. This suggested that 
different stresses had different effects on GroEL expression. 
The mechanism of transport and localisation of GroEL to the surface of C. difficile 
cells and into the extracellular space is unknown. Since GroEL lacks a signal peptide, 
its transport into the extracellular space was hypothesised to occur by surface 
adsorption to the extracellular surface of the cell wall, followed by release of the 
protein (Hennequin et al., 2001b). Surface-exposure of GroEL was thought  to be 
necessary  for its interaction with host cells via its hydrophobic domains. GroEL was 
found to adhere to Vero cells and its role as an adhesin was confirmed when this 
attachment was inhibited by antibodies to GroEL and purified GroEL protein. 
Interestingly, GroEL expression was also induced on contact with Vero cells under 
normal temperature conditions indicating that its role in adhesion is not limited to 
conditions of stress (Hennequin et al., 2001b).
5.1.1.4. Cwp66
Cwp66 (cell wall protein 66 kDa) was detected in C. difficile following heat-shock at 
60°C and was the first  adhesin to be identified in a Clostridium species (Waligora et 
al., 2001). It is encoded by  the cwp66 gene which lies in the same operon-like region 
of the genome as slpA (Fig. 5.3). This 1830 bp gene is unique. cwp66 expression 
occurs only in the early exponential phase of growth; it is polycistronically 
transcribed as a 5.5 kb transcript along with orf8 and or9f, which lie immediately 
upstream of it (Savariau-Lacomme et al., 2003). orf9 encodes a 24.9 kDa hydrophilic 
protein with no homology to any  known protein (Waligora et al., 2001). 
Polycistronic transcription of cwp66, orf9 and orf8 suggests that the protein products 
of the three genes together may form an adhesin (Savariau-Lacomme et al., 2003).
Cwp66 also shows homology to CwlB of B. subtilis, like the SLPs (Waligora et al., 
2001). Cwp66 has a surface-exposed C-terminal, a mainly  !-helical N-terminal and 
three imperfect intramolecular repeat motifs characteristic of surface-exposed 
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proteins. Although variations were observed in the N- and C-terminals of the protein, 
the latter is more variable possibly owing to its surface-exposure and subsequent 
immune selection. Several nucleotide changes have been identified in the C-terminal 
domain of Cwp66 which result in at least nine peptide sequences (Savariau-
Lacomme et al., 2003). Based on variations in Cwp66, three groups of C. difficile 
strains were identified: those with no variability in the entire protein, those with 
differences only in the C-terminal and those with variations in both terminals 
(Waligora et al., 2001). A cleavage site between Ala27 and Ser28 suggested that the 
mature Cwp66 protein is exported to the cell membrane or secreted; however, 
Cwp66 does not have any transmembrane domains or cell wall-anchoring motifs 
(Waligora et al., 2001).
Antibodies generated against the N- and C-terminals of Cwp66 were observed to 
react with proteins in the cytoplasm, cell membranes and cell walls of C. difficile
(Waligora et al., 2001). Anti-Cwp66-N antibody detected very few proteins in heat-
shocked and non-heat-shocked bacteria suggesting that this terminal was embedded 
in the cell wall. Anti-Cwp66-C antibody  detected a few proteins in non-heat-shocked 
bacteria. However, in heat-shocked bacteria, large amounts of protein were detected 
evenly distributed over the cell-surface, using the anti-Cwp66-C antibody, thus 
confirming that the C-terminal is surface-exposed and possibly involved in 
adherence. The role of Cwp66 in attachment was subsequently investigated by 
Waligora and colleagues; partial inhibition of adhesion to Vero cells was observed 
with antibodies to Cwp66 and purified protein but only for heat-shocked bacteria. 
This partial inhibition indicated the presence of several other adhesins in C. difficile. 
5.1.2. Gut-associated lymphoid tissue
The gastrointestinal (GI) tract encounters a vast number of varied microbial antigens 
and the immune system of the GI tract, the gut-associated lymphoid tissue (GALT), 
has the daunting task of differentiating between commensal and pathogenic 
organisms - providing immune tolerance to the former and protection from the latter 
(Mason et al., 2008). The GALT is the largest compartment of the immune system 
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and includes the Peyer’s patches, mesenteric lymph nodes and isolated lymphoid 
follicles (Platt & Mowat, 2008). A large variety of immune cells including 
macrophages, dendritic cells, activated T cells, mast cells and plasma cells together 
maintain immunological homeostasis in the gut through the rapid elimination of 
pathogens by  phagocytosis and enhanced production of secretory IgA (sIgA) which 
can mediate antigen neutralisation and bacterial phagocytosis, while inducing anti-
inflammatory Th2 responses and suppressing inflammatory Th1 responses (Fig. 5.5) 
(Mason et al., 2008).
Antigen recognition by  the immune system occurs through pathogen recognition 
receptors (PRRs) such as toll-like receptors (TLRs), which recognise pathogen-
associated molecular patterns (PAMPs), for example TLR-4 recognises LPS (Platt  & 
Mowat, 2008; Sherman & Kalman, 2004). Lumenal antigens are sampled by M  cells 
and dendritic cells which send dendrites into the lumen (Sherman & Kalman, 2004). 
On identification and differentiation, the immune response generated either leads to 
homeostasis or inflammation. Intestinal macrophages are crucial in these responses 
(Weber et al., 2009).
Monocytes, the precursors of macrophages and dendritic cells, are produced in the 
bone marrow (Smith et al., 2005; Weber et al., 2009). After circulating in the blood 
for several days, they reach the target tissues where they differentiate into 
macrophages. The intestinal mucosa is the largest reservoir of macrophages. Most of 
these macrophages are ideally located in the sub-epithelium and are often referred to 
as ‘resident macrophages’. They differ in phenotype and function from macrophages 
found in other tissues (Platt & Mowat, 2008; Smith et al., 2005; Weber et al., 2009). 
They  have increased cytoplasmic volume, distinct pseudopodia and prominent 
vacuoles and secondary lysosomes. They do not proliferate in the intestine and 
appear to be in a state of partial activity. They  exhibit low or no expression of TLRs, 
Fc receptors for IgA and IgG, complement receptors and receptors for pro-
inflammatory cytokines. They do not produce pro-inflammatory  cytokines such as 
TNF-!, IL-1 or IL-6 and only produce low levels of IL-8. Instead, they produce 
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IL-10 and drive anti-inflammatory Th2 responses in the gut. These alterations, 
however, do not affect their phagocytic potential (Platt & Mowat, 2008).
The characteristic mucosal phenotype of intestinal macrophages appears to be a 
response to the microenvironment of the gut (Platt & Mowat, 2008; Weber et al., 
2009). The production of soluble factors, especially  IL-10 and TGF-", by other 
intestinal cells has been found to induce this phenotype. Phagocytosis of apoptotic 
cells induces the production of IL-10 in macrophages which could also be a factor. 
However, direct contact with epithelial cells was found to be crucial for this effect 
(Weber et al., 2009). It  has been observed that mucosal dendritic cells (DCs) also 
uniquely drive a Th2 response and induce B cells to produce sIgA to maintain non-
inflammatory conditions in the gut (Rimoldi et al., 2005b). Mucosal DCs appeared to 
be conditioned through stimulation with epithelial cell-derived medium containing 
thymic stromal lymphopoeitin (TSLP). They failed to produce IL-12 in response to 
bacteria and thus, were unable to drive a Th1 response, but they did produce IL-6 
which induced IgA production by plasma cells. Since intestinal macrophages are 
physically separated from epithelial cells by the basement membrane, the mechanism 
of the interaction between intestinal macrophages and epithelial cells is unknown; 
interaction could occur if intestinal macrophages sent out protrusions through the 
epithelium similar to the dendrites of dendritic cells (Weber et al., 2009).
The mucosal phenotype of intestinal macrophages does not necessarily imply that 
they  have lost the ability to induce pro-inflammatory cytokines (Weber et al., 2009). 
During an infection they can induce TNF-! production upon TLR stimulation. 
Intestinal inflammation is characterised by the destruction of epithelial cells, the 
production of Th1-type cytokines, crypt abscesses and eventual loss of barrier 
function (Sherman & Kalman, 2004). In C. difficile infection, activated macrophages 
release TNF-! and other inflammatory mediators (Castagliuolo et al., 1997). There is 
also degranulation of mast cells, neutrophil infiltration, increased epithelial 
permeability  and fluid secretion (Wershil & Castagliuolo, 1998). In such an 
infection, macrophages and DCs previously conditioned by  epithelial cells to drive a 
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Th2 response can produce pro-inflammatory cytokines (Eckmann & Kagnoff, 2005; 
Platt & Mowat, 2008). However, it has also been suggested that  only newly recruited 
DCs and macrophages that have not been pre-conditioned by epithelial cells are able 
to induce the required protective Th1 response (Rimoldi et al., 2005b).
Fig. 5.5. Immune system of the intestine: its role in infection and health
In the intestine, a variety of immune cells act together provide protection from potential 
pathogens. During infection or inflammation, invasive pathogens or their products can 
activate the intestinal epithelial cells and immune cells such as macrophages to secrete pro-
inflammatory cytokines like TNF-α, IL-1, IL-8 and IL-12, resulting in the recruitment of 
neutrophils, monocytes and other inflammatory cells, which can eventually result in hyper-
responsiveness of the immune system and chronic inflammation. Such inflammation, 
involving the influx of large numbers of neutrophils, loss of epithelial barrier function, fluid 
accumulation and ulceration is observed in infection with C. difficile. Under non-infection 
conditions, intestinal macrophages are deficient in TLRs and other pro-inflammatory 
receptors and are hypo-responsive but maintain their phagocytic activity. Mediators such as 
TSLP, IL-10 and TGF-β  released by other cells and IL-10 released by macrophages 
themselves condition them to drive anti-inflammatory responses and maintain homeostasis. 
Adapted from Platt et al., 2008, Sherman et al., 2004, Eckmann et al., 2005, Rimoldi et al., 
2005 and Poxton et al., 2001.
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In an inflammatory  setting, macrophages can contribute to tissue pathology by  the 
recruitment of neutrophils through the production of large amounts of IL-8 and by 
TNF-! meditated up-regulation of adhesion molecules on blood vessels that aid this 
process (Platt & Mowat, 2008). IL-12 produced by the macrophages induces IFN-( 
production by T cells, which results in increased epithelial permeability. Further, 
TNF-! and IL-1 drive apoptosis of epithelial cells, barrier disruption, vascular 
damage and necrosis and can also lead to the degradation of collagen and other 
extracellular matrix proteins. It is not known whether the macrophages that drive this 
Th1 response are resident intestinal macrophages in which functional reversion has 
occurred or non-mucosal macrophages recruited to the site of inflammation. This 
increased responsiveness by  the GALT results in chronic inflammation and 
ulceration (Platt & Mowat, 2008). 
5.1.3. Immune response in CDI
Intestinal inflammation is a common pathological outcome of Clostridium difficile 
infection, which is associated with pseudomembrane formation. Pseudomembranes 
are formed of unevenly distributed ‘volcano-like’ inflammatory lesions. These 
lesions consist of sloughed epithelial cells, an array  of immune cells, especially 
neutrophils, and fibrin and lie over mucosa which also shows ulcerations consisting 
of necrotic epithelial cells and marked leukocytic infiltration of the lamina propria 
(Castagliuolo & LaMont, 1999; Hafiz & Oakley, 1976; Knoop  et al., 1993). This 
acute inflammatory response is thought to contribute to tissue damage and injury and 
directly  affect the clinical severity of disease (Savidge et al., 2003). Greater levels of 
faecal IL-8 and IL-1" have been detected in patients with moderate to severe CDI as 
compared to patients with mild disease, highlighting this correlation (Steiner et al., 
1997).
The role of the toxins of C. difficile in inflammation has been widely investigated. 
Early studies showed that C. difficile toxins could inhibit monocyte-dependent T cell 
proliferation suggesting that  monocytes were the primary targets of the toxins 
(Däubener et al., 1988). Treatment of monocytes with toxin B resulted in the 
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production of pro-inflammatory cytokines like IL-1!, IL-1", IL-6 and TNF-! (Flegel 
et al., 1991). Toxin A was also able to elicit  a similar response but at a 1000-fold 
higher dose. Moreover, a certain level of synergism between the toxins and LPS was 
observed in the production of these cytokines. In fact, small amounts of toxin A that 
were insufficient to elicit a response were able to induce cytokine production in the 
presence of LPS. No synergism was observed between the two toxins. At low 
concentrations of toxin B, there was a slow and sustained release of IL-1", while at 
higher concentrations, there was an immediate release of IL-1". Even a short pulse 
with large amounts of toxin B was able to induce a high IL-1" response in the 
monocytes, even though the toxin is highly cytotoxic. The induction of these pro-
inflammatory responses by the toxins suggested that the responses themselves could 
contribute to the damage characteristic of CDI. In another study, monocyte-toxicity 
due to toxin B was not observed but the toxin did induce TNF-! release, alter the 
morphology  of the monocytes and affect phagocytosis (Siffert et al., 1993). The 
toxins were also found to induce the production of large amounts of TNF-! by 
macrophages (Linevsky  et al., 1997; Melo Filho et al., 1997). Toxin B was found to 
be more effective at  inducing TNF-! production and more cytotoxic to macrophages 
than toxin A. Both toxins have been shown to be more cytotoxic to macrophages and 
monocytes as compared to T and B cells (Mahida et al., 1998) and macrophages 
were more sensitive than monocytes (Linevsky et al., 1997). 
The toxins are also cytotoxic to epithelial cells (Mahida et al., 1996) which respond 
by producing IL-6 (Ng et al., 2003); IL-6 production was enhanced by TNF-! and 
IL-1" (Ng et al., 2003). Apical exposure of epithelial cells to the toxins has been seen 
to alter membrane permeability resulting in a loss of epithelial barrier function 
(Canny et al., 2006; Sutton et al., 2008). Exposure to the toxins has been observed to 
cause increased expression of IL-8 by epithelial cells and macrophages (Canny et al., 
2006; Johal et al., 2004c; Savidge et al., 2003). Disruption of the surface epithelium 
is likely to allow both C. difficile cells and toxins to reach the lamina propria and 
induce deeper damage (Johal et al., 2004b). Neural responses have also been 
observed in response to the toxins. Toxin A has been seen to induce the production of 
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substance P by lamina propria macrophages in a time-dependent manner; substance 
P can stimulate the production of TNF-! and IL-1 by macrophages and also interact 
with other immune cells (Castagliuolo et al., 1997). 
One of the prominent features of inflammation in CDI is the high influx of 
neutrophils to the site of damage. Toxin A and toxin B both depend on macrophage-
derived IL-8 to mediate neutrophil infiltration (Kelly et al., 1994; Linevsky  et al., 
1997; Souza et al., 1997). Toxin A can directly affect neutrophil migration but only at 
very high concentrations, while toxin B does not do so, which makes macrophages 
key to the immune response in CDI. The production of TNF-! and IL-1" by  toxin A-
treated macrophages also induced neutrophil migration (Rocha et al., 1997; Souza et 
al., 1997). IL-8 up-regulates cell adhesion factors in neutrophils and in endothelial 
cells, thus enhancing the extravasation of neutrophils (Canny et al., 2006; Linevsky 
et al., 1997). Blocking the leukocyte adhesion molecule CD18 prevented neutrophil 
migration and toxin damage in toxin A-treated ileal loops confirming the importance 
of neutrophils in CDI (Kelly  et al., 1994). IL-8 induced neutrophil migration is also 
dependent on the presence of mast cells (Rocha et al., 1997) which produce IL-8 and 
undergo slow controlled degranulation on toxin-exposure (Meyer et al., 2007).
The C-terminal of toxin A was found to be capable of directly activating endothelial 
cells and mononucleocytes to release IL-8 and IL-6, which increased the expression 
of adhesion molecules in endothelial cells and facilitated neutrophil influx (Yeh et 
al., 2008). The C-terminal of toxin B was also able to cause intestinal epithelial cell 
damage and stimulate IL-8 production (Zemljic et al., 2010). Interestingly, the 
internalisation of the toxins into macrophages by endocytosis was crucial for the 
production of TNF-! and IL-1" (Ng et al., 2010; Sun et al., 2009). Disruption of the 
actin structure within the macrophages was not sufficient for the production of TNF-
! and it was reliant on the glucosyltransferase activity of the toxins (Sun et al., 
2009). For IL-1" however, the activity of the toxins was not essential but the 
presence of the entire protein was (Ng et al., 2010). Along with severe damage to the 
intestinal epithelium and induction of inflammatory  cytokine responses, apoptosis of 
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macrophages, T-cells and eosinophils was also observed (Mahida et al., 1996; 
Mahida et al., 1998). Apoptosis was induced by caspase-dependent pathways (Brito 
et al., 2002; Huelsenbeck et al., 2007; Qa'Dan et al., 2002). In this way, C. difficile 
toxins induce cytokine responses in a variety of cells that can further amplify the 
response inflammatory immune response.
Proteins of C. difficile other than its potent toxins can also elicit an immune response. 
A large number of proteins are released along with the toxins during growth of C. 
difficile (Mukherjee et al., 2002). In fact, serum IgG to such surface proteins has 
been detected in patients and healthy adults in many studies (Mulligan et al., 1993; 
Pantosti et al., 1989; Sánchez-Hurtado et al., 2008) and in many, a correlation 
between lower levels of antibodies to somatic antigens and the occurrence or 
recurrences of disease was identified (Kyne et al., 2000; Mulligan et al., 1993; 
Péchiné et al., 2005a). 
Several surface-associated proteins have been identified in C. difficile that can 
interact with the host immune system. A study aimed at identifying the immune 
response to these antigens in CDI patients found that patient serum reacted with 
SLPs, Cwp66, FliC, FliD and Fbp68 (Péchiné et al., 2005a). Interestingly, in this 
study, the toxins appeared to be less immunogenic than the somatic antigens; 
differences among patients and controls did not lie in the immune response elicited 
by the toxins but only  to that generated against the surface-adhesins. It  was 
concluded that adhesins were able to induce a host immune response during the 
course of infection and the intensity  of this response affected the outcome of 
infection. In another similar study, patient sera reacted with a variety of surface 
proteins (Wright et al., 2008). SLPs were the most commonly recognised antigens 
and several paralogues of this protein were also recognised by patients. Antibody 
responses to the surface antigens were investigated on the day of diagnosis and at 
day 12 and in general, the levels of antibodies increased considerably  at day 12 
showing that there was exposure of the immune system to these surface antigens and 
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that patients were mounting a response to them. In patients where antibodies were 
detected from day 1 previous infection or carriage was suspected. 
Studies with SLPs of C. difficile in vitro have identified them as strong immunogens 
that can cause monocytes to release large amounts of pro- and anti-inflammatory 
cytokines and thus, modulate induction of either a Th1 or a Th2 inflammatory 
response (Ausiello et al., 2006; Bianco et al., 2011).
5.1.4. Adherence in CDI
Common with most pathogenic bacteria adherence by C. difficile is a prerequisite to 
the infection and pathology (Drudy  et al., 2001). The importance of adherence in 
CDI was first  demonstrated by Borriello and colleagues (Borriello et al., 1988). They 
compared the ability of a highly  toxigenic strain, a poorly  toxigenic strain and a non-
toxigenic strain to attach to the gut mucosa of hamsters. The highly toxigenic strain 
was most successful at mucosal colonisation, while the poorly toxigenic strain 
adhered to the mucosa as well as the non-toxigenic strain. Interestingly, the presence 
of toxin A and toxin B increased binding of the non-toxigenic strain. The toxigenic 
strains were found to be flagellated and motile, in contrast to the non-flagellated, 
non-motile non-toxigenic strain. It was suggested that the toxins exposed surface 
receptors or reduced the host’s ability to prevent bacterial adherence. This study also 
suggested the existence of adhesins other than flagella in C. difficile.
Further investigations into adherence of C. difficile showed that  the bacteria could 
attach to the enterocyte-like Caco-2 cells and the mucus-secreting HT29-MTX cells, 
but not to HeLa cells (Eveillard et al., 1993). Bacterial adherence to Caco-2 cells was 
found to be limited to the apical mucosal surface and increased with time, reaching a 
maximum by two hours. Adhesion also varied with age of the cell line, suggesting 
that expression of receptors for C. difficile on epithelial cells increased with their 
differentiation. C. difficile adhered to HT29-MTX cells in a more diffused manner 
and binding to undifferentiated cells was not observed emphasising the effect of the 
state of differentiation of the host cells on the process. Adherent bacteria were seen to 
release a web of extracellular material following adhesion which promoted contact 
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with the cells as well as the formation of bacterial clusters. Trypsinisation destroyed 
adherence suggesting that the adhesins were proteinaceous in nature and two proteins 
were identified as putative adhesins. Further, a heat-shock between 50°C and 60°C 
and growth in the presence of blood increased adherence. It was thus suggested that 
the presence of blood in the intestinal tract could aid attachment and colonisation, 
although the role of heat-shock in vivo was debated. In another study  it was observed 
that a heat-shock at 60°C for 10 minutes increased the adherence of C. difficile to 
Caco-2 cells but the presence of blood in the growth medium had no effect on 
binding (Karjalainen et al., 1994). Adhesion to Vero and HeLa cells was also seen; 
adhesion to Vero cells was the most uniform. Heat-shocked C. difficile cells also 
attached to mucus from axenic mice ex vivo.  
A comparison of toxigenic and non-toxigenic C. difficile strains showed that both 
adhered similarly to biopsies of colonic epithelium and small intestine epithelium ex 
vivo and also to Caco-2 and HT29 cells (Drudy  et al., 2001). Adherence to primary 
human cells was always much greater than that to the cell lines but there was 
considerable variability between binding to the primary cells obtained from different 
patients. Thus, patient factors such as genetics or environmental conditions in vivo 
could affect expression of C. difficile intestinal receptors and influence the outcome 
of disease. Also, as infection with C. difficile in vivo is normally  restricted to the 
colon but the bacterium can attach to other parts of the intestine, it was hypothesised 
that the small intestine could serve as a reservoir for bacteria. Further, C. difficile 
toxins are not required for adherence but could facilitate binding and mucosal 
damage could expose more receptors (Drudy  et al., 2001; Waligora et al., 1999). 
There appears to be host-strain specificity in the binding of C. difficile, but there is 
no association with toxin production (Taha et al., 2007) and thus, the association 
between adherence and virulence remains hidden. The presence of flagella was found 
to be important in adherence to caecal cells in mice in vivo but did not affect 
colonisation; non-flagellated and flagellated strains colonised mice rapidly  and to the 
same extent (Tasteyre et al., 2001a).
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Adherence of C. difficile to epithelial cells can vary with environmental factors 
(Hennequin et al., 2001a; Waligora et al., 1999). It has been observed that the 
adhesins are up-regulated under stresses such as partially aerobic conditions, iron-
deficiency, high calcium concentrations, acidic conditions and the presence of 
antibiotics such as ampicillin. Further, adherence was found to be dependent on the 
growth-phase of the cells and the osmolarity of the medium they were grown in; 
maximum binding was observed in the stationary phase of growth when cells were 
grown in a medium with high osmolarity. These stresses could alter the bacterial 
surface directly  or lead to the increased transcription of adherence-related genes. 
Adherence also varies with the state of differentiation of the host cells as mentioned 
above. Interestingly, three putative adhesins appeared to be constitutively expressed 
irrespective of environmental conditions (Waligora et al., 1999) suggesting that C. 
difficile can adhere to the GI tract under normal conditions but alteration of the gut 
environment could enhance this process.
The aim of this study was to understand the interactions of C. difficile cells and their 
antigens with epithelial and immune cells. Five C. difficile strains were used as in the 
other studies: strain 630, strain VPI 10463 and ribotypes 027, 001 and 106. 
Specifically, the first aim was to measure the levels of different cytokines produced 
by macrophages challenged with surface antigens and toxins from these strains. The 
second aim was to investigate adherence of these strains to epithelial cells and 
determine the degree to which flagella and SLPs contribute to attachment.
5.2. Methods
Four antigens were extracted from the five C. difficile strains: SLPs (2.4.4), flagella 
(2.4.5) and crude heat-shock proteins, GroEL and Cwp66 (2.4.6). The purity of SLPs 
and flagella was checked by  SDS-PAGE and western blotting using rabbit serum 
against whole C. difficile cells at  1:100 dilution (2.5.2) and also by  LAL assay  (2.4.9) 
and silver staining (2.4.10). Protein concentrations were determined by Bradford 
assay (2.4.8). Culture supernatants used were collected at 8, 12, 20 and 24 h and 
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concentrations of toxins in them were determined during the experiments described 
in Chapter 3 (3.3.5). Genetic differences between the strains were confirmed by 
PCR; slpA (2.3.11), fliC and fliD (2.3.5) were amplified and RFLP was performed for 
the flagella genes. Surface-protein and toxin preparations were used for assays with 
THP-1 cells. The THP-1 monocyte cell line was maintained as described in 2.6.1 and 
2.6.3. For the assays, cells were counted (2.6.2) and diluted appropriately before 
differentiation with PMA (2.6.5). This differentiation of monocytes to macrophages 
was confirmed visually  under a microscope and by flow cytometry (2.6.6). The cell 
line was also checked for mycoplasma contamination (2.6.4). The macrophages were 
challenged with the antigens and the supernatants were collected for cytokine 
measurement (2.6.5). To measure cytokine production, ELISAs were developed for 
TNF-!, IL-1", IL-6, IL-8, IL-10 and IL-12p70 (2.5.6) and performed in duplicate for 
each antigen-challenge experiment (2.5.4). The data were analysed by non-linear 
regression (2.10). To study  the attachment of the five C. difficile strains to epithelial 
cells, adherence assays and adherence-inhibition assays with SLPs and flagella were 
carried out (2.6.8).  
5.3. Results
5.3.1. Preparation of C. difficile antigens 
SLPs, flagella and heat-shock proteins at 42°C and 60°C were extracted successfully 
from the five C. difficile strains (Fig. 5.6). In the SLP extracts, two major bands were 
observed for the HMW SLP and the LMW SLP. The molecular weights of these 
proteins were determined and S-layer types 5138, 5435, 5438, 5436 and 5037 were 
assigned to strain 630, VPI 10463 and ribotypes 027, 001 and 106, respectively. In 
the flagella preparations, a prominent 39 kDa band was observed which was also the 
only band detected in the western blot. The blot could not be clearly  photographed 
and hence, is not shown. A 58 kDa band was observed in the GroEL preparation as 
expected. In the Cwp66 preparation, three bands of approximately 66 kDa, 50 kDa 
and 35 kDa were observed in keeping with previous studies. All the protein samples 
were diluted to a concentration of 100 µg/ml.
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Fig. 5.6. Protein preparations from five C. difficile strains
(a) SLPs, (b) flagella and crude lysates of heat-shock proteins expressed at (c) 42°C and (d) 
60°C were prepared from the five C. difficile strains. The SLP-types for strain 630, VPI 10463 
and ribotypes 027, 001 and 106 were 5138, 5435, 5438, 5436 and 5037, respectively. The 
39 kDa band observed in the flagella preparations was the most prominent band, even 
though other bands were seen. For GroEL, a 58 kDa band was observed. For Cwp66, bands 
of approximately 66 kDa, 50 kDa and 35 kDa were observed.
5.3.2. Inter-strain differences in SLPs and flagella
Genes for the SLPs and flagella, slpA, fliC and fliD, were amplified from the five 
strains (Fig. 5.7).
Fig. 5.7. PCR amplification of slpA, fliC and fliD from the five C. difficile strains
(a) The entire slpA gene and (b) its variable region were amplified by PCR. Although the 
products obtained were not of the expected size, it was evident that there was variability in 
the slpA gene between the C. difficile strains. (c) A band of 870 bp  for fliC and (d) a 1524 bp 
band for fliD were obtained in all the strains.
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PCR amplification of the entire slpA gene and its variable region both showed the 
presence of unexpected bands (Fig. 5.6.a and 5.6.b). This showed strain-specific 
variations in SLPs at the genetic level. PCR amplification of the flagella genes fliC 
and fliD gave products of 870 bp and 1524 bp, respectively (Fig. 5.6.c and 5.6.d). 
RFLP analysis showed that both the flagella genes were variable (Fig. 5.8). 
Fig. 5.8. RFLP analysis of fliC and fliD amplified from five C. difficile strains
(a) fliC PCR products were digested with (i) RsaI, (ii) HindIII and (iii) HpaI (b) fliD products 
were digested with (i) AccI, (ii) DraI, (iii) EcoRI, (iv) HincII, (v) HindIII, (vi) HpaI, (vii) RsaI and 
(viii) XbaI. Two RFLP patterns were obtained for fliC and three for fliD.
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5.3.3. Differentiation of THP-1 cells
Monocytic THP-1 cells were cultured successfully. The cell line was found to be free 
from mycoplasma contamination (Fig. 5.9).
Fig. 5.9. Mycoplasma detection in THP-1 cells
The absence of a 315 bp  PCR 
product confirmed that there was no 
mycoplasma contamination in the 
THP-1 cell line. 
The THP-1 cells were differentiated with phorbol,12-myristate,13-acetate (PMA). 
Initially, PMA concentrations of 5, 10, 50 and 100 ng/ml were tested. PMA at 5 ng/
ml was insufficient to induce differentiation, while 100 ng/ml was too high. PMA at 
10 and 50 ng/ml concentrations were selected. Differentiation was confirmed by the 
increased expression of CD11b on the surface of the macrophages (Fig. 5.10). 
Fig. 5.10. Differentiation of THP-1 cells with PMA
(a) PMA was used to differentiate the THP-1 monocytes into macrophages. This was 
confirmed by observing an increase in CD11b expression on the cells using flow cytometry. 
(b) PMA at 10 and 50 ng/ml generated equivalent expression of CD11b on the macrophages. 
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5.3.4. Development of cytokine ELISAs
In order to measure the production of cytokines by THP-1 macrophages following 
challenge with C. difficile antigens, in-house ELISAs were developed for TNF-!, 
IL-1", IL-6, IL-8, IL-10 and IL-12p70. Checkerboard assays were performed to 
determine suitable concentrations of the primary and secondary antibodies to be used 
in the ELISAs based on concentrations suggested by  the manufacturers. From the 
standard curves generated, suitable concentration pairs were identified (Fig. 5.11).
Fig. 5.11. Development of cytokine ELISAs
Checkerboard assays were performed to develop ELISAs for (a) TNF-α, (b) IL-1β, (c) IL-6, 
(d) IL-8, (e) IL-10 and (f) IL-12p70. Standard curves were generated for each combination of 
antibody concentrations used (grey). From these, the most suitable curve (black) was used 
to identify the appropriate concentrations of both antibodies in the final assays. 
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The selected antibody concentrations were tested over a wider range of protein 
concentrations. The experiments were performed in triplicate. The results obtained 
were reproducible. The standard curves showed that the ELISAs for all six cytokines 
were suitable to detect cytokines in the range of 32 ng/ml up  to a minimum 
concentration of at least 31.25 pg/ml (Fig. 5.12). The antibodies used in these 
ELISAs, their manufacturers and the concentrations at which they were used are 
listed in Table 5.1. 
Fig. 5.12. Standardisation of cytokine ELISAs
ELISAs for (a) TNF-α, (b) IL-1β, (c) IL-6, (d) IL-8, (e) IL-10 and (f) IL-12p70 were 
standardised and were found to be sensitive and reproducible. 
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Table 5.1. Antibodies used in cytokine ELISAs and their working concentrations
Cytokine Primary antibody and 
concentration
Standard and starting 
concentration
Secondary antibody and 
concentration















































Biotin anti-human IL-8 
(PeproTech, 500-P2Bt)
0.5 μg/ml


























5.3.5. Cytokine response to C. difficile antigens 
THP-1 macrophages were challenged with the various C. difficile antigens to study 
the immune response elicited by them. Macrophages were incubated with SLPs, 
flagella and heat-shock proteins of the five strains individually  at concentrations of 
50, 25 and 5 µg/ml. Supernatants were collected at 4 h and 24 h and the amounts of 
the various cytokines present in them were tested using the ELISAs developed. In the 
experiments with culture supernatants, the challenge lasted only 3 h following which 
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the macrophages were washed and fresh medium was added to them. This was done 
to prevent extensive cytotoxicity  due to potentially high concentrations of the C. 
difficile toxins in the supernatants. The levels of toxin A and toxin B in the culture 
supernatants of the five strains are listed in Table 5.2. Supernatants for cytokine 
measurements were collected 4 h and 24 h after this. 
Table 5.2. Average concentrations of toxins in culture supernatants of five C. difficile strains 
as determined by ELISA and cytotoxicity assay
Time 
(h)










8 10.1 11.7 49.1 9.8 14.8
12 10.2 28.1 477.2 14.6 24.8
20 46.3 1234.2 1298.0 99.2 121.0
24 71.3 1522.0 1674.6 177.8 317.5
Toxin B   
(ng/ml)
8 95.6 128.9 874.6 57.7 35.7
12 91.2 195.2 844.9 73.6 34.2
20 70.7 876.2 1490.4 141.2 83.8
24 54.9 1353.9 1117.8 250.7 285.7
THP-1 cells differentiated with 10 ng/ml PMA and 50 ng/ml PMA were used 
simultaneously  in the experiments. In preliminary studies, it was observed that even 
though there was no obvious difference between the two treatments with respect to 
morphological alterations of the monocytes into macrophages or the increase in 
expression of CD11b in the differentiated cells, there was a marked difference in the 
levels of cytokines released. Levels of IL-1" and IL-8 released were significantly 
higher in macrophages differentiated with 10 ng/ml PMA as compared to those 
differentiated with 50 ng/ml PMA. Also, a dose response for these cytokines was 
evident with dilutions of the antigens only when using macrophages differentiated 
with 10 ng/ml PMA and not 50 ng/ml PMA. This could be due to large amounts of 
cytokine being produced initially  and leading to toxicity. For TNF-!, IL-6, IL-10 and 
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IL-12p70, macrophages differentiated with 10 ng/ml PMA produced low levels of 
cytokines irrespective of the concentration of antigen. When cells differentiated with 
50 ng/ml PMA were used there was a marked increase in the levels of cytokines as 
well as a notable difference in the response elicited by  different antigen 
concentrations. Thus, the results presented here for the cytokines are taken from the 
experimental setting in which optimum dose responses were detected. 
The SLPs (5.13.a), flagella (5.13.b) and crude GroEL (5.14.a) and Cwp66 
preparations (5.14.b) of the five C. difficile strains under consideration all elicited a 
pro-inflammatory response from macrophages. TNF-!, )L-1", IL-6, IL-8 and 
IL-12p70 were produced by the macrophages. IL-10 production was not detected. 
IL-8 was the most abundantly produced cytokine and all the antigens induced similar 
levels of IL-8 production. The amounts of )L-1" and IL-6 produced in response to 
the antigens were similar. The amount of IL-12p70 released by macrophages 
stimulated with SLPs was the highest. For IL-12p70 production in response to SLPs 
and Cwp66, a negative dose response was observed possibly  due to toxicity  resulting 
from high antigen concentrations. Similar results were obtained for TNF-! with these 
two antigens. Cwp66 seemed to induce the most production of TNF-!, with flagella 
and GroEL inducing intermediate levels and SLPs inducing the lowest levels of 
TNF-! production. A negative dose response was also observed for IL-6 production 
by macrophages challenged with Cwp66. No significant differences were identified 
in the immune response generated against antigens of historic or epidemic isolates. 
Culture supernatants of the five C. difficile strains induced the production of TNF-!, 
IL-1" and IL-8 (Fig. 5.15). There was an increase in TNF-! production in the late 
stationary phase of growth (20 and 24 h) as compared to the late exponential phase 
(8 and 12 h) which correlated with the levels of toxin A and toxin B in the culture 
supernatants. A more gradual increase in IL-1" levels was observed. IL-8 production 
was similar for all the samples but toxicity  due to high levels of IL-8 was indicated. 
No significant differences were identified between historic, endemic and 
hypervirulent strains.
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Fig. 5.13. Cytokine response by THP-1 macrophages to SLPs and flagella extracted from 
five C. difficile strains
(a) SLPs and (b) flagella of the five C. difficile strains both induced the production of pro-
inflammatory cytokines by macrophages. The levels of TNF-α and IL-12p70 produced in 
response to the antigens differed considerably. On challenge with SLPs, negative dose 
responses were observed for these cytokines, suggesting that they could be immunogenic 
even in small amounts. No inter-strain differences were identified. Bars indicate +/- SEM of 2 
experiments.
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Fig. 5.14. Cytokine response by THP-1 macrophages to heat-shock proteins released by five 
C. difficile strains at 42°C and 60°C
Crude preparations of heat-shock proteins (a) GroEL and (b) Cwp66 released by the five C. 
difficile strains induced the production of pro-inflammatory cytokines by macrophages. The 
amounts of cytokine, except TNF-α, detected in response to these antigens were similar. 
Negative dose responses were observed for TNF-α, IL-6 and IL-12p70 with Cwp66, 
indicating that even low amounts of the protein were sufficient to elicit an immune response. 
No inter-strain differences were identified. Bars indicate +/- SEM of 2 experiments.
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Fig. 5.15. Cytokine response by THP-1 macrophages to culture supernatants of five C. 
difficile strains 
(a) TNF-α production was greater in 
response to culture supernatants 
collected in the stationary phase of 
growth (20, 24 h) as compared to 
the exponential phase (8, 12 h), 
corresponding with the greater 
amounts of extracellular toxin 
detected in the stationary phase. (b) 
IL-1β levels were also higher in 
response to the stationary phase 
samples, although the increase was 
less prominent. (c) The amount of 
IL-8 produced remained low and did 
not vary between the samples and 
toxicity of the macrophages was 
suspected. Inter-strain differences 
were not identified. Bars indicate +/- 
SEM of 2 experiments.
5.3.6. Adherence of C. difficile to epithelial cells
Adherence of exponential phase cultures of the five C. difficile strains to different 
types of epithelial cells was investigated. The four cell types used were Vero cells, 
Caco-2 cells and non-mucus secreting and mucus-secreting HT29 cells. Adherence 
of all the strains to all the cell lines tested was observed (Fig. 5.16). The presence of 
mucus was not found to increase attachment of bacterial cells. The extent of binding 
observed was not dependent on the cell line but on the strain of C. difficile. 
Interestingly, VPI 10463 showed maximum adherence to all the cell lines, while 
strain 630 was the least adherent strain. Of the epidemic isolates, ribotype 027 
exhibited the greatest ability to bind to epithelial cells, followed by ribotypes 106 and 
001, respectively.
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Fig. 5.16. Adherence of five C. difficile strains to epithelial cells
Attachment of C. difficile cells to 
epithelial cells in the exponential 
phase of growth was investigated. 
Four cell lines were used: Vero (V), 
Caco-2 (C), HT29-NMS (H1) and 
HT29-MS (H2). The numbers of 
bacterial cells attached to epithelial 
monolayers on the cover slips were 
enumerated microscopically. (a) Strain 
630 showed the least attachment, 
while (b) strain VPI 10463 showed the 
most. Of the epidemic strains, (c) 
ribotype 027 was the most adherent, 
(d) ribotype 001 was the least and (e) 
ribotype 106 exhibited intermediate 
attachment. The degree of adherence 
was found to be independent of the 
type of cell line used. Bars indicate +/- 
SEM of 2 experiments with Caco-2 
and HT29-MS cells and 4 experiments 
with Vero and HT26-NMS cell lines. 
5.3.7. Role of SLPs and flagella in adherence 
Adherence-inhibition assays were performed to study the extent to which SLPs and 
flagella contribute to the attachment of C. difficile to epithelial cells (Fig. 5.17). 
Preliminary  assays were performed with Vero cells only  due to the ease of culture of 
this cell line. Vero cells were pre-incubated with SLPs and flagella before addition of 
exponential phase cultures of the five C. difficile strains. Proteins were tested for 
inhibition of attachment of only the strains from which they were prepared. Proteins 
were originally tested at concentrations of 5 µg/ml and 10 µg/ml. At 5 µg/ml, marked 
inhibition of binding by both proteins was observed only for strain 630 and ribotype 
027. At 10 µg/ml, both proteins caused notable inhibition of adherence and at similar 
levels, except in ribotype 106, in which flagella were more inhibitory than SLPs. 
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With Caco-2 and HT-29 cells, 100 µg/ml antigens were tested. Inhibition of binding 
to Caco-2 and HT29-NMS cells by flagella and SLPs was seen in all the strains. With 
HT29-MS cells, inhibition was only  observed for the epidemic strains; increased 
binding and aggregation of bacteria were detected for strains 630 and VPI 10463. 
Fig. 5.17. Role of flagella and SLPs of five C. difficile strains in adherence to epithelial cells
Adherence-inhibition by flagella (dark grey) and SLPs (light grey) of the C. difficile  strains 
was demonstrated. Vero cells were treated with (a) 5  and (b) 10 μg/ml of proteins and 
reduced adherence was observed with the latter. With the other cell lines, proteins were 
tested at 100 μg/ml. (c) Decreased adherence to Caco-2 cells was observed with the strains 
with flagella, but not SLPs. (d) Using HT29-MS cells, flagella and SLPs decreased 
attachment of only the epidemic ribotypes. (e) With HT29-NMS cells, only the flagella of 
strain 630 did not decrease adherence; inhibition was observed in the other strains. 
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5.4. Discussion
Mucosal surfaces are the main sites of host-pathogen interactions (Ramos et al., 
2004). Pathogenic bacteria express a wide range of surface organelles and secrete 
virulence factors such as toxins which directly  mediate these interactions. From the 
results of this study, it  is evident that  the virulence factors of C. difficile can interact 
in a dynamic way with human epithelial and immune cells during an infection. 
The virulence factors studied here are all recognised by  the immune system of 
patients with CDI and even carriers as determined by  antibody detection in their sera 
(Péchiné et al., 2005a; Wright et al., 2008). However, apart from the toxins (Flegel et 
al., 1991; Linevsky et al., 1997; Melo Filho et al., 1997) very  little is known about 
the interactions of the other virulence factors with cells of the innate immune system. 
In keeping with previous observations, it  was found that culture supernatants 
collected during the growth of five C. difficile strains were able to elicit  a strong pro-
inflammatory response; the production of TNF-!, IL-1" and IL-8 was detected 
(Canny et al., 2006). Late exponential phase supernatants were slightly less 
immunogenic than late stationary phase supernatants. Although these observations 
correlated well with the amounts of toxin A and toxin B present in the supernatants, 
the presence of other cell wall components such as lipoteichoic acid cannot be ruled 
out. Interestingly, even though culture supernatants of C. difficile ribotype 027 and 
strain VPI 10364 contained approximately ten times more toxin than those of the 
other strains, the level of cytokine production by the supernatants of all the strains 
was not significantly different. It is possible that  the large amounts of toxin rapidly 
induced toxicity in the macrophages even after exposure for three hours. 
It has been observed previously that exposure of monocytes to toxin B was lethal; 
500 ng toxin B was lethal and even 5 ng of toxin B resulted in the death of 75% of 
monocytes within just five hours (Flegel et al., 1991). Further, macrophages were 
found to be more sensitive to the toxic effects of C. difficile toxins than monocytes 
(Linevsky  et al., 1997) suggesting that greater and more rapid cell death could have 
occurred during the toxin-shock. It has been suggested that the release of pro-
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inflammatory cytokines followed by cell death could render monocytes unable to 
carry  out phagocytosis, which could foster inflammation (Flegel et al., 1991). It was 
also curious to detect rather low levels of IL-8 production with all the supernatants, 
especially when compared to the amounts produced in response to surface-associated 
proteins. This observation suggested that a toxic environment was generated either 
directly  by the toxins themselves or by the large amounts of cytokines being 
produced in response to them.
The four cell surface-associated proteins extracted from the five C. difficile strains 
were also found to induce the production of pro-inflammatory cytokines by 
macrophages. S-layer proteins (SLPs) have been shown to be strongly immunogenic 
(Ausiello et al., 2006). Monocytes challenged with SLPs from strain 630 were found 
to induce the production of large amounts of IL-1" and IL-6 pro-inflammatory 
cytokines. They also induced maturation in monocyte-derived dendritic cells, altering 
their function from antigen-processing to antigen-presenting cells and increased 
proliferation of allogenic T cells. They  were found to be capable of driving both 
IL-12p70-mediated Th1 and IL-10-mediated Th2 responses, thus affecting antibody 
responses. Similar results were observed in another study comparing SLPs from 
different C. difficile strains (Bianco et al., 2011). SLPs of hypervirulent epidemic and 
non-hypervirulent, non-epidemic strains induced production of similar levels of 
IL-1", IL-6 and IL-10. IL-12p70 production in response to SLPs of all the strains 
was negligible, except those of strain 630, which induced considerable production of 
IL-12p70. These two studies showed that C. difficile SLPs have an important role in 
the immune response generated in CDI. 
In the study presented here, SLPs of the five C. difficile strains, which include three 
of the strains used in the above-mentioned studies, were found to induce only  pro-
inflammatory cytokines; IL-10 production was not detected. Although the amount of 
protein used in the assay and the time of cytokine detection were similar, it  is 
possible that  the differences lie in the immune cells used in both studies. Monocytes 
purified from peripheral blood mononuclear cells were used in the published studies, 
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while THP-1 macrophages were used here. However, the potential of SLPs as 
immunogens and the lack of correlation of the immune response to the SLPs with 
strain-type were clearly observed. 
Flagella of the five strains also induced pro-inflammatory cytokine production at 
equivalent levels. Most investigations of flagella have been performed in Gram-
negative organisms. Flagella have been found to stimulate the production of the pro-
inflammatory cytokines TNF-! and IL-6 even at low concentrations but they  have 
also been found to induce Th2 responses and there appears to be an association 
between the dose of flagellin and the type of response induced (Ramos et al., 2004). 
Interactions of flagella with epithelial cells are perhaps the most important in 
infection. Flagella of Salmonella enterica can stimulate IL-8 production by epithelial 
cells and also induce the production of factors such as nitric oxide, chemokines and 
defensins that are involved in the recruitment of inflammatory cells (Ramos et al., 
2004; Viswanathan et al., 2004). Filamentous flagella do not induce pro-
inflammatory responses, possibly owing to the exposure of only its conserved 
domains. However, flagellin monomers induce pro-inflammatory cytokines. It is 
likely that the delivery  of monomers as part of pathogenesis or degradation of 
flagella by  host proteases results in inflammation. Thus, the type of flagellar protein 
presented to the immune system could alter the outcome of infection.
Heat-shock proteins (HSPs) of C. difficile were also highly pro-inflammatory and it 
can be suggested that Cwp66 was more potent than GroEL as significant production 
of TNF-! and IL-6 was observed even with the highest dilution of protein used. 
Since these preparations were also crude extracts, the contribution of other proteins 
and lipocarbohydrate to the cytokine response cannot be discounted. Also, in the 
experiments with HSPs, no inter-strain differences were identified. This is perhaps 
not surprising as heat-shock proteins are the most highly conserved proteins in the 
biosphere (Zügel & Kaufmann, 1999). HSPs accumulate rapidly under stressful 
conditions in many organisms and this has also been demonstrated in C. difficile 
(Hennequin et al., 2001a; Waligora et al., 1999). They are vital for the survival of 
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pathogens in the host where they encounter changes in temperature and pH and even 
oxygen radicals, enzymes and iron-deficiency on internalisation into macrophages 
(Zügel & Kaufmann, 1999). They can also be highly immunogenic because of their 
abundance under stressful conditions and also due to cross-reactive memory  owing 
to their highly conserved nature.
The data presented here identified four C. difficile surface-associated proteins as 
possible mediators of the inflammation observed in CDI, along with the toxins. The 
level of cytokine production in response to the proteins was independent  of the strain 
used. Thus, surface-proteins do not contribute to the increased virulence observed in 
the currently  epidemic ribotypes 027, 001 and 106. The large volumes of toxin 
produced by the hypervirulent ribotype 027 might elicit a greater immune response 
in vivo due to extensive damage leading to chronic inflammation but this could not 
be identified from the results obtained here. Although only pro-inflammatory 
responses were detected for the toxins and surface-associated proteins, it is likely 
that the SLPs and flagella are also capable of driving anti-inflammatory responses, as 
observed by  others (Ausiello et al., 2006; Bianco et al., 2011). One of the limitations 
of this study was the limited range of dilutions over which the antigens were tested. 
In the cases where negative dose responses were observed, it was not possible to 
determine the lowest concentration of protein that may be immunogenic. Dilutions of 
the culture supernatants could have also indicated the minimum amount of toxin 
required to elicit an immune response. Also, as macrophage survival was not 
assessed, it was not possible to determine if the proteins were toxic to them.
The adherence of C. difficile to mucosal surfaces is important in the establishment of 
infection (Borriello et al., 1988; Drudy  et al., 2001). Adhesins including flagella 
have been observed to be involved in adhesion (Hennequin et al., 2001a; Tasteyre et 
al., 2001a; Waligora et al., 1999). The role of toxins in this process, however, has 
been debated (Borriello et al., 1988; Drudy et al., 2001). In this study, C. difficile 
cells were found to attach to different types of epithelial cells under anaerobic 
conditions. The type of cell line used and the presence or absence of mucus was not 
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found to affect the extent to which C. difficile strains attached to the cells. However, 
the degree of attachment depended on the strain in question. Surprisingly, strain VPI 
10463, which is a high toxin producer and is seldom implicated in infection, was 
found to be the most adherent strain. In contrast, strain 630, which was isolated from 
a patient with severe disease during an outbreak (Wüst et al., 1982) was the least 
adherent. Of the current epidemic strains, ribotype 027 showed the most binding, 
followed by ribotypes 106 and 001. This clearly shows that the currently epidemic 
strains have an advantage over the historic strain 630. Interestingly, the adherence 
results correlated with the pattern of toxin production by these strains in the 
exponential phase as described in Chapter 3 (Fig. 3.20). However, as toxin 
production was not assessed here and neither were the experiments performed with 
cells that had been separated from the toxin, this association cannot be confirmed. 
The role of toxins in adherence could be determined by assessing toxin production at 
the time of adding C. difficile cells to epithelial cells and by  monitoring toxin 
production throughout incubation. Initial amounts of toxin could be removed by 
washing or neutralised with anti-toxin. It has also been suggested that adherence can 
be influenced by the binary toxin of C. difficile. The binary toxin has been shown to 
induce the formation of long microtubule-based protrusions on the surface of 
epithelial cells that can form a mesh and increase the adherence of bacteria (Schwan 
et al., 2009). The microtubules have been found to enhance the attachment of C. 
difficile to epithelial cells by approximately four-fold in vitro under anaerobic 
conditions. Of the five strains studied here, only  ribotype 027 produces the binary 
toxin as confirmed from the results in Chapter 6 (Fig. 6.7). Therefore, increased 
adherence of strain VPI 10463 was not a consequence of the binary toxin. Also, from 
these preliminary results it can be suggested that the binary  toxin did not contribute 
significantly to adherence. 
Flagella and SLPs of the five strains were found to contribute almost equally to the 
adherence of the strains from which they were extracted. Inhibition of adherence was 
observed under most experimental conditions suggesting that the proteins directly 
202
contributed to adhesion. Flagella are an important virulence factor and play an 
important role in adhesion and colonisation of several bacteria (Ramos et al., 2004). 
The variable domain of flagella, which is believed to induce inflammatory immune 
responses, is also suggested to mediate adhesion. In enteric organisms such as Vibrio 
cholerae, transcription of other virulence factors is linked to flagella expression. No 
such association has been found in C. difficile as yet and although the role of flagella 
in attachment has been clearly demonstrated in mice, non-flagellated C. difficile 
strains were less adherent than flagellated strains (Tasteyre et al., 2001a). SLPs have 
been shown to be responsible for adhesion in Lactobacillus acidophilus and some 
Bacillus species (Sára & Sleytr, 2000). They have also been seen to bind to basement 
membrane proteins and a role for SLPs in autoagglutination has been indicated 
(Sleytr & Messner, 1993). Thus, SLPs of C. difficile could mediate attachment not 
just at  the initial stages of infection but also to the basement membrane once the 
epithelial barrier is destroyed by toxins. 
Where inhibition of adherence to epithelial cells was not observed, the opposite 
effect was seen; instead of preventing binding of bacteria, areas of high bacterial 
density  were observed on the monolayers. The formation of clusters by  adherent C. 
difficile cells has been observed previously  owing to the release of extracellular 
materials (Eveillard et al., 1993). Although no obvious extracellular matrix was 
observed microscopically in this study, it  is possible that this was the case and that 
the flagella helped form this web. C. difficile SLPs could cause this effect by 
mediating autoagglutination (Sleytr & Messner, 1993). If such interactions occurred 
in vivo, it would explain the characteristic pathology observed in C. difficile. Often in 
pseudomembranes, small ulcerations surrounded by healthy  mucosa are observed 
(Johal et al., 2004c). Bacterial clusters attached to the mucosa could result  in targeted 
release of the toxins in small areas of the gut, which could induce massive 
inflammation in those areas causing ulceration. 
Cross-reactions with proteins tested against strains from which they were not 
extracted were not performed. However, it would be interesting to know if the 
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presence of one strain or its antigens could inhibit  colonisation by another. This 
would be most useful if competition between a toxigenic and a non-toxigenic strain 
was assessed. It would also have been interesting to investigate the role of heat-shock 
proteins in adherence, but this was not possible owing to limitations of time and 
amount of protein available. Although there is no temperature shock in vivo, aerobic, 
acidic and nutrient-shocks could result in the increased expression of large amounts 
of HSPs, which might contribute significantly to attachment. Moreover, as these 
proteins play an important  role in physical attachment to the mucosa while also 
stimulating the immune system, they could be used as constituents of multi-
component vaccines for C. difficile. Vaccination of hamsters and mice with SLPs has 
been attempted and has showed promising results (Ní Eidhin et al., 2008; O'Brien et 
al., 2005). HSPs have been used as carrier molecules in vaccines (Zügel & 
Kaufmann, 1999). However, intensive studies of the interactions of purified proteins 
in cell lines and in animal models will be required for vaccine development. 
Although macrophages are crucial to the immune responses in the gut, the epithelium 
is the first point  of contact for pathogens like C. difficile. This is the site of adherence 
as determined here and in previous studies. Moreover, cultures of C. difficile and 
their toxins have been found to induce the production of pro-inflammatory cytokines 
by epithelial cells (Canny et al., 2006; Johal et al., 2004c; Ng et al., 2003; Savidge et 
al., 2003). Thus, studying the cytokine response by  the epithelium during attachment 
would be useful. It  could indicate which proteins are more likely to induce a Th2 
anti-inflammatory response and which drive a Th1 pro-inflammatory response. 
Canny and colleagues used a ‘sided’ system to compare apical and basolateral 
responses to C. difficile cultures. Similar experiments could be performed with 
purified antigens (Canny  et al., 2006). Further experiments assessing interactions of 
bacteria, epithelial cells and dendritic cells could be performed to understand the 
immune response in greater detail. Such experiments have been performed with S. 
enterica, in which IL-10 was produced when monocyte-derived dendritic cells were 
directly  confronted with the bacterium or indirectly through epithelial cells, but 
IL-12 was produced only when there was direct  contact of the dendritic cells with 
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bacteria (Rimoldi et al., 2005a). Thus, invasion of the epithelium was required to 
drive a pro-inflammatory response. Although C. difficile is not an invasive 
bacterium, its toxins disrupt epithelial barrier function (Nusrat et al., 2001) and 
increased expression of adhesion molecules for greater recruitment of neutrophils 
requires basolateral exposure to C. difficile (Canny et al., 2006). The responses of 
epithelial and immune cells during such interaction would provide useful insights 
into the inflammation caused by C. difficile in vivo. However, studies in animal 
models would be most informative.
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6. Hypervirulent C. difficile
6.1. Introduction
C. difficile was identified as the cause of antibiotic-associated pseudomembranous 
colitis in 1978 and has been the leading cause of nosocomial diarrhoea in the 
developed world ever since. However, the early 2000s witnessed a change in the 
epidemiology of C. difficile infection the world over. A new strain of C. difficile with 
increased virulence and resistance was discovered. This is the dreaded strain known 
today  as the hypervirulent ribotype 027 (also designated as NAP1 or BI). The clonal 
spread of ribotype 027 was studied by comparing phenotypic and genetic 
characteristics of isolates collected in Scotland and the Netherlands. 
6.1.1. Emergence of hypervirulent C. difficile
An increase in the number of patients with more severe disease and increased 
morbidity, mortality and relapse was first identified in Canada during the latter half 
of 2002 (Miller et al., 2002; Pépin et al., 2004; Warny  et al., 2005). A comparison of 
the trends of CDI from 1991 to 2003 in Canada revealed that incidence had increased 
from 35.6 per 100,000 to 156.3 per 100,000 in the Sherbrooke region of Quebec and 
even in areas where incidence was previously stable, a sudden rise to 92.2 per 
100,000 was observed in 2003 (Pépin et al., 2004; Pépin et al., 2005b). This marked 
the beginning of a series of outbreaks in Canada and the extensive use of 
fluoroquinolones was identified as a major contributing factor to these (Pépin et al., 
2005a). A simultaneous outbreak in 12 hospitals in Quebec was observed (Loo et al., 
2005). Further, a survey  of the different regions of Canada showed that  ribotype 027 
was endemic in the country  and was associated with both nosocomial and 
community-acquired infection (MacCannell et al., 2006). At about the same time in 
the USA, outbreaks caused by a similar strain were reported (Centers for Disease 
Control and Prevention, 2005; McEllistrem et al., 2005; Muto et al., 2005).
Between October 2003 and June 2004, an outbreak caused by  C. difficile ribotype 
027 was identified at the Stoke Mandeville hospital in England, followed by a second 
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outbreak between October 2004 and June 2005 (Healthcare Commision, 2006). 
Another ribotype 027 outbreak then occurred at the Royal Devon and Exeter hospital 
in 2005 and this was related to a change in antibiotic usage (Kuijper et al., 2006). 
The next series of outbreaks occurred in the Netherlands in Harderwijk (van 
Steenbergen et al., 2005); three clusters of CDI were identified, the third being 
unrelated to the first two. Amsterdam and other parts of the country also witnessed 
ribotype 027 outbreaks (Kuijper et al., 2008). In the surveillance period from 2005 to 
2007, sixteen outbreaks were reported in the Netherlands; ribotype 027 was solely 
responsible for all, except one of the outbreaks in which ribotype 017 was the other 
predominant C. difficile strain. In the year 2005, several countries reported their first 
isolations of ribotype 027 strains: Poland (Pituch et al., 2008), Japan (Kato et al., 
2007), Ireland (Long et al., 2007) and Belgium (Joseph et al., 2005). The first 
documented Irish case involved a patient transferred from the UK who was receiving 
antibiotic therapy. This index case was followed by  related CDI clusters in two other 
hospitals in Ireland (Long et al., 2007). 
In 2006, France was struck by a C. difficile outbreak caused by ribotype 027 (Tachon 
et al., 2006). The possibility that  the strain had originated in Belgium was suggested 
as transfers between nursing homes and hospitals of the two countries are common 
and two of the patients had in fact been transferred from the same nursing home in 
Belgium. In the same year, C. difficile ribotype 027 was isolated in Tyrol, Austria 
from a British tourist (Indra et al., 2006). The UK experienced yet another outbreak 
in 2006, this time at Maidstone and Tunbridge Wells (Healthcare Commision, 2007). 
Clusters of CDI caused by ribotype 027 were also seen in Belgium, to which 
ribotypes 078 and 031 also contributed (Kuijper et al., 2008). Switzerland also 
witnessed an outbreak in which 17% of the isolates belonged to ribotype 027 (Fenner 
et al., 2008a). Three hospitals in Denmark also suffered a ribotype 027 outbreak, in 
which, interestingly, another isolate that shared the genomic characteristics of 
ribotype 027, but was not  ribotype 027, was also detected (Søes et al., 2009). The 
same occurred in 10 hospitals in Luxembourg (Kuijper et al., 2008). Spain reported 
its first ribotype 027 isolate in 2007; the index case was a patient transferred from the 
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UK and the second involved a laboratory worker (Kuijper et al., 2008). By March 
2007, Germany also reported its first ribotype 027 isolate (Zaiss et al., 2007) which 
was followed by an outbreak that lasted till the September of that  year (Kleinkauf et 
al., 2007). First isolation of ribotype 027 was then reported in Finland (Lyytikäinen 
et al., 2007), Hungary  (Terhes et al., 2009) and Norway (Ingebretsen et al., 2008). 
The outbreaks across Europe continued with Northern Ireland (Aldeyab et al., 2011), 
Finland (Kuijper et al., 2008), two in Scotland (NHS, 2008; NHS, 2009), Austria 
(Indra et al., 2009), Denmark (Bacci et al., 2009), France (Birgand et al., 2010) and 
ribotype 027 was also identified in Sweden (Kuijper et al., 2008) and as far as Korea 
(Tae et al., 2009), Hong Kong (Cheng et al., 2009), Costa Rica (Quesada-Gómez et 
al., 2010) and even Australia (Riley  et al., 2009); the Australian case is believed to 
be one of the first cases of travel-associated CDI. The extent of the global spread of 
C. difficile ribotype 027 today is remarkable (Fig. 6.1) (Clements et al., 2010).
Fig. 6.1. Global distribution of C. difficile PCR ribotype 027 
C. difficile PCR ribotype 027 (NAP1) has most severely affected North America and Europe. 
However, more recently it has been identified in South America, Asia and even Australia. 
Adapted from Clements et al., 2010.
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6.1.2. Increased morbidity and mortality?
Along with the increase in incidence of CDI during the emergence of ribotype 027, 
investigators the world over also noted increasing severity  of disease and an 
increased case-fatality rate associated with this strain. Severe cases were defined as 
those having one or more of these symptoms within 30 days of diagnosis: 
pseudomembranous colitis, paralytic ileus, toxic megacolon, perforation or shock, 
colectomy, intensive care or death (Hubert  et al., 2007; Loo et al., 2005; Morgan et 
al., 2008; Pépin et al., 2004).
One of the first studies to investigate disease severity  was performed by Pépin and 
colleagues in Canada (Pépin et al., 2004). A retrospective analysis of CDI over a 
period of thirteen years identified an almost 10-fold increase in annual incidence of 
CDI among people over 65 years of age. This corresponded to an increase in the 
number of severe cases from 6 to 10 per year between 1991 and 1998 with up to 71 
cases per year in 2003. To better understand the effect of ribotype 027 strains on 
patient mortality, case-control studies were performed. During an outbreak in which 
ribotype 027 was the predominant strain, mortality among patients with CDI at 30 
days was found to be 23% compared to just 7% in the control subjects (Pépin et al., 
2005b). In a similar study, 84% of the isolates were ribotype 027 and the crude 
mortality rate was approximately  25% (Loo et al., 2005). A review of CDI across 
fourteen European countries found that  more severe CDI was associated with the 
epidemic 027 ribotype and it was mostly healthcare associated (Barbut et al., 2007). 
The analysis of pre-epidemic and epidemic strains in Canada showed that the number 
of ribotype 027 strains isolated increased to 80% during the epidemic, whereas 
before the epidemic ribotype 001 was the predominant strain in about 20% of the 
hospitals investigated (Hubert  et al., 2007; Labbé et al., 2008). A closer look at the 
genotype of the strains and disease severity by Hubert and co-workers found that 
severe disease was 2.3 times more likely in patients infected with ribotype 027 as 
compared to ribotype 001, while Labbé and colleagues found that this was true for 
mortality as well. There was however, no difference in the rate of recurrence between 
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the two strains (Labbé et al., 2008). Similar observations were made in a hospital in 
England where it was observed that crude mortality and disease severity were higher 
in ribotype 027 infection - almost two to four times that of ribotype 106 infection - 
but recurrence rates were similar (Sundram et al., 2009). 
Although several case-control studies correlated ribotype 027 disease with increased 
morbidity and mortality, contradictory results were also observed. In a case-case 
study performed by Morgan and co-workers in which disease severity  was associated 
with genotype, that is ribotype 027 versus non-027 ribotypes, 24% of patients with a 
ribotype 027 infection had severe CDI as compared to 17% of patients infected with 
a non-ribotype 027 strain, but this difference was not significant (Morgan et al., 
2008). In Germany, a comparison of isolates with disease severity  did not show any 
greater effect of ribotype 027; ribotypes 001 and 078 were also associated with 
severe CDI and death (Arvand et al., 2009). In Finland too, where ribotype 027 was 
most commonly associated with outbreaks and severe disease, it appeared to be 
linked with a higher 30 day case-fatality  than other ribotypes but this was not 
significant after adjusting for age, suggesting that patient characteristics strongly 
influence disease severity (Kotila et al., 2010). Similar observations were made by 
Verdoorn and co-workers who retrospectively studied strains with deletions in tcdC 
(Verdoorn et al., 2009). They showed that morbidity  and mortality were not greater 
in CDI caused by strains containing these deletions. However, the patients affected 
were older, had longer hospital stays and had prolonged antibiotic therapy. Another 
study gave a similar outcome where isolates with tcdC deletions, which were also 
binary  toxin positive, were not significantly different from other strains with respect 
to disease severity, mortality or even length of hospitalisation (Goldenberg & French, 
2011). The authors did find, however, that a greater immune response was mounted 
against these strains which was indicated by increased white blood cell counts and C-
reactive protein. Thus, from all these studies it can be concluded that there is no 
definitive answer to whether ribotype 027 causes more severe disease than other 
strains, but it is evident that there are other risk factors involved that have led to the 
emergence of this ribotype as a global threat. 
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6.1.3. Risk factors
Over the years, several risk factors have been independently  associated with C. 
difficile infection. These include patient characteristics such as age, especially  above 
65 years, immunosuppression, the presence of co-morbidities and a high leukocyte 
count (Pépin et al., 2004). For ribotype 027 infections, disease severity  was found to 
increase with age (Hubert  et al., 2007; Labbé et al., 2008) but in patients less than 65 
years of age and in those without any co-morbidities, the strain did not contribute to 
increased mortality, possibly due to the better immune status of young healthy 
individuals (Pépin et al., 2005b). 
In early  studies, sex was not identified as a risk factor for CDI (Pépin et al., 2005a; 
Pépin et al., 2005b) but  some found it to be a significant risk factor, with women 
being less prone to severe disease (Morgan et al., 2008). This could be influenced by 
underlying conditions which could not be studied and were thus not  included in the 
risk analysis. However, others also suggested that men were at higher risk of ribotype 
027 infection (Weiss et al., 2009), although there is no conclusive evidence to 
suggest that one sex is more prone to CDI than the other. 
The duration of hospitalisation and previous incidence of CDI were found to be 
important risk factors (Pépin et al., 2005a); patients spent a longer time in hospital, 
whether at first admission or on subsequent  admissions (Pépin et al., 2005b). In 
another study  too it was found that, on average, case patients spent 10 days more in 
hospital than control patients (Weiss et al., 2009). Further, the administration of 
proton pump  inhibitors (PPIs), H2 blockers and laxatives or chemotherapy  were 
either found to be weakly associated with 027 CDI or not at  all, while antacids and 
anti-motility drugs had no association (Loo et al., 2005; Pépin et al., 2005a; Sundram 
et al., 2009). 
Perhaps the most important risk factor associated with ribotype 027 is the use of 
antibiotics, the lack of which was found to be protective for CDI (Sundram et al., 
2009). The antibiotics associated with 027 CDI risk were second and third generation 
cephalosporins, macrolides, clindamycin, fluoroquinolones and intravenous "-
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lactam/"-lactamase inhibitors (Pépin et al., 2004; Pépin et al., 2005a). In a case-
control study, it was found that 20% more ribotype 027 cases had been exposed to 
antibiotics than controls (Loo et al., 2005) and in a case-case study, it was found that 
86% of patients had received at least  one antibiotic in the two months before the 
diagnosis of CDI (Morgan et al., 2008). In another study, although ribotype 027 only 
accounted for 6.2% of all the isolates in the study, it was found that approximately 
78% of all the patients had had antibiotic treatment within the month before 
diagnosis of CDI (Barbut et al., 2007). Total antibiotic usage was associated with an 
increase in the incidence of CDI caused by ribotype 027 (van der Kooi et al., 2008).
Fluoroquinolones and cephalosporins were identified as the antibiotics related to the 
greatest risk of ribotype 027 infection (Loo et al., 2005; Pépin et al., 2005a; Weiss et 
al., 2009). The exposure of patients to fluoroquinolones was significantly associated 
with ribotype 027 infection but not ribotype 001 infection; only 4% of the patients 
with ribotype 027 infection were previously exposed to clindamycin as compared to 
29% of those with a ribotype 001 infection (Labbé et al., 2008). A similar 
observation was made by  Sundram and co-workers who found that the use of 
quinolones was associated more strongly with ribotype 027 rather than ribotype 106 
infection (Sundram et al., 2009). Exposure to moxifloxacin has also been linked to 
the subsequent development of CDI (Biller et al., 2007).
Not just the antibiotic but the duration of use was also found to alter the risk of CDI. 
For quinolones, cephalosporins, clindamycin and macrolides, extended use increased 
the risk of CDI but, for cefoxitin, a single dose was more harmful (Pépin et al., 
2005a). Similarly, the use of ciprofloxacin for more than a week was linked to CDI 
but only to that caused by  ribotype 027 (Sundram et al., 2009). The strong 
correlation of fluoroquinolones with ribotype 027 explained the epidemic caused by 
ribotype 027 as it  was found to be fluoroquinolone resistant  but this association with 
fluoroquinolones was not seen in a later study in which second generation 
cephalosporins were found to be a risk factor (van der Kooi et al., 2008). In a more 
recent study, neither cephalosporins, "-lactams nor fluoroquinolones appeared to be 
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significantly associated with CDI (Sundram et al., 2009). Despite this uncertainty, 
the role of antibiotics in CDI is clear. The link between ribotype 027-induced CDI 
and antibiotics was further established when an approximately 50% decrease in the 
use of second and third generation cephalosporins, ciprofloxacin, clindamycin and 
macrolides resulted in about 60% less incidence of CDI (Valiquette et al., 2007).
For the ribotype 027 epidemic, a combination of factors such as the increasing age of 
the population and the presence of co-morbidities, the change in antibiotic policies 
which included the extensive use of antibiotics, perhaps even the introduction of 
alcohol-based hand-washing resulted in the increase in incidence (Pépin et al., 
2005a; Pépin et al., 2005b; Søes et al., 2009). This, however, did not alter the fact 
that the responsible strain displayed increased virulence considering that patients 
with ribotype 027 disease required specific treatment with metronidazole or 
vancomycin (Barbut et al., 2007).
6.1.4. What makes it hypervirulent? 
6.1.4.1. Growth 
The growth of the Canadian epidemic ribotype 027 strains showed similar growth 
kinetics to that of several toxinotype 0 isolates, although the cell density  was always 
higher in ribotype 027 cultures over the 48 hours (Warny  et al., 2005). Despite the 
difference in cell density being significant at 24 hours, growth was rejected as a 
significant virulence factor. Additional studies also revealed that a NAP1a strain had 
a 20% higher optical density at 24 hours when compared to ribotype 001, VPI 10463 
and other strains (Akerlund et al., 2008). 
6.1.4.2. Toxin production
Ribotype 027 was observed to produce greater amounts of toxin at a much faster rate 
(Warny  et al., 2005). On average, the ribotype 027 strains produced 16 times more 
toxin A and 23 times more toxin B than toxinotype 0 reference strains. The bulk 
toxin production observed in the logarithmic phase of growth in 027 isolates was a 
clear indicator of increased virulence; if these strains behaved similarly  in vivo, it 
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would result  in greater severity of disease. This increased severity could then be 
responsible for greater dissemination of spores in the environment. In another study 
measuring intracellular, extracellular and total toxin, the ribotype 027 isolates 
produced three to 13 times more toxin than other virulent strains (Akerlund et al., 
2008). Although more toxin was produced by ribotype 027 strains, the authors 
suggested that other factors could be involved in the hypervirulence of these strains.
6.1.4.3. Spore production
Spore production was also studied by  Warny and co-workers (Warny  et al., 2005). 
They  observed that at 48 and 72 hours, 93% of ribotype 027 cultures were positive 
for spores as compared to 72% of toxinotype 0 strains. The sporulation frequencies 
of ribotype 027 isolates at 24 hours were observed to be approximately 25% and up 
to 60% for some isolates (Akerlund et al., 2008). Thus, a combination of greater 
toxin production and greater sporulation were suggested as factors for increased 
disease severity and greater transmission of ribotype 027, making it hypervirulent. 
6.1.4.4. Genotype
The epidemic ribotype associated with the outbreaks in North America and Europe 
was characterised as PCR ribotype 027 strain, NAP1 (North American pulsed-field 
type 1), restriction endonuclease group BI and toxinotype III (MacCannell et al., 
2006; Warny et al., 2005). Apart from being distinguished from other strains by 
established typing schemes (Clabots et al., 1993; Gal et al., 2005; O'Neill et al., 
1996; Rupnik et al., 1998), ribotype 027 is also characterised by the presence of the 
binary  toxin and by characteristic deletions found in tcdC, which have been 
suggested to confer hypervirulence upon this ribotype. 
6.1.4.5. Presence of the binary toxin
The binary toxin of C. difficile was first identified in a ribotype 027 strain, CD196, 
isolated from a patient suffering from pseudomembranous colitis (Popoff et al., 
1988). The strain produced large amounts of this ADP-ribosylating toxin as well as 
toxin A and toxin B. Being a binary toxin, it has two genes cdtA and cdtB, which 
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code for the enzymatic CDTa and the binding CDTb components of the toxin, 
respectively (Perelle et al., 1997). The binary  toxin was found to be toxic to Vero 
cells and considered capable of inducing intestinal lesions. It was determined that 
although not necessary for virulence, the binary toxin could be an additional 
virulence factor for strains carrying the cdtA and cdtB genes such as ribotype 027 
(Perelle et al., 1997; Rupnik et al., 2003a). 
Strains of ribotype 027 characteristically  carry  the genes for the binary toxin, cdtA 
and cdtB, and their presence is a useful tool for differentiating these strains from 
those belonging to the more common toxinotype 0 strains (Warny  et al., 2005). It has 
been observed that the binary toxin genes are present only in strains belonging to 
variant toxinotypes, that is strains with significant polymorphisms in the toxin genes 
tcdA and tcdB when compared to toxinotype 0 strains like VPI 10463 (Stubbs et al., 
2000). Also, the amplification of cdtB is more efficient and thus, it alone can be used 
as a screening method. Screening of isolates from all the above-mentioned outbreaks 
and index cases described in 6.1.1 involved PCR amplification of at least cdtB. 
6.1.4.6. Deletions in tcdC
On further characterisation, it was observed that in epidemic ribotype 027 strains, 
mutations are often present in the tcdC gene which is the negative regulator of toxin 
production in C. difficile (Smith, 2005). A study of the pathogenicity  locus of a 
variety of C. difficile strains identified the presence of variant C. difficile strains with 
respect to tcdC (Spigaglia & Mastrantonio, 2002). In this study, three nucleotide 
sequences were described for the tcdC gene. These were named types A, B and C. 
tcdC-A shows a 39 bp deletion, while tcdC-B and tcdC-C show deletions of 18 bp. 
The epidemic strain in Quebec, Canada was found to carry  an 18 bp deletion (Warny 
et al., 2005). 
Further analysis uncovered the presence of a single-base-pair deletion at position 117 
(%117) (MacCannell et al., 2006). The tcdC genotype containing the 18 bp deletion 
and %117 together (tcdC-sc1) was commonly identified in ribotype 027 strains 
isolated in several of the above-mentioned outbreaks (6.1.1); the 18 bp deletion was 
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used more frequently as a marker. Both the mutations were conserved across strains 
from different geographical areas (MacCannell et al., 2006). During the epidemic in 
Canada, along with the 18 bp  deletion, the 39 bp deletion was detected in some 
ribotype 027 isolates (Loo et al., 2005). In Switzerland, the most commonly 
identified genotypes for ribotype 027 strains were tcdC-A and tcdC-sc1 but a novel 
genotype with a 54 bp deletion (tcdC-UHBS2) was also found, although the 
implications of this deletion were unclear (Fenner et al., 2008a). 
The 39 bp deletion in tcdC leads to a truncated protein of 61 amino acids instead of 
the expected 232 amino acids and the 18 bp deletion results in a protein of 226 amino 
acids (Spigaglia & Mastrantonio, 2002). The deletion at position 117 induces a 
frameshift mutation in tcdC, truncating the TcdC protein to 65 amino acid residues 
(Curry  et al., 2007; MacCannell et al., 2006). Thus, the 39 bp deletion and %117 
have greater implications on the tcdC transcript and it was suggested that these 
deletions were responsible for the large amounts of toxin produced by ribotype 027. 
6.1.4.7. Antibiotic resistance
The epidemic ribotype 027 isolates from North America and Europe were all found 
to be resistant to a range of fluoroquinolones including ciprofloxacin, moxifloxacin, 
gatifloxacin, ofloxacin and levofloxacin and erythromycin but susceptible to 
clindamycin, vancomycin and metronidazole (Barbut  et al., 2007; Hubert  et al., 
2007; Joseph et al., 2005; Kuijper et al., 2006; Long et al., 2007; Loo et al., 2005; 
Pituch et al., 2008; Zaiss et al., 2007). This resistance to fluoroquinolones and an 
increased use of fluoroquinolones in hospitals for the treatment of respiratory tract 
infections are believed to have resulted in the emergence of the epidemic ribotype 
027 strain (McDonald et al., 2005; Pépin et al., 2005a). However, ribotype 027 was 
not always resistant to fluoroquinolones. Genotype analysis and antibiotic 
susceptibility tests have revealed that the epidemic ribotype 027 (NAP1a) was 
resistant to fluoroquinolones, but historical 027 strains (NAP1b) were all susceptible, 
clearly  indicating the acquisition of antibiotic resistance by  this strain (Hubert et al., 
2007; McDonald et al., 2005). 
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Before the emergence of the epidemic ribotype 027, the predominant ribotype 
isolated in epidemics was ribotype 001 which belongs to PFGE type J (Hubert  et al., 
2007; Johnson et al., 1999; Stubbs et al., 1999). Ribotype 001 was found to be 
resistant to clindamycin which distinguished it from ribotype 027 (Climo et al., 
1998; Pear et al., 1994). However, fluoroquinolone resistance has been observed in 
ribotype 001 too (Biller et al., 2007). Clindamycin resistance was rarely  reported in 
ribotype 027 (Kuijper et al., 2006; Long et al., 2007; McDonald et al., 2005) until 
clindamycin-resistant 027 strains were identified in Ireland (Drudy  et al., 2008). 
Since then, intermediate resistance to clindamycin has been identified in the ribotype 
027 isolate from the index case in Hungary (Terhes et al., 2009), intermediate and 
complete resistance to clindamycin was observed among ribotype 027 isolates in 
Latin America (Quesada-Gómez  et al., 2010) and highly resistant strains have been 
isolated from an outbreak in Switzerland (Fenner et al., 2008b). Interestingly, in 
Sweden, the moxifloxacin resistant isolates do not belong to ribotype 027, but to 
ribotype 012, which are also resistant to erythromycin and clindamycin (Norén et al., 
2010). Thus, different C. difficile ribotypes have overlapping resistance patterns and 
the hypervirulence of ribotype 027, although partially a result of resistance, is a 
multi-factorial phenomenon. 
6.1.4.8. Genetic basis of antibiotic resistance
Fluoroquinolones are a group  of antimicrobials that inhibit DNA synthesis through 
direct interaction with DNA complexed with DNA gyrase or with topoisomerase IV 
(Hooper, 2001). Resistance to fluoroquinolones occurs when there are mutations in 
the target enzymes, decreased entry of drugs into the bacterial cytoplasm or active 
release of the drug from the cytoplasm through efflux pumps. An early study of 
moxifloxacin resistant C. difficile strains identified mutations in gyrA at nucleotide 
82 which leads to a threonine to isoleucine substitution in the GyrA protein but this 
mutation was not characteristic of all resistant strains, indicating that mutations in 
parC or efflux mechanisms were functional in C. difficile (Ackermann et al., 2001). 
However, a later study  also failed to detect the parC gene in the genome, suggesting 
that the genes for topoisomerase are absent in C. difficile (Dridi et al., 2002). The 
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authors sequenced the quinolone resistance determining regions (QRDR) of gyrA 
(nucleotide 40 to 145) and gyrB (nucleotide 366 to 473). The mutations identified in 
GyrA were Thr82*lIe, Asp71*Val and Ala118*Thr, while those in GyrB were 
Asp426*Asn and Arg447*Leu. Most of these mutations have been previously 
identified in other bacteria and linked to fluoroquinolone resistance, except the gyrA 
mutation at nucleotide 71 (Hooper, 1999). Further, in a cluster of Irish ribotype 027 
isolates, it  was found that only  the GyrA Thr82*lIe was associated with a high level 
of resistance, while gyrB remained mutation-free (Drudy et al., 2007b). This 
mutation has been most commonly found in epidemic ribotype 027 isolates 
(Spigaglia et al., 2008) but it has also been observed in other ribotypes (Carman et 
al., 2009).
To study the induction of these mutations, Spigaglia and co-workers generated 
resistant mutants in vitro by selection using moxifloxacin and levofloxacin 
(Spigaglia et al., 2009). Using moxifloxacin as the selective agent, high resistance 
was only observed after mutations in gyrA or gyrB were detected. Interestingly, in 
the epidemic 027 ribotype, the Asp81*Asn mutation in GyrA was only induced at 
the third step of the selection process. However, during selection with levofloxacin, 
at the second step, Leu451*Phe in GyrB was observed which was then followed by 
the more common Thr82*lIe in GyrA in the next step. These double mutations 
resulted in high fluoroquinolone resistance, although the significance of 
Leu451*Phe in GyrB in resistance is unknown. Similar observations correlating 
double mutations with high fluoroquinolone resistance, specifically Thr82*lIe along 
with another mutation, were made by  Walkty and colleagues (Walkty  et al., 2010). 
Mutations in the DNA gyrase genes were not  exclusive to ribotype 027 and reduced 
susceptibility to fluoroquinolones was also observed in the absence of any mutations, 
suggesting the presence of other mechanisms (Spigaglia et al., 2009).
Resistance to clindamycin is associated with the presence of the ermB gene, a marker 
for transposon-mediated macrolide-lincosamide-streptogramin B resistance which 
was absent from epidemic ribotype 027 strains (Labbé et al., 2008; MacCannell et 
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al., 2006). Interestingly, most ribotype 001 isolates were found to be clindamycin 
resistant and positive for ermB (Labbé et al., 2008). However, recently, clindamycin 
resistant ermB positive ribotype 027 strains have been isolated (Drudy et al., 2008), 
suggesting the acquisition of greater antibiotic resistance in this emerging ribotype.
6.1.5. Clonality
During the development of typing methods such as ribotyping and toxinotyping, it 
became evident that there was clonal diffusion of different strains of C. difficile in 
different parts of the world (Rupnik et al., 1998; Stubbs et al., 1999). To investigate 
this further and possibly identify  hypervirulent  clones, Lemée and colleagues used 
multilocus sequence typing (MLST) (Lemée et al., 2004). However, they  could not 
identify any such clones related specifically to either severe disease or particular 
geographical locations. They inferred that several stable C. difficile populations 
existed, exhibiting clonal population structure and suggested that the evolution of 
strains was guided by point mutations rather than recombinational exchange.
The clonal spread of ribotype 027 strains was, however, observed in several studies. 
Clusters of ribotype 027 isolates were observed in the Netherlands using multilocus 
variable-number tandem-repeat analysis (MLVA) (van den Berg et al., 2007). It was 
observed that clusters with 100% similarity of isolates were hospital-specific but 
those from different outbreaks were only 86% similar. These groups however, were 
considerably dissimilar from a sporadic isolate. Further, the possibility of country-
specific clusters was suggested; there was only 40% similarity between a UK isolate 
and several isolates from the Netherlands. MLVA was also used to identify clusters of 
CDI among 91 isolates from England (Fawley et al., 2008). Twenty-three MLVA 
types were detected, of which 77% could be clustered to a single hospital and 95% to 
an institution. Two large clusters of CDI identified by surveillance information were 
confirmed by  MLVA and two additional groups were identified. Specific sub-types 
could be linked to different incidences and trends in CDI could be identified. This 
clonal spread was also evident in Ireland (Solomon et al., 2011). Using rep-PCR the 
investigators found that all ribotype 027 isolates from healthcare facilities grouped 
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into the same sub-type and this predominant sub-type was 89% similar to the NAP1 
isolate from North America. Although heterogeneity existed among ribotype 027 
isolates, they exhibited limited genetic diversity, suggesting adaptation to a particular 
niche and microevolution (Stabler et al., 2006). However, infections by this clone 
have also been identified in animals (Songer et al., 2009a).
The presence of a hypervirulent clade was confirmed by microarray  analysis (Stabler 
et al., 2006). The results showed that 20 of the 21 studied ribotype 027 strains 
formed a distinct lineage characterised by the presence of several deletions as 
compared to reference strain 630. They also identified clear differences between a 
historic ribotype 027 isolate, CD196, and an epidemic ribotype 027 isolate, R20291, 
and uncovered differences between these and strain 630 (Stabler et al., 2009). Both 
ribotype 027 isolates contained the %117 and the 18 bp deletions in tcdC and were 
binary  toxin positive, unlike 630 which could enhance virulence. They also had 
altered tcdB sequences in the 3’ region which resulted in a considerably  different 
TcdB protein but not a truncated one (Stabler et al., 2008). However, this could affect 
toxicity  and cell specificity. Also, the F1 flagellar locus in ribotype 027 strains is 
variable or lost, which could lead to greater motility  (Stabler et al., 2006). Moreover, 
the F2 flagellar region of ribotype 027 isolates contained glycosyl transferases that 
could affect autoagglutination. The ribotype 027 isolates were more motile than 
strain 630 and the epidemic ribotype 027 showed greater autoagglutination than the 
historic ribotype 027 isolate (Stabler et al., 2009). The ribotype 027 isolates also 
contained an additional copy of the arg locus and additional regulatory genes that 
could be involved in p-cresol tolerance or production when compared to strain 630, 
which could aid survival. 
Overall, ribotype 027 strains showed the presence of several deletions and inversions 
as compared to strain 630 which indicated significant adaptation that may have led to 
the emergence of the hypervirulent clone (Stabler et al., 2010). Further, epidemic 
ribotype 027 appeared to have accumulated a variety of genetic elements such as 
putative antibiotic ABC transporter genes, putative cell surface proteins and a toxin-
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antitoxin system which could explain the increased virulence linked to it in humans 
and in animal models (Razaq et al., 2007).
The primary  aim of this study was to characterise seven ribotype 027 isolates from 
Scotland and five outbreak ribotype 027 isolates from the Netherlands and determine 
if these clusters of isolates shared any  similarities. The secondary  aim was to extend 
the phenotypic and genetic characterisation studies to include ribotypes 001 and 106, 
which are currently predominant in Scotland, and strain 630, belonging to the 
previously  dominant ribotype 012, in order to identify traits that might contribute to 
ribotype 027 being more virulent than these successful strains.
6.2. Methods
The strains used in this study comprised seven isolates from Scotland (4868-83) and 
five isolates from the Netherlands (4828-4832) collected from outbreaks and 
recognised as ribotype 027 (Table 2.1). C. difficile strains 630 and VPI 10463 were 
used as reference strains and the representative isolates of ribotypes 027, 001 and 
106 (2.1.2 and chapter 3) were also included. The phenotypic characteristics of the 
isolates such as growth, toxin production, spore production, motility and 
autoagglutination (2.2.1-2.2.7) were studied first, followed by S-layer typing (2.2.8), 
ribotyping, toxinotyping, binary toxin detection and flagellum analysis (2.3.2-2.3.5). 
Further, the tcdC gene of the isolates was amplified by  PCR (2.3.6) along with the 
gyrA and gyrB genes of the binary toxin (2.3.10). These amplified products were 
sequenced (2.3.13) to identify any  chromosomal mutations carried by these strains. 
Finally, antibiotic susceptibility testing was performed on all the isolates (2.8.2) and 
the results were interpreted using the values listed in Table 2.4. 
6.3. Results
6.3.1. Growth 
Growth of all the C. difficile isolates was determined by measuring the OD600 at 48 h. 
There was no marked difference between the growth of the reference strains and the 
ribotype 027 strains or between the Scottish and Dutch isolates (Fig. 6.2.a). Thus, a 
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greater growth rate or more cell numbers were not identified as contributory factors 
to the virulence of ribotype 027 strains. 
6.3.2. Toxin production 
Total toxin (A+B) production was measured by ELISA and it was found that the 
ribotype 027 strains produced considerably  greater amount of total toxin at 48 h as 
compared to strain 630 and even produced more toxin than VPI 10463 (Fig. 6.2.b). 
There was no difference in toxin production between the two ribotype 027 groups. 
The isolates belonging to the epidemic ribotypes 001 and 106 produced markedly 
less toxin than ribotype 027 isolates. 
6.3.3. Sporulation
Spore production varied slightly between the ribotype 027 isolates. However, they  all 
produced greater number of alcohol-resistant spores than strain 630 and even 
ribotype 001 (Fig. 6.2.c). The average spore production of all the ribotype 027 
isolates was similar to ribotype 106. VPI 10463 was the lowest spore producer.
6.3.4. Motility assay
All the C. difficile strains tested were found to be similarly motile (Fig. 6.2.d). From 
the length of growth observed in 0.05% BHI agar, it was determined that on average, 
ribotype 027 strains were more motile than reference strains 630 and VPI 10463. The 
ribotype 106 isolate was found to be as motile as ribotype 027, however, the ribotype 
001 isolate demonstrated the greatest motility. 
6.3.5. Autoagglutination assay
Although slight variations in the percentage of autoagglutination were observed 
between some ribotype 027 isolates, there was no marked difference between the 
strains of the ribotypes studied (Fig. 6.2.e). 
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Fig. 6.2. Phenotypic characteristics of ribotype 027 isolates, the reference strains and 
isolates belonging to ribotypes 001 and 106
(a) No marked difference in growth was 
observed among the isolates of ribotype 
027 at 48 h. (b) The isolates did, however, 
produce greater amounts of total toxin (A
+B) as compared to the reference strain 
630 and the isolates of ribotypes 106 and 
001. (c) Spore production was found to be 
variable among ribotype 027 isolates, but 
on average was much higher than the 
reference strains. The isolate belonging to 
ribotype 106 showed the same level of 
spore production as the average of the 
ribotype 027 isolates combined. (d) All the 
strains in this study were motile. The 
ribotype 001 isolate was found to be 
slightly more if not as motile as the 
ribotype 027 strains. (e) There was no 
marked difference in the autoagglutination 
observed between the different isolate 
types. From these results, it would appear 
that although increased growth does not 
contribute to the hypervirulence of 
ribotype 027, high toxin and spore 
production and perhaps increased motility 
are the factors that cause the altered 
behaviour of this ribotype. 
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6.3.6. S-layer typing 
S-layer typing of the strains showed that all ribotype 027 isolates belonged to the 
same S-layer type (Fig. 6.3). All the strains had a high molecular weight  SLP of 54 
kDa and a low molecular weight SLP of 38 kDa, classifying them as S-layer type 
5438.
Fig. 6.3. S-layer typing of isolates in this study
The S-layer proteins extracted with GHCl were run on an SDS-PAGE gel to obtain the above 
banding pattern. All ribotype 027 isolates had the same pattern with a low molecular weight 
SLP of 38 kDa and a high molecular weight SLP of 54 kDa. Thus, the assigned S-layer time 
for ribotype 027 was 5438. 
6.3.7. Ribotyping 
Ribotyping was performed and, as expected, the banding patterns of the reference 
strains and the isolates belonging to ribotypes 027, 001 and 106 were all different 
from each other (Fig. 6.4). The patterns obtained for the isolates from Scotland and 
the Netherlands were identical and matched precisely to that of ribotype 027 in the 
laboratory database, confirming that all these isolates belonged to PCR ribotype 027.
Fig. 6.4. Ribotyping of isolates in this study
The amplification of the 16S-23S rRNA intergenic spacer region revealed identical bands for 
all ribotype 027 isolates, which matched reference isolates of the same ribotype. 
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6.3.8. Toxinotyping 
The 3.1 kb products expected for the A3 and B1 regions of the toxin genes tcdA and 
tcdB respectively were found in all the strains tested (Fig. 6.5). From the restriction 
of these products and the patterns obtained, it was confirmed that all ribotype 027 
isolates belonged to toxinotype III. 
Fig. 6.5. Toxinotyping of isolates in this study
(a) tcdA and (c) tcdB were amplified by PCR to give products of 3.1 kb. Restriction of (b) 
tcdA with EcoRI gave pattern 2 and tcdB with (d) AccI and (e) HincII gave pattern 4. The 
resultant type for all ribotype 027 isolates was thus determined as toxinotype III.
6.3.9. Flagellum analysis 
PCR amplification of fliC in all the strains gave a product of 870 bp (Fig. 6.6). For 
all ribotype 027 strains, the restriction pattern obtained was bbb, putting them in 
RFLP group VII. Group VII strains belong to serogroup A/B, both of which 
correspond to toxinotype III.
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Fig. 6.6. Analysis of the fliC gene and flagellar typing of isolates in this study
(a) The fliC gene was amplified by PCR to give a product of 870 bp. The product was then 
restricted with (b) RsaI, (c) HindIII and (d) HpaI. All ribotype 027 strains belonged to fliC 
group VII which corresponds to toxinotype III and ribotype 027.
6.3.10. Binary toxin detection
All ribotype 027 isolates were found to be binary toxin positive; 375 bp bands were 
observed for cdtA and 510 bp bands for cdtB (Fig. 6.7). The reference strains and the 
isolates of ribotypes 106 and 001 did not show the presence of either of the binary 
toxin genes as expected. 
Fig. 6.7. Detection of the binary toxin genes of isolates in this study
All ribotype 027 isolates were positive for the binary toxin genes (a) cdtA and (b) cdtB.
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6.3.11. PCR amplification and sequencing of tcdC 
The expected 718 bp tcdC band was observed in all the isolates (Fig. 6.8.a). The 
sequencing of tcdC revealed that all ribotype 027 isolates carried the %117 mutation 
(Fig. 6.8.b) which was not present in the reference strains or in ribotypes 001 and 
106 (Fig. 6.8.c). Ribotype 027 isolates also carried the characteristic 18 bp deletion 
from nucleotides 330 to 347 (Fig. 6.8.d) which was also not observed in the other 
strains (Fig. 6.8.e). Hence, the truncated TcdC protein was found only in the isolates 
belonging to PCR ribotype 027 (Fig. 6.8.f and 6.8.g). 
6.3.12. PCR amplification and sequencing of gyrA and gyrB
The gyrA and gyrB genes were amplified from all the isolates, giving bands of 633 
bp (Fig. 6.9.a) and 514 bp (Fig. 6.9.f), respectively. All the isolates belonging to 
ribotype 027 had a mutation in the gyrA gene (Fig. 6.9.b). This mutation was also 
found in the isolates of ribotypes 106 and 001 (Fig. 6.9.c). This mutation leads to a 
Thr82*Ile substitution in the GyrA protein (Fig. 6.9.d,e) which is commonly linked 
to increased fluoroquinolone resistance. No mutations were observed in the gyrB 
gene of any ribotype.
6.3.13. Antimicrobial susceptibility testing 
By performing antimicrobial susceptibility tests, minimum inhibitory concentrations 
(MICs) for the different isolates were obtained for each antibiotic. These values were 
then interpreted using CLSI criteria and the isolates were classified as being 
susceptible, resistant or of intermediate resistance to a particular antibiotic as 
appropriate (Table 6.1). All the isolates tested were found to be susceptible to 
vancomycin (V), metronidazole (M) and tetracycline (T). All the ribotype 027 
isolates showed intermediate resistance to ceftriaxone (C) and were resistant to 
clindamycin (CL), erythromycin (E), moxifloxacin (MX) and ciprofloxacin (CP). 
The isolates of ribotypes 001 and 106 were resistant  to ceftriaxone, but showed the 
same sensitivities to the other antibiotics as ribotype 027, while the reference strains 
differed from the ribotype 027 isolates by being sensitive to moxifloxacin and 
ciprofloxacin. 
228
Fig. 6.8. Amplification and sequencing of tcdC of isolates in this study
(a) tcdC was successfully amplified by PCR in all strains. Only ribotype 027 isolates carried 
(b, c) a ∆117 and (d, e) an 18 bp deletion in tcdC, leading to (f,g) a truncated TcdC protein. 
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Fig. 6.9. Amplification and sequencing of gyrA and gyrB of isolates in this study
The (a) gyrA gene in all the isolates was amplified by PCR, followed by sequencing. (c) 
Analysis of the obtained gene sequences identified a mutation in gyrA in all isolates of 
ribotype 027 and (d) also in the isolates of ribotype 106 and ribotype 001, but not in strains 
630 or VPI 10463. (d, e) This ACT→ATT mutation caused the Thr82→Ile substitution in the 
GyrA protein in these ribotypes, which is associated with fluoroquinolone resistance. (f) The 
gyrB gene was also amplified in all isolates but no mutations were observed in the gene 
sequence of any ribotype (not shown).
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Table 6.1. Antimicrobial susceptibility testing of isolates in this study
Antibiotics testedb 
and 
the inferred susceptibility of the isolates to themc
Strain V M C CL T E MX CP
Strain 630 S S I R S R S S
Strain VPI 10463 S S I R S R S S
Ribotype 027 S S I R S R R R
Ribotype 001 S S R R S R R R
Ribotype 106 S S R R S R R R
4828 S S I R S R R R
4829 S S I R S R R R
4830 S S I R S R R R
4831 S S I R S R R R
4832 S S I R S R R R
4863 S S I R S R R R
4864 S S I R S R R R
4865 S S I R S R R R
4866 S S I R S R R R
4867 S S I R S R R R
4868 S S I R S R R R
4883 S S I R S R R R
b The antibiotics used in this study were: V= Vancomycin, M= Metronidazole, C= Ceftriaxone, 
CL= Clindamycin, T= Tetracycline, E= Erythromycin, MX= Moxifloxacin, CP= Ciprofloxacin
c Using the guidelines and from the MIC values obtained, the isolates were classified as: 
S= Susceptible, I= Intermediate, R= Resistant 
Ribotype 027 isolates were all resistant to erythromycin, clindamycin, moxifloxacin and 
ciprofloxacin but were sensitive to vancomycin and metronidazole. They all showed 
intermediate resistance to ceftriaxone. 
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6.4. Discussion
Ever since the emergence of the hypervirulent epidemic C. difficile ribotype 027, 
characterisation studies have been carried out in several countries that have 
experienced outbreaks caused by  this strain. Ribotype 027 epidemics were identified 
in the UK from 2004 onwards but these were limited to England and Wales (Brazier 
et al., 2007). The first  Scottish ribotype 027 isolate was identified in 2006 (Kuijper et 
al., 2007) when ribotype 106 and 001 were the predominant strains; the frequency  of 
isolation of ribotype 027 in Scotland increased from the beginning of 2008 (Wiuff et 
al., 2011). By the end of 2008, our laboratory collection included seven 027 isolates 
from four hospitals across Scotland. By characterisation of these strains and by 
comparison and contrast with other predominant ribotypes and outbreak isolates, an 
insight into the virulence of this ribotype was obtained. 
As previously  described for other ribotype 027 isolates, both the Scottish and Dutch 
isolates showed similar characteristics. As there was no historic isolate in this study, 
comparisons were made with strains 630 and VPI 10463 and ribotypes 001 and 106. 
Ribotype 027 isolates did not show increased growth at 48 hours, but produced 
markedly more toxin than the other strains, as shown by Warny and colleagues for 
the Canadian epidemic strain (Warny  et al., 2005). Also, they  showed increased 
sporulation capacity  compared with the other strains, except ribotype 106. This is 
also a trait  of the epidemic ribotype 027 strain that had been previously  reported 
(Akerlund et al., 2008). They also exhibited greater motility  than the reference 
strains, but not the other predominant ribotypes 001 and 106; in fact, ribotype 001 
was found to be the most motile strain. Increased motility in ribotype 027 strains 
compared to strain 630 has also been observed with both a historic ribotype 027 
isolate and one epidemic strain from both the UK and North America (Stabler et al., 
2009). Although significant differences in autoagglutination were also found between 
ribotype 027 strains and strain 630 (Stabler et al., 2009), none were identified in this 
study. Of all the phenotypic traits studied here, it appears as though increased toxin 
production is the only one that contributes to the difference in virulence observed 
between ribotype 027 and the other ribotypes. 
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All the Scottish and Dutch isolates were characterised as ribotype 027, toxinotype 
III, S-layer type 5438 and fliC group VII. They were all binary toxin positive, unlike 
strains 630 and VPI 10463 and ribotypes 001 and 106 (Rupnik et al., 2003a; Stubbs 
et al., 2000). The binary toxin is considered to be an additional virulence factor in C. 
difficile and its absence from the other ribotypes identified it as a factor in the greater 
virulence of ribotype 027. All ribotype 027 isolates also had deletions in tcdC, the 
negative regulator of toxin production (Matamouros et al., 2007) and showed the 
tcdC-sc1 genotype which has both the 18 bp deletion from nucleotide positions 330 
to 347 and the frameshift mutation at position 117 (MacCannell et al., 2006). These 
deletions, which result  in a truncated TcdC protein of 65 amino acid residues have 
been linked to the high toxin levels produced by ribotype 027 strains. The non-
ribotype 027 strains were all binary  toxin negative and did not have any  mutations in 
the tcdC gene, which clearly differentiated them from ribotype 027 isolates. 
Ribotype 027 isolates were all resistant to clindamycin, erythromycin, moxifloxacin 
and ciprofloxacin, but sensitive to vancomycin and metronidazole. The same 
antibiotic sensitivity  pattern was observed for ribotypes 001 and 106, except that 
they  were also resistant to ceftriaxone, while ribotype 027 isolates showed 
intermediate resistance to this antibiotic. Not surprisingly, the ACT*ATT mutation 
in gyrA resulting in the Thr82*lIe substitution in the GyrA protein, which is linked 
to fluoroquinolone resistance was observed in all ribotype 027 isolates (Ackermann 
et al., 2001). However, this mutation was not exclusive to ribotype 027; it  was also 
observed in ribotypes 001 and 106. No mutations in the gyrB gene were detected in 
any of the strains, despite the high level of resistance observed. It has previously 
been observed that ribotypes 027, 001 and 106 had high levels of resistance to 
erythromycin and moxifloxacin and higher MIC values for metronidazole (Brazier et 
al., 2008). Further, fluoroquinolone resistance has also been seen in ribotypes 001 
and 106 (Balassiano et al., 2009; Walkty  et al., 2010) and the GyrA mutation 
Thr82*Ile has been detected in ribotype 001 (Saxton et al., 2009). 
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The change in epidemiology associated with the emergence of ribotype 027 was 
noted for the severity  of disease and the ability to affect healthy individuals (Centers 
for Disease Control and Prevention, 2005). It also correlated with an increased use of 
antibiotics, especially  fluoroquinolones (Pépin et al., 2005a). The epidemic ribotype 
027 strain exhibited high toxin and spore production (Akerlund et al., 2008; Warny  et 
al., 2005). It  was suggested that these characteristics and the acquisition of resistance 
to antibiotics by ribotype 027 led to the superimposition of epidemic ribotype 027 
over the previously predominant ribotype 001 (Labbé et al., 2008). The 
epidemiology of CDI, however, is still changing; highly virulent strains other than 
ribotype 027 also exist (Cartman et al., 2010). Ribotype 001 has been responsible for 
several large outbreaks (Graf et al., 2009; Johnson et al., 1999). Ribotype 106 is now 
a dominant strain in the UK, replacing ribotype 001 (Brazier et al., 2007; Brazier et 
al., 2008). Ribotype 078 has been identified as a high toxin producer in vitro (Jhung 
et al., 2008); ribotype 017 has been associated with lethal CDI (Arvand et al., 2009) 
and increased sporulation has been identified in ribotype 002 (Cheng et al., 2011). 
Lemée and colleagues postulated that for the existence of hypervirulent lineages in 
C. difficile, the horizontal exchange of genes between strains was necessary (Lemée 
et al., 2004). Since the hypervirulent ribotype 027 lineage does exist (Stabler et al., 
2006) we can presume that genetic exchange between C. difficile strains is ongoing, 
explaining why previously identified ribotype 027-specific markers can be identified 
appear to be distributed amongst other ribotypes to varying degrees (Marsden et al., 
2010); ribotype 078 is binary  toxin-positive and has deletions in the tcdC gene. From 
the results presented here, it  can be concluded that there has been a clonal spread of 
the hypervirulent ribotype 027 across Europe. Ribotype 027 isolates from Scotland 
and the Netherlands share these properties with the epidemic strain first seen in 
Canada. However, this study did not include in-depth genomic analysis of the strains 
which could estimate the degree of similarity between the strains or identify genomic 
regions that could enhance virulence. Although the epidemic C. difficile ribotype 027 
is hypervirulent compared to previously common strains, all C. difficile strains 
should be considered to be equally dangerous pathogens.
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7. Conclusions
Clostridium difficile is a fascinating pathogen. Although it was identified as the 
causative agent of CDI and pseudomembranous colitis in the late 1970s, the 
mechanisms involved in its virulence are still being discovered today. One of the 
most significant advances in C. difficile studies has been the ClosTron system which 
enables us to knock-out genes from C. difficile to isolate the effects of individual 
virulence factors (Heap  et al., 2007). However, in the absence of genetic 
manipulation systems, a comparison of strains of different pathogenic potential is 
useful to gain insight into the variations that affect the outcome of infection. In the 
studies included in this thesis, this approach has been used to identify differences 
between historic and epidemic strains of C. difficile in several different settings. 
The five main C. difficile strains studied were selected based on the epidemiology of 
CDI in Scotland. Ribotype 012, which includes strain 630, was once prevalent in the 
region and represented an historic isolate. Ribotypes 106 and 001 were the most 
common locally endemic strains when these studies began. Ribotype 027 was the 
epidemic hypervirulent strain that steadily  increased in prevalence over the duration 
of these investigations. Lastly, VPI 10463 was used as a reference strain to facilitate 
comparisons with previous studies. 
The expression of toxins and spores was found to be significantly different between 
these five strains, although their patterns of growth were similar. The production of 
toxin A and toxin B were highest in ribotype 027, followed by ribotypes 106, 001 
and 630, respectively. VPI 10463 produced almost equivalent amounts of toxin to 
ribotype 027 confirming previous observations. The production of spores was highest 
in ribotype 106, followed by ribotype 027, ribotype 001 and strain 630, respectively. 
VPI 10463 produced the least number of spores, also agreeing with previous studies. 
Thus, ribotypes 027 and 106 both demonstrated a more virulent phenotype than the 
other strains, which correlates with the increased incidence and severity of disease 
recently  associated with them. This could also be a reason why ribotype 001 was 
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replaced by ribotype 106 as the most prevalent strain in Scotland. Thus, it is evident 
that increased toxin and spore production were advantageous in virulence.
These inter-strain differences in phenotype were also observed at the genetic level. 
Not surprisingly, transcription studies showed that expression of the toxin genes, 
tcdA and tcdB, was higher in the strains that produced most toxin. The level of tcdR 
expression was also slightly higher in ribotypes 027 and 106 at 24 hours, suggesting 
that this auto-regulated gene was positively inducing toxin production even in the 
late stationary phase of growth. A more significant observation was that the 
expression of tcdC, which negatively regulates toxin production, did not decrease 
over time as expected and previously observed and also expected from a negative 
regulator. This observation was not limited to the higher toxin producers and thus 
suggested that  tcdC had a modulatory  rather than a repressive effect on toxin 
production. The expression of tcdE however, was highest  in ribotype 027 and VPI 
10436 and could be responsible for the high levels of toxin detected extracellularly in 
cultures of these strains. Increased toxin production coupled with increased toxin 
release could contribute to the hypervirulence of ribotype 027. Another important 
observation was that spo0A expression in ribotypes 106 and 027, the highest spore 
producers, remained high over the early  exponential phase. This indicated a longer 
duration of activation of the sporulation cycle, which could result in greater numbers 
of spores being produced. This was another contributory factor in the virulence of the 
epidemic strains. Although these phenotypic and genetic differences were identified 
in vitro, they could mirror the virulence of the strains in vivo. 
The susceptibility to disinfectants also varied between strains. Vegetative cells and 
spores of all five strains were effectively  neutralised under laboratory conditions, but 
not under stimulated ‘real-life’ conditions. Although neutralisation was observed, the 
epidemic ribotypes were more resistant to higher concentrations of the agents as 
compared to strain 630. For some agents, just a 2-fold dilution lower than the 
recommended concentration could be ineffective, emphasising the need to 
reconstitute disinfectants properly before use. Moreover, whether this neutralisation 
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was the result  of cell-death or merely dormancy was not identified. The focus of 
these studies, however, was on the more practical aspect of disinfection - that of 
surfaces. Of the agents studied, only  chlorine-based Actichlor was suitable for the 
decontamination of hard, non-porous surfaces but between two and ten minutes’ 
exposure was required for the complete elimination of C. difficile spores. The other 
agents, all of which are used in laboratories, showed poor efficacy which decreased 
even further in the presence of organic matter. Here too, spores of the epidemic 
ribotypes 027, 001 and 106 were more resistant to the agents. The use of chlorine-
based agents is not preferred due to their side-effects, but on the other hand, surface 
application of disinfectants for prolonged periods of time is not practical. Actichlor is 
commonly used in hospitals for intensive cleaning but there is a need for a similar 
disinfectant in the laboratory. Laboratory-acquired CDI is not unheard of (Hell et al., 
2009) and, from the spread of C. difficile detected in and around the laboratory in 
this study, it is evident that workers can be exposed to the bacterium even away from 
the work-bench. If spores of epidemic strains are more resistant  to disinfection, it 
implies that they persist longer in the environment which would increase the 
incidence of disease caused by them. 
The response of the strains to sub-inhibitory concentrations was also found to be 
variable. Exposure to such dilutions of non-chlorine agents was investigated and it 
was observed that such exposure did not affect the growth of the strains but 
dramatically increased sporulation in the epidemic ribotypes. This effect was most 
marked in ribotype 001 in agreement with previous observations. These observations 
suggest that sub-inhibitory concentrations of disinfectants could lead to the increased 
dissemination of spores in the environment, which would also affect the incidence of 
disease by such ribotypes. Although the significance of exposure to sub-inhibitory 
concentrations of disinfectants ex vivo on virulence in vivo is unknown, it  suggests 
that under stressful - but  not cidal - conditions they could affect  the phenotype of C. 
difficile strains. From these results, it was evident that epidemic ribotypes were more 
likely to persist and spread in the environment. 
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The interactions of C. difficile proteins with macrophages were not variable between 
strains. The toxins, surface-layer proteins, flagella and heat-shock proteins of the five 
strains were all able to stimulate production of pro-inflammatory  cytokines. Despite 
marked differences in the amounts of toxin produced between the strains during 
growth, the immune response to culture supernatants was similar. Also, there were no 
strain-specific differences in the cytokine response to other proteins. This suggested 
that surface-associated proteins of C. difficile have the potential to elicit 
inflammatory responses irrespective of toxin production and may contribute to the 
inflammation and ulceration observed in CDI. 
The adherence of the strains to epithelial cells did vary. The epidemic strains were 
more adherent than strain 630 to all types of epithelial cells used in the study, but 
surprisingly, VPI 10463 showed the most attachment. The flagella and S-layer 
proteins of the strains were found to contribute equally to the levels of attachment of 
the strain from which they were extracted. In some cases, these proteins were found 
to notably increase adherence of C. difficile cells, possibly by the formation of 
extracellular webs or by inducing autoagglutination. These preliminary studies 
showed that surface-proteins of C. difficile may influence the physical binding of 
bacteria to the epithelium and also the immune responses that follow. 
A study  of ribotype 027 strains showed that certain characteristics were conserved 
within this group. They exhibited the same phenotype, were identical by  molecular 
and phenotypic typing methods and showed identical deletions in tcdC and gyrA. The 
strains were binary  toxin positive and more resistant to antibiotics than ribotypes 001 
and 106 and strains 630 and VPI 10463. The deletions in tcdC, especially the 
frameshift mutation at position 117, could contribute to the hypervirulence of 
ribotype 027. Mutations in gyrA associated with increased antibiotic resistance were 
observed in all the hypervirulent isolates but were not exclusive to ribotype 027; 
ribotypes 001 and 106 carried identical mutations. Thus, the epidemic strains had 
genetic potential for greater antibiotic resistance. 
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In conclusion, the sum of observations from the studies in this thesis suggests that 
there have been genetic and phenotypic changes in C. difficile strains over time. 
Together, factors such as enhanced expression of virulence factors, longer persistence 
in the environment, increased adherence in vivo and greater antibiotic-resistance may 
have resulted in increased virulence and a subsequent increase in the prevalence of 
the currently epidemic C. difficile strains. However, only single isolates from each 
ribotype were used in the three main studies. It is, thus, possible that  variations exist 
within ribotypes. Similar experiments with multiple isolates of the same ribotype 
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Clostridium difficile is a major cause of nosocomial diarrhoea. The toxins that it produces (TcdA
and TcdB) are responsible for the characteristic pathology of C. difficile infection (CDI), while its
spores persist in the environment, causing its widespread transmission. Many different strains of
C. difficile exist worldwide and the epidemiology of the strains is ever-changing: in Scotland,
PCR ribotype 012 was once prevalent, but currently ribotypes 106, 001 and 027 are endemic.
This study aimed to identify the differences among these ribotypes with respect to their growth,
and toxin and spore production in vitro. It was observed that the hypervirulent ribotype 027
produces significantly more toxin than the other ribotypes in the exponential and stationary
phases of growth. Further, the endemic strains produce significantly more toxins and spores than
ribotype 012. Of note was the observation that tcdC expression did not decrease into the
stationary phase of growth, implying that it may have a modulatory rather than repressive effect
on toxin production. Further, the increased expression of tcdE in ribotype 027 suggests its
importance in the release of the toxins. It can thus be concluded that several genotypic and
phenotypic traits might synergistically contribute to the hypervirulence of ribotype 027. These
observations might suggest a changing trend towards increased virulence in the strains currently
responsible for CDI.
INTRODUCTION
Clostridium difficile is a Gram-positive, anaerobic, spore-
forming bacillus that was first identified as the cause of
antibiotic-associated pseudomembranous colitis in 1978
(Bartlett et al., 1978; George et al., 1978; Larson et al.,
1978). Today, it is the most common cause of nosocomial
diarrhoea. Once mainly associated with the use of
antibiotics and being elderly, it is now also found in
young, previously healthy adults with no history of
antibiotic usage (McFarland et al., 2007). C. difficile is
acquired from the environment in the form of spores and
transmitted by the faecal–oral route. The organism is able
to colonize the gut when the normal protective flora is
disrupted by the use of broad-spectrum antibiotics. Once
the infection is established, the bacterium produces two
large Rho glucosylating exotoxins, toxin A (TcdA), an
enterotoxin, and toxin B (TcdB), a cytotoxin, which result
in the characteristic pathology of Clostridium difficile
infection (CDI). Though asymptomatic carriage of C.
difficile is common (Riggs et al., 2007), the presentation of
CDI can vary from mild self-limiting diarrhoea to severe
diarrhoea, which can progress to pseudomembrane
formation, toxic megacolon, perforation, shock and even
death. During carriage or an infection, patients have the
potential to release large amounts of spores into the
environment (Jump et al., 2007). In this way, the toxins
and spores of C. difficile ensure a continual presence and
spread in the human population.
TcdA and TcdB are encoded on the 19.6 kb pathogenicity
locus (PaLoc), along with the positive regulator TcdR, the
negative regulator TcdC and a putative holin, TcdE. Study
of the five genes of the PaLoc has shown an increased
transcription of tcdA, tcdB, tcdR and tcdE and a decreased
transcription of tcdC during the progression of C. difficile
from the exponential to the stationary phase of growth
(Hundsberger et al., 1997).
Since the early 2000s, ribotype 027 (BI/NAP1) has
emerged as the cause of several outbreaks and disease of
increased severity, morbidity and mortality (Loo et al.,
2005; Pépin et al., 2005). It has been dubbed the
hypervirulent strain, following the observation of excess-
ive toxin production by this ribotype: up to 16 times more
toxin A and 23 times more toxin B (Warny et al., 2005).
An explanation of this increased toxin production has
been found in the deletions observed in the tcdC gene of
most, but not all, ribotype 027 strains (MacCannell et al.,
2006; Spigaglia & Mastrantonio, 2002). The D117 frame-
shift mutation results in a truncated protein lacking in
Abbreviations: CDI, Clostridium difficile infection; PaLoc, pathogenicity
locus.
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function. Strains with both D117 and an 18 bp deletion
have also been found to produce more toxin in the
exponential phase of growth and to cause more severe
disease (Curry et al., 2007). However, it has also been
shown that this ribotype does not produce more toxin
than others, although the duration of the toxin produc-
tion is increased (Freeman et al., 2007). Interestingly, it
has been observed that 027 strains not only produce more
toxins but also have increased sporulation rates, giving
them an added advantage in dissemination (Akerlund
et al., 2008).
The changing epidemiology of C. difficile in Scotland
has been studied extensively and has revealed changes in
the ribotypes implicated in CDI over the years (Taori
et al., 2009). Ribotype 012, to which the reference and
the first sequenced strain 630 belongs, represented 5%
of the C. difficile isolates collected between 1979 and
2004, but is no longer reported in the infected
population. The incidence of ribotype 001 has increased
over the years from 1.5 to 75.8% (Mutlu et al., 2007).
Ribotype 106, not identified in Scottish isolates till 2004,
represented 8.1% of the isolates collected in 2005. In
2006, the prevalence of ribotype 001 started declining
and that of ribotype 106 increased steadily. The same
year saw the first case of ribotype 027 infection in
Scotland, and its incidence has since been on the rise.
The most common causes of CDI in Scotland today are
ribotypes 106, 001 and 027 (Health Protection Scotland,
2008, 2010).
All the ribotypes mentioned above are multidrug-resistant
and have been isolated from CDI patients. Though only
ribotype 027 is considered to be hypervirulent, strains 106
and 001 have also been shown to cause severe disease
(Arvand et al., 2009; Sundram et al., 2009). Strain 630 was
isolated from a patient with pseudomembranous colitis
during a diarrhoeal outbreak in a Zurich hospital (Wüst
et al., 1982). These observations led to the hypothesis that
not only excessive toxin production but also enhanced
growth and increased sporulation might explain the
severity of disease caused by these strains, as well as their
ability to spread in the environment. To test this, the
growth of these strains over a 24 h period was studied,
along with toxin production and sporulation. For a more
detailed understanding, the transcription of the genes of
the PaLoc and the sporulation initiator spo0A were
investigated over the same time period. Strain VPI
10463 was used as the reference strain, as it is known to
be a high toxin and low spore producer (Akerlund et al.,
2006).
METHODS
Bacterial strains. Three ribotypes of C. difficile were used in this
study: 027 (a clinical isolate obtained from E. J. Kuijper, Leiden
University Medical Center), 001 and 106 (isolates from toxin-
positive faecal samples from CDI cases in south-east Scotland;
Mutlu et al., 2007). Strain 630 (ribotype 012, obtained from P.
Mullany, UCL Eastman Dental Institute, London, UK) was used as
a reference strain, representing a historic isolate. VPI 10463
(obtained from Unipath, Bedford, UK), a known high toxin
producer, was the other reference strain. The strains were purified
and maintained as spore suspensions in Robertson’s cooked meat
medium.
Growth measurement. A starter culture was prepared by inoculat-
ing 0.5 ml of the spore suspension into 3 ml pre-reduced anaerobic
incubation medium (AIM) (Brown et al., 1996). This was incubated
anaerobically (80% N2, 10% H2, 10% CO2) for 16 h at 37 uC in a
Mark III workstation (Don Whitley Scientific) till OD600 1.0
(±0.05) was achieved. The starter culture (3 ml) was inoculated
into 300 ml pre-reduced AIM. Growth was determined by measuring
OD600 at 4, 8, 12, 16, 20 and 24 h. Cultures were checked for purity
by Gram-staining and aerobic and anaerobic subculture on blood
agar. All growth curves and related studies were performed in
triplicate.
Total toxin production. Total toxin (A+B) production was
measured using the C. difficile TOX A/B II kit (TechLab) according
to the manufacturer’s instructions. Culture supernatants were
collected every 4 h by centrifugation at 13 000 g for 1 min and stored
at 280 uC. The supernatants were diluted 1 : 5 in the supplied diluent
and run in duplicate. Total toxin levels were determined by measuring
A450/OD600.
ELISA for toxin A. A sandwich ELISA was developed for the
quantification of toxin A. ELISA plates were coated with 50 ml of
1.5 mg ml21 rabbit polyclonal antibody to C. difficile toxin A
(Meridian Life Science) in 0.1 M carbonate/bicarbonate buffer
(pH 9.6). The plates were incubated at 4 uC overnight. They were
then washed with PBS (pH 7.4) containing 0.05% Tween 20 and
blocked with 100 ml PBS containing 3% gelatin. Culture super-
natants (50 ml) diluted in PBS with 1% gelatin were then added to
the plate in duplicate and incubated. To generate standard curves,
twofold dilutions of toxin A (Calbiochem, Merck) from 250 to
0.25 ng ml21 were added to each plate. The plates were washed as
above and 50 ml of 0.5 mg ml21 mouse monoclonal antibody to toxin
A (Novus Biologicals) was added to the plate and incubated. After
washing, 50 ml 1 : 1000 anti-mouse IgG (whole molecule)–peroxidase
antibody produced in rabbits (Sigma) was added to the plates. All
the above incubations were performed for 1 h at 37 uC. Finally, the
plates were washed and 100 ml substrate, 3,39,5,59-tetramethylbenzi-
dine (TMB), was added for 5 min at room temperature. The
reaction was stopped with 100 ml 0.2 M H2SO4 and A450 was
measured.
Quantitative cytotoxicity assay for toxin B. It proved impossible
to develop an ELISA for toxin B with commercially available reagents,
and thus a modified cytotoxicity assay was performed for its
quantification. Vero cells were cultured in Dulbecco’s Modified
Eagle’s medium (DMEM) with 10% fetal bovine serum, 1% non-
essential amino acids, 100 units penicillin ml21 and 100 mg
streptomycin ml21 at 37 uC in 5% CO2. The monolayers were
trypsinized at 37 uC for 5 min, washed with medium and resus-
pended at 56105 cells ml21. The cells were added to a 96-well tissue
culture plate in 50 ml volumes and incubated overnight. The medium
was replaced with 50 ml of suitable dilutions of culture supernatant
prepared in medium, in duplicate. To generate standard curves,
twofold dilutions of toxin B (Calbiochem, Merck) from 250 to
0.25 ng ml21 were added to each plate. The plates were incubated for
48 h, washed with pre-warmed PBS and then 20 ml of 5 mg ml21
thiazolyl blue tetrazolium bromide (Sigma) was added to the wells,
followed by incubation at 37 uC for 4 h. Any formazan produced by
the cells was dissolved in 100 ml DMSO (Sigma) and A570 was
measured.
P. Vohra and I. R. Poxton
1344 Microbiology 157
Real-time RT-PCR. Transcriptional analysis of the PaLoc genes and
spo0A was performed. Culture was collected every 4 h corresponding
to approximately 56108 cells (50 ml at 4 h to 5 ml at 24 h) by
centrifuging at 4000 g for 10 min. The pellets obtained were
immediately treated with 500 ml RNAwiz (Ambion) or TRIzol
(Invitrogen), vortexed vigorously in a Mini-BeadBeater (Biospec
Products) and stored at 280 uC for a maximum of 7 days before use.
RNA was extracted according to the manufacturer’s instructions and
treated with DNase I (Ambion) at 37 uC for 1 h, followed by
deactivation of the DNase with DNase Inactivation Reagent
(Ambion) for 2 min at room temperature. The quantity and quality
of the RNA were assessed using a NanoDrop spectrophotometer, and
aliquots were stored at 280 uC. The SuperScript VILO cDNA
Synthesis kit (Invitrogen) was used to convert 2 mg RNA into cDNA
according to the manufacturer’s instructions. The cDNA was
aliquoted and stored at 220 uC. Primers for tcdA, tcdB, tcdC,
tcdR, tcdE, spo0A and rrn (16S rRNA gene) were designed using
Primer3 software (Rozen & Skaletsky, 2000) based on the genome of
strain 630 (Table 1). These were first tested by conventional PCR
with genomic DNA to confirm specificity and product size. The real-
time RT-PCRs were performed in duplicate in 20 ml volumes using
50 ng cDNA, primers at 200 nM for tcdA–R, 500 nM for tcdE
and 100 nM for spo0A and rrn, and 10 ml SYBR Green JumpStart
Taq ReadyMix (Sigma) in an Mx3000P quantitative PCR system
(Stratagene). Standard curves were generated using fourfold
dilutions of cDNA pools on each plate for each gene to determine
the efficiency of the reactions. RNA and diethylpyrocarbonate
(DEPC) water controls were also maintained. The thermal profile
used was: initial denaturation at 95 uC for 3 min, 40 cycles of
denaturation at 95 uC for 20 s, annealing at 56 uC for 20 s, and
extension at 72 uC for 20 s. This was followed by a dissociation curve
to check the product specificity. The expression of the test genes was
normalized to that of rrn and calculated by the Pfaffl method (Pfaffl,
2001) using the amplification efficiencies determined in each run.
The 4 h value was used as the calibrator for expression at the
successive time points.
Spore production. Spore production was assessed using 10 ml of the
culture every 4 h from the same culture as above. Pellets were
obtained by centrifugation at 4000 g for 10 min, washed twice in
distilled water and treated with 50% ethanol for 1 h. After washing
twice, the pellets were suspended in 1 ml distilled water and 10-fold
serial dilutions were plated onto blood agar. After anaerobic
incubation for 48 h, the colonies were counted and the number of
spores per millilitre of culture was determined.
Statistical analysis. Statistical analyses were performed using
GraphPad Prism 4.0 software. Strain comparison at individual time
points was performed by one-way ANOVA. To assess the overall
trends of growth and the corresponding phenotypic traits over
the time-course, area under curve (AUC) analysis was performed
for each strain, and strains were then compared by one-way
ANOVA.
RESULTS AND DISCUSSION
The hypervirulence of ribotype 027 has been of increasing
interest since the emergence of this strain and its apparent
ability to cause severe disease and be responsible for many
outbreaks (Kuijper et al., 2007; Pépin et al., 2004; Smith,
2005). The hypervirulence has been directly associated with
the excessive toxin production observed in this ribotype.
Here we show that ribotype 027 produces much greater
amounts of toxin than other strains in this study. Also,
ribotypes 106 and 001 produce more toxins than strain
630, and ribotype 106 produces markedly more spores than
the other strains.
All the C. difficile strains show similar patterns of
growth
The growth curves obtained for all the C. difficile
strains were similar (Fig. 1). Ribotypes 001 and 106
showed slightly but significantly increased growth at 4 h
when compared with strains 630 and VPI 10463
(P,0.001), but not when compared with ribotype 027.
Throughout the 24 h, the growth of all the strains was

















Fig. 1. Growth curves of five C. difficile strains. The growth of
strain 630 (&), VPI 10463 (m), ribotype 027 (.), ribotype 001
(X) and ribotype 106 ($) was measured by OD600 over 24 h. The
patterns of growth were similar for all the strains. Error bars, SEM of
12 growth curves (performed in triplicate on four different
occasions).
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significantly higher than that of strain 630 (P,0.001).
Thus, varying growth rates do not appear to explain the
degrees of virulence observed in different strains of C.
difficile.
C. difficile ribotype 027 produces significantly
more toxin than other strains
Total toxin (A+B) production as measured by the
combined ELISA kit varied significantly between the
strains studied (Fig. 2a). In ribotype 027, total toxin
production increased significantly between 8 and 12 h. By
12 h, ribotype 027 and VPI 10463 produced significantly
more toxin than the other strains (P,0.001), which
showed a gradual increase in toxin production over time.
Ribotype 106 produced more toxin than 001, which in
turn was greater than strain 630. Over the 24 h, ribotype
027 and VPI 10463 produced significantly higher
amounts of total toxin (P,0.001). Beyond 12 h, the
levels of toxin production in ribotype 027 and VPI
10463 could not be determined due to saturation of the
assay. Thus, to investigate further the amounts of
individual toxins produced by the different strains,
quantitative methods were developed to detect each of
the toxins.
Toxin A was detected in the cultures of all strains by ELISA
(Fig. 2b). Ribotype 027 produced the most toxin A up to
12 h (P,0.001) and the amounts increased till 24 h. All the
other strains produced low levels of toxin A till 12 h.
Beyond 12 h, large amounts of toxin A were detected in
cultures of VPI 10463, as expected, and the amounts were
similar to those of ribotype 027. Ribotypes 106 and 001
produced toxin A at similar levels, which were significantly
lower than those of VPI 10463 and ribotype 027 (P,0.001)
and slightly higher than those of strain 630. Toxin B
production was assessed using a modified cytotoxicity
assay, and levels were marginally higher than those of toxin
A in all strains over time (Fig. 2c). VPI 10463 showed a
steady increase in toxin B production that reached high
levels at 24 h. Ribotype 027 produced significantly more
toxin B than the other strains at 8 h (P,0.01) and this
level remained almost constant till 24 h. In ribotypes 106
and 001, toxin B production increased gradually up to
20 h and then increased sharply at 24 h, possibly due to
accumulation in the culture medium. Interestingly, in
strain 630, toxin B production decreased over time.
Overall, toxin B production in the hypervirulent ribotype
027 was significantly higher than that in the other test
strains (P,0.01).
From these results, it is evident that ribotype 027 produces
significantly more toxin than the other strains. As
Fig. 2. Toxin production in five C. difficile strains. Toxin
production in strain 630 (&), VPI 10463 (m), ribotype 027 (.),
ribotype 001 (X) and ribotype 106 ($) was measured over the
24 h period studied. (a) Total toxin production (A+B) measured
using a combined kit showed significantly higher toxin production
in ribotype 027 and VPI 10463. Error bars, SEM of three
experiments. (b) Toxin A was quantified by a newly developed
in-house ELISA. In all the strains, extracellular levels of toxin A
increased over 24 h. Ribotype 027 produced significantly greater
amounts of toxin A from 8 h. By the stationary phase, ribotype
027 and VPI 10463 produced markedly more toxin than ribotypes
106 and 001. Strain 630 produced the least toxin A. Error bars,
SEM of six experiments. Lower y axis, 0–100 ng ml”1; upper y axis,
100–2000 ng ml”1. (c) Toxin B was quantified by a modified
cytotoxicity assay. Ribotype 027 produced significantly greater
amounts of toxin B from 8 h, while that in VPI 10463 increased
steadily over time. In ribotypes 106 and 001, the amounts of toxin
B increased gradually till 20 h and then showed a sudden
increase at 24 h. In strain 630, toxin B levels decreased over time.
Error bars, SEM of six experiments. Lower y axis, 0–250 ng ml”1;
upper y axis, 250–2000 ng ml”1.
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observed by others, our data also suggested that ribotype
027 is capable of producing up to 20 times more toxin (A
or B) than other strains (Warny et al., 2005), except VPI
10463. This was also true for seven isolates of ribotype 027
from Scotland and five from the Netherlands (data not
shown) (Vohra & Poxton, 2010). This appears to be a
phenotypic advantage for this strain, enabling it to cause
severe disease.
Another observation was the detection of moderately more
toxin A than toxin B at 24 h in ribotypes 027 and 106
(Fig. 4). Toxin A, an enterotoxin with the ability to bind to
epithelial cells in the gut via receptors (Krivan et al., 1986;
Tucker & Wilkins, 1991), causes initial damage by
glucosylation of Rho proteins (Aktories et al., 2000). In
animal studies, it has been observed that in the absence of
toxin A, toxin B is unable to induce the pathology
characteristic of CDI (Lyerly et al., 1985). Even in cell
cultures with Caco2 cells, it has been demonstrated that
when toxin A challenge is removed, no damage is caused
to the epithelial barrier (Sutton et al., 2008). Thus, large
amounts of toxin A may contribute to increased disease
severity and perhaps the increased potential of ribotypes
027, 106 and 001 to induce CDI in healthy humans: the
greater the initial damage to the gut by toxin A, the
greater the chance of toxin B causing extensive cytotoxi-
city. However, outbreaks caused by A2B+ strains have
been reported (Drudy et al., 2007), questioning the
clinical importance of toxin A in disease. Toxin B is
1000-fold more cytotoxic than toxin A; however, its role
in the development of the characteristic pathology of CDI
is debated, though A+B2 strains have not yet been
isolated. It has also been shown that toxin B knockout
strains are ineffective at causing fatal disease in hamsters
(Lyras et al., 2009). However, more recently it has been
suggested that both toxins are important in CDI (Kuehne
et al., 2010). Whatever the importance of toxin B in
disease, it is clear that the current epidemic strains
produce large quantities of it. This, coupled with the
production of large amounts of toxin A, could explain
the severity of disease associated with ribotypes 027, 106
and 001.
High toxin producers show increased
transcription of the PaLoc genes
Transcriptional analysis of the PaLoc genes was performed
by real-time RT-PCR (Fig. 3). In VPI 10463, the transcrip-
tion of tcdA, tcdB and tcdR increased over 24 h, while that of
tcdC decreased after 8 h, as shown by Hundsberger et al.
(1997). tcdE levels were found to increase till 12 h, after
which they decreased, with a transient increase at 24 h. This
served as a basis for transcription studies in the other strains
using the methodology developed. However, varying
patterns of PaLoc gene expression were observed in the
other strains.
tcdA expression increased till 12 h in ribotype 027,
ribotype 106 and strain 630, and then decreased, whilst
remaining almost constant in ribotype 001 over time. A
similar trend was observed for tcdB in ribotype 106
and strain 630, though in the latter, the levels were below
the 4 h value. In ribotype 001, an increase in tcdB
transcription was observed at 20 h. Interestingly, ribotype
027 was the only strain to show constantly increasing tcdB
expression over the 24 h period studied, though it was
less than that of tcdA. The pattern of tcdA expres-
sion suggests that transcription peaks at 12 h and the
toxin levels detected in culture thereafter are the result
of accumulation. This was observed less markedly
and from 8 h for toxin B. This observed correlation
between gene expression and toxin detection (Fig. 4) was
analysed by expressing the results as the ratio of toxin
production to toxin gene transcription. Though the
transcription of tcdB was lower than that of tcdA in all
the strains, the levels of toxin B detected were always
higher than those of toxin A, suggesting more efficient
production of TcdB or perhaps greater degradation of
TcdA in culture.
tcdR transcription increased steadily over time in strain
630, but in ribotypes 027, 001 and 106, peak expression was
observed at 12 h, followed by a decline. A transient increase
in expression was observed at 24 h in ribotypes 027 and
106. Notably, tcdC transcription showed a similar pattern
and at similar levels, contrary to the observations in VPI
10463.
tcdC is the negative regulator of toxin production (Dupuy
et al., 2008; Matamouros et al., 2007), and it has been
shown that its transcription decreases as cultures enter
stationary phase (Hundsberger et al., 1997). The levels of
the protein itself have also been shown to diminish over
time (Govind et al., 2006). Further, the deletions found in
tcdC in ribotype 027 have been used to explain the
excessive toxin production in this strain, as the truncated
TcdC protein would be ineffective in preventing the
complexing of TcdR with RNA polymerase (Curry et al.,
2007). Contrary to the gene and protein studies, our data
showed that tcdC transcription increased over time, at
least till 12 h, and then decreased. Though there was an
evident decrease in tcdC expression, it was not considered
to fit into the pattern described elsewhere (Hundsberger et
al., 1997), as the tcdR expression observed showed a
similar pattern and was at similar levels. This suggests that
tcdC might have a modulatory effect on toxin production,
rather than a strictly inhibitory one. Also, both toxins, A
and B, were detected in the exponential and stationary
phases of growth, despite increasing tcdC expression.
Others have also shown this expression of tcdC in both the
phases of growth, though slightly diminished in the
stationary phase (Dineen et al., 2007; Karlsson et al.,
2008). It is possible that TcdC, being a membrane-
associated protein, has an effect on the release of toxins.
These hypotheses could be tested by gene knockout and
protein interaction studies, and would greatly add to the
understanding of toxin production and release in C.
difficile.
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Fig. 3. Transcription of the PaLoc in five C.
difficile strains. Transcription of the PaLoc
genes was studied by real-time RT-PCR in (a)
strain 630, (b) VPI 10463, (c) ribotype 027, (d)
ribotype 001 and (e) ribotype 106. The
expression of all the genes was normalized to
that of rrn, using the 4 h value as the baseline
of expression. (a) In strain 630, tcdA expres-
sion increased till 12 h and then decreased,
similar to tcdB, though that of tcdB was below
the 4 h value. tcdR and tcdC expression
increased over time, while that of tcdE
remained constant. (b) In VPI 10463, the
expression of tcdR, tcdA, tcdB and tcdE
increased over the 24 h, while that of tcdC
decreased. (c) In ribotype 027, the transcrip-
tion of tcdR, tcdE, tcdA and tcdC peaked at
12 h and then decreased. tcdB transcription
increased over 24 h. (d) In ribotype 001, tcdR
and tcdC transcription was similar, while that
of tcdB, tcdE and tcdA did not vary consid-
erably over time. (e) In ribotype 106, tcdR,
tcdB, tcdA and tcdC transcription peaked at
12 h, while that of tcdE increased till 16 h.
Thereafter, expression of all the genes
decreased. Error bars, SEM of six experiments
for tcdA and tcdB expression, and four experi-
ments for tcdR, tcdE and tcdC expression.
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Fig. 4. tcdA and tcdB transcription and the
corresponding toxin A and toxin B production.
The transcription of the toxin genes tcdA and
tcdB and the corresponding production of
toxin A and toxin B was studied in (a) strain
630, (b) VPI 10463, (c) ribotype 027, (d)
ribotype 001 and (e) ribotype 106. The
extracellular levels of both toxins increased
over time in all the strains, even when gene
expression decreased. Ribotype 027 pro-
duced greater amounts of both toxins and also
showed greater gene expression. The correla-
tion of toxin production to toxin gene tran-
scription was assessed by analysing ratios of
toxin A value : tcdA expression and toxin B
value : tcdB expression at the different time
points. This is represented by the line graphs
above the toxin values for each toxin (log10
scale ranging from 10”1 to 105). In all the
strains, the release of toxin A at 12 h is evident.
For toxin B, earlier release is indicated. Error
bars, SEM of six experiments.
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tcdE transcription was also studied, though not in a very
efficient reaction. However, the results obtained showed
that there was a major increase, approximately 15-fold,
in tcdE expression till 12 h in ribotype 027 and VPI
10463, the highest toxin producers, which corresponds to
the time beyond which large amounts of toxin are
detected in the cultures of these strains. The almost
steady expression of tcdE in the other strains corre-
sponded to the slower release of toxins seen in those
strains. Thus, it is likely that TcdE plays an important
role in the release of the C. difficile toxins, given its
holin-like properties (Tan et al., 2001). The increased
tcdE transcription in ribotype 027 may also contribute to
hypervirulence.
Currently common C. difficile ribotypes produce
more spores than a previously dominant strain
Sporulation is the other key trait of C. difficile that enables
it to survive and spread in the environment. That
sporulation and toxin production are alternate mecha-
nisms for survival has been debated (Kamiya et al., 1992).
VPI 10463 fits this idea, showing high toxin production
and low sporulation. Contrary to this, ribotype 027 has
been shown to produce high levels of both toxins and
spores, and this has been observed in 12 different isolates
of ribotype 027 (data not shown) (Vohra & Poxton,
2010).
All the strains studied here produced alcohol-resistant
spores, and their numbers in culture increased over time
(Fig. 5). Ribotype 106 produced significantly more spores
(P,0.001) than the other strains, though this significance
was less when compared with spore production by
ribotype 027 (P,0.05). At 24 h, a final count of 443
spores (ml culture)21 was obtained for ribotype 106,
which was significantly higher than that of the other
strains. VPI 10463 produced the fewest spores. The
number of spores obtained was very low, although this
was possibly due to the absence of bile salts, which
enhance spore germination (Wilson, 1983), in the
medium used.
spo0A, the master regulator of sporulation, was selected as
the indicator of the magnitude of the spore-produc-
ing capacity of the C. difficile strains studied. spo0A
Fig. 5. spo0A transcription and spore production in five C.
difficile strains. spo0A transcription, normalized to that of rrn, in
(a) strain 630, (b) VPI 10463, (c) ribotype 027, (d) ribotype 001
and (e) ribotype 106 decreased over time, except for the slight
increase in ribotype 027 at 8 and 12 h. The number of spores
detected in the cultures of all the strains increased over the 24 h,
with ribotype 106 producing the highest number of spores,
followed by ribotypes 027 and 001 and strain 630. VPI 10463
produced the lowest number of spores. Error bars, SEM of six
experiments for the transcription of spo0A and three experiments
for spore production.
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transcription in all the strains decreased over time (Fig.
5). In the epidemic strains, however, there was a slight
difference in the pattern of expression: in ribotype 027,
spo0A expression increased at 8 h before decreasing
and then spiked at 24 h, whilst in ribotypes 106 and
001, the levels of expression increased marginally at 12 h
before falling. These differences, however, were not
significant.
Despite the expected decrease in gene expression, the
trends over the first few hours suggested subtle inter-
strain differences. Perhaps the increased duration of
transcription of spo0A in the early stages of growth
enhances the expression of the subsequent genes involved
in the process, resulting in a greater number of spores
being produced and released into the environment,
irrespective of environmental stresses. The link between
toxin and spore production has recently been described:
spo0A mutants show decreased sporulation and toxin
production (Underwood et al., 2009). Thus, the observed
increase in spo0A transcription in ribotype 027 might
also increase its toxin production and add to its
hypervirulence.
During the preparation of this manuscript, a similar
study was published comparing hypervirulent ribotype
027 (BI) strains with non-hypervirulent strains (Merrigan
et al., 2010). The increase in the transcription of the
PaLoc genes, including tcdC, was also observed in that
study, and those authors too hypothesize a modulatory
function for TcdC. However, unlike their results, we
detected toxin production in all our strains in the
exponential phase of growth as well as the stationary
phase. It is possible that this difference was due to the
medium used. We used anaerobic incubation medium
(AIM) in our experiments, a medium that does not
contain any glucose, which inhibits toxin production
(Dupuy & Sonenshein, 1998; Karlsson et al., 1999). It
does contain cysteine, though at subinhibitory levels. This
might explain the earlier detection of toxins in our
study and the greater levels detected in the stationary
phase of growth. This might also address the significantly
higher tcdA transcription in ribotype 027 observed in our
study.
Although a single isolate was tested for each ribotype, from
the data presented here, we can conclude that ribotype 027
has the ability to produce large amounts of toxins and
spores, both key phenotypic advantages that are likely to
have aided its emergence. Further, ribotype 106 possesses
traits that may directly address its presence as the strain
most commonly associated with CDI in Scotland. The
increased toxin and spore production in the current
epidemic strains corresponds directly with the severity of
disease and extent of spread associated with them, and
gives further insight into the evolving bacterial factors that
affect the epidemiology of CDI.
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Clostridium difficile is a common nosocomial pathogen transmitted mainly via its spores. These
spores can remain viable on contaminated surfaces for several months and are resistant to most
commonly used cleaning agents. Thus, effective decontamination of the environment is essential
in preventing the transmission of C. difficile in health-care establishments. However, this
emphasis on decontamination must also be extended to laboratories due to risk of exposure of
staff to potentially virulent strains. Though few cases of laboratory-acquired infection have been
reported, the threat of infection by C. difficile in the laboratory is real. Our aim was to test the
efficacy of four disinfectants, Actichlor, MicroSol 3+, TriGene Advance and Virkon, and one
laboratory decontaminant, Decon 90, against vegetative cells and spores of C. difficile. Five
strains were selected for the study: the three most commonly encountered epidemic strains in
Scotland, PCR ribotypes 106, 001 and 027, and control strains 630 and VPI 10463. MICs were
determined by agar dilution and broth microdilution. All the agents tested inhibited the growth of
vegetative cells of the selected strains at concentrations below the recommended working
concentrations. Additionally, their effect on spores was determined by exposing the spores of
these strains to different concentrations of the agents for different periods of time. For some of the
agents, an exposure of 10 min was required for sporicidal activity. Further, only Actichlor was able
to bring about a 3 log10 reduction in spore numbers under clean and dirty conditions. It was also
the only agent that decontaminated different hard, non-porous surfaces artificially contaminated
with C. difficile spores. However, this too required an exposure time of more than 2 min and up to
10 min. In conclusion, only the chlorine-releasing agent Actichlor was found to be suitable for the
elimination of C. difficile spores from the environment, making it the agent of choice for the
decontamination of laboratory surfaces.
INTRODUCTION
Clostridium difficile is the causative agent of C. difficile
infection (CDI) (Bartlett et al., 1978; Bartlett, 2008; George
et al., 1978). Though CDI is a common nosocomial
infection, it is not limited to the hospital environment;
community-acquired CDI and asymptomatic carriage are
also common (Freeman et al., 2010).
C. difficile is acquired via the faecal–oral route as spores
(Lyerly et al., 1988). Symptomatic patients shed large
amounts of both vegetative cells and spores into the
environment (Wilcox et al., 2003). Though vegetative cells
survive under aerobic conditions for only 15 min on dry
surfaces, they can survive for up to 6 h on moist surfaces
(Weber et al., 2010). The spores of C. difficile, however, can
persist on hospital floors for up to 5 months (Kim et al.,
1981) and are resistant to several cleaning agents, especially
in the presence of organic matter (Fawley et al., 2007;
Wheeldon et al., 2008). Surfaces contaminated with C.
difficile spores can facilitate cross-colonization (Fawley &
Wilcox, 2001). It has been suggested that health-care
workers (and patients) acquire C. difficile from contami-
nated surfaces (Gerding et al., 1995; McFarland & Stamm,
1986) such as portable commodes, bedpans, blood pressure
cuffs, walls, floors, washbasins and furniture (Fekety et al.,
1981; Samore et al., 1996; Weber et al., 2010). A correlation
between transmission of C. difficile among patients and
contamination of the hands of health-care workers has
been clearly observed (McFarland et al., 1989).
Although C. difficile is a dreaded nosocomial pathogen, the
risk of laboratory-acquired CDI has not been given much
attention, in spite of the exposure of laboratory workers to
relatively high inocula of C. difficile. However, cases of CDI
have been reported in laboratory personnel (Bouza et al.,
2008) as well as in health-care workers (Arfons et al., 2005;
Hell et al., 2009; Ray & Donskey, 2003). Thus, it is
important to ensure proper decontamination of surfaces in
the laboratory as well as proper hand-washing technique toAbbreviation: CDI, Clostridium difficile infection.
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prevent potential transmission of C. difficile from the
laboratory environment into the community and hospitals.
The aim of this study was to test the efficacy of five
commonly used agents against both vegetative cells and
spores of C. difficile using laboratory tests as well as a more
real-life surface cleaning approach.
METHODS
Bacterial strains. Five strains of C. difficile were used in this study:
strain 630 (ribotype 012, obtained from P. Mullany, London, UK),
strain VPI 10463 (obtained from Unipath, Bedford, UK), ribotype
027 (obtained from E. J. Kuijper, Leiden, The Netherlands), ribotype
001 and ribotype 106 (local strains from Edinburgh, UK). The strains
were purified and maintained as spore suspensions in Robertson’s
cooked meat medium (Oxoid). All culturing of strains was performed
anaerobically (80% H2, 10% N2, 10% CO2) at 37 uC in a Mark III
workstation (Don Whitley Scientific).
Agents. Five agents were tested in this study: Actichlor, a disinfectant
routinely used in hospitals; Decon 90, a laboratory decontaminant;
and three commonly used laboratory disinfectants, Microsol 3+,
TriGene Advance and Virkon. The active ingredients, recommended
concentrations and manufacturers are listed in Table 1.
MIC testing. MICs of the agents for the vegetative cells of the
different C. difficile strains were determined by the Wadsworth agar
dilution method (NCCLS, 2004). Strains were cultured anaerobically
on blood agar at 37 uC for 24 h, followed by culturing in pre-reduced
thioglycollate broth supplemented with 5 mg haemin ml21 and 1 mg
vitamin K1 ml
21 for 8 h. This ensured that the cultures were in the
exponential phase when used for MIC testing, and thus consisted of
mainly vegetative cells and very few spores. These cultures were
diluted to a 0.5 McFarland standard for inoculation onto pre-reduced
Brucella agar (Oxoid) supplemented with 5% defibrinated horse
blood, 5 mg haemin ml21 and 1 mg vitamin K1 ml
21 containing
doubling dilutions of one of the five agents ranging from the
manufacturer’s recommended working concentration to 1/1024 of the
same. The plates were incubated anaerobically at 37 uC for 48 h and
then examined for growth. The lowest concentration of the tested
agent to inhibit visible bacterial growth was recorded as the MIC of
that agent. The experiments were performed in triplicate.
MICs were also performed by broth microdilution in a 96-well plate.
Doubling dilutions of the five agents ranging from the manufacturer’s
recommended working concentration to 1/1024 of the same were
prepared in pre-reduced anaerobic incubation medium and 100 ml of
each dilution was added to wells of the plate in duplicate. To the
wells, 10 ml culture adjusted to a 0.5 McFarland standard was added.
The plates were incubated anaerobically at 37 uC for 48 h and then
examined for growth by eye and by measurement of OD600. Negative
controls with no added culture and positive controls without the
agents were also maintained in duplicate. The lowest concentration of
the tested agent to inhibit visible bacterial growth and OD600 ¢0.1
was recorded as the MIC of that agent. The experiments were
performed in triplicate.
Preparation of spores. Strains were cultured in 500 ml pre-reduced
anaerobic incubation medium (Brown et al., 1996) anaerobically at
37 uC for 7 days. The cultures were then collected by centrifugation at
4000 g for 10 min. The pellets obtained were washed twice with sterile
PBS and then treated with 50% ethanol for 1 h with constant
shaking. The pellets were collected by centrifugation, washed twice in
PBS and then resuspended in 1 ml sterile distilled water and stored at
4 uC. Before each experiment, spore counts were determined from 10-
fold serial dilutions of the final spore suspension plated on blood agar
and incubated for 48 h.
Sporicidal assays. Spore preparations were standardized to 106
spores ml21. The agents were tested for their sporicidal activity in a
Table 1. Agents used in this study
Agent Active ingredient(s) Manufacturer Recommended working
concentration
Actichlor Sodium dichloroisocyanurate Ecolab 1000 p.p.m. chlorine
Decon 90 Anionic and non-anionic surfactants Decon Laboratories 1 : 10 dilution
Microsol 3+ Tertiary alylamine and quaternary ammonium
compounds
Anachem 1 : 10 dilution
TriGene Advance Polymeric biguanide hydrochloride and organic
quaternary compounds
Medichem International 1 : 100 dilution
Virkon Potassium peroxymonosulfate Antec International 1 : 100 dilution
Table 2. MIC of each agent for vegetative cells of five C. difficile strains represented as a fraction of the recommended working
concentration
Values are the median from both the agar-dilution and the broth microdilution methods for MIC testing.
Agent Strain 630 Strain VPI 10463 Ribotype 027 Ribotype 001 Ribotype 106
Actichlor 1/8 1/8 1/2 1/8 1/8
Decon 90 1/4 1/4 1/2 1/2 1/4
Microsol 3+ 1/128 1/128 1/128 1/128 1/128
TriGene Advance 1/32 1/32 1/32 1/32 1/32
Virkon 1/8 1/8 1/4 1/4 1/8
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suspension test at the recommended working concentration and 1/2
and 1/5 of the same. For each test, 100 ml spore suspension containing
105 spores was added to 900 ml of each of the dilutions and mixed
thoroughly. At 2 min, 10 min and 30 min, 100 ml of the test was
inoculated into 900 ml pre-reduced anaerobic incubation medium,
mixed and incubated at 37 uC for 5 days in duplicate. Positive
controls without any disinfectant and negative controls without
spores were also maintained in duplicate to check that the medium
was sustaining the germination of spores and growth of the resulting
vegetative cells and that it was not contaminated, respectively. The
tubes were examined for growth and the lowest concentration of the
agent showing no growth was recorded as the minimum sporicidal
concentration. Samples from tubes with no visible growth were plated
to identify cidal or static activity and these were examined for growth
after 5 days of anaerobic incubation.
Determination of log10 reduction. To determine the log10
reduction in C. difficile spores in suspension tests, spores were treated
with the cleaning agents at the recommended working concentration
in the presence or absence of organic matter. For the tests in the
absence of organic matter, 100 ml spores in distilled water (approx.
104 spores ml21) was added to 900 ml agent. After 10 min, the spores
were collected by centrifugation at 16 000 g for 2 min. The spore
pellets were washed twice with 1 ml distilled water. The spores were
then resuspended in 1 ml distilled water and 100 ml of this suspension
was spread onto blood agar plates in duplicate and incubated at 37 uC
anaerobically for 48 h. Untreated positive controls were maintained
in duplicate. For the tests in the presence of organic matter, BSA
(Sigma) was introduced into the test at a final concentration of
0.27%. The log10 reduction was calculated as log10 (N0/N10), where
N05the number of spores in the positive control and N105the
number of viable spores recovered from the test at 10 min.
Surface decontamination testing. Five different surfaces were used
in this study: aluminium, glass, plastic, self-adhesive vinyl tiles and
white ceramic tiles. The surfaces were autoclaved and dried in a hot
air oven before use: the self-adhesive vinyl tiles could not be
autoclaved and were cleaned with 70% ethanol before use. On all the
clean surfaces, squares of approximately 1 cm2 were marked out with
a wax crayon. These were then artificially contaminated with spores of
the five C. difficile strains and tested for cleaning efficiency with all the
cleaning agents. Each square was contaminated with 10 ml spore
suspension (105 spores ml21) and left to air dry for 2 h. Fifty
microlitres of cleaning agent at the manufacturer’s recommended
concentration was then added to the square on top of the dried spore
suspension. After 2 min and 10 min, the area was scratched with a
pipette tip 10 times in an attempt to mimic scrubbing and the agent
was aspirated. The area was then washed with 100 ml distilled water.
The aspirated agent and wash were added to 850 ml distilled water to
obtain a final volume of 1 ml. One hundred microlitres of this was
plated on blood agar and incubated anaerobically for 48 h. The
surfaces were also cleaned only with water and these served as positive
Table 3. Minimum sporicidal concentration of the agents for five C. difficile strains represented as a fraction of the recommended
working concentration after different times of exposure
The tests were performed in 1 ml volumes with 105 spores being exposed to the disinfectants.
Agent* Time of exposure
(min)
Minimum sporicidal concentration
Strain 630 Strain VPI 10463 Ribotype 027 Ribotype 001 Ribotype 106
Actichlor 2 ,1/5 ,1/5 1/2 ,1/5 1/2
10 ,1/5 ,1/5 ,1/5 ,1/5 ,1/5
30 ,1/5 ,1/5 ,1/5 ,1/5 ,1/5
Decon 90 2 1 1/2 1/2 1 1/2
10 1/2 ,1/5 ,1/5 1/2 ,1/5
30 ,1/5 ,1/5 ,1/5 ,1/5 ,1/5
Virkon 2 1 1 1 1 1
10 1 ,1/5 1 ,1/5 ,1/5
30 1 ,1/5 1 ,1/5 ,1/5
*The minimum sporicidal concentration for Microsol 3+ and TriGene Advance for all the strains was less than 1/5 at 2, 10 and 30 min.
Table 4. Mean log10 reduction in C. difficile spores of five strains in the absence and presence of organic matter
The log10 reduction is a mean of the values obtained for all five C. difficile strains.
Agent Log10 reduction (mean±SEM)
Organic matter negative Organic matter positive
Actichlor 3.093±0.2239 3.076±0.2429
Decon 90 0.5159±0.06722 0.3384±0.101
Microsol 3+ 1.519±0.1025 0.7288±0.1294
TriGene Advance 1.698±0.0806 0.5399±0.09384
Virkon 1.171±0.1705 0.1657±0.04113
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controls. The log10 reduction was calculated as above from two
independent experiments.
Statistical analysis. Statistical analyses were performed using
GraphPad Prism 4.0 software. In order to compare agents and
strains, one-way analysis of variance (ANOVA) was performed.
RESULTS AND DISCUSSION
Efficacy against vegetative cells
The growth of vegetative C. difficile was effectively
suppressed by all the agents tested. The MICs of all agents
for the strains were found to be the same by agar dilution
and broth microdilution and these values were lower than
the manufacturer’s recommended concentration (Table 2).
However, for Actichlor, Decon 90 and Virkon, higher
concentrations seemed to be required to destroy vegetative
cells of the epidemic ribotypes 027, 001 and 106. Microsol
3+ appeared to be the most effective agent, active at a 128-
fold dilution of the recommended concentration, followed
by TriGene, which was effective at a 32-fold dilution of the
recommended concentration. Actichlor, used for routinely
cleaning hospitals, was effective at its recommended
concentration, but less than a 2-fold dilution was unable
to inhibit the growth of the hypervirulent ribotype 027.
These observations suggest that the epidemic ribotypes
may have a greater resistance to commonly used cleaning
agents. Also, they emphasize the importance of preparing
these agents at the correct concentration.
Efficacy against spores
The agents tested were also found to be sporicidal at the
recommended concentration in suspension tests at 2, 10
and 30 min of testing (Table 3). Once again it was observed
that ribotype 027 required a greater concentration of
Actichlor for destruction of its spores. This was true for the
epidemic ribotype 106 as well. For Virkon, any dilution
below the recommended concentration was not sporicidal
at 2 min, making it a less effective disinfectant than
Actichlor. Interestingly, Microsol 3+ and TriGene
Advance were found to be sporicidal at a fivefold dilution
of the recommended concentration even at 2 min of
exposure. However, a neutralizer was not used in these
experiments, and the agents were not removed by washing:
they were diluted 10-fold into the recovery medium. Thus,
it is possible that there was a prolonged exposure of the
spores to low but effective concentrations of the agents
tested.
Effect of organic matter on efficacy
All the selected agents except Decon 90 are marketed as
sporicidal agents. Thus, it was of interest to determine the
log10 reduction in spore numbers brought about by them
at the recommended concentration. Under clean condi-
tions, Actichlor was found to be the most effective
Fig. 1. Efficacy of Actichlor (A), Decon 90 (D), Microsol 3+ (M),
TriGene Advance (T) and Virkon (V) (log10 reduction) against the
spores of five strains of C. difficile in the absence and presence of
organic matter. Only Actichlor effectively destroyed spores of all
the strains in the absence or presence of organic matter, causing 3
log10 reduction in spores. The efficacy of all the other agents
decreased significantly in the presence of organic matter,
especially in destroying spores of the epidemic ribotypes 027,
001 and 106. Bars indicate ±SEM of two experiments.
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sporicidal agent (P,0.001), bringing about a 3 log10
reduction of C. difficile spores at 10 min, at which time
Microsol 3+, TriGene Advance and Virkon only caused
approximately 1.5, 1.7 and 1.2 log10 reduction (Table 4).
However, these disinfectants were still significantly more
effective than Decon 90 (P,0.001 compared to Microsol
3+ and TriGene Advance; P,0.01 compared to Virkon).
The superior efficacy of chlorine-releasing agents as
compared to peroxy compounds against the spores of C.
difficile has been observed previously (Lawley et al., 2010).
Fig. 2. Decontamination of different surfaces contaminated with spores of five C. difficile strains by Actichlor (A), Decon 90 (D),
Microsol 3+ (M), TriGene Advance (T) and Virkon (V) tested at 2 min and 10 min of exposure. Actichlor (A) was the most
effective decontaminant at both the time points and destroyed 100% of spores of all the strains by 10 min. The other agents
fared poorly, especially against the epidemic ribotypes 027, 001 and 106. Bars indicate ±SEM of two experiments.
P. Vohra and I. R. Poxton
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No inter-strain differences were observed, except when
Decon 90 was used; the least log10 reduction was observed
for ribotype 027 (P,0.05). In the presence of organic
matter, the efficacy of all the cleaning agents, except
Actichlor, dropped considerably. Actichlor was the most
effective disinfectant even in the presence of organic matter
(P,0.001). Of note was the drop in efficacy of Virkon from
approximately 1.2 log10 in the absence of organic matter to
approximately 0.2 log10 in the presence of it. Also,
interestingly, in the presence of organic matter, for all the
agents except Actichlor, the log10 reduction for the
epidemic strains was more markedly reduced as compared
to that for the non-epidemic strains (Fig. 1). Although for
Actichlor, Microsol 3+ and TriGene Advance this
difference was not significant, when using Virkon, ribotype
001 was the least effectively destroyed strain (P,0.05), and
when using Decon 90, strain 630 was the most effectively
destroyed (P,0.001). As contamination with organic
matter is common in the environment, the efficacy of
cleaning agents in its presence is of greater practical
significance. From the observations above, it is clear that
chlorine-based agents are a better choice for disinfection,
especially to eliminate the currently epidemic C. difficile
strains.
Surface decontamination
To test the decontamination of surfaces using the selected
agents, 1 cm2 areas were artificially contaminated with 103
spores of each strain, allowed to dry and then cleaned, in an
attempt to mimic a real-life situation. Further, washing of
the surface was performed by aspiration of disinfectant and
subsequent washes. It was observed that only the chlorine-
releasing Actichlor was able to completely decontaminate
all the surfaces tested; however, it required more than
2 min and up to 10 min to see this effect (Fig. 2). For all
the other agents, although there was a greater log10
reduction in spore numbers after 10 min of treatment, it
was not significant. Here too it was found that the
epidemic strains were less effectively cleaned. Spores of
strain 630, which was previously epidemic, were also more
resistant to the cleaning, while spores of VPI 10463, which
is rarely isolated from patients, were the most effectively
destroyed. Thus, though chlorine-releasing agents destroy
C. difficile spores, the contact times required for surfaces to
be decontaminated might be unrealistic due to time
constraints as well as the odour, corrosive effects on
surfaces and irritation to users (Block, 2004; Ungurs et al.,
2011). However, the natural environment might not be as
heavily contaminated as the surfaces in these experiments
and thus may be more efficiently cleaned. In the laboratory,
however, contamination of surfaces by high concentrations
of spores is a possibility, and they must be cleaned and
decontaminated carefully and thoroughly.
The contaminated environment is important in the
transmission of C. difficile (Fawley & Wilcox, 2001;
Weber et al., 2010), and just as in hospitals, laboratories
can be a source of transmission of CDI, due to both the
virulent types of strains and the high concentrations of C.
difficile routinely used. Reports of laboratory-acquired CDI
led us to evaluate the type of disinfectants and cleaning
agents used in our laboratory in this study. From these
experiments, which are preliminary and do not strictly
follow the guidelines for disinfectant testing, we can
conclude that vegetative cells of C. difficile as well as
spores can be destroyed by a variety of agents in suspension
tests with long contact times. However, hard non-porous
surfaces were only decontaminated by the use of a
chlorine-releasing agent. Even then, a contact time of up
to 10 min was required to eliminate high concentrations of
C. difficile spores. Thus, chlorine-releasing agents should be
the decontaminants of choice, not only in hospitals (Fraise,
2011), but also in laboratories.
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